

AUSTRALIAN NSP SURVEY NATIONAL DATA REPORT 2013 - 2017

Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees



UNSW
SYDNEY



The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health. The Kirby Institute is affiliated with the Faculty of Medicine, UNSW Sydney. June 2018

© The Kirby Institute
for infection and immunity in society

ISSN 1448-5915

This publication is available at: <http://www.kirby.unsw.edu.au>

The Kirby Institute
for infection and immunity in society
UNSW Sydney
Sydney NSW 2052
Australia

Telephone: **02 9385 0900** Facsimile: **02 9385 0920** International prefix: **612** Email: recpt@kirby.unsw.edu.au

Suggested citation: Heard S, Iversen J, Geddes L, and Maher L. Australian Needle Syringe Program Survey National Data Report 2013-2017: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Sydney: Kirby Institute, UNSW Sydney; 2018. ISSN: 1448-5915.

AUSTRALIAN NSP SURVEY
Prevalence of HIV, HCV and injecting and
sexual behaviour among NSP attendees

NATIONAL DATA REPORT
2013 - 2017

Report prepared by

Sue Heard, Jenny Iversen, Louise Geddes and Lisa Maher

The Kirby Institute

for infection and immunity in society
UNSW Sydney
Sydney NSW 2052
Australia

June 2018

The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health. The Kirby Institute is affiliated with the Faculty of Medicine, UNSW Sydney.

ACKNOWLEDGEMENTS

We would like to acknowledge the many people who assist each year in the development and conduct of the Australian NSP Survey (ANSPS), particularly the clients, staff and managers at participating NSP services. We also appreciate the dedication and vision of the founding members of the project and the late Dr Margaret MacDonald who was responsible for the development and conduct of the ANSPS until 2003.

Special thanks go to Mr Philip Cunningham, Senior Scientist and Operations Manager and Ms Beth Catlett, DBS Coordinator from the NSW State Reference Laboratory for HIV at St Vincent's Hospital and St Vincent's Centre for Applied Medical Research (AMR). We also appreciate the assistance provided by Ms Rachel McCleave and Ms Sonja Memedovic from the Kirby Institute and Mr Greg Smith and Mr Ashwin Prekesh from Educational Assessment Australia, UNSW Global Pty Limited.

In 2017, the project received support and input from the following members of the Australian NSP Survey National Advisory Group: Ms Helene Delany (ACT); Ms Marlene Velecky (NSW); Mr David Decolongon (NT); Mr Stephen Lymb and Mr Rob Gerrie (SA); Ms Francine Smith (TAS); Ms Cath Williams (VIC); Ms Jude Bevan (WA); Ms Melanie Walker (Australian Injecting and Illicit Drug Users League); and Ms Sonja Memedovic, Ms Sue Heard, Dr Jenny Iversen and Professor Lisa Maher (Kirby Institute). We would particularly like to thank Mr Robert Kemp (QLD) for chairing the National Advisory Group.

Ethical approvals were obtained from institutional ethics committees associated with the investigators and participating NSP sites. The Australian Needle Syringe Program Survey is funded by the Australian Government Department of Health and Ageing. The Kirby Institute is affiliated with the Faculty of Medicine, UNSW Sydney.

ABBREVIATIONS

ANSPS	Australian Needle and Syringe Program Survey
DAA	Direct acting antiviral
DBS	Dried blood spot
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
NSP	Needle syringe program
OST	Opioid substitution therapy
PIEDs	Performance and image-enhancing drugs
PBS	Pharmaceutical Benefits Scheme
RNA	Ribonucleic acid
RSS	Receptive syringe sharing

TABLE OF CONTENTS

Summary

Key Points	i
Introduction	1
Demographic characteristics.....	1
Injecting behaviour.....	2
Sexual behaviour	4
Drug treatment	5
HIV antibody prevalence	5
HCV antibody prevalence	6
HIV and HCV testing	8
HCV treatment uptake.....	9
HCV RNA prevalence.....	10
References	11

Tables

1. National	12
2. Australian Capital Territory	36
3. New South Wales	48
4. Northern Territory.....	68
5. Queensland	80
6. South Australia	100
7. Tasmania	120
8. Victoria	132
9. Western Australia	152

Appendix

A. Participating NSP services	172
B. Methodological notes	174
C. List of tables	176

KEY POINTS

- The Australian NSP Survey (ANSPS) functions as a strategic early-warning system designed to monitor blood borne viral infections and associated risk behaviour among people who inject drugs.
- In 2017, 52 Needle and Syringe Programs (NSPs) throughout Australia participated in the ANSPS and 2,600 NSP attendees completed the survey. The response rate was 41%.

Demographic characteristics:

- Over the period 2013 to 2017, the median age of survey respondents increased from 39 to 42 years, with a concurrent decline in the proportion of young injectors (aged <25 years) from 8% in 2013 to 5% in 2017 (χ^2 trend $p<0.001$).
- The median time since first injection increased from 18 years in 2013 to 21 years in 2017, and the proportion of new initiates (those injecting for less than three years) declined from 7% in 2013 to 6% in 2017 (χ^2 trend $p=0.002$).
- The proportion of respondents from an Indigenous Australian background increased from 13% to 18% over the period 2013 to 2017 (χ^2 trend $p<0.001$).

Injecting behaviour:

- Daily or more frequent injecting in the month prior to the survey was reported by approximately half of respondents in all survey years 2013 to 2017.
- The proportion of respondents reporting methamphetamine as the last drug injected increased from 29% in 2013 to 41% in 2017 (χ^2 trend $p<0.001$). Since 2014 methamphetamine was the most commonly reported drug last injected nationally.
- The proportion of respondents reporting heroin as the last drug injected was stable between 2013 (29%) and 2017 (30%, χ^2 trend $p=0.637$).
- Pharmaceutical opioids were the third most commonly reported class of drugs last injected in all years 2013 to 2017, however prevalence declined from 14% to 9% over this period (χ^2 trend $p<0.001$).
- The proportion of respondents who reported last injecting performance and image enhancing drugs (PIEDs) declined from 7% in 2013 to 5% in 2017 (χ^2 trend $p<0.001$).
- In 2013, one in two (49%) new initiates to injection (those injecting for less than 3 years) reported last injecting PIEDs and one in four (27%) reported last injecting methamphetamine. Conversely in 2017, one in two (48%) new initiates reported last injecting methamphetamine and one in four (26%) reported last injecting PIEDs.
- The proportion of respondents reporting reuse of needles and syringes (including reuse of one's own syringes) was stable, from 23% in 2013 to 24% in 2017 (χ^2 trend $p<0.078$). However, there was an increase in the proportion of respondents reporting receptive sharing of needles and syringes, from 15% in 2013 to 17% in 2017 (χ^2 trend $p=0.019$).
- The prevalence of receptive sharing of drug preparation equipment remained stable, ranging from 31% to 32% over the five-year period (χ^2 trend $p=0.359$).
- The proportion of respondents who reported a drug overdose in the past 12 months increased from 12% in 2013 to 17% in 2017 (χ^2 trend $p<0.001$).

HIV antibody prevalence:

- HIV antibody prevalence remained low and stable nationally, ranging from 1.4% to 2.1% over the period 2013 to 2017 (χ^2 trend $p=0.898$).
- In all years 2013 to 2017, HIV antibody prevalence was higher among homosexual men compared to bisexual or heterosexual men, and compared to women.
- In 2017, HIV antibody prevalence was higher among Aboriginal and Torres Strait Islander respondents compared to non-Indigenous respondents (3.6% vs 1.9% respectively, $p=0.024$). Further, prevalence of HIV infection among Aboriginal and Torres Strait Islander respondents increased from 1.3% in 2013 to 3.6% in 2017 (χ^2 trend $p=0.035$).

HCV antibody prevalence:

- Hepatitis C virus (HCV) antibody prevalence declined from 54% in 2013 to 49% in 2017 (χ^2 trend $p=0.028$). HCV antibody prevalence of <50% has only previously occurred once since the ANSPS commenced in 1995, with HCV prevalence of 49% last observed two decades ago (in 1998).
- Across all survey years 2013 to 2017, prevalence of HCV antibody was higher among older respondents and those with longer injection histories.

HCV treatment uptake:

- The proportion of respondents who reported a lifetime history of HCV treatment was stable between 2012 and 2015 (range 10-13%, 3-year χ^2 trend $p=0.251$) but increased to 29% in 2016 and 45% in 2017 (5-year χ^2 trend $p<0.001$).
- Similarly, the proportion of respondents who reported recent (last 12 months) HCV treatment was low and stable between 2011 and 2015 (range 1-3%, χ^2 trend $p=0.455$) but increased to 22% in 2016 and 36% in 2017 (5-year χ^2 trend $p<0.001$).

HCV RNA prevalence:

- In 2015, the ANSPS commenced HCV ribonucleic acid (RNA) testing in addition to HCV antibody testing. Data from 2015 and 2016 are presented for the first time in this report.
- It should be noted that only a subset of respondents had sufficient remaining dried blood spot (DBS) samples for HCV RNA testing. To account for potential sample bias in the HCV RNA tested sample, data were weighted for gender and HCV antibody status.
- Among respondents tested for HCV RNA, the weighted proportion with detectable HCV RNA declined from 53% in 2015 to 33% in 2016 ($p<0.001$).
- The unweighted proportion of HCV antibody positive respondents with detectable HCV RNA also declined from 79% in 2015 to 63% in 2016 ($p=0.026$).

INTRODUCTION

The Australian Needle and Syringe Program Survey (ANSPS) provides serial point prevalence estimates of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antibody prevalence and sexual and injecting risk behaviour among people who inject drugs (PWID) in Australia. Conducted annually over a one-two week period in October, all clients attending participating Needle and Syringe Program (NSP) services are invited to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and HCV antibody testing (see methodological notes [Appendix B] for further details on the ANSPS design and implementation). Commencing in 2015, HCV ribonucleic acid (RNA) testing has been conducted among HCV antibody positive respondents with sufficient dried blood spot (DBS) sample. This report presents national and state/territory findings for the period 2013 to 2017 and HCV RNA data for 2015 and 2016.

In 2017, 52 NSP services participated in the ANSPS. Over the period 2013 to 2017, the number of ANSPS respondents ranged from 2,210 to 2,600 and the annual response rate ranged from 41% to 48% (Table 1.1.1). Of the 2,600 ANSPS respondents in 2017, the majority (84%) were recruited from the 41 NSP services that participated in the ANSPS in all years 2013 to 2017. A list of participating NSP services is provided at Appendix A.

Demographic Characteristics

Approximately two thirds of survey respondents were male and less than one percent identified as transgender across all survey years 2013 to 2017. In 2017, the majority (78%) of respondents identified as heterosexual, while 9% identified as bisexual and 5% as homosexual (Table 1.1.1).

The proportion of respondents from an Indigenous Australian background increased significantly, from 13% to 18% over the period 2013 to 2017 (χ^2 trend $p < 0.001$)^{1,2}. In all survey years, the majority of respondents were born in Australia (ranging from 85% to 87%), with the United Kingdom and Ireland (4%) and New Zealand (3%) the predominant countries of birth outside Australia in 2017. Most respondents also reported that their parents spoke English at home (range 92% to 94% over the period 2013 to 2017).

The median age at survey completion increased from 39 years in 2013 to 42 years in 2017 and there was a concurrent significant decline in the proportion of young injectors (aged <25 years) from 8% in 2013 to 5% in 2017 (χ^2 trend $p < 0.001$). The median time since first injection increased from 18 years in 2013 to 21 years in 2017, and the proportion of new initiates (those injecting for less than 3 years) declined from 7% in 2013 to 6% in 2017 (χ^2 trend $p = 0.002$). The median age at first drug injection was stable across the period 2013 to 2017, ranging from 18 to 19 years of age (Table 1.1.1).


The proportion of respondents reporting incarceration in the 12 months prior to survey completion increased from 10% to 12% over the five-year period 2013 to 2017 (χ^2 trend $p = 0.031$). Approximately one in three respondents with a history of recent incarceration reported injecting while in prison (Table 1.1.1).

Injecting behaviour

Methamphetamine was the most commonly reported drug last injected nationally since 2014 (Table 1.1.2). Reports of methamphetamine injection increased significantly over the five-year period, from 29% in 2013 to 41% in 2017 (χ^2 trend $p < 0.001$, Figure 1). In 2017, methamphetamine was the most commonly injected drug in the majority of jurisdictions, including New South Wales (36%), Northern Territory (47%), Queensland (43%), South Australia (49%), Tasmania (33%) and Western Australia (54%).

Heroin was the second most commonly reported drug last injected nationally in 2017, with prevalence stable between 2013 (29%) and 2017 (30%, χ^2 trend $p = 0.637$). As in all previous years since 2013, heroin remained the most commonly reported drug last injected in the Australian Capital Territory (49%) and Victoria (62%) in 2017. Heroin was the second most commonly reported drug last injected in NSW (33%), South Australia (33%) and Western Australia (22%) in 2017.

Figure 1. Proportion of respondents (%) reporting last injecting heroin, methamphetamine and all other drugs, 2013–2017



The third most commonly reported class of drugs last injected nationally was pharmaceutical opioids (including morphine, oxycodone and fentanyl), although prevalence declined from 14% to 9% over the period 2013 to 2017 (χ^2 trend $p < 0.001$, Figure 2). In 2017, pharmaceutical opioids were the second most commonly reported class of drugs last injected in the Northern Territory (33%), Queensland (19%) and Tasmania (24%)^{3,4}.


Methadone was reported as the last drug injected by less than ten percent of ANSPS respondents in all years 2013 to 2017 (range 7% to 5%) with a significant decline in prevalence over this period (χ^2 trend $p = 0.013$). In 2017, methadone was the equal second (24%) most commonly reported class of drugs last injected in Tasmania. Buprenorphine and buprenorphine-naloxone injection

were reported by a minority of survey respondents. The prevalence of buprenorphine-naloxone injection declined from 2% to 1% (χ^2 trend $p=0.044$) over the period 2013 to 2017, and the prevalence of buprenorphine injection declined from 3% to 2% in the same period (χ^2 trend $p=0.016$).

A minority of survey respondents (1% across all survey years) reported cocaine as the last drug injected. The prevalence of performance and image enhancing drugs (PIEDs) as the last drug injected declined significantly over the period 2013 to 2017 (χ^2 trend $p<0.001$, Figure 2). PIEDs injection declined from 13% in 2013 to 8% in 2017 in Queensland ($p<0.001$), while prevalence remained stable at between 10% and 12% in NSW (χ^2 trend $p=0.719$). The proportion of respondents who reported last injecting PIEDs was $\leq 2\%$ in all other jurisdictions in 2017.

In 2013 and 2014, PIEDs were the most commonly reported last drug injected among new initiates (less than 3 years since first injection) nationally, but since 2015, methamphetamine was the most commonly reported last drug injected among this group (48% in 2017). In 2017, one in four new initiates (26%) reported last injecting PIEDs.


Figure 2. Proportion of respondents (%) reporting last injecting pharmaceutical opioids, methadone and performance and image enhancing drugs, 2013–2017



Daily or more frequent injection was reported by approximately half of respondents in all of the past five years (Table 1.1.2). Prevalence of at least one public injection (injection in a car, beach, park, street or squat) in the month prior to survey completion increased significantly from 39% in 2013 to 44% in 2017 (χ^2 trend $p<0.001$, Table 1.1.3). In 2017, almost one in five respondents reported they had experienced a drug overdose in the previous 12 months ($n=463$, 18%, Table 1.1.2), a significant increase over the period 2013 (12%) to 2017 (18%) (χ^2 trend $p<0.001$).

As shown in Figure 3, there was a significant increase in one of the three key injecting risk behaviours over the five-year period 2013 to 2017. The proportion of respondents who reported reuse of needles and syringes (including one's own) in the month preceding the survey was stable, from 23% in 2013 to 24% in 2017 (χ^2 trend $p=0.078$). However, there was a significant increase in the prevalence of receptive sharing of needles and syringes in the month prior to survey completion, from 15% in 2013 to 17% in 2017 (χ^2 trend $p=0.019$). Receptive sharing of ancillary equipment was stable over the period 2013 to 2017 (range 31% to 33%, χ^2 trend $p=0.359$). As in previous years, spoons and water were the most commonly identified receptively shared ancillary items in 2017 (Table 1.1.3).

Figure 3. Proportion of respondents (%) reporting reuse and receptive sharing of needles and syringes and receptive sharing of ancillary equipment in the last month, 2013–2017



Sexual behaviour

Approximately half of respondents reported sex with a regular sex partner in the month prior to survey completion, in all years 2013 to 2017 (range 43% to 48%, Table 1.1.6). Of these, the majority (70% to 77%) reported that they did not use condoms with their regular sex partner. A smaller proportion of respondents (13% to 15%) reported sex with other partners in the month preceding survey participation. Condom use was higher among this group, with approximately two thirds reporting some condom use and one quarter reporting always using condoms. The proportion of respondents reporting sex work in the month prior to the survey remained low and stable at 4% to 6% over the last five years (χ^2 trend $p=0.182$) and the use of condoms at last paid sex was relatively high at between 62% and 73% in all years between 2013 and 2017 (Table 1.1.6). Of the respondents who reported sex work in the previous month in 2017 ($n=133$), 47% were women, 47% were men and 5% identified as transgender.

Drug treatment


Engagement with drug treatment services was high (Table 1.1.4), with almost three quarters (71%) of respondents reporting a lifetime history of drug treatment in 2017. Nonetheless, there was a significant decline in the overall proportion of respondents reporting current opioid substitution therapy (OST; methadone, buprenorphine or buprenorphine-naloxone treatment) from 43% in 2013 to 33% in 2017 (χ^2 trend $p < 0.001$). Notwithstanding this overall decline, current OST among respondents who reported last injecting opioids was stable over the period 2013 to 2017 (range 48% to 51%, χ^2 trend $p = 0.540$). In 2017, current methadone maintenance treatment was reported by 24% of respondents, with current buprenorphine treatment reported by 7% of respondents and buprenorphine-naloxone treatment by 8% of respondents.

HIV antibody prevalence

HIV antibody prevalence remained low and stable nationally over the period 2013 to 2017 (range 1.4% to 2.1%, χ^2 trend $p = 0.898$, Table 1.2.1). At the jurisdictional level (Figure 4), HIV antibody prevalence was also low and stable, however there was a significant increase in HIV antibody prevalence among women in New South Wales (χ^2 trend $p = 0.020$, Table 3.2.1) and conversely, a significant decline in HIV antibody prevalence among women in South Australia (χ^2 trend $p = 0.007$, Table 6.2.1).

No respondents in Tasmania or the Australian Capital Territory tested positive to HIV antibodies in any of the previous five years, 2013 to 2017, and no respondents in Northern Territory tested positive to HIV antibodies in any of the previous four years, 2014 to 2017.


Figure 4. HIV antibody prevalence (%) by jurisdiction, 2013–2017



Nationally, across all survey years, HIV antibody prevalence was consistently higher among homosexual male respondents than among bisexual and heterosexual male respondents or female respondents (Table 1.2.2 and Figure 5). In the last five years (2013 to 2017), HIV prevalence was also higher among men who reported methamphetamine as the last drug injected (3.4% in 2017) compared to men who reported last injecting other drugs (1.2% in 2017, Table 1.2.4) and among men who reported sex work in the month preceding the survey compared to men who did not report sex work (Table 1.2.10)⁵.

In 2017, respondents from an Aboriginal and/or Torres Strait Islander background were significantly more likely to test HIV antibody positive than non-Indigenous respondents (3.6% vs 1.9% respectively, $p=0.024$). Further, prevalence of HIV infection among Aboriginal and Torres Strait Islander respondents increased from 1.3% in 2013 to 3.6% in 2017 (χ^2 trend $p=0.035$). Of the $n=14$ Indigenous respondents who tested HIV antibody positive in 2017 and who reported their sexual identity ($n=2$ not reported), 43% ($n=6$) identified as heterosexual.

Figure 5. HIV antibody prevalence (%) by gender and sexual identity, 2013–2017



In 2017, the median age of HIV antibody positive respondents was 47 years (range 24-64 years) and respondents first injected a median of 20 years prior to survey participation (range 2-50 years). In 2017, HIV antibody positive respondents had a significantly higher median age compared to HIV negative respondents ($p=0.012$). There was no difference in the median time since first injection ($p=0.908$) among HIV positive and HIV negative respondents.

HCV antibody prevalence

HCV antibody prevalence declined nationally from 54% in 2013 to 49% in 2017 (χ^2 trend $p=0.028$, Table 1.3.1). Over the five-year period, 2013 to 2017, HCV antibody prevalence was stable among men (range 50% to 57%, χ^2 trend $p=0.259$) but declined among women (from 55% in 2013 to 48%

in 2017, χ^2 trend $p=0.031$). At the jurisdictional level (Figure 6), HCV antibody prevalence remained stable over the period 2013 to 2017, including among men and women. Across all five years of the survey, HCV antibody prevalence was significantly higher among older respondents and those with longer injection histories (Table 1.3.3 and 1.3.5). Figure 7 illustrates the correlation between exposure to HCV and time since first injection among respondents in 2017.

Figure 6. HCV antibody prevalence (%) by jurisdiction, 2013–2017






Figure 7. HCV antibody prevalence (%) by time since first injection, 2017



In all survey years, prevalence of HCV was also higher among respondents reporting heroin or other opioids as the last drug injected compared to respondents who last injected methamphetamine (Figure 8). HCV antibody prevalence was also consistently higher among respondents who reported imprisonment in the year preceding survey completion compared to those who had not been incarcerated ($p < 0.001$ in all years 2013 to 2017) and among respondents who reported receptive syringe sharing in the last month compared to respondents who did not report recent receptive syringe sharing ($p < 0.05$ in 2014, 2015 and 2017).

Figure 8. HCV antibody prevalence (%) by drug last injected and gender, 2013–2017



HIV and HCV testing


Prevalence of HIV diagnostic screening among ANSPS respondents over the period 2013 to 2017 was high, with 81% to 85% reporting a lifetime history of HIV diagnostic testing (Table 1.1.5). In 2017, 49% of respondents reported an HIV diagnostic test in the previous 12 months. Among the $n=53$ respondents who tested HIV antibody positive, the majority (81%, $n=43$) were aware of their HIV positive status. A minority (6%, $n=3$) reported that they were HIV negative, 4% ($n=2$) reported they did not know their HIV status and 9% ($n=5$) did not report their HIV status.

Respondents also reported high prevalence of lifetime HCV diagnostic screening (range 81% to 88%). In 2017, just over half (55%) of respondents reported an HCV diagnostic test in the previous 12 months.

HCV treatment uptake

Among respondents who tested HCV antibody positive and after excluding those who self-reported spontaneous HCV clearance, the proportion who reported a lifetime history of HCV treatment was stable between 2012 and 2015 (range 10-13%, χ^2 trend $p=0.251$) but increased significantly to 29% in 2016 and 45% in 2017 (5-year χ^2 trend $p<0.001$, Figure 9). Similarly, among respondents who tested HCV antibody positive and after excluding those who reported spontaneous or treatment-induced clearance more than 12 months previously, the proportion who reported recent (last 12 months) HCV treatment was low and stable between 2011 and 2015 (range 1-3%, χ^2 trend $p=0.455$) but increased significantly to 22% in 2016 and 36% in 2017 (5-year χ^2 trend $p<0.001$). As occurred nationally, an increase in the proportion of respondents who reported recent initiation of HCV treatment was observed in all jurisdictions in 2016, with a further increase observed in 2017 in all jurisdictions except the Northern Territory.

Figure 9. Proportion of respondents (%) reporting lifetime and current antiviral treatment among HCV antibody positive respondents, 2013–2017




It should be noted that there is likely overlap between reports of recent (last 12 months) HCV treatment across more than one survey year. This is due to the likelihood that duration of treatment spanned concurrent survey years.

HCV RNA prevalence

Given universal access to HCV Direct Acting Antiviral (DAA) therapy through the Australian Government’s Pharmaceutical Benefits Scheme (PBS) from March 2016 and a projected increase in treatment uptake⁶, in 2015 the Australian Needle Syringe Program Survey commenced HCV RNA testing in addition to antibody testing. Results of national RNA testing in 2015 (baseline) and 2016 are shown in Tables 1.4.1 to 1.4.11. Laboratory procedures are detailed in the Methodological Notes (Appendix B). Because the current ANSPS laboratory protocol prioritises HIV and HCV antibody testing and HCV RNA testing requires one whole DBS, only a subset of the total sample had sufficient DBS for RNA testing. Weightings were therefore applied to account for possible sample bias among the subset eligible for RNA testing with respect to gender (given higher rates of spontaneous clearance among women⁷) and HCV antibody status (given a higher proportion of HCV antibody positive respondents who has sufficient DBS for HCV RNA testing).

Between 2015 and 2016, HCV antibody prevalence declined significantly from 57% to 52% ($p=0.021$). Similarly, the weighted proportion of respondents with detectable HCV RNA declined significantly from 53% in 2015 to 33% in 2016 ($p<0.001$, Figure 10). The unweighted proportion of HCV antibody positive respondents with detectable HCV RNA also declined significantly from 79% in 2015 to 63% in 2016 ($p=0.026$).

Figure 10. Weighted proportion of respondents (%) with detectable HCV RNA by gender, 2015–2016



References

1. Doyle M, Maher L, Graham S, Wand H, Iversen J. Hepatitis C virus prevalence and associated risk factors among Indigenous Australians who inject drugs. *Aust N Z J Public Health*. 2018;42(1):52-6.
2. Graham S, Maher L, Wand H, Doyle M, Iversen J. Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996-2015. *Int J Drug Policy*. 2017;47:69-76.
3. Iversen J, Dertadian G, Geddes L, Maher L. High risk injecting behaviour among people who inject pharmaceutical opioids in Australia. *Int J Drug Policy*. 2017;42:1-6.
4. Geddes L, Iversen J, Memedovic S, Maher L. Intravenous fentanyl use among people who inject drugs in Australia. *Drug Alcohol Rev*. 2018;37 Suppl 1:S314-S22.
5. Iversen J, Wand H, Topp L, Kaldor J, Maher L. Extremely low and sustained HIV incidence among people who inject drugs in a setting of harm reduction. *AIDS*. 2014;28(2):275-8.
6. The Kirby Institute. Monitoring hepatitis C treatment uptake in Australia (Issue 8). The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia, December 2017 (available online <https://kirby.unsw.edu.au/report/monitoring-hepatitis-c-treatment-uptake-australia-issue-8-december-2017>).
7. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. *Hepatology*. 2014;59(1):109-20.

National

Table 1.1.1 Number (percentage) of respondents by demographic characteristics and survey year

National	2013	2014	2015	2016	2017
Number of sites	50	50	47	50	52
N° surveyed	N=2407	N=2378	N=2304	N=2210	N=2600
Response rate (%)	44%	48%	41%	41%	41%
Gender (%)					
Male	1636 (68)	1635 (69)	1568 (68)	1449 (66)	1721 (66)
Female	754 (31)	725 (30)	716 (31)	740 (33)	848 (33)
Transgender	13 (<1)	16 (<1)	18 (1)	15 (1)	24 (1)
Not reported	4 (<1)	2 (<1)	2 (<1)	6 (<1)	7 (<1)
Sexual identity (%)					
Heterosexual	1934 (80)	1914 (80)	1900 (82)	1727 (78)	2019 (78)
Bisexual	180 (7)	209 (9)	192 (8)	220 (10)	233 (9)
Homosexual	108 (4)	92 (4)	95 (4)	93 (4)	132 (5)
Not reported	185 (8)	163 (7)	117 (5)	170 (8)	216 (8)
Aboriginal and Torres Strait Islander origin (%)					
No	2003 (83)	2010 (85)	1930 (84)	1738 (79)	2081 (80)
Yes	324 (13)	321 (14)	334 (15)	395 (18)	460 (18)
Not reported	80 (3)	47 (2)	40 (2)	77 (3)	59 (2)
Region/country of birth (%)					
Australia	2070 (86)	2021 (85)	1961 (85)	1904 (86)	2257 (87)
Other Oceania	74 (3)	89 (4)	83 (4)	74 (3)	81 (3)
Asia	35 (1)	40 (2)	42 (2)	25 (1)	31 (1)
UK & Ireland	108 (4)	100 (4)	107 (5)	81 (4)	111 (4)
Other	109 (5)	107 (5)	73 (3)	76 (3)	86 (3)
Not reported	11 (<1)	21 (<1)	38 (2)	50 (2)	34 (1)
Main language spoken at home by parents (%)					
English	2239 (93)	2195 (92)	2158 (94)	2036 (92)	2455 (94)
Non-English	159 (7)	165 (7)	117 (5)	133 (6)	130 (5)
Not reported	9 (<1)	18 (<1)	29 (1)	41 (2)	15 (1)
Age and time since first injection (years)					
<i>Median age</i>	39	39	40	42	42
<i>Age range</i>	15-67	14-68	15-70	17-76	16-76
Age group (%)					
<25 years	181 (8)	143 (6)	108 (5)	86 (4)	122 (5)
25+ years	2217 (92)	2226 (94)	2191 (95)	2119 (96)	2466 (95)
Not reported	9 (<1)	9 (<1)	5 (<1)	5 (<1)	12 (<1)
Median age first injection					
<i>Median age first injection</i>	19	18	19	18	19
<i>Age range</i>	10-61	14-68	10-63	10-76	10-76
<i>N° not reported</i>	91	67	62	83	127
Median yrs since first injection					
<i>Median yrs since first injection</i>	18	19	20	21	21
Range					
<i>Range</i>	<1-51	<1-49	<1-52	<1-53	<1-59
Years since first injection					
<3 years	177 (7)	165 (7)	147 (6)	110 (5)	149 (6)
3+ years	2139 (89)	2140 (90)	2093 (91)	2016 (91)	2324 (89)
Not reported	91 (4)	73 (3)	64 (3)	84 (4)	127 (5)
Imprisonment last year (%)					
No	1990 (83)	1947 (82)	1958 (85)	1821 (82)	2105 (81)
Yes	252 (10)	254 (11)	231 (10)	269 (12)	316 (12)
Not reported	165 (7)	177 (7)	115 (5)	120 (5)	179 (7)
N° in prison					
<i>N° in prison</i>	N=252	N=254	N=231	N=269	N=316
Injected in prison	74 (29)	91 (36)	80 (35)	89 (33)	100 (32)

Table 1.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

National N° surveyed	2013 N=2407	2014 N=2378	2015 N=2304	2016 N=2210	2017 N=2600
Drug last injected (%)					
Cocaine	31 (1)	29 (1)	20 (1)	17 (1)	27 (1)
Methamphetamine	703 (29)	779 (33)	838 (36)	953 (43)	1070 (41)
Heroin	709 (29)	727 (31)	725 (31)	608 (28)	778 (30)
Pharm. opioids	332 (14)	252 (11)	226 (10)	176 (8)	227 (9)
Methadone	163 (7)	139 (6)	139 (6)	121 (5)	130 (5)
Buprenorphine	78 (3)	53 (2)	62 (3)	52 (2)	51 (2)
Buprenorphine/naloxone	46 (2)	42 (2)	26 (1)	38 (2)	30 (1)
PIEDs	157 (7)	156 (7)	148 (6)	86 (4)	117 (5)
More than one	156 (6)	128 (5)	92 (4)	129 (6)	120 (5)
Other	19 (1)	62 (3)	28 (1)	30 (1)	25 (1)
Not reported	13 (1)	11 (<1)	0 (0)	0 (0)	25 (1)
Ever injected opioids					
Yes	-	-	-	1757 (80)	2013 (77)
No	-	-	-	445 (20)	573 (22)
Not reported	-	-	-	8 (<1)	14 (1)
Frequency of injection last month (%)					
Not last month	223 (9)	206 (9)	200 (9)	170 (8)	249 (10)
Less than weekly	451 (19)	364 (15)	377 (16)	338 (15)	387 (15)
Weekly not daily	590 (25)	617 (26)	605 (26)	545 (25)	593 (23)
Daily or more	1070 (44)	1160 (49)	1089 (47)	1110 (50)	1334 (51)
Not reported	73 (3)	31 (1)	33 (1)	47 (2)	37 (1)
Present when someone injected for the first time in the last 12 months (%)					
Yes	311 (13)	403 (17)	367 (16)	382 (17)	452 (17)
No	1730 (72)	1902 (80)	1881 (82)	1771 (80)	2048 (79)
Not reported	366 (15)	73 (3)	56 (2)	57 (3)	100 (4)
Overdosed in last 12 months					
Yes	279 (12)	367 (15)	328 (14)	403 (18)	463 (18)
No	2055 (83)	1935 (81)	1922 (83)	1739 (79)	2029 (78)
Not reported	73 (3)	76 (3)	54 (2)	68 (3)	108 (4)

Table 1.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

National	2013	2014	2015	2016	2017
N° injected last month	N=2111	N=2141	N=2071	N=1993	N=2314
Places injected last month (%)					
Any public	828 (39)	781 (36)	774 (37)	915 (46)	1022 (44)
All private	1262 (60)	1346 (63)	1287 (62)	1067 (54)	1275 (55)
Not reported	21 (1)	14 (<1)	10 (<1)	11 (1)	17 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	1586 (75)	1657 (77)	1537 (74)	1424 (71)	1734 (75)
Most of the time	420 (20)	381 (18)	426 (21)	442 (22)	457 (20)
Half of the time	34 (2)	33 (2)	55 (3)	49 (2)	46 (2)
Some of the time	31 (1)	20 (1)	23 (1)	33 (2)	30 (1)
Not last month	9 (<1)	8 (<1)	11 (1)	19 (1)	12 (1)
Not reported	31 (1)	42 (2)	19 (1)	26 (1)	35 (2)
Re-used someone else's used needle & syringe last month (%)					
None	1770 (84)	1772 (83)	1728 (83)	1597 (80)	1890 (82)
Once	105 (5)	129 (6)	104 (5)	114 (6)	126 (5)
Twice	79 (4)	84 (4)	85 (4)	111 (6)	115 (5)
3-5 times	63 (3)	71 (3)	85 (4)	78 (4)	87 (4)
>5 times	67 (3)	48 (2)	58 (3)	73 (4)	61 (3)
Not reported	27 (1)	37 (2)	11 (1)	20 (1)	35 (2)
Number of people needle & syringe was re-used after last month (%)					
None	1770 (84)	1772 (83)	1728 (83)	1597 (80)	1890 (82)
One	139 (7)	136 (6)	142 (7)	152 (8)	158 (7)
Two	31 (1)	27 (1)	36 (2)	37 (2)	39 (2)
Three to five	13 (1)	12 (<1)	19 (1)	31 (2)	24 (1)
More than five	19 (1)	18 (1)	11 (1)	22 (1)	17 (1)
Don't know	69 (3)	60 (3)	72 (3)	76 (4)	101 (4)
Not reported	70 (3)	116 (5)	63 (3)	78 (4)	85 (4)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	131 (6)	132 (6)	117 (6)	155 (8)	131 (6)
Casual sex partner	19 (1)	10 (<1)	17 (1)	16 (1)	21 (1)
Close friend	88 (4)	62 (3)	94 (5)	98 (5)	115 (5)
Acquaintance	54 (3)	36 (2)	38 (2)	52 (3)	54 (2)
Other	32 (2)	26 (1)	32 (2)	20 (1)	40 (2)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	511 (24)	460 (21)	461 (22)	428 (21)	506 (22)
Water	373 (18)	362 (17)	358 (17)	379 (19)	435 (19)
Filter	241 (11)	223 (10)	228 (11)	195 (10)	251 (11)
Drug mix	189 (9)	177 (8)	221 (11)	191 (10)	210 (9)
None	1436 (68)	1477 (69)	1415 (68)	1354 (68)	1541 (67)
Injected by someone after that person injected themselves or others last month (%)					
No	1754 (83)	1740 (81)	1761 (85)	1638 (82)	1905 (82)
Yes	278 (13)	316 (15)	288 (14)	329 (17)	377 (16)
Not reported	79 (4)	85 (4)	22 (1)	26 (1)	32 (1)
Source of needle acquisition					
Needle Syringe Program	1952 (92)	1916 (89)	1865 (90)	1757 (88)	2019 (87)
Chemist/Pharmacy	436 (21)	456 (21)	465 (22)	495 (25)	539 (23)
Personal sources	197 (9)	230 (11)	255 (12)	268 (13)	272 (12)
Dispensing/Vending Machine	240 (11)	279 (13)	280 (14)	324 (16)	351 (15)
Other sources	42 (2)	37 (2)	52 (3)	49 (2)	71 (3)

Table 1.1.4 Number (percentage) of respondents by treatment for drug use and survey year

National	2013	2014	2015	2016	2017
N° surveyed	N=2407	N=2378	N=2304	N=2210	N=2600
Ever any treatment/therapy for drug use (%)					
No	575 (24)	582 (24)	590 (26)	566 (26)	693 (27)
Yes	1800 (75)	1750 (74)	1672 (73)	1566 (71)	1837 (71)
Not reported	32 (1)	46 (2)	42 (2)	78 (4)	70 (3)
History of methadone maintenance treatment (%)					
Currently	718 (29)	641 (27)	600 (26)	538 (24)	617 (24)
Previously	559 (23)	565 (24)	550 (24)	522 (24)	575 (22)
Never	1112 (46)	1123 (47)	1105 (48)	1048 (47)	1343 (52)
Not reported	18 (1)	49 (2)	49 (2)	102 (5)	65 (3)
History of buprenorphine (Subutex®) treatment (%)					
Currently	193 (8)	197 (8)	177 (8)	143 (6)	184 (7)
Previously	694 (29)	653 (27)	655 (28)	575 (26)	638 (25)
Never	1475 (61)	1472 (62)	1422 (62)	1408 (64)	1715 (66)
Not reported	45 (2)	56 (2)	50 (2)	84 (4)	63 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	219 (9)	196 (8)	187 (8)	164 (7)	196 (8)
Previously	529 (22)	526 (22)	533 (23)	482 (22)	568 (22)
Never	1602 (67)	1597 (67)	1530 (66)	1487 (67)	1775 (68)
Not reported	57 (2)	59 (2)	54 (2)	77 (3)	61 (2)

Table 1.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

National	2013	2014	2015	2016	2017
N° surveyed	N=2407	N=2378	N=2304	N=2210	N=2600
Previous HIV test (%)					
Yes, ever	2017 (84)	1951 (82)	1950 (85)	1840 (83)	2097 (81)
Yes, last year	1205 (50)	1170 (49)	1151 (50)	1120 (51)	1273 (49)
>1 year ago	812 (34)	781 (33)	799 (35)	720 (33)	824 (32)
Never tested	320 (13)	332 (14)	297 (13)	293 (13)	369 (14)
Not reported	70 (3)	95 (4)	57 (2)	77 (3)	134 (5)
Previous HCV test (%)					
Yes, ever	2013 (83)	2047 (86)	2016 (88)	1825 (83)	2099 (81)
Yes, last year	1235 (51)	1276 (54)	1244 (54)	1203 (54)	1420 (55)
>1 year ago	778 (32)	771 (32)	772 (34)	622 (28)	679 (26)
Never tested	196 (8)	214 (9)	187 (8)	185 (8)	253 (10)
Not reported	198 (8)	117 (5)	101 (4)	200 (9)	248 (10)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=746	N=709	N=713	N=643	N=697
Antiviral treatment	79 (11)	89 (13)	79 (11)	184 (29)	314 (45)
No antiviral treatment	648 (87)	603 (85)	604 (85)	454 (71)	376 (54)
Not reported	19 (3)	17 (2)	30 (4)	5 (1)	7 (1)
Treatment for HCV in past 12 months (%)#*					
N° self-reported HCV diagnosis	N=716	N=669	N=685	N=617	N=639
Antiviral treatment	21 (3)	7 (1)	14 (2)	137 (22)	227 (36)
No antiviral treatment	676 (94)	645 (96)	641 (94)	475 (77)	405 (63)
Not reported	19 (3)	17 (3)	30 (4)	5 (1)	7 (1)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 1.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

National	2013	2014	2015	2016	2017
N° surveyed	N=2407	N=2378	N=2304	N=2210	N=2600
Sex with a regular partner last month (%)					
No	1176 (49)	1166 (49)	1116 (48)	1089 (49)	1329 (51)
Yes	1151 (48)	1114 (47)	1086 (47)	1039 (47)	1129 (43)
Not reported	80 (3)	98 (4)	102 (4)	82 (4)	142 (5)
Condom used with regular partner last month (%)					
N° surveyed	N=1151	N=1114	N=1086	N=1039	N=1129
Never	801 (70)	800 (72)	832 (77)	746 (72)	822 (73)
Sometimes	166 (14)	145 (13)	106 (10)	135 (13)	136 (12)
Every time	113 (10)	110 (10)	113 (10)	105 (10)	126 (11)
Not reported	71 (6)	59 (5)	35 (3)	53 (5)	45 (4)
Sex with other partner(s) last month (%)					
No	1929 (80)	1895 (80)	1901 (83)	1777 (80)	2074 (80)
Yes	364 (15)	357 (15)	319 (14)	331 (15)	349 (13)
Not reported	114 (5)	126 (5)	84 (4)	102 (5)	177 (7)
Condom used with other partner(s) last month (%)					
N° surveyed	N=364	N=357	N=319	N=331	N=349
Never	117 (32)	118 (33)	112 (35)	124 (37)	126 (36)
Sometimes	103 (28)	98 (27)	99 (31)	105 (32)	123 (35)
Every time	128 (35)	101 (28)	95 (30)	95 (29)	84 (24)
Not reported	16 (4)	40 (11)	13 (4)	7 (2)	16 (5)
Sex work last month (%)					
No	2141 (89)	2050 (86)	2137 (93)	1969 (89)	2274 (87)
Yes	98 (4)	133 (6)	96 (4)	121 (5)	133 (5)
Not reported	168 (7)	195 (8)	71 (3)	120 (5)	193 (7)
Condom used at last sex work (%)					
Yes	72 (73)	83 (62)	66 (69)	82 (68)	94 (71)

HIV antibody prevalence

Table 1.2.1 HIV antibody prevalence by gender and survey year

National Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013	1563	41 (2.6)	727	6 (0.8)	2307	48 (2.1)
2014	1558	33 (2.1)	702	3 (0.4)	2273	39 (1.7)
2015	1502	33 (2.2)	696	3 (0.4)	2217	38 (1.7)
2016	1412	24 (1.7)	727	5 (0.7)	2160	31 (1.4)
2017	1641	45 (2.7)	820	7 (0.9)	2492	53 (2.1)
X ² p trend		0.949		0.711		0.898

Table 1.2.2 HIV antibody prevalence by sexual identity, gender and survey year

National Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heterosexual	1322	9 (0.7)	519	6 (1.2)	1848	15 (0.8)
Bisexual	59	6 (10.2)	114	0 (0.0)	175	7 (4.0)
Homosexual	73	24 (32.9)	26	0 (0.0)	105	24 (22.9)
p value		<0.001		0.684		<0.001
2014						
Heterosexual	1332	8 (0.6)	497	3 (0.6)	1832	11 (0.6)
Bisexual	58	5 (8.6)	134	0 (0.0)	199	8 (4.0)
Homosexual	64	19 (29.7)	23	0 (0.0)	88	19 (21.6)
p value		<0.001		1.000		<0.001
2015						
Heterosexual	1315	7 (0.5)	514	2 (0.4)	1835	9 (0.5)
Bisexual	69	4 (5.8)	110	1 (0.9)	185	6 (3.2)
Homosexual	53	21 (39.6)	28	0 (0.0)	84	21 (25.0)
p value		<0.001		0.511		<0.001
2016						
Heterosexual	1193	6 (0.5)	492	3 (0.6)	1691	9 (0.5)
Bisexual	61	3 (4.9)	148	1 (0.7)	214	5 (2.3)
Homosexual	58	14 (24.1)	27	0 (0.0)	90	15 (16.7)
p value		<0.001		1.000		<0.001
2017						
Heterosexual	1352	12 (0.9)	577	3 (0.5)	1934	16 (0.8)
Bisexual	82	6 (7.3)	135	3 (2.2)	227	9 (4.0)
Homosexual	68	24 (35.3)	44	0 (0.0)	122	24 (19.7)
p value		<0.001		0.165		<0.001

Table 1.2.3 HIV antibody prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
<25 years	110	2 (1.8)	60	0 (0.0)	170	2 (1.2)
25-34 years	394	6 (1.5)	215	2 (0.9)	616	9 (1.5)
35-44 years	569	15 (2.6)	256	0 (0.0)	828	15 (1.8)
45+ years	483	18 (3.7)	195	4 (2.1)	684	22 (3.2)
p value		0.239		0.097		0.127
2014						
<25 years	98	1 (1.0)	33	0 (0.0)	133	1 (0.8)
25-34 years	363	7 (1.9)	204	0 (0.0)	570	8 (1.4)
35-44 years	596	8 (1.3)	273	2 (0.7)	874	12 (1.4)
45+ years	495	17 (3.4)	190	1 (0.5)	688	18 (2.6)
p value		0.114		0.681		0.224
2015						
<25 years	67	0 (0.0)	32	1 (3.1)	101	1 (1.0)
25-34 years	347	10 (2.9)	187	1 (0.5)	540	13 (2.4)
35-44 years	545	6 (1.1)	248	0 (0.0)	796	6 (0.8)
45+ years	539	17 (3.2)	229	1 (0.4)	776	18 (2.3)
p value		0.055		0.092		0.033
2016						
<25 years	51	1 (2.0)	32	0 (0.0)	86	1 (1.2)
25-34 years	262	7 (2.7)	169	1 (0.6)	433	8 (1.9)
35-44 years	528	3 (0.6)	274	1 (0.4)	808	4 (0.5)
45+ years	568	13 (2.3)	251	3 (1.2)	829	18 (2.2)
p value		0.039		0.640		0.016
2017						
<25 years	76	1 (1.3)	40	0 (0.0)	118	1 (0.9)
25-34 years	275	7 (2.6)	166	0 (0.0)	454	8 (1.8)
35-44 years	587	14 (2.4)	302	2 (0.7)	894	16 (1.8)
45+ years	695	23 (3.3)	308	5 (1.6)	1014	28 (2.8)
p value		0.716		0.329		0.390

Table 1.2.4 HIV antibody prevalence by last drug injected, gender and survey year

National Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heroin	449	5 (1.1)	230	4 (1.7)	683	9 (1.3)
Methamphetamine	413	24 (5.8)	249	2 (0.8)	668	26 (3.9)
Other opioids	423	8 (1.9)	177	0 (0.0)	601	8 (1.3)
PIEDs	136	1 (0.7)	3	0 (0.0)	141	1 (0.7)
Other drugs	133	3 (2.3)	65	0 (0.0)	201	4 (2.0)
p value		<0.001		0.340		0.007
2014						
Heroin	460	6 (1.3)	233	1 (0.4)	696	8 (1.2)
Methamphetamine	472	20 (4.2)	265	1 (0.4)	741	21 (2.8)
Other opioids	326	3 (0.9)	145	0 (0.0)	474	3 (0.6)
PIEDs	144	2 (1.4)	5	0 (0.0)	150	2 (1.3)
Other drugs	149	2 (1.3)	52	1 (1.9)	203	5 (2.5)
p value		0.011		0.416		0.024
2015						
Heroin	468	9 (1.9)	230	1 (0.4)	704	11 (1.6)
Methamphetamine	516	21 (4.1)	271	2 (0.7)	798	24 (3.0)
Other opioids	300	2 (0.7)	142	0 (0.0)	444	2 (0.5)
PIEDs	140	1 (0.7)	6	0 (0.0)	146	1 (0.7)
Other drugs	78	0 (0.0)	47	0 (0.0)	125	0 (0.0)
p value		0.008		0.842		0.005
2016						
Heroin	384	5 (1.3)	207	4 (1.9)	595	9 (1.5)
Methamphetamine	582	16 (2.8)	339	1 (0.3)	929	19 (2.1)
Other opioids	254	0 (0.0)	125	0 (0.0)	381	0 (0.0)
PIEDs	80	1 (1.3)	0	0 (0.0)	82	1 (1.2)
Other drugs	112	2 (1.8)	56	0 (0.0)	173	2 (1.2)
p value		0.035		0.146		0.028
2017						
Heroin	468	7 (1.5)	274	3 (1.1)	751	10 (1.3)
Methamphetamine	651	31 (4.8)	356	3 (0.8)	1016	35 (3.4)
Other opioids	292	3 (1.0)	131	0 (0.0)	428	3 (0.7)
PIEDs	99	0 (0.0)	3	0 (0.0)	105	0 (0.0)
Other drugs	131	4 (3.1)	56	1 (1.8)	192	5 (2.6)
p value		0.001		0.479		0.001

Table 1.2.5 HIV antibody prevalence by years of injection, gender and survey year

National Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
<3 years	120	5 (4.2)	38	0 (0.0)	160	5 (3.1)
3 to 10 years	228	10 (4.4)	140	0 (0.0)	369	10 (2.7)
11 + years	1150	25 (2.2)	527	6 (1.1)	1689	32 (1.9)
p value		0.079		0.536		0.323
2014						
<3 years	116	3 (2.6)	41	0 (0.0)	158	3 (1.9)
3 to 10 years	215	10 (4.7)	119	0 (0.0)	335	10 (3.0)
11+ years	1176	19 (1.6)	526	3 (0.6)	1712	24 (1.4)
p value		0.020		1.000		0.097
2015						
<3 years	110	4 (3.6)	32	0 (0.0)	143	4 (2.8)
3 to 10 years	222	10 (4.5)	108	1 (0.9)	337	11 (3.3)
11+ years	1130	18 (1.6)	537	2 (0.4)	1678	22 (1.3)
p value		0.013		0.502		0.020
2016						
<3 years	67	0 (0.0)	39	0 (0.0)	108	0 (0.0)
3 to 10 years	191	10 (5.2)	102	1 (1.0)	296	11 (3.7)
11+ years	1097	12 (1.1)	564	4 (0.7)	1676	18 (1.1)
p value		0.001		0.673		0.003
2017						
<3 years	97	1 (1.0)	44	0 (0.0)	143	1 (0.7)
3 to 10 years	212	10 (4.7)	122	0 (0.0)	339	11 (3.2)
11+ years	1332	34 (2.6)	654	7 (1.1)	2010	41 (2.0)
p value		0.129		0.731		0.215

Table 1.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

National Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No receptive sharing	1155	27 (2.3)	534	6 (1.1)	1701	33 (1.9)
Receptive sharing	207	4 (1.9)	98	0 (0.0)	306	5 (1.6)
p value		1.000		0.597		1.000
2014						
No receptive sharing	1163	22 (1.9)	520	2 (0.4)	1693	26 (1.5)
Receptive sharing	213	4 (1.9)	102	1 (1.0)	316	6 (1.9)
p value		1.000		0.416		0.636
2015						
No receptive sharing	1117	29 (2.6)	535	3 (0.6)	1665	34 (2.0)
Receptive sharing	217	3 (1.4)	96	0 (0.0)	315	3 (1.0)
p value		0.464		1.000		0.257
2016						
No receptive sharing	1018	18 (1.8)	527	4 (0.8)	1559	23 (1.5)
Receptive sharing	243	4 (1.7)	124	0 (0.0)	370	4 (1.1)
p value		1.000		1.000		0.805
2017						
No receptive sharing	1190	31 (2.6)	603	5 (0.8)	1817	36 (2.0)
Receptive sharing	250	7 (2.8)	119	2 (1.7)	372	10 (2.7)
p value		0.861		0.325		0.386

Table 1.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

National Frequency of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Less than daily	662	20 (3.0)	334	5 (1.5)	1001	25 (2.5)
Daily or more	713	13 (1.8)	310	1 (0.3)	1031	15 (1.5)
Not last month	146	6 (4.1)	61	0 (0.0)	208	6 (2.9)
p value		0.172		0.339		0.171
2014						
Less than daily	641	11 (1.7)	301	0 (0.0)	946	11 (1.2)
Daily or more	753	16 (2.1)	336	3 (0.9)	1096	22 (2.0)
Not last month	144	6 (4.2)	55	0 (0.0)	201	6 (3.0)
p value		0.186		0.416		0.127
2015						
Less than daily	652	18 (2.8)	276	2 (0.7)	937	21 (2.2)
Daily or more	690	14 (2.0)	357	1 (0.3)	1053	16 (1.5)
Not last month	136	1 (0.7)	54	0 (0.0)	194	1 (0.5)
p value		0.339		0.674		0.215
2016						
Less than daily	559	12 (2.2)	300	1 (0.3)	868	14 (1.6)
Daily or more	715	10 (1.4)	358	3 (0.8)	1081	13 (1.2)
Not last month	110	1 (0.9)	54	1 (1.9)	166	2 (1.2)
p value		0.581		0.347		0.712
2017						
Less than daily	643	22 (3.4)	292	3 (1.0)	944	25 (2.7)
Daily or more	817	17 (2.1)	440	4 (0.9)	1276	22 (1.7)
Not last month	153	5 (3.3)	81	0 (0.0)	236	5 (2.1)
p value		0.240		1.000		0.310

Table 1.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

National Imprisonment last year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No imprisonment	1266	36 (2.8)	634	6 (1.0)	1912	43 (2.3)
Imprisonment	189	4 (2.1)	50	0 (0.0)	241	4 (1.7)
p value		0.811		1.000		0.814
2014						
No imprisonment	1260	26 (2.1)	609	3 (0.5)	1874	29 (1.6)
Imprisonment	180	0 (0.0)	51	0 (0.0)	236	3 (1.3)
p value		0.065		1.000		1.000
2015						
No imprisonment	1249	29 (2.3)	625	2 (0.3)	1890	33 (1.8)
Imprisonment	168	1 (0.6)	48	0 (0.0)	219	1 (0.5)
p value		0.247		1.000		0.250
2016						
No imprisonment	1135	16 (1.4)	632	1 (0.2)	1781	18 (1.0)
Imprisonment	200	6 (3.0)	59	2 (3.4)	261	8 (3.1)
p value		0.125		0.020		0.013
2017						
No imprisonment	1300	40 (3.1)	698	5 (0.7)	2023	46 (2.3)
Imprisonment	229	2 (0.9)	67	1 (1.5)	299	3 (1.0)
p value		0.076		0.424		0.196

Table 1.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

National Condom use at last sex	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No condom use	448	6 (1.3)	319	1 (0.3)	770	7 (0.9)
Condom use	187	8 (4.3)	76	2 (2.6)	268	11 (4.1)
p value		0.022		0.096		0.001
2014						
No condom use	468	7 (1.5)	302	1 (0.3)	771	8 (1.0)
Condom use	177	5 (2.8)	66	0 (0.0)	246	7 (2.9)
p value		0.265		1.000		0.041
2015						
No condom use	495	9 (1.8)	303	0 (0.0)	802	11 (1.4)
Condom use	139	2 (1.4)	66	1 (1.5)	208	3 (1.4)
p value		1.000		0.179		1.000
2016						
No condom use	429	10 (2.3)	289	1 (0.4)	724	11 (1.5)
Condom use	151	2 (1.3)	83	1 (1.2)	237	4 (1.7)
p value		0.740		0.397		0.771
2017						
No condom use	462	17 (3.7)	319	2 (0.6)	786	19 (2.4)
Condom use	170	7 (4.1)	81	1 (1.2)	254	8 (3.2)
p value		0.798		0.494		0.523

Table 1.2.10 HIV antibody prevalence by sex work last month, gender and survey year

National Sex work last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No sex work	1415	35 (2.5)	624	6 (1.0)	2052	41 (2.0)
Sex work	36	4 (11.1)	56	0 (0.0)	94	5 (5.3)
p value		0.014		1.000		0.048
2014						
No sex work	1364	21 (1.5)	599	3 (0.5)	1969	25 (1.3)
Sex work	58	5 (8.6)	60	0 (0.0)	124	7 (5.7)
p value		<0.001		1.000		<0.001
2015						
No sex work	1415	25 (1.8)	631	3 (0.5)	2059	29 (1.4)
Sex work	34	6 (17.7)	54	0 (0.0)	94	7 (7.5)
p value		<0.001		1.000		<0.001
2016						
No sex work	1286	18 (1.4)	621	3 (0.5)	1921	23 (1.2)
Sex work	50	3 (6.0)	65	1 (1.5)	121	4 (3.3)
p value		0.041		0.329		0.072
2017						
No sex work	1464	39 (2.7)	696	6 (0.9)	2182	45 (2.1)
Sex work	57	4 (7.0)	61	0 (0.0)	126	5 (4.0)
p value		0.074		1.000		0.192

Table 1.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Non Indigenous	1322	34 (2.6)	587	6 (1.0)	1920	41 (2.1)
Indigenous	184	4 (2.2)	124	0 (0.0)	312	4 (1.3)
p value		1.000		0.597		0.391
2014						
Non Indigenous	1352	26 (1.9)	558	2 (0.4)	1922	30 (1.6)
Indigenous	174	4 (2.3)	132	1 (0.8)	307	6 (2.0)
p value		0.769		0.472		0.612
2015						
Non Indigenous	1282	28 (2.2)	565	1 (0.2)	1864	31 (1.7)
Indigenous	197	5 (2.5)	122	2 (1.6)	319	7 (2.2)
p value		0.754		0.083		0.503
2016						
Non Indigenous	1127	14 (1.2)	555	2 (0.4)	1696	17 (1.0)
Indigenous	233	9 (3.9)	152	2 (1.3)	391	11 (2.8)
p value		0.010		0.204		0.012
2017						
Non Indigenous	1341	33 (2.5)	627	3 (0.5)	1991	37 (1.9)
Indigenous	266	12 (4.5)	172	4 (2.3)	446	16 (3.6)
p value		0.064		0.042		0.024

Table 1.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
English speaking	1441	37 (2.6)	689	6 (0.9)	2145	44 (2.1)
Non-English speaking	114	4 (3.5)	38	0 (0.0)	153	4 (2.6)
p value		0.537		1.000		0.557
2014						
English speaking	1426	29 (2.0)	659	2 (0.3)	2096	34 (1.6)
Non-English speaking	120	2 (1.7)	38	1 (2.6)	160	3 (1.9)
p value		1.000		0.155		0.744
2015						
English speaking	1390	31 (2.2)	666	3 (0.5)	2075	36 (1.7)
Non-English speaking	92	2 (2.2)	25	0 (0.0)	117	2 (1.7)
p value		1.000		1.000		1.000
2016						
English speaking	1283	22 (1.7)	688	4 (0.6)	1990	28 (1.4)
Non-English speaking	102	1 (1.0)	26	0 (0.0)	130	1 (0.8)
p value		1.000		1.000		1.000
2017						
English speaking	1534	43 (2.8)	790	7 (0.9)	2352	51 (2.2)
Non-English speaking	96	2 (2.1)	27	0 (0.0)	126	2 (1.6)
p value		1.000		1.000		1.000

Table 1.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

National Region/country of birth	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Australia	1329	32 (2.4)	642	6 (0.9)	1983	38 (1.9)
Other Oceania	50	2 (4.0)	20	0 (0.0)	71	3 (4.2)
Asia	30	3 (10.0)	5	0 (0.0)	35	3 (8.6)
UK & Ireland	70	1 (1.4)	31	0 (0.0)	102	1 (1.0)
Other	76	3 (4.0)	27	0 (0.0)	105	3 (2.9)
p value		0.088		1.000		0.048
2014						
Australia	1304	26 (2.0)	620	2 (0.3)	1934	29 (1.5)
Other Oceania	63	1 (1.6)	20	0 (0.0)	85	3 (3.5)
Asia	35	1 (2.9)	4	1 (25.0)	39	2 (5.1)
UK & Ireland	70	0 (0.0)	28	0 (0.0)	98	0 (0.0)
Other	72	3 (4.2)	26	0 (0.0)	99	3 (3.0)
p value		0.372		0.048		0.056
2015						
Australia	1266	29 (2.3)	606	3 (0.5)	1888	33 (1.8)
Other Oceania	61	1 (1.6)	18	0 (0.0)	80	2 (2.5)
Asia	32	1 (3.1)	9	0 (0.0)	42	1 (2.4)
UK & Ireland	63	1 (1.6)	40	0 (0.0)	104	1 (1.0)
Other	51	0 (0.0)	18	0 (0.0)	69	0 (0.0)
p value		0.878		1.000		0.699
2016						
Australia	1216	22 (1.8)	632	4 (0.6)	1864	27 (1.5)
Other Oceania	46	0 (0.0)	24	0 (0.0)	72	1 (1.4)
Asia	21	0 (0.0)	2	0 (0.0)	24	0 (0.0)
UK & Ireland	47	0 (0.0)	30	0 (0.0)	78	0 (0.0)
Other	50	1 (2.0)	23	0 (0.0)	74	1 (1.4)
p value		0.947		1.000		0.890
2017						
Australia	1415	39 (2.8)	729	6 (0.8)	2167	46 (2.1)
Other Oceania	43	1 (2.3)	31	0 (0.0)	77	1 (1.3)
Asia	18	1 (5.6)	9	0 (0.0)	27	1 (3.7)
UK & Ireland	73	1 (1.4)	33	0 (0.0)	107	1 (0.9)
Other	68	1 (1.5)	10	0 (0.0)	82	1 (1.2)
p value		0.740		1.000		0.820

HCV antibody prevalence

Table 1.3.1 HCV antibody prevalence by gender and survey year

National Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013	1554	831 (53)	726	396 (55)	2296	1235 (54)
2014	1506	802 (53)	684	380 (56)	2203	1188 (54)
2015	1382	790 (57)	654	375 (57)	2054	1173 (57)
2016	1326	695 (52)	672	315 (47)	2016	1019 (51)
2017	1577	786 (50)	799	381 (48)	2404	1178 (49)
X ² p trend		0.259		0.031		0.028

Table 1.3.2 HCV antibody prevalence by sexual identity, gender and survey year

National Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heterosexual	1316	717 (54)	518	283 (55)	1841	1005 (55)
Bisexual	58	29 (50)	114	61 (54)	173	90 (52)
Homosexual	72	19 (26)	26	12 (46)	104	33 (32)
p value		<0.001		0.692		<0.001
2014						
Heterosexual	1286	692 (54)	481	266 (55)	1770	959 (54)
Bisexual	57	28 (49)	133	72 (54)	197	104 (53)
Homosexual	64	22 (34)	23	12 (52)	88	34 (39)
p value		0.008		0.936		0.017
2015						
Heterosexual	1214	698 (58)	481	273 (57)	1701	974 (57)
Bisexual	58	34 (59)	103	63 (61)	167	98 (59)
Homosexual	50	19 (38)	27	15 (56)	80	36 (45)
p value		0.023		0.699		0.085
2016						
Heterosexual	1115	597 (54)	451	207 (46)	1570	806 (51)
Bisexual	58	24 (41)	145	76 (52)	208	103 (50)
Homosexual	57	22 (39)	23	6 (26)	84	30 (36)
p value		0.021		0.051		0.020
2017						
Heterosexual	1292	657 (51)	560	265 (47)	1856	923 (50)
Bisexual	80	40 (50)	132	66 (50)	221	109 (49)
Homosexual	70	15 (21)	45	16 (36)	125	36 (29)
p value		<0.001		0.239		<0.001

Table 1.3.3 HCV antibody prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<25 years	109	11 (10)	60	15 (25)	169	26 (15)
25-34 years	392	155 (40)	215	105 (49)	613	263 (43)
35-44 years	565	346 (61)	255	148 (58)	823	494 (60)
45+ years	481	316 (66)	195	127 (65)	682	448 (66)
p value		<0.001		<0.001		<0.001
2014						
<25 years	98	12 (12)	33	8 (24)	133	20 (15)
25-34 years	355	136 (38)	198	109 (55)	556	247 (44)
35-44 years	572	336 (59)	266	144 (54)	843	482 (57)
45+ years	475	315 (66)	185	117 (63)	663	434 (65)
p value		<0.001		<0.001		<0.001
2015						
<25 years	60	11 (18)	29	5 (17)	91	16 (18)
25-34 years	325	127 (39)	176	102 (58)	507	232 (46)
35-44 years	507	302 (60)	232	120 (52)	742	423 (57)
45+ years	486	347 (71)	217	148 (68)	710	499 (70)
p value		<0.001		<0.001		<0.001
2016						
<25 years	50	10 (20)	29	12 (41)	82	24 (29)
25-34 years	248	92 (37)	159	67 (42)	408	160 (39)
35-44 years	502	286 (57)	254	123 (48)	761	410 (54)
45+ years	523	306 (59)	229	113 (49)	761	424 (56)
p value		<0.001		0.459		<0.001
2017						
<25 years	73	6 (8)	40	9 (23)	115	15 (13)
25-34 years	264	104 (39)	163	72 (44)	438	180 (41)
35-44 years	558	278 (50)	296	143 (48)	859	422 (49)
45+ years	674	394 (58)	296	155 (52)	980	555 (57)
p value		<0.001		0.003		<0.001

Table 1.3.4 HCV antibody prevalence by years since first injection, gender and survey year

National Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<3 years	120	5 (4)	38	9 (24)	160	15 (9)
3 to 10 years	224	58 (26)	140	62 (44)	365	120 (33)
11+ years	1145	723 (63)	526	317 (60)	1682	1046 (62)
p value		<0.001		<0.001		<0.001
2014						
<3 years	116	7 (6)	41	5 (12)	158	12 (8)
3 to 10 years	212	67 (32)	119	54 (45)	332	121 (37)
11+ years	1126	704 (63)	508	311 (61)	1644	1021 (62)
p value		<0.001		<0.001		<0.001
2015						
<3 years	101	14 (14)	27	6 (22)	128	20 (16)
3 to 10 years	206	67 (33)	101	40 (40)	314	108 (34)
11+ years	1040	693 (67)	508	321 (63)	1559	1021 (65)
p value		<0.001		<0.001		<0.001
2016						
<3 years	67	5 (7)	38	8 (21)	107	14 (13)
3 to 10 years	184	55 (30)	93	34 (37)	280	91 (33)
11+ years	1022	601 (59)	522	265 (51)	1556	872 (56)
p value		<0.001		<0.001		<0.001
2017						
<3 years	96	4 (4)	44	5 (11)	142	9 (6)
3 to 10 years	207	55 (27)	122	37 (30)	333	93 (28)
11+ years	1199	684 (57)	594	323 (54)	1813	1016 (56)
p value		<0.001		<0.001		<0.001

Table 1.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

National Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No receptive sharing	111	8 (7)	1538	869 (57)	1694	910 (54)
Receptive sharing	14	3 (21)	270	162 (60)	303	177 (58)
p value		0.108		0.284		0.131
2014						
No receptive sharing	113	10 (9)	1496	840 (56)	1647	869 (53)
Receptive sharing	9	1 (11)	282	195 (69)	302	205 (68)
p value		0.586		<0.001		<0.001
2015						
No receptive sharing	92	13 (14)	1428	862 (60)	1545	888 (57)
Receptive sharing	13	4 (31)	275	180 (65)	294	190 (65)
p value		0.218		0.113		0.023
2016						
No receptive sharing	75	10 (13)	1341	699 (52)	1460	736 (50)
Receptive sharing	18	2 (11)	318	177 (56)	347	187 (54)
p value		1.000		0.256		0.244
2017						
No receptive sharing	106	6 (6)	1580	801 (51)	1747	841 (48)
Receptive sharing	18	2 (11)	317	188 (59)	359	204 (57)
p value		0.328		0.005		0.003

Table 1.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

National Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heroin	13	4 (31)	651	438 (67)	681	453 (67)
Methamphetamine	43	7 (16)	596	281 (47)	662	305 (46)
Other opioids	15	2 (13)	565	338 (60)	599	354 (59)
PIEDs	75	1 (1)	63	1 (1)	141	2 (1)
Other drugs	11	1 (9)	169	105 (62)	200	116 (58)
p value		0.004		<0.001		<0.001
2014						
Heroin	17	4 (24)	639	429 (67)	674	444 (66)
Methamphetamine	46	4 (9)	568	336 (51)	717	347 (48)
Other opioids	11	3 (27)	437	272 (62)	456	279 (61)
PIEDs	68	0 (0)	72	1 (1)	149	2 (1)
Other drugs	15	1 (7)	168	102 (61)	198	113 (57)
p value		0.001		<0.001		<0.001
2015						
Heroin	10	2 (20)	646	475 (74)	663	483 (73)
Methamphetamine	51	10 (20)	665	321 (48)	729	340 (47)
Other opioids	9	3 (33)	388	263 (68)	402	271 (67)
PIEDs	49	1 (2)	69	2 (3)	127	3 (2)
Other drugs	7	3 (43)	90	59 (66)	104	64 (62)
p value		0.007		<0.001		<0.001
2016						
Heroin	7	2 (29)	518	346 (67)	539	354 (66)
Methamphetamine	59	8 (14)	783	336 (43)	870	362 (42)
Other opioids	5	3 (60)	326	192 (59)	340	202 (59)
PIEDs	26	0 (0)	46	0 (0)	75	0 (0)
Other drugs	7	1 (14)	130	68 (52)	152	78 (51)
p value		0.005		<0.001		<0.001
2017						
Heroin	16	4 (25)	653	442 (68)	703	473 (67)
Methamphetamine	70	4 (6)	883	343 (39)	987	363 (37)
Other opioids	8	1 (13)	380	229 (60)	412	240 (58)
PIEDs	36	0 (0)	64	2 (3)	103	2 (2)
Other drugs	12	0 (0)	144	80 (56)	166	84 (51)
p value		0.010		<0.001		<0.001

Table 1.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

National Frequency of injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Less than daily	89	5 (6)	872	489 (56)	996	515 (52)
Daily or more	38	7 (18)	955	554 (58)	1025	587 (57)
Not last month	30	3 (10)	165	84 (51)	208	90 (43)
p value		0.080		0.218		<0.001
2014						
Less than daily	63	3 (5)	840	464 (55)	926	480 (52)
Daily or more	61	8 (13)	966	589 (61)	1055	612 (58)
Not last month	33	1 (3)	147	75 (51)	194	79 (41)
p value		0.165		0.011		<0.001
2015						
Less than daily	65	7 (11)	792	467 (59)	875	483 (55)
Daily or more	41	10 (24)	919	578 (63)	973	598 (61)
Not last month	20	2 (10)	147	75 (51)	177	80 (45)
p value		0.181		0.015		<0.001
2016						
Less than daily	56	7 (13)	743	391 (53)	815	407 (50)
Daily or more	37	5 (14)	933	498 (53)	1010	529 (52)
Not last month	11	2 (18)	127	53 (42)	151	60 (40)
p value		0.840		0.046		0.014
2017						
Less than daily	66	4 (6)	815	398 (49)	913	416 (46)
Daily or more	59	4 (7)	1107	607 (55)	1223	647 (53)
Not last month	17	1 (6)	202	91 (45)	235	99 (42)
p value		1.000		0.005		<0.001

Table 1.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

National Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No imprisonment	146	14 (10)	1691	913 (54)	1905	965 (51)
Imprisonment	8	0 (0)	224	166 (74)	238	171 (72)
p value		1.000		<0.001		<0.001
2014						
No imprisonment	143	8 (6)	1618	908 (56)	1814	942 (52)
Imprisonment	7	2 (29)	215	144 (67)	228	149 (65)
p value		0.070		0.003		<0.001
2015						
No imprisonment	113	17 (15)	1590	914 (54)	1750	950 (54)
Imprisonment	7	3 (43)	188	152 (76)	200	152 (76)
p value		0.090		<0.001		<0.001
2016						
No imprisonment	87	9 (10)	1519	760 (50)	1663	801 (48)
Imprisonment	11	2 (18)	222	151 (68)	245	160 (65)
p value		0.607		<0.001		<0.001
2017						
No imprisonment	126	8 (6)	1742	860 (49)	1955	908 (46)
Imprisonment	8	0 (0)	258	166 (64)	285	182 (64)
p value		1.000		<0.001		<0.001

Table 1.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Non Indigenous	1314	689 (52)	586	305 (52)	1910	998 (52)
Indigenous	184	111 (60)	124	80 (65)	312	194 (62)
p value		0.044		0.011		0.001
2014						
Non Indigenous	1307	675 (52)	545	293 (54)	1864	974 (52)
Indigenous	169	112 (66)	127	79 (62)	297	191 (64)
p value		<0.001		0.085		<0.001
2015						
Non Indigenous	1190	654 (55)	529	298 (56)	1735	958 (55)
Indigenous	173	129 (75)	116	73 (63)	289	202 (70)
p value		<0.001		0.193		<0.001
2016						
Non Indigenous	1056	544 (52)	513	236 (46)	1580	786 (50)
Indigenous	218	122 (56)	141	68 (48)	365	193 (53)
p value		0.231		0.639		0.281
2017						
Non Indigenous	1290	603 (47)	611	288 (47)	1922	899 (47)
Indigenous	254	163 (64)	167	83 (50)	428	249 (58)
p value		<0.001		0.556		<0.001

Table 1.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
English speaking	1432	761 (53)	688	373 (54)	2134	1142 (54)
Non-English speaking	114	66 (58)	38	23 (61)	153	89 (58)
p value		0.328		0.447		0.265
2014						
English speaking	1381	732 (53)	641	355 (55)	2033	1092 (54)
Non-English speaking	114	65 (57)	38	21 (55)	154	87 (56)
p value		0.409		0.989		0.505
2015						
English speaking	1275	723 (57)	625	356 (57)	1918	1087 (57)
Non-English speaking	89	56 (63)	24	16 (67)	113	72 (64)
p value		0.252		0.345		0.142
2016						
English speaking	1201	626 (52)	638	294 (46)	1855	928 (50)
Non-English speaking	99	54 (55)	22	14 (64)	123	69 (56)
p value		0.643		0.105		0.192
2017						
English speaking	1476	729 (49)	769	366 (48)	2270	1106 (49)
Non-English speaking	91	51 (56)	27	14 (52)	121	65 (54)
p value		0.218		0.663		0.284

Table 1.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

National Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Australia	1322	708 (54)	641	351 (55)	1975	1067 (54)
Other Oceania	50	24 (48)	20	12 (60)	70	36 (51)
Asia	29	21 (72)	5	4 (80)	34	25 (74)
UK & Ireland	70	37 (53)	31	16 (52)	102	53 (52)
Other	75	37 (49)	27	11 (41)	104	48 (46)
p value		0.257		0.466		0.088
2014						
Australia	1257	687 (55)	602	327 (54)	1869	1018 (54)
Other Oceania	63	26 (41)	19	10 (53)	84	37 (44)
Asia	35	22 (63)	4	3 (75)	39	25 (64)
UK & Ireland	68	35 (51)	29	21 (72)	97	56 (58)
Other	70	28 (40)	26	16 (62)	97	45 (46)
p value		0.027		0.318		0.095
2015						
Australia	1167	674 (58)	571	339 (59)	1753	1020 (58)
Other Oceania	54	26 (48)	15	6 (40)	70	33 (47)
Asia	32	16 (50)	8	3 (38)	41	19 (46)
UK & Ireland	55	31 (56)	37	17 (46)	93	48 (52)
Other	49	28 (57)	18	8 (44)	67	36 (54)
p value		0.619		0.117		0.132
2016						
Australia	1141	596 (52)	588	271 (46)	1743	874 (50)
Other Oceania	45	27 (60)	23	12 (52)	69	40 (58)
Asia	19	11 (58)	2	0 (0)	22	11 (50)
UK & Ireland	44	22 (50)	25	12 (48)	70	35 (50)
Other	49	24 (49)	19	12 (63)	69	36 (52)
p value		0.806		0.422		0.788
2017						
Australia	1357	665 (49)	709	344 (49)	2086	1017 (49)
Other Oceania	41	21 (51)	30	11 (37)	74	34 (46)
Asia	17	9 (53)	9	6 (67)	26	15 (58)
UK & Ireland	71	40 (56)	33	13 (39)	105	54 (51)
Other	67	35 (52)	10	3 (30)	81	38 (47)
p value		0.775		0.287		0.832

HCV RNA PREVALENCE

Table 1.4.1 HCV RNA prevalence by gender and survey year

National	HCV antibody		HCV RNA			HCV RNA among HCV antibody positive	
	N ^o tested	N ^o detected (%)	N ^o tested	N ^o detected (%)	Weighted (%) ^	N ^o tested	N ^o detected (%)
Male							
2015	1382	790 (57)	586	365 (62)	(56)	399	324 (81)
2016	1326	695 (52)	448	176 (39)	(35)	263	170 (65)
X ² p trend value		0.180		<0.001	<0.001		0.065
Female							
2015	654	375 (57)	324	167 (52)	(47)	207	156 (75)
2016	672	315 (47)	250	86 (34)	(29)	140	85 (61)
X ² p trend value		0.032		0.010	0.004		0.213
Total							
2015	2054	1173 (57)	925	539 (58)	(53)	613	483 (79)
2016	2016	1019 (51)	703	262 (37)	(33)	405	255 (63)
X ² p trend value		0.021		<0.001	<0.001		0.026

^ Weightings applied to adjust for over-representation of anti-HCV positive and female respondents among the HCV RNA tested sample.

Table 1.4.2 HCV RNA prevalence by sexual identity and survey year

National	HCV antibody		HCV RNA			HCV RNA among HCV antibody positive	
	N ^o tested	N ^o detected (%)	N ^o tested	N ^o detected (%)	Weighted (%) ^	N ^o tested	N ^o detected (%)
2015							
Heterosexual	1701	974 (57)	753	449 (60)	(54)	505	405 (80)
Bisexual	167	98 (59)	96	51 (53)	(49)	58	43 (74)
Homosexual	80	36 (45)	30	12 (35)	(35)	17	11 (65)
p value		0.085		0.057	0.081		0.186
2016							
Heterosexual	1570	806 (51)	531	206 (39)	(35)	313	201 (64)
Bisexual	208	103 (50)	86	33 (38)	(33)	47	32 (68)
Homosexual	84	30 (36)	36	7 (19)	(16)	11	6 (55)
p value		0.020		0.061	0.053		0.655

Table 1.4.3 HCV RNA prevalence by age group and survey year

National Age group	HCV antibody		HCV RNA			HCV RNA among HCV antibody positive	
	N° tested	N° detected (%)	N° tested	N° detected (%)	Weighted (%) ^	N° tested	N° detected (%)
2015							
<25 years	91	16 (18)	31	11 (35)	(32)	8	5 (63)
25-34 years	507	232 (46)	209	107 (51)	(46)	119	91 (76)
35-44 years	742	423 (57)	354	200 (56)	(51)	237	186 (78)
45+ years	710	499 (70)	330	221 (67)	(63)	248	201 (81)
p value		<0.001		<0.001	<0.001		0.427
2016							
<25 years	82	24 (29)	24	5 (21)	(17)	10	5 (50)
25-34 years	408	160 (39)	135	47 (35)	(30)	68	46 (68)
35-44 years	761	410 (54)	280	112 (40)	(37)	169	109 (64)
45+ years	761	424 (56)	264	98 (37)	(33)	158	95 (60)
p value		<0.001		0.265	0.166		0.557

Table 1.4.4 HCV RNA prevalence by years since first injection and survey year

National Years of injection	HCV antibody		HCV RNA			HCV RNA among HCV antibody positive	
	N° tested	N° detected (%)	N° tested	N° detected (%)	Weighted (%) ^	N° tested	N° detected (%)
2015							
<3 years	128	20 (16)	40	10 (25)	(34)	9	4 (44)
3 to 10 years	314	108 (34)	118	60 (51)	(44)	53	46 (87)
11+years	1559	1021 (65)	751	461 (61)	(56)	539	425 (79)
p value		<0.001		<0.001	<0.001		0.015
2016							
<3 years	107	14 (13)	29	5 (17)	(15)	6	5 (83)
3 to 10 years	280	91 (33)	98	26 (27)	(23)	39	26 (67)
11+years	1556	872 (56)	551	222 (40)	(36)	342	215 (63)
p value		<0.001		0.002	0.003		0.635

Table 1.4.5 HCV RNA prevalence by re-use of someone else's used needle syringe last month by survey year

National Re-used someone else's used needle & syringe last month	HCV antibody		HCV RNA			HCV RNA among HCV antibody positive	
	N° tested	N° detected (%)	N° tested	N° detected (%)	Weighted (%) ^	N° tested	N° detected (%)
2015							
No receptive sharing	1545	888 (57)	701	400 (57)	(51)	457	358 (78)
Receptive sharing	294	190 (65)	134	93 (69)	(67)	99	85 (86)
p value		0.023		0.008	0.004		0.092
2016							
No receptive sharing	1460	736 (50)	504	183 (36)	(33)	292	179 (61)
Receptive sharing	347	187 (54)	114	55 (48)	(43)	67	53 (79)
p value		0.244		0.018	0.121		0.006

Table 1.4.6 HCV RNA prevalence by last drug injected and survey year

National	HCV antibody		HCV RNA			HCV RNA among HCV antibody positive	
	N ^o tested	N ^o detected (%)	N ^o tested	N ^o detected (%)	Weighted (%) ^	N ^o tested	N ^o detected (%)
2015							
Heroin	663	483 (73)	338	221 (65)	(59)	256	208 (81)
Methamphetamine	729	340 (47)	346	176 (51)	(46)	184	145 (79)
Other opioids	402	271 (67)	178	102 (57)	(54)	127	93 (73)
PIEDs	127	3 (2)	2	1 (50)	(50)	1	1 (100)
Other drugs	104	64 (62)	50	33 (66)	(59)	37	30 (81)
p value		<0.001		0.002	0.009		0.453
2016							
Heroin	539	354 (66)	230	97 (42)	(39)	150	95 (63)
Methamphetamine	870	362 (42)	260	85 (33)	(29)	132	82 (62)
Other opioids	340	202 (59)	119	53 (45)	(40)	80	52 (65)
PIEDs	75	0 (0)	22	0 (0)	(0)	0	0 (0)
Other drugs	152	78 (51)	55	19 (35)	(34)	31	18 (58)
p value		<0.001		<0.001	<0.001		0.917

Table 1.4.7 HCV RNA prevalence by frequency of injection last month and survey year

National	HCV antibody		HCV RNA			HCV RNA among HCV antibody positive	
	N ^o tested	N ^o detected (%)	N ^o tested	N ^o detected (%)	Weighted (%) ^	N ^o tested	N ^o detected (%)
2015							
Less than daily	875	483 (55)	405	233 (58)	(52)	262	206 (79)
Daily or more	973	598 (61)	431	260 (60)	(55)	295	237 (80)
Not last month	177	80 (45)	78	40 (51)	(45)	48	34 (71)
p value		<0.001		0.300	0.411		0.325
2016							
Less than daily	815	407 (50)	290	97 (33)	(30)	158	94 (59)
Daily or more	1010	529 (52)	332	142 (43)	(39)	204	139 (68)
Not last month	151	60 (40)	64	15 (23)	(20)	31	14 (45)
p value		0.014		0.003	0.009		0.025

Table 1.4.8 HCV RNA prevalence by imprisonment last year and survey year

National	HCV antibody		HCV RNA			HCV RNA among HCV antibody positive	
	N ^o tested	N ^o detected (%)	N ^o tested	N ^o detected (%)	Weighted (%) ^	N ^o tested	N ^o detected (%)
2015							
No imprisonment	1750	950 (54)	773	438 (57)	(51)	488	388 (80)
Imprisonment	200	152 (76)	104	71 (68)	(65)	85	66 (77)
p value		<0.001		0.024	0.031		0.666
2016							
No imprisonment	1663	801 (48)	596	211 (35)	(31)	326	204 (63)
Imprisonment	245	160 (65)	66	37 (56)	(55)	51	37 (73)
p value		<0.001		0.001	0.001		0.168

Table 1.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status and survey year

National Aboriginal and Torres Strait Islander origin	HCV antibody		HCV RNA			HCV RNA among HCV antibody positive	
	N ^o tested	N ^o detected (%)	N ^o tested	N ^o detected (%)	Weighted (%) ^	N ^o tested	N ^o detected (%)
2015							
Non Indigenous	1735	958 (55)	766	455 (59)	(53)	490	403 (82)
Indigenous	289	202 (70)	147	79 (54)	(52)	115	75 (65)
p value		<0.001		0.202	0.728		<0.001
2016							
Non Indigenous	1580	786 (50)	575	204 (35)	(32)	319	198 (62)
Indigenous	365	193 (53)	108	49 (45)	(41)	73	48 (66)
p value		0.281		0.051	0.094		0.557

Table 1.4.10 HCV RNA prevalence by main language spoken at home by parents and survey year

National Main language spoken at home by parents	HCV antibody		HCV RNA			HCV RNA among HCV antibody positive	
	N ^o tested	N ^o detected (%)	N ^o tested	N ^o detected (%)	Weighted (%) ^	N ^o tested	N ^o detected (%)
2015							
English speaking	1918	1087 (57)	861	497 (58)	(52)	567	443 (78)
Non-English speaking	113	72 (64)	57	37 (65)	(60)	40	35 (88)
p value		0.142		0.287	0.398		0.229
2016							
English speaking	1855	928 (50)	647	232 (36)	(32)	367	226 (62)
Non-English speaking	123	69 (56)	45	25 (56)	(51)	31	24 (77)
p value		0.192		0.008	0.026		0.080

Table 1.4.11 HCV RNA prevalence by region/country of birth and survey year

National Region/Country of birth	HCV antibody		HCV RNA			HCV RNA among HCV antibody positive	
	N ^o tested	N ^o detected (%)	N ^o tested	N ^o detected (%)	Weighted (%) ^	N ^o tested	N ^o detected (%)
2015							
Australia	1753	1020 (58)	818	475 (58)	(53)	542	425 (78)
Other Oceania	70	33 (47)	20	10 (50)	(43)	13	10 (77)
Asia	41	19 (46)	13	12 (92)	(85)	11	11 (100)
UK & Ireland	93	48 (52)	37	21 (57)	(48)	20	16 (80)
Other	67	36 (54)	24	13 (54)	(50)	18	13 (72)
p value		0.142		0.109	0.474		0.451
2016							
Australia	1743	874 (50)	608	225 (37)	(33)	346	218 (63)
Other Oceania	69	40 (58)	19	10 (53)	(47)	14	10 (71)
Asia	22	11 (50)	12	5 (42)	(38)	7	5 (71)
UK & Ireland	70	35 (50)	27	6 (22)	(17)	16	6 (38)
Other	69	36 (52)	25	10 (40)	(34)	14	10 (71)
p value		0.788		0.306	0.277		0.262

Australian Capital Territory

Table 2.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Australian Capital Territory	2013	2014	2015	2016	2017
Number of sites	1	1	1	1	1
N° surveyed	N=100	N=99	N=110	N=112	N=119
Response rate (%)	80%	69%	71%	82%	89%
Gender (%)					
Male	67 (67)	76 (77)	77 (70)	78 (70)	80 (67)
Female	32 (32)	23 (23)	33 (30)	32 (29)	38 (32)
Transgender	1 (1)	0 (0)	0 (0)	2 (2)	1 (1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	85 (85)	81 (82)	98 (89)	93 (83)	92 (77)
Bisexual	4 (4)	9 (9)	7 (6)	12 (11)	15 (13)
Homosexual	1 (1)	2 (2)	2 (2)	1 (1)	1 (1)
Not reported	10 (10)	7 (7)	3 (3)	6 (5)	11 (9)
Aboriginal and Torres Strait Islander origin (%)					
No	80 (80)	87 (88)	85 (77)	84 (75)	90 (76)
Yes	18 (18)	11 (11)	25 (23)	23 (21)	28 (24)
Not reported	2 (2)	1 (1)	0 (0)	5 (4)	1 (1)
Region/country of birth (%)					
Australia	88 (88)	88 (89)	95 (86)	101 (90)	105 (88)
Other Oceania	0 (0)	3 (3)	1 (1)	1 (1)	3 (3)
Asia	2 (2)	2 (2)	3 (3)	1 (1)	2 (2)
UK & Ireland	5 (5)	4 (4)	5 (5)	6 (5)	2 (2)
Other	4 (4)	1 (1)	4 (4)	2 (2)	5 (4)
Not reported	1 (1)	1 (1)	2 (2)	1 (1)	2 (2)
Main language spoken at home by parents (%)					
English	93 (93)	92 (93)	101 (92)	104 (93)	114 (96)
Non-English	7 (7)	6 (6)	8 (7)	8 (7)	3 (3)
Not reported	0 (0)	1 (1)	1 (1)	0 (0)	2 (2)
Age and time since first injection (years)					
<i>Median age</i>	40	41	42	44	41.5
<i>Age range</i>	20-67	19-60	21-61	19-64	18-64
<i>Age group (%)</i>					
<25 years	4 (4)	6 (6)	3 (3)	4 (4)	3 (3)
25+ years	96 (96)	92 (93)	106 (96)	107 (96)	115 (97)
Not reported	0 (0)	1 (1)	1 (1)	1 (1)	1 (1)
<i>Median age first injection</i>	17	17	18	19	18
<i>Age range</i>	10-51	12-55	11-45	12-55	10-49
N° not reported	6	1	2	4	6
<i>Median yrs since first injection</i>	20	22	22	24	20
<i>Range</i>	<1-51	<1-38	<1-47	<1-48	<1-46
<i>Years since first injection</i>					
<3 years	1 (1)	5 (5)	3 (3)	2 (2)	3 (3)
3+ years	93 (93)	92 (93)	105 (95)	106 (95)	110 (92)
Not reported	6 (6)	2 (2)	2 (2)	4 (4)	6 (5)
Imprisonment last year (%)					
No	76 (76)	83 (84)	103 (94)	97 (87)	95 (80)
Yes	16 (16)	9 (9)	5 (5)	14 (13)	18 (15)
Not reported	8 (8)	7 (7)	2 (2)	1 (1)	6 (5)
N° in prison	N=16	N=9	N=5	N=14	N=18
Injected in prison	4 (25)	3 (33)	2 (40)	4 (29)	6 (33)

Table 2.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Australian Capital Territory	2013	2014	2015	2016	2017
N° surveyed	N=100	N=99	N=110	N=112	N=119
Drug last injected (%)					
Cocaine	0 (0)	0 (0)	0 (0)	1 (1)	3 (3)
Methamphetamine	30 (30)	31 (31)	45 (41)	41 (37)	48 (40)
Heroin	56 (56)	44 (44)	50 (45)	45 (40)	58 (49)
Pharm. opioids	4 (4)	6 (6)	1 (1)	4 (4)	1 (1)
Methadone	6 (6)	6 (6)	7 (6)	8 (7)	3 (3)
Buprenorphine	0 (0)	2 (2)	2 (2)	5 (4)	1 (1)
Buprenorphine/naloxone	1 (1)	2 (2)	0 (0)	3 (3)	2 (2)
PIEDs	0 (0)	0 (0)	3 (3)	0 (0)	0 (0)
More than one	3 (3)	4 (4)	2 (2)	3 (3)	3 (3)
Other	0 (0)	4 (4)	0 (0)	2 (2)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Ever injected opioids					
Yes	-	-	-	98 (88)	110 (92)
No	-	-	-	13 (12)	7 (6)
Not reported	-	-	-	1 (1)	2 (2)
Frequency of injection last month (%)					
Not last month	5 (5)	3 (3)	5 (5)	9 (8)	16 (13)
Less than weekly	17 (17)	13 (13)	11 (10)	14 (13)	16 (13)
Weekly not daily	28 (28)	40 (40)	47 (43)	29 (26)	27 (23)
Daily or more	47 (47)	43 (43)	46 (42)	58 (52)	57 (48)
Not reported	3 (3)	0 (0)	1 (1)	2 (2)	3 (3)
Present when someone injected for the first time in the last 12 months (%)					
Yes	12 (12)	14 (14)	17 (15)	15 (13)	15 (13)
No	76 (76)	82 (83)	92 (84)	96 (86)	100 (84)
Not reported	12 (12)	3 (3)	1 (1)	1 (1)	4 (3)
Overdosed in last 12 months					
Yes	10 (10)	18 (18)	13 (12)	24 (21)	24 (20)
No	86 (83)	78 (79)	94 (85)	87 (78)	90 (76)
Not reported	4 (4)	3 (3)	3 (3)	1 (1)	5 (4)

Table 2.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Australian Capital Territory	2013	2014	2015	2016	2017
N° injected last month	N=92	N=96	N=104	N=101	N=100
Places injected last month (%)					
Any public	43 (47)	27 (28)	39 (38)	49 (49)	47 (47)
All private	49 (53)	69 (72)	65 (63)	52 (51)	52 (52)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	60 (65)	77 (80)	78 (75)	75 (74)	64 (64)
Most of the time	29 (32)	16 (17)	23 (22)	16 (16)	31 (31)
Half of the time	2 (2)	1 (1)	2 (2)	4 (4)	2 (2)
Some of the time	0 (0)	1 (1)	0 (0)	2 (2)	2 (2)
Not last month	0 (0)	0 (0)	1 (1)	2 (2)	0 (0)
Not reported	1 (1)	1 (1)	0 (0)	2 (2)	1 (1)
Re-used someone else's used needle & syringe last month (%)					
None	74 (80)	82 (85)	88 (85)	81 (80)	71 (71)
Once	9 (10)	6 (6)	4 (4)	5 (5)	12 (12)
Twice	1 (1)	3 (3)	3 (3)	6 (6)	8 (8)
3-5 times	4 (4)	3 (3)	8 (8)	5 (5)	7 (7)
>5 times	3 (3)	0 (0)	1 (1)	3 (3)	2 (2)
Not reported	1 (1)	2 (2)	0 (0)	1 (1)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	74 (80)	82 (85)	88 (85)	81 (80)	71 (71)
One	9 (10)	5 (5)	4 (4)	8 (8)	10 (10)
Two	1 (1)	3 (3)	1 (1)	2 (2)	2 (2)
Three to five	1 (1)	0 (0)	1 (1)	3 (3)	0 (0)
More than five	1 (1)	0 (0)	0 (0)	1 (1)	1 (1)
Don't know	3 (3)	2 (2)	6 (6)	2 (2)	13 (13)
Not reported	3 (3)	4 (4)	4 (4)	4 (4)	3 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	8 (9)	6 (6)	6 (6)	8 (8)	10 (10)
Casual sex partner	0 (0)	0 (0)	1 (1)	1 (1)	2 (2)
Close friend	8 (9)	1 (1)	3 (3)	5 (5)	7 (7)
Acquaintance	2 (2)	2 (2)	1 (1)	1 (1)	6 (6)
Other	0 (0)	1 (1)	2 (2)	1 (1)	2 (2)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	33 (36)	32 (33)	23 (22)	26 (26)	31 (31)
Water	16 (17)	10 (10)	10 (10)	18 (18)	21 (21)
Filter	14 (15)	9 (9)	5 (5)	10 (10)	16 (16)
Drug mix	12 (13)	11 (11)	8 (8)	12 (12)	10 (10)
None	53 (58)	57 (59)	71 (68)	63 (62)	65 (65)
Injected by someone after that person injected themselves or others last month (%)					
No	81 (88)	79 (82)	92 (88)	85 (84)	85 (85)
Yes	9 (10)	14 (15)	12 (12)	16 (16)	15 (15)
Not reported	2 (2)	3 (3)	0 (0)	0 (0)	0 (0)
Source of needle acquisition					
Needle Syringe Program	81 (81)	83 (86)	92 (88)	87 (86)	90 (90)
Chemist/Pharmacy	30 (30)	29 (30)	28 (27)	36 (36)	36 (36)
Personal sources	19 (19)	13 (14)	14 (13)	20 (20)	22 (22)
Dispensing/Vending Machine	24 (24)	23 (24)	20 (19)	23 (23)	28 (28)
Other sources	2 (2)	2 (2)	2 (2)	3 (3)	0 (0)

Table 2.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Australian Capital Territory	2013	2014	2015	2016	2017
N° surveyed	N=100	N=99	N=110	N=112	N=119
Ever any treatment/therapy for drug use (%)					
No	5 (5)	9 (9)	23 (21)	26 (23)	21 (18)
Yes	94 (94)	90 (91)	87 (79)	86 (77)	96 (81)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	2 (2)
History of methadone maintenance treatment (%)					
Currently	47 (47)	37 (38)	46 (42)	41 (37)	44 (37)
Previously	31 (31)	29 (29)	31 (28)	23 (21)	20 (17)
Never	21 (21)	32 (32)	31 (28)	46 (41)	51 (43)
Not reported	1 (1)	1 (1)	2 (2)	2 (2)	4 (3)
History of buprenorphine (Subutex®) treatment (%)					
Currently	10 (10)	11 (11)	10 (9)	8 (7)	12 (10)
Previously	35 (35)	27 (27)	27 (25)	24 (21)	32 (27)
Never	51 (51)	59 (60)	72 (65)	76 (68)	74 (62)
Not reported	4 (4)	2 (2)	1 (1)	4 (4)	1 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	8 (8)	10 (10)	7 (6)	9 (8)	11 (9)
Previously	27 (27)	25 (25)	18 (16)	23 (21)	29 (24)
Never	63 (63)	63 (64)	84 (76)	77 (69)	75 (63)
Not reported	2 (2)	1 (1)	1 (1)	3 (3)	4 (3)

Table 2.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Australian Capital Territory	2013	2014	2015	2016	2017
N° surveyed	N=100	N=99	N=110	N=112	N=119
Previous HIV test (%)					
Yes, ever	88 (88)	82 (83)	91 (83)	98 (88)	97 (82)
Yes, last year	44 (44)	50 (51)	51 (46)	49 (44)	59 (50)
>1 year ago	44 (44)	32 (32)	40 (36)	49 (44)	38 (32)
Never tested	8 (8)	12 (12)	19 (17)	11 (10)	19 (16)
Not reported	4 (4)	5 (5)	0 (0)	3 (3)	3 (3)
Previous HCV test (%)					
Yes, ever	86 (86)	88 (89)	99 (90)	94 (84)	92 (77)
Yes, last year	41 (41)	53 (54)	53 (48)	57 (51)	63 (53)
>1 year ago	45 (45)	35 (35)	46 (42)	37 (33)	29 (24)
Never tested	5 (5)	7 (7)	4 (4)	11 (10)	11 (9)
Not reported	9 (9)	4 (4)	7 (6)	7 (6)	16 (13)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=43	N=41	N=51	N=34	N=35
Antiviral treatment	4 (9)	4 (10)	4 (8)	8 (24)	16 (46)
No antiviral treatment	39 (91)	36 (88)	46 (90)	26 (76)	19 (54)
Not reported	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)#*					
N° self-reported HCV diagnosis	N=42	N=40	N=51	N=33	N=28
Antiviral treatment	2 (5)	0 (0)	2 (4)	7 (21)	9 (32)
No antiviral treatment	40 (95)	39 (98)	48 (94)	26 (79)	19 (68)
Not reported	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 2.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Australian Capital Territory	2013	2014	2015	2016	2017
N° surveyed	N=100	N=99	N=110	N=112	N=119
Sex with a regular partner last month (%)					
No	59 (59)	58 (59)	61 (55)	73 (65)	75 (63)
Yes	36 (36)	35 (35)	45 (41)	38 (34)	39 (33)
Not reported	5 (5)	6 (6)	4 (4)	1 (1)	5 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=36	N=35	N=45	N=38	N=39
Never	24 (67)	27 (77)	36 (87)	22 (58)	29 (74)
Sometimes	5 (14)	5 (14)	3 (7)	7 (18)	4 (10)
Every time	2 (6)	2 (6)	4 (9)	7 (18)	5 (13)
Not reported	5 (14)	1 (3)	2 (4)	2 (5)	1 (3)
Sex with other partner(s) last month (%)					
No	86 (86)	86 (87)	92 (84)	101 (90)	107 (90)
Yes	11 (11)	8 (8)	14 (13)	8 (7)	7 (6)
Not reported	3 (3)	5 (5)	4 (4)	3 (3)	5 (4)
Condom used with other partner(s) last month (%)					
N° surveyed	N=11	N=8	N=14	N=8	N=7
Never	5 (45)	3 (38)	5 (36)	2 (25)	3 (43)
Sometimes	2 (18)	3 (38)	5 (36)	5 (63)	1 (14)
Every time	4 (36)	2 (25)	3 (21)	1 (13)	1 (14)
Not reported	0 (0)	0 (0)	1 (7)	0 (0)	2 (29)
Sex work last month (%)					
No	92 (92)	89 (90)	106 (96)	105 (94)	111 (93)
Yes	2 (2)	4 (4)	3 (3)	3 (3)	3 (3)
Not reported	6 (6)	6 (6)	1 (1)	4 (4)	5 (4)
Condom used at last sex work (%)					
Yes	1 (50)	3 (75)	1 (33)	1 (33)	1 (33)

HIV antibody prevalence

Table 2.2.1 HIV antibody prevalence by gender and survey year

Aust. Capital Territory	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013	67	0 (0.0)	32	0 (0.0)	100	0 (0.0)
2014	73	0 (0.0)	23	0 (0.0)	96	0 (0.0)
2015	76	0 (0.0)	33	0 (0.0)	109	0 (0.0)
2016	72	0 (0.0)	31	0 (0.0)	105	0 (0.0)
2017	80	0 (0.0)	38	0 (0.0)	119	0 (0.0)
X ² p trend		--		--		--

HCV antibody prevalence

Table 2.3.1 HCV antibody prevalence by gender and survey year

Aust. Capital Territory	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013	67	49 (73)	32	18 (56)	100	67 (67)
2014	71	49 (69)	23	12 (52)	94	61 (65)
2015	70	54 (77)	29	21 (72)	99	75 (76)
2016	68	39 (57)	27	14 (52)	97	54 (56)
2017	77	46 (60)	38	23 (61)	116	70 (60)
X ² p trend		0.331		0.884		0.478

Table 2.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Aust. Capital Territory	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heterosexual	60	44 (73)	24	11 (46)	85	55 (65)
Bisexual	1	1 (100)	3	3 (100)	4	4 (100)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		0.222		0.395
2014						
Heterosexual	65	45 (69)	12	5 (42)	77	50 (65)
Bisexual	1	0 (0)	8	5 (63)	9	5 (56)
Homosexual	1	1 (100)	1	0 (0)	2	1 (50)
p value		0.532		0.513		0.755
2015						
Heterosexual	65	50 (77)	24	18 (75)	89	68 (76)
Bisexual	2	2 (100)	3	1 (33)	5	3 (60)
Homosexual	0	0 (0)	2	2 (100)	2	2 (100)
p value		1.000		0.237		0.765
2016						
Heterosexual	60	34 (57)	21	11 (52)	81	45 (56)
Bisexual	5	3 (60)	5	2 (40)	11	6 (55)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		1.000		1.000
2017						
Heterosexual	66	42 (64)	23	15 (65)	89	57 (64)
Bisexual	5	1 (20)	9	3 (33)	15	5 (33)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
p value		0.075		0.126		0.031

Table 2.3.3 HCV antibody prevalence by age group, gender and survey year

Aust. Capital Territory Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<25 years	3	1 (33)	1	0 (0)	4	1 (25)
25-34 years	12	7 (58)	15	8 (53)	28	15 (56)
35-44 years	27	21 (78)	10	7 (70)	37	28 (76)
45+ years	25	20 (80)	6	3 (50)	31	23 (74)
p value		0.181		0.600		0.059
2014						
<25 years	4	1 (25)	2	0 (0)	6	1 (17)
25-34 years	11	5 (45)	5	3 (60)	16	8 (50)
35-44 years	29	22 (76)	10	9 (90)	39	31 (79)
45+ years	26	20 (77)	6	0 (0)	32	20 (63)
p value		0.053		<0.001		0.009
2015						
<25 years	1	0 (0)	1	0 (0)	2	0 (0)
25-34 years	14	8 (57)	7	4 (57)	21	12 (57)
35-44 years	28	25 (89)	10	7 (70)	38	32 (84)
45+ years	26	20 (77)	11	10 (91)	37	30 (81)
p value		0.030		0.132		0.010
2016						
<25 years	0	0 (0)	4	3 (75)	4	3 (75)
25-34 years	7	4 (57)	6	2 (33)	13	6 (46)
35-44 years	24	16 (67)	7	4 (57)	33	21 (64)
45+ years	36	19 (53)	10	5 (50)	46	24 (52)
p value		0.592		0.704		0.560
2017						
<25 years	0	0 (0)	3	1 (33)	3	1 (33)
25-34 years	15	7 (47)	10	5 (50)	26	13 (50)
35-44 years	27	19 (70)	12	7 (58)	39	26 (67)
45+ years	34	19 (56)	13	10 (77)	47	29 (62)
p value		0.287		0.393		0.417

Table 2.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Aust. Capital Territory Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<3 years	0	0 (0)	1	1 (100)	1	1 (100)
3 to 10 years	5	3 (60)	7	1 (14)	12	4 (33)
11+ years	57	43 (75)	23	16 (70)	81	59 (73)
p value		0.597		0.025		0.016
2014						
<3 years	4	1 (25)	1	0 (0)	5	1 (20)
3 to 10 years	8	4 (50)	4	0 (0)	12	4 (33)
11+ years	57	42 (74)	18	12 (52)	75	54 (72)
p value		0.043		0.014		0.003
2015						
<3 years	2	1 (50)	1	0 (0)	3	1 (33)
3 to 10 years	12	6 (50)	4	2 (50)	16	8 (50)
11+ years	54	45 (83)	24	19 (79)	78	64 (82)
p value		0.017		0.112		0.005
2016						
<3 years	1	0 (0)	1	1 (100)	2	1 (50)
3 to 10 years	3	1 (33)	7	3 (43)	10	4 (40)
11+ years	60	36 (60)	19	10 (53)	81	47 (58)
p value		0.384		1.000		0.510
2017						
<3 years	1	0 (0)	2	1 (50)	3	1 (33)
3 to 10 years	10	5 (50)	6	2 (33)	16	7 (44)
11+ years	63	39 (62)	28	18 (64)	92	58 (63)
p value		0.383		0.391		0.213

Table 2.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Aust. Capital Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No receptive sharing	0	0 (0)	68	45 (66)	74	48 (65)
Receptive sharing	0	0 (0)	17	13 (76)	17	13 (76)
p value		--		0.564		0.408
2014						
No receptive sharing	4	1 (25)	71	47 (66)	77	50 (65)
Receptive sharing	0	0 (0)	12	8 (67)	12	8 (67)
p value		--		0.975		0.907
2015						
No receptive sharing	3	1 (33)	74	57 (77)	79	60 (76)
Receptive sharing	0	0 (0)	14	11 (79)	14	11 (79)
p value		--		1.000		1.000
2016						
No receptive sharing	2	1 (50)	70	41 (59)	74	44 (59)
Receptive sharing	0	0 (0)	13	6 (46)	13	6 (46)
p value		--		0.407		0.371
2017						
No receptive sharing	3	1 (33)	65	37 (57)	71	41 (58)
Receptive sharing	0	0 (0)	26	16 (62)	27	17 (63)
p value		--		0.687		0.639

Table 2.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Aust. Capital Territory Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heroin	0	0 (0)	54	37 (69)	56	37 (66)
Methamphetamine	1	1 (100)	26	16 (62)	30	19 (63)
Other opioids	0	0 (0)	10	8 (80)	11	9 (82)
Other drugs	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		0.762		0.730
2014						
Heroin	0	0 (0)	40	25 (63)	42	27 (64)
Methamphetamine	2	0 (0)	27	15 (56)	29	15 (52)
Other opioids	2	1 (50)	13	11 (85)	15	12 (80)
Other drugs	1	0 (0)	7	7 (100)	8	7 (88)
p value		0.392		0.066		0.138
2015						
Heroin	1	0 (0)	43	37 (86)	44	37 (84)
Methamphetamine	2	1 (50)	38	26 (68)	41	28 (68)
Other opioids	0	0 (0)	8	6 (75)	9	7 (78)
Other drugs	0	0 (0)	4	3 (75)	4	3 (75)
p value		0.386		0.304		0.397
2016						
Heroin	2	1 (50)	36	26 (72)	40	28 (70)
Methamphetamine	0	0 (0)	34	14 (41)	35	14 (40)
Other opioids	0	0 (0)	15	8 (53)	15	8 (53)
Other drugs	0	0 (0)	4	2 (50)	5	3 (60)
p value		--		0.072		0.076
2017						
Heroin	1	1 (100)	49	33 (67)	52	36 (69)
Methamphetamine	2	0 (0)	45	22 (49)	48	23 (48)
Other opioids	0	0 (0)	6	3 (50)	7	4 (57)
Other drugs	0	0 (0)	6	5 (83)	6	5 (83)
p value		0.083		0.172		0.104

Table 2.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Aust. Capital Territory Frequency of injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Less than daily	0	0 (0)	40	29 (73)	45	31 (69)
Daily or more	0	0 (0)	46	30 (65)	47	31 (66)
Not last month	1	1 (100)	4	2 (50)	5	3 (60)
p value		--		0.546		0.883
2014						
Less than daily	3	0 (0)	46	30 (65)	50	31 (62)
Daily or more	2	1 (50)	38	26 (68)	41	28 (68)
Not last month	0	0 (0)	3	2 (67)	3	2 (67)
p value		0.400		0.918		0.847
2015						
Less than daily	2	1 (50)	51	38 (75)	55	41 (75)
Daily or more	1	0 (0)	37	30 (81)	38	30 (79)
Not last month	0	0 (0)	5	4 (80)	5	4 (80)
p value		1.000		0.837		0.920
2016						
Less than daily	2	1 (50)	36	23 (64)	39	25 (64)
Daily or more	0	0 (0)	47	24 (51)	49	25 (51)
Not last month	0	0 (0)	6	3 (50)	7	3 (43)
p value		--		0.500		0.425
2017						
Less than daily	0	0 (0)	39	19 (49)	43	23 (53)
Daily or more	3	1 (33)	52	34 (65)	55	35 (64)
Not last month	0	0 (0)	15	10 (67)	15	10 (67)
p value		--		0.244		0.511

Table 2.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Aust. Capital Territory Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No imprisonment	1	1 (100)	71	47 (66)	76	49 (64)
Imprisonment	0	0 (0)	16	11 (69)	16	11 (69)
p value		--		0.845		0.744
2014						
No imprisonment	5	1 (20)	72	49 (68)	79	52 (66)
Imprisonment	0	0 (0)	8	5 (63)	8	5 (63)
p value		--		0.750		0.851
2015						
No imprisonment	1	1 (100)	89	68 (76)	92	71 (77)
Imprisonment	1	0 (0)	4	3 (75)	5	3 (60)
p value		--		1.000		0.589
2016						
No imprisonment	2	1 (50)	78	43 (55)	84	46 (55)
Imprisonment	0	0 (0)	12	7 (58)	12	7 (58)
p value		--		0.835		0.816
2017						
No imprisonment	3	1 (33)	85	48 (56)	92	52 (57)
Imprisonment	0	0 (0)	17	11 (65)	18	12 (67)
p value		--		0.530		0.425

Table 2.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aust. Capital Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Non Indigenous	52	38 (73)	27	15 (56)	80	53 (66)
Indigenous	13	9 (69)	5	3 (60)	18	12 (67)
p value		0.743		1.000		0.973
2014						
Non Indigenous	62	41 (66)	21	41 (66)	83	51 (61)
Indigenous	8	7 (88)	8	7 (88)	10	9 (90)
p value		0.220		0.478		0.075
2015						
Non Indigenous	57	42 (74)	20	14 (70)	77	56 (73)
Indigenous	13	12 (93)	9	7 (78)	22	19 (86)
p value		0.272		1.000		0.263
2016						
Non Indigenous	52	31 (60)	18	9 (50)	71	40 (56)
Indigenous	13	5 (38)	7	3 (43)	21	9 (43)
p value		0.170		1.000		0.277
2017						
Non Indigenous	62	38 (61)	25	15 (60)	88	54 (61)
Indigenous	14	7 (50)	13	8 (62)	27	15 (56)
p value		0.438		1.000		0.590

Table 2.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Aust. Capital Territory Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
English speaking	63	46 (73)	29	16 (55)	93	62 (67)
Non-English speaking	4	3 (75)	3	2 (67)	7	5 (71)
p value		1.000		1.000		1.000
2014						
English speaking	67	48 (72)	20	12 (60)	87	60 (69)
Non-English speaking	3	0 (0)	3	0 (0)	6	0 (0)
p value		0.028		0.093		0.001
2015						
English speaking	62	49 (79)	28	21 (75)	90	70 (78)
Non-English speaking	7	4 (57)	1	0 (0)	8	4 (50)
p value		0.340		0.276		0.098
2016						
English speaking	62	37 (60)	27	14 (52)	91	52 (57)
Non-English speaking	6	2 (33)	0	0 (0)	6	2 (33)
p value		0.390		--		0.401
2017						
English speaking	73	43 (59)	37	22 (59)	111	66 (59)
Non-English speaking	3	2 (67)	0	0 (0)	3	2 (67)
p value		1.000		--		1.000

Table 2.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Aust. Capital Territory	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Australia	61	45 (74)	27	15 (56)	88	60 (68)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	2	2 (100)	0	0 (0)	2	2 (100)
UK & Ireland	2	1 (50)	3	1 (33)	5	2 (40)
Other	2	1 (50)	1	1 (100)	4	2 (50)
p value		0.516		0.773		0.386
2014						
Australia	62	43 (69)	21	11 (52)	83	54 (65)
Other Oceania	3	3 (100)	0	0 (0)	3	3 (100)
Asia	2	0 (0)	0	0 (0)	2	0 (0)
UK & Ireland	3	2 (67)	1	1 (100)	4	3 (75)
Other	0	0 (0)	0	0 (0)	1	0 (0)
p value		0.128		1.000		0.105
2015						
Australia	59	45 (76)	26	19 (73)	85	64 (75)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	3	2 (67)	0	0 (0)	3	2 (67)
UK & Ireland	2	1 (50)	2	2 (100)	4	3 (75)
Other	3	3 (100)	1	0 (0)	4	3 (75)
p value		0.681		0.330		1.000
2016						
Australia	64	37 (58)	25	13 (52)	91	51 (56)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	2	1 (50)	4	2 (50)
Other	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.837		1.000		0.884
2017						
Australia	64	38 (59)	37	22 (59)	102	61 (60)
Other Oceania	3	0 (0)	0	0 (0)	3	0 (0)
Asia	2	2 (100)	0	0 (0)	2	2 (100)
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)
Other	4	3 (75)	1	1 (100)	5	4 (80)
p value		0.180		1.000		0.134

New South Wales

Table 3.1.1 Number (percentage) of respondents by demographic characteristics and survey year

New South Wales	2013	2014	2015	2016	2017
Number of sites	20	19	16	17	17
N° surveyed	N=686	N=761	N=639	N=532	N=575
Response rate (%)	38%	45%	35%	36%	31%
Gender (%)					
Male	475 (69)	539 (71)	464 (73)	372 (70)	402 (70)
Female	206 (30)	212 (28)	167 (26)	153 (29)	159 (28)
Transgender	5 (<1)	9 (1)	7 (1)	6 (1)	11 (2)
Not reported	0 (0)	1 (<1)	1 (<1)	1 (<1)	3 (1)
Sexual identity (%)					
Heterosexual	548 (80)	610 (80)	515 (81)	417 (78)	443 (77)
Bisexual	50 (7)	69 (9)	61 (10)	52 (10)	45 (8)
Homosexual	45 (7)	44 (6)	33 (5)	32 (6)	43 (7)
Not reported	43 (6)	38 (5)	30 (5)	31 (6)	44 (8)
Aboriginal and Torres Strait Islander origin (%)					
No	543 (79)	609 (80)	510 (80)	418 (79)	466 (81)
Yes	124 (18)	136 (18)	117 (18)	99 (19)	97 (17)
Not reported	19 (3)	16 (2)	12 (2)	15 (3)	12 (2)
Region/country of birth (%)					
Australia	602 (88)	646 (85)	548 (86)	455 (86)	492 (86)
Other Oceania	19 (3)	30 (4)	25 (4)	25 (5)	23 (4)
Asia	9 (1)	11 (1)	11 (2)	10 (2)	11 (2)
UK & Ireland	22 (3)	27 (4)	27 (4)	11 (2)	18 (3)
Other	32 (5)	37 (5)	18 (3)	22 (4)	21 (4)
Not reported	2 (<1)	10 (1)	10 (2)	9 (2)	10 (2)
Main language spoken at home by parents (%)					
English	636 (93)	698 (92)	602 (94)	495 (93)	546 (95)
Non-English	48 (7)	56 (7)	32 (5)	31 (6)	26 (5)
Not reported	2 (<1)	7 (1)	5 (1)	6 (1)	3 (1)
Age and time since first injection (years)					
<i>Median age</i>	39	40	41	42	43
<i>Age range</i>	18-65	17-67	18-70	18-75	17-76
<i>Age group (%)</i>					
<25 years	52 (8)	57 (7)	27 (4)	20 (4)	28 (5)
25+ years	634 (92)	702 (92)	612 (96)	512 (96)	545 (95)
Not reported	0 (0)	2 (<1)	0 (0)	0 (0)	2 (<1)
<i>Median age first injection</i>					
<i>Age range</i>	10-54	10-47	10-63	10-76	10-76
N° not reported	25	25	18	16	36
<i>Median yrs since first injection</i>					
<i>Range</i>	<1-48	<1-47	<1-52	<1-49	<1-50
<i>Years since first injection</i>					
<3 years	61 (9)	66 (9)	60 (9)	30 (6)	46 (8)
3+ years	600 (87)	670 (88)	561 (88)	485 (91)	493 (86)
Not reported	25 (4)	25 (3)	18 (3)	17 (3)	36 (6)
Imprisonment last year (%)					
No	569 (83)	601 (79)	531 (83)	430 (81)	455 (79)
Yes	85 (12)	99 (13)	76 (12)	71 (13)	69 (12)
Not reported	32 (5)	61 (8)	32 (5)	31 (6)	51 (9)
N° in prison					
Injected in prison	31 (36)	38 (38)	31 (41)	34 (48)	26 (38)

Table 3.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

New South Wales	2013	2014	2015	2016	2017
N° surveyed	N=686	N=761	N=639	N=532	N=575
Drug last injected (%)					
Cocaine	22 (3)	19 (3)	9 (1)	12 (2)	13 (2)
Methamphetamine	218 (32)	259 (34)	204 (32)	189 (36)	205 (36)
Heroin	178 (26)	216 (28)	194 (30)	170 (32)	190 (33)
Pharm. opioids	57 (8)	40 (5)	48 (8)	16 (3)	20 (3)
Methadone	75 (11)	70 (9)	60 (9)	49 (9)	39 (7)
Buprenorphine	11 (2)	9 (1)	10 (2)	5 (1)	5 (1)
Buprenorphine/naloxone	2 (<1)	3 (<1)	5 (1)	1 (<1)	2 (<1)
PIEDs	73 (11)	77 (10)	76 (12)	52 (10)	57 (10)
More than one	33 (5)	33 (4)	25 (4)	33 (6)	29 (5)
Other	9 (1)	32 (4)	8 (1)	5 (1)	9 (2)
Not reported	8 (1)	3 (<1)	0 (0)	0 (0)	6 (1)
Ever injected opioids					
Yes	-	-	-	428 (80)	429 (75)
No	-	-	-	103 (19)	144 (25)
Not reported	-	-	-	1 (<1)	2 (<1)
Frequency of injection last month (%)					
Not last month	102 (15)	89 (12)	71 (11)	46 (9)	73 (13)
Less than weekly	150 (22)	138 (18)	111 (17)	95 (18)	99 (17)
Weekly not daily	161 (23)	186 (24)	159 (25)	140 (26)	131 (23)
Daily or more	251 (37)	339 (44)	286 (45)	240 (45)	263 (46)
Not reported	22 (3)	9 (1)	12 (2)	11 (2)	9 (2)
Present when someone injected for the first time in the last 12 months (%)					
Yes	95 (14)	130 (17)	114 (18)	99 (19)	82 (14)
No	471 (69)	604 (79)	512 (80)	420 (79)	463 (81)
Not reported	120 (17)	27 (4)	13 (2)	13 (2)	30 (5)
Overdosed in last 12 months					
Yes	63 (9)	122 (16)	82 (13)	86 (16)	88 (15)
No	604 (88)	610 (80)	539 (84)	431 (81)	453 (79)
Not reported	19 (3)	29 (4)	19 (3)	15 (3)	34 (6)

Table 3.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

New South Wales	2013	2014	2015	2016	2017
N° injected last month	N=562	N=663	N=556	N=475	N=493
Places injected last month (%)					
Any public	166 (30)	212 (32)	166 (30)	186 (39)	169 (34)
All private	393 (70)	447 (67)	385 (69)	284 (60)	321 (65)
Not reported	3 (<1)	4 (<1)	5 (1)	5 (1)	3 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	445 (79)	527 (79)	429 (77)	362 (76)	406 (82)
Most of the time	87 (15)	103 (16)	98 (18)	83 (17)	67 (14)
Half of the time	11 (2)	10 (2)	13 (2)	8 (2)	6 (1)
Some of the time	11 (2)	4 (<1)	7 (1)	13 (3)	4 (1)
Not last month	2 (<1)	6 (1)	3 (1)	2 (0)	3 (1)
Not reported	6 (1)	13 (2)	6 (1)	7 (1)	7 (1)
Re-used someone else's used needle & syringe last month (%)					
None	485 (86)	548 (83)	478 (86)	415 (87)	428 (87)
Once	24 (4)	45 (7)	23 (4)	19 (4)	19 (4)
Twice	27 (5)	27 (4)	18 (3)	16 (3)	21 (4)
3-5 times	11 (2)	20 (3)	16 (3)	9 (2)	9 (2)
>5 times	13 (2)	13 (2)	18 (3)	13 (3)	8 (2)
Not reported	2 (<1)	10 (2)	3 (1)	3 (1)	8 (2)
Number of people needle & syringe was re-used after last month (%)					
None	485 (86)	548 (83)	478 (86)	415 (87)	428 (87)
One	28 (5)	45 (7)	24 (4)	22 (5)	19 (4)
Two	8 (1)	8 (1)	11 (2)	5 (1)	5 (1)
Three to five	2 (<1)	4 (<1)	3 (1)	5 (1)	3 (1)
More than five	5 (1)	6 (1)	5 (1)	6 (1)	5 (1)
Don't know	16 (3)	18 (3)	18 (3)	11 (2)	14 (3)
Not reported	18 (3)	34 (5)	17 (3)	11 (2)	19 (4)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	26 (5)	44 (7)	27 (5)	23 (5)	23 (5)
Casual sex partner	5 (1)	7 (1)	4 (1)	5 (1)	1 (<1)
Close friend	22 (4)	16 (2)	16 (3)	12 (3)	16 (3)
Acquaintance	11 (2)	14 (2)	8 (1)	8 (2)	5 (1)
Other	8 (1)	7 (1)	4 (1)	3 (1)	3 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	118 (21)	128 (19)	97 (17)	81 (17)	95 (19)
Water	86 (15)	99 (15)	76 (14)	64 (13)	59 (12)
Filter	51 (9)	63 (10)	42 (8)	36 (8)	30 (6)
Drug mix	47 (8)	47 (7)	60 (11)	35 (7)	31 (6)
None	418 (74)	480 (72)	403 (72)	356 (75)	367 (74)
Injected by someone after that person injected themselves or others last month (%)					
No	487 (87)	544 (82)	491 (88)	419 (88)	432 (88)
Yes	61 (11)	89 (13)	54 (10)	48 (10)	57 (12)
Not reported	14 (2)	30 (5)	11 (2)	8 (2)	4 (1)
Source of needle acquisition					
Needle Syringe Program	518 (92)	585 (88)	494 (89)	427 (90)	428 (87)
Chemist/Pharmacy	96 (17)	132 (20)	103 (19)	93 (20)	80 (16)
Personal sources	55 (10)	70 (11)	65 (12)	59 (12)	39 (8)
Dispensing/Vending Machine	136 (24)	190 (29)	133 (24)	143 (30)	111 (23)
Other sources	17 (3)	16 (2)	14 (3)	19 (4)	16 (3)

Table 3.1.4 Number (percentage) of respondents by treatment for drug use and survey year

New South Wales	2013	2014	2015	2016	2017
N° surveyed	N=686	N=761	N=639	N=532	N=575
Ever any treatment/therapy for drug use (%)					
No	162 (24)	200 (26)	158 (25)	121 (23)	151 (26)
Yes	512 (75)	543 (71)	466 (73)	397 (75)	408 (71)
Not reported	12 (2)	18 (2)	15 (2)	14 (3)	16 (3)
History of methadone maintenance treatment (%)					
Currently	263 (38)	251 (33)	225 (35)	196 (37)	192 (33)
Previously	146 (21)	158 (21)	122 (19)	105 (20)	104 (18)
Never	269 (39)	336 (44)	278 (44)	216 (41)	262 (46)
Not reported	8 (1)	16 (2)	14 (2)	15 (3)	17 (3)
History of buprenorphine (Subutex®) treatment (%)					
Currently	42 (6)	47 (6)	46 (7)	21 (4)	39 (7)
Previously	164 (24)	182 (24)	147 (23)	155 (29)	122 (21)
Never	468 (68)	511 (67)	428 (67)	338 (64)	396 (69)
Not reported	12 (2)	21 (3)	18 (3)	18 (3)	18 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	36 (5)	45 (6)	54 (8)	21 (4)	41 (7)
Previously	119 (17)	127 (17)	118 (18)	112 (21)	98 (17)
Never	513 (75)	571 (75)	451 (71)	379 (71)	420 (73)
Not reported	18 (3)	18 (2)	16 (3)	20 (4)	16 (3)

Table 3.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

New South Wales	2013	2014	2015	2016	2017
N° surveyed	N=686	N=761	N=639	N=532	N=575
Previous HIV test (%)					
Yes, ever	576 (84)	610 (80)	545 (85)	471 (89)	461 (80)
Yes, last year	336 (49)	374 (49)	328 (51)	283 (53)	283 (49)
>1 year ago	240 (35)	236 (31)	217 (34)	188 (35)	178 (31)
Never tested	100 (15)	116 (15)	78 (12)	48 (9)	69 (12)
Not reported	10 (1)	35 (5)	16 (3)	13 (2)	45 (8)
Previous HCV test (%)					
Yes, ever	571 (83)	648 (85)	550 (86)	448 (84)	456 (79)
Yes, last year	342 (50)	389 (51)	339 (53)	282 (53)	316 (55)
>1 year ago	229 (33)	259 (34)	211 (33)	166 (31)	140 (24)
Never tested	62 (9)	80 (11)	60 (9)	36 (7)	56 (10)
Not reported	53 (8)	33 (4)	29 (5)	48 (9)	63 (11)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=215	N=231	N=202	N=169	N=157
Antiviral treatment	23 (11)	29 (13)	32 (16)	53 (31)	77 (49)
No antiviral treatment	189 (88)	197 (85)	165 (82)	116 (69)	78 (50)
Not reported	3 (1)	5 (2)	5 (2)	0 (0)	2 (1)
Treatment for HCV in past 12 months (%)#*					
N° self-reported HCV diagnosis	N=206	N=218	N=190	N=163	N=142
Antiviral treatment	5 (2)	4 (2)	5 (3)	44 (27)	57 (40)
No antiviral treatment	198 (96)	209 (96)	180 (95)	119 (73)	83 (58)
Not reported	3 (1)	5 (2)	5 (3)	0 (0)	2 (1)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 3.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

New South Wales	2013	2014	2015	2016	2017
N° surveyed	N=686	N=761	N=639	N=532	N=575
Sex with a regular partner last month (%)					
No	320 (47)	355 (47)	292 (46)	257 (48)	286 (50)
Yes	348 (51)	377 (50)	319 (50)	257 (48)	247 (43)
Not reported	18 (3)	29 (4)	28 (4)	18 (3)	42 (7)
Condom used with regular partner last month (%)					
N° surveyed	N=348	N=377	N=319	N=257	N=247
Never	232 (67)	265 (70)	250 (78)	186 (72)	187 (76)
Sometimes	62 (18)	49 (13)	28 (9)	28 (11)	24 (10)
Every time	42 (12)	43 (11)	29 (9)	29 (11)	27 (11)
Not reported	12 (3)	20 (5)	12 (4)	14 (5)	9 (4)
Sex with other partner(s) last month (%)					
No	540 (79)	588 (77)	527 (82)	416 (78)	441 (77)
Yes	120 (17)	133 (17)	95 (15)	92 (17)	78 (14)
Not reported	26 (4)	40 (5)	17 (3)	24 (5)	56 (10)
Condom used with other partner(s) last month (%)					
N° surveyed	N=120	N=133	N=95	N=92	N=78
Never	38 (32)	45 (34)	35 (37)	29 (32)	31 (40)
Sometimes	35 (29)	34 (26)	30 (32)	28 (30)	23 (29)
Every time	40 (33)	43 (32)	27 (28)	35 (38)	22 (28)
Not reported	7 (6)	11 (8)	3 (3)	0 (0)	2 (3)
Sex work last month (%)					
No	607 (88)	642 (84)	595 (93)	479 (90)	482 (84)
Yes	33 (5)	51 (7)	29 (5)	29 (5)	35 (6)
Not reported	46 (7)	68 (9)	15 (2)	24 (5)	58 (10)
Condom used at last sex work (%)					
Yes	27 (82)	35 (69)	21 (72)	17 (59)	24 (69)

HIV antibody prevalence

Table 3.2.1 HIV antibody prevalence by gender and survey year

New South Wales Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013	456	20 (4.4)	204	0 (0.0)	665	21 (3.2)
2014	505	15 (3.0)	202	0 (0.0)	714	18 (2.5)
2015	436	16 (3.7)	164	2 (1.2)	608	19 (3.1)
2016	354	11 (3.1)	148	1 (0.7)	509	13 (2.6)
2017	369	17 (4.6)	150	3 (2.0)	533	21 (3.9)
X ² p trend		0.867		0.020		0.499

Table 3.2.2 HIV antibody prevalence by sexual identity, gender and survey year

New South Wales Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heterosexual	384	2 (0.5)	143	0 (0.0)	528	2 (0.4)
Bisexual	21	1 (4.8)	28	0 (0.0)	50	2 (4.0)
Homosexual	31	16 (51.6)	11	0 (0.0)	45	16 (35.6)
p value		<0.001		--		<0.001
2014						
Heterosexual	434	3 (0.7)	135	0 (0.0)	571	3 (0.5)
Bisexual	17	2 (11.8)	44	0 (0.0)	65	5 (7.7)
Homosexual	31	10 (32.3)	10	0 (0.0)	42	10 (23.8)
p value		<0.001		--		<0.001
2015						
Heterosexual	369	2 (0.5)	125	1 (0.8)	497	3 (0.6)
Bisexual	26	2 (7.7)	28	1 (3.6)	56	4 (7.1)
Homosexual	23	12 (52.2)	2	0 (0.0)	26	12 (46.2)
p value		<0.001		0.351		<0.001
2016						
Heterosexual	293	0 (0.0)	106	0 (0.0)	401	0 (0.0)
Bisexual	16	1 (6.3)	32	1 (3.1)	48	2 (4.2)
Homosexual	25	9 (36.0)	0	0 (0.0)	29	10 (34.5)
p value		<0.001		0.232		<0.001
2017						
Heterosexual	293	3 (1.0)	119	1 (0.8)	415	5 (1.2)
Bisexual	24	2 (4.2)	15	2 (13.3)	41	3 (7.3)
Homosexual	25	12 (48.0)	5	0 (0.0)	36	12 (33.3)
p value		<0.001		0.054		<0.001

Table 3.2.3 HIV antibody prevalence by age group, gender and survey year

New South Wales Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
<25 years	38	1 (2.6)	11	0 (0.0)	49	1 (2.0)
25-34 years	105	3 (2.9)	50	0 (0.0)	157	3 (2.6)
35-44 years	173	8 (4.6)	77	0 (0.0)	251	8 (3.2)
45+ years	140	8 (5.7)	66	0 (0.0)	208	8 (3.9)
p value		0.756		--		0.912
2014						
<25 years	42	1 (2.4)	7	0 (0.0)	50	1 (2.0)
25-34 years	105	3 (2.9)	59	0 (0.0)	167	4 (2.4)
35-44 years	187	3 (1.6)	81	0 (0.0)	271	5 (1.9)
45+ years	171	8 (4.7)	53	0 (0.0)	224	8 (3.6)
p value		0.393		--		0.674
2015						
<25 years	21	0 (0.0)	6	1 (16.7)	27	1 (3.7)
25-34 years	101	2 (2.0)	51	1 (2.0)	155	4 (2.6)
35-44 years	138	3 (2.2)	52	0 (0.0)	192	3 (2.6)
45+ years	176	11 (6.3)	55	0 (0.0)	234	11 (4.7)
p value		0.179		0.024		0.249
2016						
<25 years	18	0 (0.0)	2	0 (0.0)	20	0 (0.0)
25-34 years	59	4 (6.8)	32	0 (0.0)	93	4 (4.3)
35-44 years	131	2 (1.5)	54	1 (1.9)	186	3 (1.6)
45+ years	146	5 (3.4)	60	0 (0.0)	210	6 (2.9)
p value		0.249		0.595		0.498
2017						
<25 years	19	0 (0.0)	5	0 (0.0)	24	0 (0.0)
25-34 years	55	0 (0.0)	21	0 (0.0)	80	1 (1.3)
35-44 years	114	6 (5.3)	61	2 (3.3)	177	8 (4.5)
45+ years	180	11 (6.1)	62	1 (1.6)	250	12 (4.8)
p value		0.230		0.786		0.462

Table 3.2.4 HIV antibody prevalence by last drug injected, gender and survey year

New South Wales Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heroin	109	2 (1.8)	61	0 (0.0)	171	2 (1.2)
Methamphetamine	137	10 (7.3)	71	0 (0.0)	211	10 (4.7)
Other opioids	100	4 (4.0)	44	0 (0.0)	144	4 (2.8)
PIEDs	67	1 (1.5)	1	0 (0.0)	68	1 (1.5)
Other drugs	37	3 (8.1)	25	0 (0.0)	63	4 (6.4)
p value		0.128		--		0.141
2014						
Heroin	130	1 (0.8)	70	0 (0.0)	202	2 (1.0)
Methamphetamine	164	9 (5.5)	80	0 (0.0)	245	9 (3.7)
Other opioids	81	2 (2.5)	33	0 (0.0)	115	2 (1.7)
PIEDs	69	1 (1.5)	2	0 (0.0)	72	1 (1.4)
Other drugs	60	2 (3.3)	16	0 (0.0)	78	4 (5.1)
p value		0.173		--		0.187
2015						
Heroin	124	3 (2.4)	60	0 (0.0)	187	4 (2.1)
Methamphetamine	134	10 (7.5)	54	2 (3.7)	191	12 (6.3)
Other opioids	85	2 (2.4)	32	0 (0.0)	119	2 (1.7)
PIEDs	70	1 (1.4)	4	0 (0.0)	74	1 (1.4)
Other drugs	23	0 (0.0)	14	0 (0.0)	37	0 (0.0)
p value		0.165		0.352		0.098
2016						
Heroin	106	1 (0.9)	57	1 (1.8)	165	2 (1.2)
Methamphetamine	121	9 (7.4)	56	0 (0.0)	180	10 (5.6)
Other opioids	47	0 (0.0)	21	0 (0.0)	68	0 (0.0)
PIEDs	48	0 (0.0)	0	0 (0.0)	49	0 (0.0)
Other drugs	32	1 (3.1)	14	0 (0.0)	47	1 (2.1)
p value		0.024		1.000		0.046
2017						
Heroin	110	3 (2.7)	61	1 (1.6)	177	4 (2.3)
Methamphetamine	134	11 (8.2)	51	2 (3.9)	188	14 (7.5)
Other opioids	43	1 (2.3)	21	0 (0.0)	65	1 (1.5)
PIEDs	43	0 (0.0)	3	0 (0.0)	47	0 (0.0)
Other drugs	39	2 (5.1)	14	0 (0.0)	56	2 (3.6)
p value		0.134		0.831		0.051

Table 3.2.5 HIV antibody prevalence by years of injection, gender and survey year

New South Wales Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
<3 years	53	4 (7.6)	4	0 (0.0)	57	4 (7.0)
3 to 10 years	61	6 (9.8)	42	0 (0.0)	103	6 (5.8)
11+ years	324	9 (2.8)	151	0 (0.0)	480	10 (2.1)
p value		0.015		--		0.017
2014						
<3 years	53	1 (1.9)	8	0 (0.0)	62	1 (1.6)
3 to 10 years	81	6 (7.4)	39	0 (0.0)	120	6 (5.0)
11+ years	355	7 (2.0)	149	0 (0.0)	509	9 (1.8)
p value		0.042		--		0.111
2015						
<3 years	45	2 (4.4)	12	0 (0.0)	58	2 (3.5)
3 to 10 years	61	4 (6.6)	21	1 (4.8)	84	5 (6.0)
11+ years	317	9 (2.8)	126	1 (0.8)	448	11 (2.5)
p value		0.287		0.373		0.193
2016						
<3 years	21	0 (0.0)	7	0 (0.0)	29	0 (0.0)
3 to 10 years	59	4 (6.8)	21	0 (0.0)	81	4 (4.9)
11+ years	263	6 (2.3)	116	1 (0.9)	384	8 (2.1)
p value		0.189		1.000		0.349
2017						
<3 years	34	0 (0.0)	8	0 (0.0)	42	0 (0.0)
3 to 10 years	50	4 (8.0)	11	0 (0.0)	63	5 (7.9)
11+ years	285	13 (4.6)	131	3 (2.3)	428	16 (3.7)
p value		0.236		1.000		0.114

Table 3.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

New South Wales Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No receptive sharing	328	13 (4.0)	141	0 (0.0)	473	13 (2.8)
Receptive sharing	50	2 (4.0)	21	0 (0.0)	72	3 (4.2)
p value		1.000		--		0.456
2014						
No receptive sharing	362	9 (2.5)	143	0 (0.0)	510	11 (2.2)
Receptive sharing	70	2 (2.9)	28	0 (0.0)	99	3 (3.0)
p value		0.695		--		0.485
2015						
No receptive sharing	329	13 (4.0)	119	2 (1.7)	453	16 (3.5)
Receptive sharing	49	2 (4.1)	20	0 (0.0)	71	2 (2.8)
p value		1.000		1.000		1.000
2016						
No receptive sharing	279	9 (3.2)	114	1 (0.9)	398	10 (2.5)
Receptive sharing	37	0 (0.0)	18	0 (0.0)	55	0 (0.0)
p value		0.606		1.000		0.618
2017						
No receptive sharing	277	13 (4.7)	112	2 (1.8)	398	15 (3.8)
Receptive sharing	38	1 (2.6)	15	1 (6.7)	54	3 (5.6)
p value		1.000		0.316		0.463

Table 3.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

New South Wales Frequency of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Less than daily	211	11 (5.2)	92	0 (0.0)	305	11 (3.6)
Daily or more	168	5 (3.0)	71	0 (0.0)	242	6 (2.5)
Not last month	66	3 (4.6)	33	0 (0.0)	99	3 (3.0)
p value		0.592		--		0.750
2014						
Less than daily	221	4 (1.8)	87	0 (0.0)	309	4 (1.3)
Daily or more	218	8 (3.7)	86	0 (0.0)	309	11 (3.6)
Not last month	60	3 (5.0)	26	0 (0.0)	87	3 (3.4)
p value		0.257		--		0.138
2015						
Less than daily	194	8 (4.1)	55	1 (1.8)	252	9 (3.6)
Daily or more	187	7 (3.7)	84	1 (1.2)	275	9 (3.3)
Not last month	47	1 (2.1)	21	0 (0.0)	69	1 (1.5)
p value		1.000		1.000		0.845
2016						
Less than daily	165	5 (3.0)	60	0 (0.0)	229	5 (2.2)
Daily or more	153	4 (2.6)	73	1 (1.4)	227	5 (2.2)
Not last month	30	1 (3.3)	12	0 (0.0)	43	1 (2.3)
p value		1.000		1.000		1.000
2017						
Less than daily	169	7 (4.1)	45	2 (4.4)	215	9 (4.2)
Daily or more	150	7 (4.7)	85	1 (1.2)	245	9 (3.7)
Not last month	44	2 (4.6)	19	0 (0.0)	65	2 (3.1)
p value		1.000		0.520		0.949

Table 3.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

New South Wales Imprisonment last year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No imprisonment	378	17 (4.5)	172	0 (0.0)	553	18 (3.3)
Imprisonment	57	2 (3.5)	22	0 (0.0)	81	2 (2.5)
p value		1.000		--		1.000
2014						
No imprisonment	399	12 (3.0)	167	0 (0.0)	568	12 (2.1)
Imprisonment	65	0 (0.0)	22	0 (0.0)	91	3 (3.3)
p value		0.389		--		0.448
2015						
No imprisonment	355	13 (3.7)	143	2 (1.4)	504	16 (3.2)
Imprisonment	56	1 (1.8)	16	0 (0.0)	74	1 (1.4)
p value		0.703		1.000		0.711
2016						
No imprisonment	278	6 (2.2)	131	0 (0.0)	412	6 (1.5)
Imprisonment	58	3 (5.2)	10	1 (10.0)	68	4 (5.9)
p value		0.190		0.071		0.040
2017						
No imprisonment	283	16 (5.7)	128	1 (0.8)	421	18 (4.3)
Imprisonment	51	0 (0.0)	10	1 (10.0)	63	1 (1.6)
p value		0.145		0.140		0.491

Table 3.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

New South Wales		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2013							
No condom use	138	3 (2.2)	87	0 (0.0)	226	3 (1.3)	
Condom use	72	2 (2.8)	26	0 (0.0)	101	3 (3.0)	
p value		1.000		--		0.378	
2014							
No condom use	157	1 (0.6)	96	0 (0.0)	253	1 (0.4)	
Condom use	65	2 (3.1)	20	0 (0.0)	88	4 (4.6)	
p value		0.206		--		0.017	
2015							
No condom use	166	6 (3.6)	73	0 (0.0)	240	7 (2.9)	
Condom use	42	1 (2.4)	13	1 (7.7)	55	2 (3.6)	
p value		1.000		0.151		0.676	
2016							
No condom use	116	5 (4.3)	60	0 (0.0)	176	5 (2.8)	
Condom use	35	0 (0.0)	17	1 (5.9)	54	2 (3.7)	
p value		0.590		0.221		0.668	
2017							
No condom use	107	11 (10.3)	63	1 (1.6)	171	12 (7.0)	
Condom use	37	0 (0.0)	11	0 (0.0)	49	0 (0.0)	
p value		0.066		1.000		0.073	

Table 3.2.10 HIV antibody prevalence by sex work last month, gender and survey year

New South Wales		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2013							
No sex work	411	15 (3.7)	173	0 (0.0)	588	15 (2.6)	
Sex work	12	3 (25.0)	20	0 (0.0)	33	4 (12.1)	
p value		0.011		--		0.015	
2014							
No sex work	439	8 (1.8)	165	0 (0.0)	606	9 (1.5)	
Sex work	17	3 (17.7)	22	0 (0.0)	44	5 (11.4)	
p value		0.006		--		<0.001	
2015							
No sex work	414	11 (2.7)	147	2 (1.4)	567	13 (2.3)	
Sex work	11	3 (27.3)	15	0 (0.0)	28	4 (14.3)	
p value		0.004		1.000		0.006	
2016							
No sex work	324	6 (1.9)	129	1 (0.8)	457	8 (1.8)	
Sex work	15	3 (20.0)	11	0 (0.0)	29	3 (10.3)	
p value		0.005		1.000		0.023	
2017							
No sex work	316	14 (4.4)	124	2 (1.6)	447	16 (3.6)	
Sex work	15	2 (13.3)	12	0 (0.0)	33	3 (9.1)	
p value		0.159		1.000		0.135	

Table 3.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

New South Wales Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Non Indigenous	376	17 (4.5)	147	0 (0.0)	526	18 (3.4)
Indigenous	68	1 (1.5)	51	0 (0.0)	121	1 (0.8)
p value		0.332		--		0.226
2014						
Non Indigenous	421	12 (2.9)	142	0 (0.0)	569	14 (2.5)
Indigenous	73	1 (1.4)	57	0 (0.0)	131	2 (1.5)
p value		0.703		--		0.749
2015						
Non Indigenous	358	15 (4.2)	122	0 (0.0)	486	16 (3.3)
Indigenous	71	1 (1.4)	41	2 (4.9)	112	3 (2.7)
p value		0.489		0.062		1.000
2016						
Non Indigenous	283	7 (2.5)	109	0 (0.0)	399	8 (2.0)
Indigenous	59	3 (5.1)	37	1 (2.7)	96	4 (4.2)
p value		0.386		0.253		0.260
2017						
Non Indigenous	306	14 (4.6)	110	1 (0.9)	428	16 (3.7)
Indigenous	56	3 (5.4)	37	2 (5.4)	95	5 (5.3)
p value		0.734		0.156		0.561

Table 3.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

New South Wales Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
English speaking	419	19 (4.5)	193	0 (0.0)	616	20 (3.3)
Non-English speaking	35	1 (2.9)	11	0 (0.0)	47	1 (2.1)
p value		1.000		--		1.000
2014						
English speaking	459	13 (2.8)	189	0 (0.0)	654	16 (2.5)
Non-English speaking	41	0 (0.0)	11	0 (0.0)	53	0 (0.0)
p value		0.613		--		0.624
2015						
English speaking	408	15 (3.7)	157	2 (1.3)	573	18 (3.1)
Non-English speaking	25	1 (4.0)	7	0 (0.0)	32	1 (3.1)
p value		1.000		1.000		1.000
2016						
English speaking	324	10 (3.1)	142	1 (0.7)	472	12 (2.5)
Non-English speaking	25	0 (0.0)	5	0 (0.0)	31	0 (0.0)
p value		1.000		1.000		1.000
2017						
English speaking	350	17 (4.9)	143	3 (2.1)	507	21 (4.1)
Non-English speaking	17	0 (0.0)	7	0 (0.0)	24	0 (0.0)
p value		1.000		1.000		0.616

Table 3.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

New South Wales		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2013							
Australia	392	15 (3.8)	188	0 (0.0)	582	15 (2.6)	
Other Oceania	12	1 (8.3)	6	0 (0.0)	19	2 (10.5)	
Asia	8	1 (12.5)	1	0 (0.0)	9	1 (11.1)	
UK & Ireland	14	1 (7.1)	7	0 (0.0)	22	1 (4.6)	
Other	28	2 (7.1)	2	0 (0.0)	31	2 (6.5)	
p value		0.602		--			0.131
2014							
Australia	421	11 (2.6)	179	0 (0.0)	604	12 (2.0)	
Other Oceania	20	0 (0.0)	7	0 (0.0)	29	2 (6.9)	
Asia	10	0 (0.0)	1	0 (0.0)	11	0 (0.0)	
UK & Ireland	19	0 (0.0)	7	0 (0.0)	26	0 (0.0)	
Other	28	2 (7.1)	5	0 (0.0)	34	2 (5.9)	
p value		0.508		--			0.169
2015							
Australia	373	13 (3.5)	143	2 (1.4)	523	15 (2.9)	
Other Oceania	17	1 (5.9)	6	0 (0.0)	24	2 (8.3)	
Asia	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)	
UK & Ireland	19	1 (5.3)	7	0 (0.0)	26	1 (3.9)	
Other	12	0 (0.0)	5	0 (0.0)	17	0 (0.0)	
p value		0.704		1.000			0.401
2016							
Australia	304	10 (3.3)	125	1 (0.8)	434	11 (2.5)	
Other Oceania	14	0 (0.0)	10	0 (0.0)	25	1 (4.0)	
Asia	8	0 (0.0)	1	0 (0.0)	10	0 (0.0)	
UK & Ireland	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
Other	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)	
p value		1.000		1.000			0.825
2017							
Australia	317	14 (4.4)	131	2 (1.5)	459	17 (3.7)	
Other Oceania	14	1 (7.1)	6	0 (0.0)	21	1 (4.8)	
Asia	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
UK & Ireland	11	0 (0.0)	5	0 (0.0)	17	0 (0.0)	
Other	14	1 (7.1)	4	0 (0.0)	19	1 (5.3)	
p value		0.651		1.000			0.743

HCV antibody prevalence

Table 3.3.1 HCV antibody prevalence by gender and survey year

New South Wales Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013	453	232 (51)	204	120 (59)	661	354 (54)
2014	502	264 (53)	200	123 (62)	709	390 (55)
2015	371	215 (58)	143	96 (67)	521	316 (61)
2016	331	174 (53)	137	75 (55)	473	252 (53)
2017	357	172 (48)	146	73 (50)	515	252 (49)
X ² p trend		0.729		0.347		0.425

Table 3.3.2 HCV antibody prevalence by sexual identity, gender and survey year

New South Wales Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heterosexual	383	206 (54)	143	84 (59)	527	291 (55)
Bisexual	21	11 (52)	28	17 (61)	49	28 (57)
Homosexual	30	6 (20)	11	5 (45)	44	12 (27)
p value		0.002		0.720		0.001
2014						
Heterosexual	432	233 (54)	133	80 (60)	567	314 (55)
Bisexual	17	8 (47)	44	27 (61)	65	37 (57)
Homosexual	31	10 (32)	10	6 (60)	42	16 (38)
p value		0.060		0.989		0.087
2015						
Heterosexual	313	185 (59)	108	71 (66)	424	258 (61)
Bisexual	21	12 (57)	25	18 (72)	48	31 (65)
Homosexual	22	9 (41)	2	1 (50)	25	11 (44)
p value		0.247		0.737		0.202
2016						
Heterosexual	271	147 (54)	96	51 (53)	368	199 (54)
Bisexual	16	6 (38)	32	20 (63)	48	26 (54)
Homosexual	25	9 (36)	0	0 (0)	28	11 (39)
p value		0.108		0.355		0.315
2017						
Heterosexual	281	149 (53)	115	62 (54)	398	212 (53)
Bisexual	24	8 (33)	15	6 (40)	40	15 (38)
Homosexual	25	3 (12)	5	3 (60)	36	10 (28)
p value		<0.001		0.628		0.004

Table 3.3.3 HCV antibody prevalence by age group, gender and survey year

New South Wales Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<25 years	38	2 (5)	11	4 (36)	49	6 (12)
25-34 years	105	38 (36)	50	25 (50)	156	64 (41)
35-44 years	172	102 (59)	77	47 (61)	250	149 (60)
45+ years	138	90 (65)	66	44 (67)	206	135 (66)
p value		<0.001		0.127		<0.001
2014						
<25 years	42	5 (12)	7	2 (29)	50	7 (14)
25-34 years	104	39 (38)	59	38 (64)	166	79 (48)
35-44 years	187	116 (62)	79	44 (56)	269	161 (60)
45+ years	169	104 (62)	53	37 (70)	222	141 (64)
p value		<0.001		0.116		<0.001
2015						
<25 years	16	2 (13)	3	0 (0)	19	2 (11)
25-34 years	87	31 (36)	46	30 (65)	136	63 (46)
35-44 years	126	82 (65)	45	30 (67)	173	113 (65)
45+ years	142	100 (70)	49	36 (73)	193	138 (72)
p value		<0.001		0.089		<0.001
2016						
<25 years	17	4 (24)	2	1 (50)	19	5 (26)
25-34 years	56	14 (25)	31	18 (58)	88	33 (38)
35-44 years	125	74 (59)	49	23 (47)	175	97 (55)
45+ years	133	82 (62)	55	33 (60)	191	117 (61)
p value		<0.001		0.566		<0.001
2017						
<25 years	17	0 (0)	5	1 (20)	22	1 (5)
25-34 years	52	17 (33)	20	9 (45)	75	27 (36)
35-44 years	110	48 (44)	60	33 (55)	172	82 (48)
45+ years	177	107 (60)	60	30 (50)	244	142 (58)
p value		<0.001		0.489		<0.001

Table 3.3.4 HCV antibody prevalence by years since first injection, gender and survey year

New South Wales Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<3 years	53	0 (0)	4	2 (50)	57	2 (4)
3 to 10 years	61	14 (23)	42	21 (50)	103	35 (34)
11+ years	321	207 (65)	151	94 (62)	476	303 (64)
p value		<0.001		0.334		<0.001
2014						
<3 years	53	1 (20)	8	1 (13)	62	2 (3)
3 to 10 years	80	22 (28)	39	22 (56)	19	44 (37)
11+ years	353	231 (65)	147	96 (65)	505	330 (65)
p value		<0.001		0.009		<0.001
2015						
<3 years	36	5 (14)	8	2 (25)	44	7 (16)
3 to 10 years	50	16 (32)	17	8 (57)	69	25 (36)
11+ years	275	191 (69)	113	84 (74)	393	279 (71)
p value		<0.001		0.002		<0.001
2016						
<3 years	21	2 (10)	7	1 (14)	29	4 (14)
3 to 10 years	55	15 (27)	18	8 (44)	74	23 (31)
11+ years	245	152 (62)	109	65 (60)	357	219 (61)
p value		<0.001		0.048		<0.001
2017						
<3 years	34	2 (6)	8	0 (0)	42	2 (5)
3 to 10 years	48	17 (35)	11	4 (36)	60	21 (35)
11+ years	252	142 (56)	118	67 (57)	380	216 (57)
p value		<0.001		0.002		<0.001

Table 3.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

New South Wales Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No receptive sharing	33	1 (3)	430	249 (58)	472	256 (54)
Receptive sharing	5	0 (0)	59	34 (58)	69	38 (55)
p value		1.000		0.967		0.896
2014						
No receptive sharing	44	2 (5)	454	259 (57)	507	267 (53)
Receptive sharing	2	0 (0)	90	69 (77)	99	75 (76)
p value		1.000		0.001		<0.001
2015						
No receptive sharing	32	5 (16)	350	232 (66)	389	238 (61)
Receptive sharing	3	1 (33)	56	36 (64)	60	38 (63)
p value		0.442		0.769		0.750
2016						
No receptive sharing	23	4 (17)	337	190 (56)	369	197 (53)
Receptive sharing	3	0 (0)	47	28 (60)	52	30 (58)
p value		1.000		0.679		0.560
2017						
No receptive sharing	28	2 (7)	337	178 (53)	383	188 (49)
Receptive sharing	3	0 (0)	43	25 (58)	52	27 (52)
p value		1.000		0.510		0.701

Table 3.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

New South Wales Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heroin	3	1 (33)	163	116 (71)	171	119 (70)
Methamphetamine	8	1 (13)	198	107 (54)	209	111 (53)
Other opioids	4	0 (0)	137	85 (62)	143	87 (61)
PIEDs	36	0 (0)	30	1 (3)	68	1 (1)
Other drugs	3	0 (0)	50	28 (56)	62	34 (55)
p value		0.029		<0.001		<0.001
2014						
Heroin	4	1 (25)	192	130 (68)	200	133 (67)
Methamphetamine	14	1 (7)	221	130 (59)	243	135 (56)
Other opioids	2	0 (0)	111	73 (66)	114	74 (65)
PIEDs	36	0 (0)	33	1 (3)	72	2 (3)
Other drugs	5	0 (0)	67	40 (60)	78	46 (59)
p value		0.089		<0.001		<0.001
2015						
Heroin	5	1 (20)	158	120 (76)	165	123 (75)
Methamphetamine	12	2 (17)	145	86 (59)	161	90 (56)
Other opioids	3	2 (67)	96	74 (77)	99	76 (77)
PIEDs	20	1 (5)	32	0 (0)	56	1 (2)
Other drugs	3	1 (33)	26	21 (81)	30	22 (73)
p value		0.086		<0.001		<0.001
2016						
Heroin	1	0 (0)	151	94 (62)	156	95 (61)
Methamphetamine	10	3 (30)	148	81 (55)	162	86 (53)
Other opioids	1	1 (100)	60	45 (75)	62	47 (76)
PIEDs	15	0 (0)	28	0 (0)	45	0 (0)
Other drugs	1	0 (0)	37	19 (51)	40	21 (53)
p value		0.028		<0.001		<0.001
2017						
Heroin	4	0 (0)	152	100 (66)	170	110 (65)
Methamphetamine	15	2 (13)	156	67 (43)	179	70 (39)
Other opioids	0	0 (0)	59	39 (66)	62	40 (65)
PIEDs	20	0 (0)	24	0 (0)	46	0 (0)
Other drugs	3	0 (0)	45	28 (62)	50	28 (56)
p value		0.286		<0.001		<0.001

Table 3.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

New South Wales Frequency of injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Less than daily	28	1 (4)	268	144 (54)	302	150 (50)
Daily or more	11	1 (9)	222	139 (63)	241	145 (60)
Not last month	16	0 (0)	75	44 (59)	99	46 (46)
p value		0.444		0.139		0.018
2014						
Less than daily	26	1 (4)	275	151 (55)	307	157 (51)
Daily or more	20	1 (5)	277	183 (66)	308	191 (62)
Not last month	15	0 (0)	65	35 (54)	85	36 (42)
p value		1.000		0.016		0.001
2015						
Less than daily	22	2 (9)	186	113 (61)	213	115 (54)
Daily or more	13	4 (31)	222	156 (70)	238	162 (68)
Not last month	8	1 (13)	49	32 (65)	60	35 (58)
p value		0.291		0.125		0.008
2016						
Less than daily	15	2 (13)	195	101 (52)	212	104 (49)
Daily or more	11	2 (18)	192	120 (63)	212	126 (59)
Not last month	2	0 (0)	37	18 (49)	41	19 (46)
p value		1.000		0.064		0.063
2017						
Less than daily	20	2 (10)	182	89 (49)	209	91 (44)
Daily or more	11	0 (0)	205	119 (58)	234	129 (55)
Not last month	11	0 (0)	49	26 (53)	64	28 (44)
p value		0.489		0.197		0.035

Table 3.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

New South Wales Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No imprisonment	52	1 (2)	479	261 (54)	550	272 (49)
Imprisonment	4	0 (0)	74	56 (76)	80	58 (73)
p value		1.000		0.001		<0.001
2014						
No imprisonment	58	1 (2)	492	275 (56)	564	285 (51)
Imprisonment	3	1 (33)	84	67 (80)	91	71 (78)
p value		0.097		<0.001		<0.001
2015						
No imprisonment	38	6 (16)	376	235 (63)	427	244 (57)
Imprisonment	2	1 (50)	64	53 (83)	67	55 (82)
p value		0.323		0.002		<0.001
2016						
No imprisonment	24	2 (8)	349	193 (55)	382	200 (52)
Imprisonment	3	1 (33)	58	36 (62)	64	37 (58)
p value		0.308		0.336		0.418
2017						
No imprisonment	40	2 (5)	343	174 (51)	406	183 (45)
Imprisonment	0	0 (0)	52	43 (83)	61	49 (80)
p value		--		<0.001		<0.001

Table 3.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

New South Wales Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Non Indigenous	373	186 (50)	147	83 (56)	522	269 (52)
Indigenous	68	41 (60)	51	33 (65)	121	76 (63)
p value		0.114		0.303		0.025
2014						
Non Indigenous	418	206 (49)	140	84 (60)	564	293 (52)
Indigenous	73	53 (73)	57	36 (63)	131	89 (68)
p value		<0.001		0.680		0.001
2015						
Non Indigenous	311	167 (54)	105	67 (64)	421	237 (56)
Indigenous	55	44 (80)	37	28 (76)	92	72 (78)
p value		<0.001		0.187		<0.001
2016						
Non Indigenous	263	130 (49)	101	55 (54)	369	188 (51)
Indigenous	56	37 (66)	34	19 (56)	90	56 (62)
p value		0.024		0.885		0.055
2017						
Non Indigenous	297	128 (43)	107	50 (47)	414	184 (44)
Indigenous	53	38 (72)	36	21 (58)	91	60 (66)
p value		<0.001		0.228		<0.001

Table 3.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

New South Wales Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
English speaking	416	216 (52)	193	112 (58)	612	330 (54)
Non-English speaking	35	15 (43)	11	8 (73)	47	23 (49)
p value		0.303		0.531		0.509
2014						
English speaking	456	242 (53)	187	114 (61)	649	358 (55)
Non-English speaking	41	20 (49)	11	7 (64)	53	28 (53)
p value		0.598		0.860		0.743
2015						
English speaking	346	201 (58)	137	93 (68)	490	299 (61)
Non-English speaking	23	13 (57)	6	3 (50)	29	16 (55)
p value		0.883		0.395		0.531
2016						
English speaking	303	164 (54)	132	71 (54)	439	238 (54)
Non-English speaking	23	8 (35)	4	3 (75)	28	11 (39)
p value		0.073		0.625		0.125
2017						
English speaking	340	166 (49)	139	69 (50)	491	242 (49)
Non-English speaking	15	5 (33)	7	4 (57)	22	9 (41)
p value		0.296		1.000		0.442

Table 3.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

New South Wales		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2013							
Australia	390	204 (52)	188	110 (59)	580	316 (54)	
Other Oceania	12	6 (50)	6	4 (67)	18	10 (56)	
Asia	8	3 (38)	1	0 (0)	9	3 (33)	
UK & Ireland	14	8 (57)	7	4 (57)	22	12 (55)	
Other	27	11 (41)	2	2 (100)	30	13 (43)	
p value		0.711		0.724		0.566	
2014							
Australia	420	230 (55)	177	108 (61)	601	339 (56)	
Other Oceania	20	10 (50)	7	3 (43)	29	14 (48)	
Asia	10	5 (50)	1	0 (0)	11	5 (45)	
UK & Ireland	18	7 (39)	7	5 (71)	25	12 (48)	
Other	27	10 (37)	5	5 (100)	33	16 (49)	
p value		0.305		0.179		0.635	
2015							
Australia	324	198 (61)	127	89 (70)	457	291 (64)	
Other Oceania	11	4 (36)	4	1 (25)	16	6 (38)	
Asia	8	1 (13)	2	2 (100)	10	3 (30)	
UK & Ireland	14	7 (50)	5	2 (40)	19	9 (47)	
Other	10	4 (40)	5	2 (40)	15	6 (40)	
p value		0.016		0.057		0.009	
2016							
Australia	285	150 (53)	116	62 (53)	405	215 (53)	
Other Oceania	14	7 (50)	10	5 (50)	24	12 (50)	
Asia	6	2 (33)	1	0 (0)	8	2 (25)	
UK & Ireland	7	4 (57)	3	3 (100)	10	7 (70)	
Other	13	8 (62)	6	4 (67)	19	12 (63)	
p value		0.851		0.440		0.356	
2017							
Australia	306	144 (47)	127	64 (50)	442	213 (48)	
Other Oceania	13	9 (69)	6	3 (50)	20	13 (65)	
Asia	5	2 (40)	3	1 (33)	8	3 (38)	
UK & Ireland	11	6 (55)	5	3 (60)	17	10 (59)	
Other	14	6 (43)	4	2 (50)	19	8 (42)	
p value		0.576		1.000		0.466	

Northern Territory

Table 4.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Northern Territory	2013	2014	2015	2016	2017
Number of sites	3	3	3	3	3
N° surveyed	N=70	N=70	N=60	N=87	N=66
Response rate (%)	33%	39%	27%	49%	39%
Gender (%)					
Male	49 (70)	54 (77)	46 (77)	59 (68)	34 (52)
Female	21 (30)	16 (23)	14 (23)	26 (30)	30 (45)
Transgender	0 (0)	0 (0)	0 (0)	2 (2)	2 (3)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	61 (87)	63 (90)	54 (90)	67 (77)	46 (70)
Bisexual	5 (7)	3 (4)	3 (5)	9 (10)	8 (12)
Homosexual	1 (1)	0 (0)	1 (2)	4 (5)	2 (3)
Not reported	3 (4)	4 (6)	2 (3)	7 (8)	10 (15)
Aboriginal and Torres Strait Islander origin (%)					
No	55 (79)	55 (79)	42 (70)	52 (60)	42 (64)
Yes	13 (19)	14 (20)	16 (27)	31 (36)	18 (27)
Not reported	2 (3)	1 (1)	2 (3)	4 (5)	6 (9)
Region/country of birth (%)					
Australia	59 (84)	61 (87)	53 (88)	75 (86)	59 (89)
Other Oceania	1 (1)	2 (3)	3 (5)	1 (1)	2 (3)
Asia	0 (0)	1 (1)	1 (2)	1 (1)	0 (0)
UK & Ireland	7 (10)	3 (4)	2 (3)	0 (0)	1 (2)
Other	3 (4)	3 (4)	0 (0)	5 (6)	1 (2)
Not reported	0 (0)	0 (0)	1 (2)	5 (6)	3 (5)
Main language spoken at home by parents (%)					
English	68 (97)	66 (94)	57 (95)	79 (91)	63 (95)
Non-English	2 (3)	4 (6)	2 (3)	4 (5)	0 (0)
Not reported	0 (0)	0 (0)	1 (2)	4 (5)	3 (5)
Age and time since first injection (years)					
<i>Median age</i>	42	42	42	43	43
<i>Age range</i>	19-62	21-61	26-57	21-65	19-62
<i>Age group (%)</i>					
<25 years	2 (3)	3 (4)	0 (0)	2 (2)	5 (8)
25+ years	68 (97)	67 (96)	60 (100)	85 (98)	61 (92)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age first injection</i>	20	20	18	19	20
<i>Age range</i>	13-40	10-45	12-43	11-45	14-40
N° not reported	2	0	2	2	4
<i>Median yrs since first injection</i>	21	21	20	21	20.5
<i>Range</i>	3-46	0-45	2-41	2-46	0-44
<i>Years since first injection</i>					
<3 years	0 (0)	4 (6)	1 (2)	4 (5)	3 (5)
3+ years	68 (97)	65 (93)	57 (95)	81 (93)	59 (89)
Not reported	2 (3)	1 (1)	2 (3)	2 (2)	4 (6)
Imprisonment last year (%)					
No	62 (89)	63 (90)	50 (83)	72 (83)	57 (86)
Yes	7 (14)	2 (3)	7 (12)	8 (9)	3 (5)
Not reported	1 (1)	5 (7)	3 (5)	7 (8)	6 (9)
N° in prison	N=7	N=2	N=7	N=8	N=3
Injected in prison	1 (14)	0 (0)	0 (0)	1 (13)	0 (0)

Table 4.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Northern Territory	2013	2014	2015	2016	2017
N° surveyed	N=70	N=70	N=60	N=87	N=66
Drug last injected (%)					
Cocaine	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)
Methamphetamine	8 (11)	19 (27)	21 (35)	37 (43)	31 (47)
Heroin	7 (10)	6 (9)	1 (2)	4 (5)	3 (5)
Pharm. opioids	43 (61)	35 (50)	25 (42)	30 (34)	22 (33)
Methadone	1 (1)	6 (9)	4 (7)	2 (2)	3 (5)
Buprenorphine	1 (1)	1 (1)	5 (8)	2 (2)	0 (0)
Buprenorphine/naloxone	0 (0)	1 (1)	3 (5)	4 (5)	3 (5)
PIEDs	3 (4)	1 (1)	0 (0)	1 (1)	1 (2)
More than one	5 (7)	0 (0)	1 (2)	7 (8)	1 (2)
Other	1 (1)	0 (0)	0 (0)	0 (0)	1 (2)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Ever injected opioids					
Yes	-	-	-	73 (84)	56 (85)
No	-	-	-	13 (15)	10 (15)
Not reported	-	-	-	1 (1)	0 (0)
Frequency of injection last month (%)					
Not last month	8 (11)	3 (4)	2 (3)	8 (9)	8 (12)
Less than weekly	11 (16)	9 (13)	7 (12)	10 (11)	5 (8)
Weekly not daily	12 (17)	9 (13)	8 (13)	15 (17)	11 (17)
Daily or more	39 (56)	48 (69)	43 (72)	54 (62)	42 (64)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Present when someone injected for the first time in the last 12 months (%)					
Yes	4 (6)	7 (10)	7 (12)	13 (15)	8 (12)
No	54 (77)	63 (90)	50 (83)	69 (79)	54 (82)
Not reported	12 (17)	0 (0)	3 (5)	5 (6)	4 (6)
Overdosed in last 12 months					
Yes	10 (14)	2 (3)	9 (15)	13 (15)	6 (9)
No	57 (81)	68 (97)	50 (83)	68 (78)	56 (85)
Not reported	3 (4)	0 (0)	1 (2)	6 (7)	4 (6)

Table 4.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Northern Territory	2013	2014	2015	2016	2017
N° injected last month	N=62	N=66	N=58	N=79	N=58
Places injected last month (%)					
Any public	18 (29)	14 (21)	20 (34)	27 (34)	27 (47)
All private	43 (69)	52 (79)	38 (66)	52 (66)	31 (53)
Not reported	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	51 (82)	56 (85)	47 (81)	67 (85)	50 (86)
Most of the time	9 (15)	7 (11)	9 (16)	9 (11)	3 (5)
Half of the time	0 (0)	1 (2)	1 (2)	0 (0)	1 (2)
Some of the time	1 (2)	2 (3)	0 (0)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Not reported	1 (2)	0 (0)	1 (2)	2 (3)	4 (7)
Re-used someone else's used needle & syringe last month (%)					
None	55 (89)	62 (94)	56 (97)	70 (89)	52 (90)
Once	3 (5)	2 (3)	1 (2)	3 (4)	2 (3)
Twice	2 (3)	1 (2)	1 (2)	3 (4)	0 (0)
3-5 times	0 (0)	1 (2)	0 (0)	1 (1)	3 (5)
>5 times	1 (2)	0 (0)	0 (0)	2 (3)	1 (2)
Not reported	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	55 (89)	62 (94)	56 (97)	70 (89)	52 (90)
One	1 (2)	1 (2)	0 (0)	2 (3)	0 (0)
Two	0 (0)	2 (3)	0 (0)	0 (0)	2 (3)
Three to five	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
More than five	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Don't know	2 (3)	0 (0)	1 (2)	2 (3)	1 (2)
Not reported	4 (6)	1 (2)	1 (2)	4 (5)	2 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	1 (2)	0 (0)	1 (2)	2 (3)	2 (3)
Casual sex partner	0 (0)	0 (0)	0 (0)	1 (1)	1 (2)
Close friend	0 (0)	0 (0)	0 (0)	1 (1)	2 (3)
Acquaintance	1 (2)	3 (5)	0 (0)	1 (1)	1 (2)
Other	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	22 (35)	11 (17)	10 (17)	21 (27)	9 (16)
Water	7 (11)	2 (3)	7 (12)	18 (23)	13 (22)
Filter	7 (11)	9 (14)	4 (7)	7 (9)	5 (9)
Drug mix	3 (5)	1 (2)	4 (7)	9 (11)	5 (9)
None	39 (63)	55 (83)	43 (74)	50 (63)	40 (69)
Injected by someone after that person injected themselves or others last month (%)					
No	58 (94)	57 (86)	54 (93)	67 (85)	46 (79)
Yes	2 (3)	7 (11)	4 (7)	10 (13)	9 (16)
Not reported	2 (3)	2 (3)	0 (0)	2 (3)	3 (5)
Source of needle acquisition					
Needle Syringe Program	58 (94)	62 (94)	57 (98)	75 (95)	46 (79)
Chemist/Pharmacy	6 (10)	7 (11)	9 (16)	9 (11)	10 (17)
Personal sources	7 (11)	9 (14)	5 (9)	12 (15)	10 (17)
Dispensing/Vending Machine	0 (0)	1 (2)	0 (0)	0 (0)	12 (21)
Other sources	0 (0)	3 (5)	1 (2)	1 (1)	0 (0)

Table 4.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Northern Territory	2013	2014	2015	2016	2017
N° surveyed	N=70	N=70	N=60	N=87	N=66
Ever any treatment/therapy for drug use (%)					
No	29 (41)	24 (34)	18 (30)	37 (43)	28 (42)
Yes	41 (59)	45 (64)	40 (67)	45 (52)	35 (53)
Not reported	0 (0)	1 (1)	2 (3)	5 (6)	3 (5)
History of methadone maintenance treatment (%)					
Currently	11 (16)	2 (3)	5 (8)	1 (1)	1 (2)
Previously	18 (26)	15 (21)	18 (30)	19 (22)	10 (15)
Never	41 (59)	48 (69)	36 (60)	60 (69)	51 (77)
Not reported	0 (0)	5 (7)	1 (2)	7 (8)	4 (6)
History of buprenorphine (Subutex®) treatment (%)					
Currently	3 (4)	3 (4)	2 (3)	9 (10)	2 (3)
Previously	16 (23)	22 (31)	15 (25)	15 (17)	13 (20)
Never	50 (71)	43 (61)	43 (72)	58 (67)	48 (73)
Not reported	1 (1)	2 (3)	0 (0)	5 (6)	3 (5)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	9 (13)	5 (7)	4 (7)	12 (14)	7 (11)
Previously	11 (16)	19 (27)	16 (27)	13 (15)	10 (15)
Never	48 (69)	45 (64)	36 (60)	56 (64)	46 (70)
Not reported	2 (3)	1 (1)	4 (7)	6 (7)	3 (5)

Table 4.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Northern Territory	2013	2014	2015	2016	2017
N° surveyed	N=70	N=70	N=60	N=87	N=66
Previous HIV test (%)					
Yes, ever	60 (86)	60 (86)	51 (85)	72 (83)	50 (76)
Yes, last year	35 (50)	28 (40)	22 (37)	48 (55)	34 (52)
>1 year ago	25 (36)	32 (46)	29 (48)	24 (28)	16 (24)
Never tested	10 (14)	10 (14)	8 (13)	10 (11)	10 (15)
Not reported	0 (0)	0 (0)	1 (2)	5 (6)	6 (9)
Previous HCV test (%)					
Yes, ever	60 (86)	66 (94)	50 (83)	74 (85)	49 (74)
Yes, last year	36 (51)	31 (44)	26 (43)	49 (56)	32 (48)
>1 year ago	24 (34)	35 (50)	24 (40)	25 (29)	17 (26)
Never tested	7 (10)	4 (6)	5 (8)	5 (6)	8 (12)
Not reported	3 (4)	0 (0)	5 (8)	8 (9)	9 (14)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=20	N=24	N=17	N=21	N=15
Antiviral treatment	2 (10)	11 (46)	1 (6)	4 (19)	3 (20)
No antiviral treatment	18 (90)	13 (54)	16 (94)	17 (81)	9 (60)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	3 (20)
Treatment for HCV in past 12 months (%)^{##}					
N° self-reported HCV diagnosis	N=19	N=17	N=17	N=21	N=14
Antiviral treatment	0 (0)	0 (0)	0 (0)	4 (19)	1 (7)
No antiviral treatment	19 (100)	17 (100)	17 (100)	17 (81)	10 (71)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	3 (21)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 4.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Northern Territory	2013	2014	2015	2016	2017
N° surveyed	N=70	N=70	N=60	N=87	N=66
Sex with a regular partner last month (%)					
No	43 (61)	41 (59)	40 (67)	52 (60)	36 (55)
Yes	26 (37)	29 (41)	19 (32)	28 (32)	25 (38)
Not reported	1 (1)	0 (0)	1 (2)	7 (8)	5 (8)
Condom used with regular partner last month (%)					
N° surveyed	N=26	N=29	N=19	N=28	N=25
Never	24 (92)	16 (55)	15 (79)	16 (57)	16 (64)
Sometimes	0 (0)	5 (17)	1 (5)	6 (21)	5 (20)
Every time	1 (4)	4 (14)	3 (16)	5 (18)	2 (8)
Not reported	1 (4)	4 (14)	0 (0)	1 (4)	2 (8)
Sex with other partner(s) last month (%)					
No	57 (81)	60 (86)	52 (87)	69 (79)	49 (74)
Yes	13 (19)	10 (14)	6 (10)	15 (17)	12 (18)
Not reported	0 (0)	0 (0)	2 (3)	3 (3)	5 (8)
Condom used with other partner(s) last month (%)					
N° surveyed	N=13	N=10	N=6	N=15	N=12
Never	5 (38)	1 (10)	2 (33)	3 (20)	2 (17)
Sometimes	2 (15)	6 (60)	1 (17)	6 (40)	4 (33)
Every time	5 (38)	3 (30)	3 (50)	5 (33)	6 (50)
Not reported	1 (8)	0 (0)	0 (0)	1 (7)	0 (0)
Sex work last month (%)					
No	64 (91)	64 (91)	56 (93)	70 (80)	52 (79)
Yes	3 (4)	6 (9)	2 (3)	9 (10)	7 (11)
Not reported	3 (4)	0 (0)	2 (3)	8 (9)	7 (11)
Condom used at last sex work (%)					
Yes	2 (67)	4 (67)	1 (50)	8 (90)	6 (86)

HIV antibody prevalence

Table 4.2.1 HIV antibody prevalence by gender and survey year

Northern Territory Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013	47	2 (4.3)	19	0 (0.0)	66	2 (3.0)
2014	54	0 (0.0)	16	0 (0.0)	70	0 (0.0)
2015	45	0 (0.0)	14	0 (0.0)	59	0 (0.0)
2016	59	0 (0.0)	26	0 (0.0)	87	0 (0.0)
2017	34	0 (0.0)	29	0 (0.0)	65	0 (0.0)
X ² p trend		--		--		--

HCV antibody prevalence

Table 4.3.1 HCV antibody prevalence by gender and survey year

Northern Territory Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013	46	21 (46)	19	12 (63)	65	33 (51)
2014	53	30 (57)	16	8 (50)	69	38 (55)
2015	31	19 (61)	12	7 (58)	43	26 (60)
2016	59	23 (39)	26	12 (46)	87	35 (40)
2017	32	15 (47)	29	8 (28)	63	23 (37)
X ² p trend		0.634		0.148		0.166

Table 4.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Northern Territory Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heterosexual	40	21 (53)	17	12 (71)	57	33 (58)
Bisexual	4	0 (0)	0	0 (0)	4	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.075		--		0.018
2014						
Heterosexual	50	29 (58)	12	6 (50)	62	35 (56)
Bisexual	2	0 (0)	1	0 (0)	3	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.191		1.000		0.093
2015						
Heterosexual	31	19 (61)	7	5 (71)	38	24 (63)
Bisexual	0	0 (0)	2	1 (50)	2	1 (50)
Homosexual	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		1.000		1.000
2016						
Heterosexual	49	19 (39)	17	9 (53)	67	28 (42)
Bisexual	2	0 (0)	6	1 (17)	9	1 (11)
Homosexual	3	2 (67)	1	1 (100)	4	3 (75)
p value		0.486		0.166		0.071
2017						
Heterosexual	28	12 (43)	15	2 (13)	43	14 (33)
Bisexual	0	0 (0)	7	1 (14)	8	1 (13)
Homosexual	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.051		0.079

Table 4.3.3 HCV antibody prevalence by age group, gender and survey year

Northern Territory Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<25 years	1	0 (0)	1	0 (0)	2	0 (0)
25-34 years	9	4 (44)	3	0 (0)	12	4 (33)
35-44 years	17	8 (47)	8	7 (88)	25	15 (60)
45+ years	19	9 (47)	7	5 (71)	26	14 (54)
p value		1.000		0.026		0.237
2014						
<25 years	1	0 (0)	2	1 (50)	3	1 (33)
25-34 years	10	4 (40)	3	2 (67)	13	6 (46)
35-44 years	20	11 (55)	5	3 (60)	25	14 (56)
45+ years	22	15 (68)	6	2 (33)	28	17 (61)
p value		0.311		0.814		0.722
2015						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	11	3 (27)	1	0 (0)	12	3 (25)
35-44 years	11	10 (91)	5	3 (60)	16	13 (81)
45+ years	9	6 (67)	6	4 (67)	15	10 (67)
p value		0.010		0.747		0.008
2016						
<25 years	1	0 (0)	0	0 (0)	2	0 (0)
25-34 years	7	4 (57)	2	0 (0)	9	4 (44)
35-44 years	23	3 (13)	10	6 (60)	33	9 (27)
45+ years	28	16 (57)	14	6 (43)	43	22 (51)
p value		0.003		0.443		0.111
2017						
<25 years	2	1 (50)	3	0 (0)	5	1 (20)
25-34 years	5	0 (0)	2	1 (50)	8	1 (13)
35-44 years	13	4 (31)	10	3 (30)	23	7 (30)
45+ years	12	10 (83)	14	4 (29)	27	14 (52)
p value		0.003		0.729		0.152

Table 4.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Northern Territory Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	6	0 (0)	3	0 (0)	9	0 (0)
11+ years	39	20 (51)	15	12 (80)	54	32 (59)
p value		0.027		0.025		0.001
2014						
<3 years	1	0 (0)	3	0 (0)	4	0 (0)
3 to 10 years	6	3 (50)	2	2 (100)	8	5 (63)
11+ years	45	27 (60)	11	6 (55)	56	33 (59)
p value		0.509		0.097		0.070
2015						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	8	3 (38)	0	0 (0)	8	3 (38)
11+ years	26	16 (70)	9	5 (56)	32	21 (66)
p value		0.206		1.000		0.158
2016						
<3 years	1	0 (0)	2	1 (50)	4	1 (25)
3 to 10 years	4	0 (0)	2	1 (50)	6	1 (17)
11+ years	54	23 (43)	21	9 (43)	75	32 (43)
p value		0.200		1.000		0.507
2017						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	4	2 (50)	5	0 (0)	9	2 (22)
11+ years	25	11 (44)	20	8 (40)	47	19 (40)
p value		1.000		0.197		0.282

Table 4.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Northern Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No receptive sharing	0	0 (0)	49	27 (55)	50	28 (56)
Receptive sharing	0	0 (0)	6	4 (67)	6	4 (67)
p value		--		0.686		0.691
2014						
No receptive sharing	3	0 (0)	57	34 (60)	61	34 (56)
Receptive sharing	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		1.000		0.628
2015						
No receptive sharing	1	0 (0)	36	23 (64)	39	25 (64)
Receptive sharing	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.149		0.146
2016						
No receptive sharing	4	1 (25)	65	29 (45)	70	31 (44)
Receptive sharing	0	0 (0)	6	3 (50)	7	3 (43)
p value		--		1.000		1.000
2017						
No receptive sharing	3	3 (100)	42	17 (40)	49	19 (39)
Receptive sharing	0	0 (0)	6	1 (17)	6	1 (17)
p value		--		0.388		0.399

Table 4.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Northern Territory Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Methamphetamine	0	0 (0)	6	2 (33)	6	2 (33)
Pharm. Opioids	0	0 (0)	43	24 (56)	43	24 (56)
OST*	0	0 (0)	2	2 (100)	2	2 (100)
Other drugs	0	0 (0)	12	4 (33)	14	5 (36)
p value		--		0.206		0.224
2014						
Methamphetamine	3	0 (0)	16	8 (50)	19	8 (42)
Pharm. Opioids	0	0 (0)	33	25 (76)	34	25 (74)
OST*	1	0 (0)	7	2 (29)	8	2 (25)
Other drugs	0	0 (0)	8	3 (38)	8	3 (38)
p value		--		0.035		0.019
2015						
Methamphetamine	1	0 (0)	14	6 (43)	15	6 (40)
Pharm. Opioids	0	0 (0)	15	10 (67)	17	12 (71)
OST*	0	0 (0)	10	7 (70)	10	7 (70)
Other drugs	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		0.380		0.222
2016						
Methamphetamine	2	1 (50)	35	10 (29)	37	11 (30)
Pharm. Opioids	0	0 (0)	29	14 (48)	30	15 (50)
OST*	1	0 (0)	7	4 (57)	8	4 (50)
Other drugs	1	0 (0)	10	5 (50)	12	5 (42)
p value		0.513		0.265		0.360
2017						
Methamphetamine	1	1 (100)	28	7 (25)	30	7 (23)
Pharm. Opioids	0	0 (0)	19	10 (53)	22	12 (55)
OST*	1	1 (100)	4	2 (50)	5	2 (40)
Other drugs	1	1 (100)	5	2 (40)	6	2 (33)
p value		--		0.261		0.146

*OST = methadone, buprenorphine & buprenorphine/naloxone

Table 4.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Northern Territory Frequency of injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Less than daily	0	0 (0)	20	14 (70)	20	14 (70)
Daily or more	0	0 (0)	36	17 (47)	37	18 (49)
Not last month	0	0 (0)	7	1 (14)	8	1 (13)
p value		--		0.037		0.020
2014						
Less than daily	1	0 (0)	17	11 (65)	18	11 (61)
Daily or more	2	0 (0)	44	26 (59)	47	26 (55)
Not last month	1	0 (0)	2	1 (50)	3	1 (33)
p value		--		0.891		0.677
2015						
Less than daily	1	0 (0)	8	5 (63)	11	7 (64)
Daily or more	0	0 (0)	30	18 (60)	30	18 (60)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000
2016						
Less than daily	2	0 (0)	22	9 (41)	25	10 (40)
Daily or more	2	1 (50)	51	23 (45)	54	24 (44)
Not last month	0	0 (0)	8	1 (13)	8	1 (13)
p value		1		0.229		0.248
2017						
Less than daily	2	2 (100)	12	5 (42)	15	5 (33)
Daily or more	1	1 (100)	36	13 (36)	40	15 (38)
Not last month	0	0 (0)	8	3 (38)	8	3 (38)
p value		--		0.922		1.000

Table 4.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Northern Territory Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No imprisonment	0	0 (0)	55	25 (45)	57	26 (46)
Imprisonment	0	0 (0)	7	7 (100)	7	7 (100)
p value		--		0.011		0.011
2014						
No imprisonment	2	0 (0)	59	36 (61)	62	36 (58)
Imprisonment	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.164		0.187
2015						
No imprisonment	1	0 (0)	32	18 (56)	35	20 (57)
Imprisonment	0	0 (0)	5	4 (80)	5	5 (4)
p value		--		0.629		0.631
2016						
No imprisonment	4	1 (25)	67	29 (43)	72	31 (43)
Imprisonment	0	0 (0)	7	2 (29)	8	2 (25)
p value		--		0.692		0.459
2017						
No imprisonment	3	3 (100)	50	19 (38)	56	21 (38)
Imprisonment	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.527		0.530

Table 4.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Northern Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Non Indigenous	39	18 (46)	11	5 (45)	50	23 (46)
Indigenous	5	2 (40)	8	7 (88)	13	9 (69)
p value		1.000		0.147		0.213
2014						
Non Indigenous	44	24 (55)	11	5 (45)	55	29 (53)
Indigenous	9	6 (67)	4	2 (50)	13	8 (62)
p value		0.504		1.000		0.566
2015						
Non Indigenous	21	16 (76)	7	5 (71)	28	21 (75)
Indigenous	10	3 (30)	4	2 (50)	14	5 (36)
p value		0.021		0.576		0.020
2016						
Non Indigenous	35	19 (54)	17	8 (47)	52	27 (52)
Indigenous	21	4 (19)	8	4 (50)	31	8 (26)
p value		0.012		1.000		0.020
2017						
Non Indigenous	24	12 (50)	15	5 (33)	40	17 (43)
Indigenous	5	1 (20)	11	2 (18)	17	3 (18)
p value		0.343		0.658		0.128

Table 4.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Northern Territory Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
English speaking	44	20 (45)	19	12 (63)	63	32 (51)
Non-English speaking	2	1 (50)	0	0 (0)	2	1 (50)
p value		1.000		--		1.000
2014						
English speaking	49	27 (55)	16	8 (50)	65	35 (54)
Non-English speaking	4	3 (75)	0	0 (0)	4	3 (75)
p value		0.624		--		0.622
2015						
English speaking	30	18 (60)	11	6 (55)	41	24 (59)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		--		1.000
2016						
English speaking	52	22 (42)	25	12 (48)	79	34 (43)
Non-English speaking	4	1 (25)	0	0 (0)	4	1 (25)
p value		0.636		--		0.635
2017						
English speaking	30	14 (47)	28	8 (29)	60	22 (37)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

Table 4.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Northern Territory Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Australia	41	20 (49)	15	10 (67)	56	30 (54)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	3	1 (33)	2	2 (100)	5	3 (60)
Other	1	0 (0)	2	0 (0)	3	0 (0)
p value		1.000		0.237		0.196
2014						
Australia	47	28 (60)	13	7 (54)	60	35 (58)
Other Oceania	2	0 (0)	0	0 (0)	2	0 (0)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	2	0 (0)	1	1 (100)	3	1 (33)
Other	1	1 (100)	2	0 (0)	3	1 (33)
p value		0.053		0.467		0.353
2015						
Australia	28	17 (61)	10	6 (60)	38	23 (61)
Other Oceania	2	1 (50)	0	0 (0)	2	1 (50)
Asia	0	0 (0)	1	0 (0)	1	0 (0)
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.455		0.828
2016						
Australia	51	20 (39)	23	11 (48)	75	31 (41)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	3	1 (33)	1	1 (100)	5	2 (40)
p value		0.527		1.000		0.552
2017						
Australia	26	11 (42)	28	8 (29)	56	19 (34)
Other Oceania	2	2 (100)	0	0 (0)	2	2 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.143		--		0.075

Queensland

Table 5.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Queensland	2013	2014	2015	2016	2017
Number of sites	8	7	8	8	8
N° surveyed	N=565	N=490	N=532	N=349	N=619
Response rate (%)	45%	51%	36%	30%	33%
Gender (%)					
Male	397 (70)	356 (73)	386 (73)	230 (66)	447 (72)
Female	167 (30)	133 (27)	144 (27)	117 (34)	171 (28)
Transgender	1 (<1)	1 (<1)	2 (<1)	1 (<1)	1 (<1)
Not reported	0 (0)	0 (0)	0 (0)	1 (<1)	
Sexual identity (%)					
Heterosexual	471 (83)	398 (81)	453 (85)	258 (74)	483 (78)
Bisexual	42 (7)	36 (7)	41 (8)	47 (13)	55 (9)
Homosexual	19 (3)	22 (4)	19 (4)	18 (5)	33 (5)
Not reported	33 (6)	34 (7)	19 (4)	26 (7)	48 (8)
Aboriginal and Torres Strait Islander origin (%)					
No	493 (87)	428 (87)	459 (86)	294 (84)	501 (81)
Yes	58 (10)	49 (10)	67 (13)	44 (13)	100 (16)
Not reported	14 (2)	13 (3)	6 (1)	11 (3)	18 (3)
Region/country of birth (%)					
Australia	504 (89)	421 (86)	467 (88)	304 (87)	548 (89)
Other Oceania	29 (5)	30 (6)	24 (5)	13 (4)	32 (5)
Asia	0 (0)	2 (<1)	5 (1)	2 (1)	2 (<1)
UK & Ireland	13 (2)	15 (3)	17 (3)	16 (5)	19 (3)
Other	17 (3)	17 (3)	9 (2)	5 (1)	11 (2)
Not reported	2 (<1)	5 (1)	10 (2)	9 (3)	7 (1)
Main language spoken at home by parents (%)					
English	544 (96)	468 (96)	515 (97)	329 (94)	594 (96)
Non-English	19 (3)	17 (3)	9 (2)	12 (3)	22 (4)
Not reported	2 (<1)	5 (1)	8 (2)	8 (2)	3 (<1)
Age and time since first injection (years)					
<i>Median age</i>	37	37	38	40	41
<i>Age range</i>	16-65	14-64	16-62	17-76	16-75
<i>Age group (%)</i>					
<25 years	68 (12)	52 (11)	44 (8)	21 (6)	37 (6)
25+ years	495 (88)	436 (89)	487 (92)	328 (94)	581 (94)
Not reported	2 (<1)	2 (<1)	1 (<1)	0 (0)	1 (<1)
<i>Median age first injection</i>	19	19	19	19	19
<i>Age range</i>	11-61	10-49	11-50	11-55	10-65
N° not reported	15	15	13	16	16
<i>Median yrs since first injection</i>	15	16	17	19	20
<i>Range</i>	<1-46	<1-47	<1-44	<1-53	<1-59
<i>Years since first injection</i>					
<3 years	68 (12)	55 (11)	46 (9)	22 (6)	47 (8)
3+ years	482 (85)	420 (86)	472 (89)	311 (89)	556 (90)
Not reported	15 (3)	15 (3)	14 (3)	16 (5)	16 (3)
Imprisonment last year (%)					
No	497 (88)	415 (85)	468 (88)	299 (86)	528 (85)
Yes	45 (8)	48 (10)	43 (8)	39 (11)	69 (11)
Not reported	23 (4)	27 (6)	21 (4)	11 (3)	22 (4)
N° in prison					
Injected in prison	N=45	N=48	N=43	N=39	N=69
	17 (38)	18 (38)	22 (51)	16 (41)	27 (39)

Table 5.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Queensland	2013	2014	2015	2016	2017
N° surveyed	N=565	N=490	N=532	N=349	N=619
Drug last injected (%)					
Cocaine	3 (<1)	3 (<1)	5 (1)	1 (0)	5 (1)
Methamphetamine	162 (29)	155 (31)	183 (34)	136 (39)	265 (43)
Heroin	91 (16)	75 (15)	107 (20)	56 (16)	89 (14)
Pharm. opioids	117 (21)	94 (19)	92 (17)	53 (15)	117 (19)
Methadone	36 (6)	22 (4)	31 (6)	28 (8)	27 (4)
Buprenorphine	32 (6)	20 (4)	21 (4)	11 (3)	23 (4)
Buprenorphine/naloxone	16 (3)	14 (3)	6 (1)	13 (4)	11 (2)
PIEDs	71 (13)	71 (14)	62 (12)	21 (6)	49 (8)
More than one	35 (6)	16 (3)	18 (3)	22 (6)	22 (4)
Other	1 (<1)	16 (3)	7 (1)	8 (2)	6 (1)
Not reported	1 (<1)	4 (<1)	0 (0)	0 (0)	5 (1)
Ever injected opioids					
Yes	-	-	-	274 (79)	446 (72)
No	-	-	-	74 (21)	173 (28)
Not reported	-	-	-	1 (<1)	0 (0)
Frequency of injection last month (%)					
Not last month	41 (7)	47 (10)	54 (10)	31 (9)	54 (9)
Less than weekly	107 (19)	64 (13)	92 (17)	49 (14)	94 (15)
Weekly not daily	153 (27)	134 (27)	114 (21)	80 (23)	150 (24)
Daily or more	254 (45)	238 (49)	268 (50)	177 (51)	316 (51)
Not reported	10 (2)	7 (1)	4 (1)	12 (3)	5 (1)
Present when someone injected for the first time in the last 12 months (%)					
Yes	82 (15)	88 (18)	80 (15)	57 (16)	106 (17)
No	428 (76)	392 (80)	442 (83)	287 (82)	496 (80)
Not reported	55 (10)	10 (2)	10 (2)	5 (1)	17 (3)
Overdosed in last 12 months					
Yes	65 (12)	65 (13)	67 (13)	57 (16)	93 (15)
No	493 (87)	415 (85)	458 (86)	285 (82)	512 (83)
Not reported	7 (1)	10 (2)	7 (1)	7 (2)	14 (2)

Table 5.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Queensland	2013	2014	2015	2016	2017
N° injected last month	N=514	N=436	N=474	N=306	N=560
Places injected last month (%)					
Any public	163 (32)	140 (32)	146 (31)	96 (31)	182 (33)
All private	347 (68)	294 (67)	326 (69)	208 (68)	375 (67)
Not reported	4 (1)	2 (<1)	2 (<1)	2 (1)	3 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	391 (76)	340 (78)	350 (74)	240 (78)	434 (78)
Most of the time	101 (20)	84 (19)	98 (21)	52 (17)	98 (18)
Half of the time	12 (2)	3 (1)	14 (3)	5 (2)	8 (1)
Some of the time	5 (1)	3 (1)	2 (<1)	3 (1)	12 (2)
Not last month	1 (<1)	0 (0)	3 (1)	2 (1)	4 (1)
Not reported	4 (1)	6 (1)	7 (1)	4 (1)	4 (1)
Re-used someone else's used needle & syringe last month (%)					
None	437 (85)	361 (83)	400 (84)	245 (80)	471 (84)
Once	21 (4)	24 (6)	26 (5)	14 (5)	27 (5)
Twice	18 (4)	18 (4)	10 (2)	18 (6)	22 (4)
3-5 times	13 (3)	15 (3)	18 (4)	11 (4)	19 (3)
>5 times	19 (4)	11 (3)	17 (4)	15 (5)	16 (3)
Not reported	6 (1)	7 (2)	3 (1)	3 (1)	5 (1)
Number of people needle & syringe was re-used after last month (%)					
None	437 (85)	361 (83)	400 (84)	245 (80)	471 (84)
One	39 (8)	27 (6)	33 (7)	24 (8)	32 (6)
Two	7 (1)	6 (1)	5 (1)	7 (2)	7 (1)
Three to five	3 (<1)	4 (1)	6 (1)	1 (0)	5 (1)
More than five	2 (<1)	2 (<1)	3 (1)	3 (1)	3 (1)
Don't know	15 (3)	13 (3)	14 (3)	13 (4)	27 (5)
Not reported	11 (2)	23 (5)	13 (3)	13 (4)	15 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	33 (6)	27 (6)	25 (5)	20 (7)	24 (4)
Casual sex partner	4 (1)	0 (0)	3 (1)	3 (1)	4 (1)
Close friend	20 (4)	10 (2)	21 (4)	14 (5)	25 (4)
Acquaintance	12 (2)	5 (1)	9 (2)	12 (4)	12 (2)
Other	6 (1)	3 (1)	10 (2)	4 (1)	9 (2)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	104 (20)	75 (17)	97 (20)	59 (19)	102 (18)
Water	85 (17)	82 (19)	82 (17)	45 (15)	106 (19)
Filter	55 (11)	36 (8)	53 (11)	33 (11)	69 (12)
Drug mix	45 (9)	38 (9)	46 (10)	37 (12)	52 (9)
None	379 (74)	305 (70)	332 (70)	223 (73)	381 (68)
Injected by someone after that person injected themselves or others last month (%)					
No	438 (85)	351 (81)	404 (85)	249 (81)	474 (85)
Yes	65 (13)	72 (17)	68 (14)	51 (17)	81 (14)
Not reported	11 (2)	13 (3)	2 (<1)	6 (2)	5 (1)
Source of needle acquisition					
Needle Syringe Program	487 (95)	394 (90)	437 (92)	274 (90)	502 (90)
Chemist/Pharmacy	109 (21)	107 (25)	122 (26)	88 (29)	138 (25)
Personal sources	34 (7)	36 (8)	38 (8)	27 (9)	53 (9)
Dispensing/Vending Machine	52 (10)	38 (9)	70 (15)	50 (16)	76 (14)
Other sources	3 (1)	6 (1)	9 (2)	6 (2)	16 (3)

Table 5.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Queensland	2013	2014	2015	2016	2017
N° surveyed	N=565	N=490	N=532	N=349	N=619
Ever any treatment/therapy for drug use (%)					
No	188 (33)	168 (34)	171 (32)	98 (28)	196 (32)
Yes	373 (66)	308 (63)	351 (66)	241 (69)	412 (67)
Not reported	4 (1)	14 (3)	10 (2)	10 (3)	11 (2)
History of methadone maintenance treatment (%)					
Currently	95 (17)	80 (16)	79 (15)	63 (18)	89 (14)
Previously	114 (20)	94 (19)	117 (22)	83 (24)	125 (20)
Never	354 (63)	303 (62)	329 (62)	193 (55)	394 (64)
Not reported	2 (1)	13 (3)	7 (1)	10 (3)	11 (2)
History of buprenorphine (Subutex®) treatment (%)					
Currently	51 (9)	48 (10)	41 (8)	30 (9)	41 (7)
Previously	149 (26)	100 (20)	144 (27)	93 (27)	138 (22)
Never	358 (63)	330 (67)	340 (64)	214 (61)	429 (69)
Not reported	7 (1)	12 (2)	7 (1)	12 (3)	11 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	56 (10)	35 (7)	42 (8)	23 (7)	37 (6)
Previously	110 (19)	99 (20)	119 (22)	89 (26)	128 (21)
Never	389 (70)	340 (69)	362 (68)	229 (66)	442 (71)
Not reported	10 (2)	16 (3)	9 (2)	8 (2)	12 (2)

Table 5.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Queensland	2013	2014	2015	2016	2017
N° surveyed	N=565	N=490	N=532	N=349	N=619
Previous HIV test (%)					
Yes, ever	477 (84)	408 (83)	437 (82)	292 (84)	510 (82)
Yes, last year	277 (49)	253 (52)	250 (47)	186 (53)	302 (49)
>1 year ago	200 (35)	155 (32)	187 (35)	106 (30)	208 (34)
Never tested	82 (15)	68 (14)	82 (15)	45 (13)	90 (15)
Not reported	6 (1)	14 (3)	13 (2)	12 (3)	19 (3)
Previous HCV test (%)					
Yes, ever	466 (82)	414 (84)	449 (84)	294 (84)	516 (83)
Yes, last year	269 (48)	273 (56)	279 (52)	211 (60)	343 (55)
>1 year ago	197 (35)	141 (29)	170 (32)	83 (24)	173 (28)
Never tested	56 (10)	52 (11)	64 (12)	28 (8)	63 (10)
Not reported	43 (8)	24 (5)	19 (4)	27 (8)	40 (6)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=155	N=112	N=126	N=104	N=156
Antiviral treatment	18 (12)	13 (12)	11 (9)	34 (33)	69 (44)
No antiviral treatment	133 (86)	94 (84)	109 (87)	69 (66)	87 (56)
Not reported	4 (3)	5 (4)	6 (5)	1 (1)	0 (0)
Treatment for HCV in past 12 months (%)^{##}					
N° self-reported HCV diagnosis	N=149	N=102	N=121	N=102	N=143
Antiviral treatment	6 (4)	2 (2)	1 (1)	28 (27)	52 (36)
No antiviral treatment	125 (94)	85 (96)	80 (92)	57 (71)	91 (64)
Not reported	2 (2)	2 (2)	6 (7)	1 (1)	0 (0)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance

^{*} excludes people who reported treatment induced clearance more than 12 months previously

Table 5.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Queensland	2013	2014	2015	2016	2017
N° surveyed	N=565	N=490	N=532	N=349	N=619
Sex with a regular partner last month (%)					
No	255 (45)	229 (47)	239 (45)	165 (47)	316 (51)
Yes	304 (54)	250 (51)	274 (52)	175 (50)	279 (45)
Not reported	6 (1)	11 (2)	19 (4)	9 (3)	24 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=304	N=250	N=274	N=175	N=279
Never	221 (73)	174 (70)	212 (77)	130 (74)	198 (71)
Sometimes	40 (13)	39 (16)	30 (11)	24 (14)	37 (13)
Every time	27 (9)	25 (10)	26 (9)	15 (9)	33 (12)
Not reported	16 (5)	12 (5)	6 (2)	6 (3)	11 (4)
Sex with other partner(s) last month (%)					
No	461 (82)	398 (81)	440 (83)	294 (84)	497 (80)
Yes	83 (15)	74 (15)	79 (15)	44 (13)	92 (15)
Not reported	21 (4)	18 (4)	13 (2)	11 (3)	30 (5)
Condom used with other partner(s) last month (%)					
N° surveyed	N=83	N=74	N=79	N=44	N=92
Never	26 (31)	23 (31)	26 (33)	21 (48)	31 (34)
Sometimes	22 (37)	25 (34)	25 (32)	11 (25)	33 (36)
Every time	34 (41)	13 (18)	24 (30)	11 (25)	23 (25)
Not reported	1 (1)	13 (18)	4 (5)	1 (2)	5 (5)
Sex work last month (%)					
No	525 (93)	439 (90)	508 (95)	314 (90)	568 (92)
Yes	9 (2)	19 (4)	14 (3)	18 (5)	22 (4)
Not reported	31 (5)	32 (7)	10 (2)	17 (5)	29 (5)
Condom used at last sex work (%)					
Yes	6 (67)	10 (53)	9 (64)	12 (67)	17 (77)

HIV antibody prevalence

Table 5.2.1 HIV antibody prevalence by gender and survey year

Queensland Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013	372	7 (1.9)	160	0 (0.0)	533	7 (1.3)
2014	349	11 (3.2)	131	0 (0.0)	481	11 (2.3)
2015	382	6 (1.6)	144	0 (0.0)	528	7 (1.3)
2016	224	4 (1.8)	115	0 (0.0)	341	4 (1.2)
2017	441	14 (3.2)	167	1 (0.6)	609	15 (2.5)
X ² p trend		0.488		0.174		0.372

Table 5.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Queensland Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heterosexual	322	1 (0.3)	119	0 (0.0)	442	1 (0.2)
Bisexual	13	1 (7.7)	28	0 (0.0)	41	1 (2.4)
Homosexual	17	5 (29.4)	2	0 (0.0)	19	5 (26.3)
p value		<0.001		--		<0.001
2014						
Heterosexual	297	1 (0.3)	95	0 (0.0)	392	1 (0.3)
Bisexual	11	1 (9.1)	24	0 (0.0)	35	1 (2.9)
Homosexual	17	8 (47.1)	3	0 (0.0)	20	8 (40.0)
p value		<0.001		--		<0.001
2015						
Heterosexual	339	1 (0.3)	111	0 (0.0)	450	1 (0.2)
Bisexual	18	1 (5.6)	22	0 (0.0)	41	1 (2.4)
Homosexual	14	4 (28.6)	5	0 (0.0)	19	4 (21.1)
p value		<0.001		--		<0.001
2016						
Heterosexual	184	0 (0.0)	67	0 (0.0)	253	0 (0.0)
Bisexual	13	1 (7.7)	33	0 (0.0)	46	1 (2.2)
Homosexual	10	3 (30.0)	8	0 (0.0)	18	3 (16.7)
p value		<0.001		--		<0.001
2017						
Heterosexual	358	3 (0.8)	118	0 (0.0)	476	3 (0.6)
Bisexual	27	3 (11.1)	28	1 (3.6)	55	4 (7.3)
Homosexual	22	7 (31.8)	7	0 (0.0)	30	7 (23.3)
p value		<0.001		0.229		<0.001

Table 5.2.3 HIV antibody prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
<25 years	43	0 (0.0)	20	0 (0.0)	63	0 (0.0)
25-34 years	111	0 (0.0)	49	0 (0.0)	160	0 (0.0)
35-44 years	106	5 (4.7)	52	0 (0.0)	158	5 (3.2)
45+ years	110	2 (1.8)	39	0 (0.0)	150	2 (1.3)
p value		0.074		--		0.084
2014						
<25 years	35	0 (0.0)	16	0 (0.0)	51	0 (0.0)
25-34 years	110	1 (0.9)	45	0 (0.0)	155	1 (0.7)
35-44 years	107	4 (3.7)	45	0 (0.0)	152	4 (2.6)
45+ years	95	6 (6.3)	25	0 (0.0)	121	6 (5.0)
p value		0.119		--		0.091
2015						
<25 years	32	0 (0.0)	12	0 (0.0)	44	0 (0.0)
25-34 years	120	2 (1.7)	44	0 (0.0)	165	3 (1.8)
35-44 years	135	1 (0.7)	47	0 (0.0)	182	1 (0.6)
45+ years	94	3 (3.2)	41	0 (0.0)	136	3 (2.2)
p value		0.489		--		0.529
2016						
<25 years	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)
25-34 years	56	0 (0.0)	29	0 (0.0)	85	0 (0.0)
35-44 years	79	0 (0.0)	41	0 (0.0)	121	0 (0.0)
45+ years	75	4 (5.3)	38	0 (0.0)	114	4 (3.5)
p value		0.060		--		0.060
2017						
<25 years	25	0 (0.0)	11	0 (0.0)	37	0 (0.0)
25-34 years	86	3 (3.5)	41	0 (0.0)	127	3 (2.4)
35-44 years	157	5 (3.2)	53	0 (0.0)	210	5 (2.4)
45+ years	172	6 (3.5)	62	1 (1.6)	234	7 (3.0)
p value		1.000		1.000		0.935

Table 5.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Queensland Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heroin	58	0 (0.0)	30	0 (0.0)	88	0 (0.0)
Methamphetamine	91	6 (6.6)	62	0 (0.0)	153	6 (3.9)
Other opioids	133	1 (0.8)	60	0 (0.0)	194	1 (0.5)
PIEDs	60	0 (0.0)	0	0 (0.0)	60	0 (0.0)
Other drugs	29	0 (0.0)	8	0 (0.0)	37	0 (0.0)
p value		0.020		--		0.065
2014						
Heroin	53	1 (1.9)	21	0 (0.0)	74	1 (1.4)
Methamphetamine	98	8 (8.2)	54	0 (0.0)	152	8 (5.3)
Other opioids	103	1 (1.0)	44	0 (0.0)	148	1 (0.7)
PIEDs	67	1 (1.5)	3	0 (0.0)	70	1 (1.4)
Other drugs	25	0 (0.0)	9	0 (0.0)	34	0 (0.0)
p value		0.051		--		0.106
2015						
Heroin	76	1 (1.3)	31	0 (0.0)	107	1 (0.9)
Methamphetamine	120	5 (4.2)	60	0 (0.0)	182	6 (3.3)
Other opioids	107	0 (0.0)	42	0 (0.0)	149	0 (0.0)
PIEDs	61	0 (0.0)	1	0 (0.0)	62	0 (0.0)
Other drugs	18	0 (0.0)	10	0 (0.0)	28	0 (0.0)
p value		0.126		--		0.108
2016						
Heroin	32	0 (0.0)	22	0 (0.0)	54	0 (0.0)
Methamphetamine	88	3 (3.4)	44	0 (0.0)	133	3 (2.3)
Other opioids	65	0 (0.0)	37	0 (0.0)	103	0 (0.0)
PIEDs	20	1 (5.0)	0	0 (0.0)	20	1 (5.0)
Other drugs	19	0 (0.0)	12	0 (0.0)	31	0 (0.0)
p value		0.313		--		0.199
2017						
Heroin	57	0 (0.0)	31	1 (3.2)	88	1 (1.1)
Methamphetamine	176	11 (6.3)	84	0 (0.0)	261	11 (4.2)
Other opioids	132	1 (0.8)	45	0 (0.0)	177	1 (0.6)
PIEDs	48	0 (0.0)	0	0 (0.0)	48	0 (0.0)
Other drugs	28	2 (7.1)	7	0 (0.0)	35	2 (5.7)
p value		0.011		0.228		0.045

Table 5.2.5 HIV antibody prevalence by years of injection, gender and survey year

Queensland Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
<3 years	51	1 (2.0)	10	0 (0.0)	61	1 (1.6)
3 to 10 years	74	1 (1.4)	34	0 (0.0)	108	1 (0.9)
11+ years	237	5 (2.1)	113	0 (0.0)	351	5 (1.4)
p value		1.000		--		1.000
2014						
<3 years	39	2 (5.1)	15	0 (0.0)	54	2 (3.7)
3 to 10 years	59	1 (1.7)	27	0 (0.0)	86	1 (1.2)
11+ years	238	8 (3.4)	88	0 (0.0)	327	8 (2.5)
p value		0.555		--		0.559
2015						
<3 years	41	1 (2.4)	4	0 (0.0)	45	1 (2.2)
3 to 10 years	81	2 (2.5)	28	0 (0.0)	110	2 (1.8)
11+ years	250	3 (1.2)	108	0 (0.0)	359	4 (1.1)
p value		0.526		--		0.533
2016						
<3 years	16	0 (0.0)	5	0 (0.0)	21	0 (0.0)
3 to 10 years	46	3 (6.5)	12	0 (0.0)	58	3 (5.2)
11+ years	151	1 (0.7)	94	0 (0.0)	247	1 (0.4)
p value		0.061		--		0.041
2017						
<3 years	31	0 (0.0)	15	0 (0.0)	46	0 (0.0)
3 to 10 years	63	4 (6.4)	35	0 (0.0)	98	4 (4.1)
11+ years	347	10 (2.9)	117	1 (0.9)	465	11 (2.4)
p value		0.280		1.000		0.302

Table 5.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Queensland Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No receptive sharing	289	2 (0.7)	124	0 (0.0)	414	2 (0.5)
Receptive sharing	45	2 (4.4)	26	0 (0.0)	71	2 (2.8)
p value		0.089		--		0.104
2014						
No receptive sharing	258	8 (3.1)	96	0 (0.0)	355	8 (2.3)
Receptive sharing	46	0 (0.0)	22	0 (0.0)	68	0 (0.0)
p value		0.612		--		0.365
2015						
No receptive sharing	284	5 (1.8)	110	0 (0.0)	396	6 (1.5)
Receptive sharing	49	1 (2.0)	22	0 (0.0)	71	1 (1.4)
p value		1.000		--		1.000
2016						
No receptive sharing	153	3 (2.0)	86	0 (0.0)	239	3 (1.3)
Receptive sharing	41	1 (2.4)	15	0 (0.0)	57	1 (1.8)
p value		1.000		--		0.577
2017						
No receptive sharing	337	11 (3.3)	129	1 (0.8)	467	12 (2.6)
Receptive sharing	55	1 (1.8)	28	0 (0.0)	83	1 (1.2)
p value		1.000		1.000		0.703

Table 5.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Queensland	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Less than daily	173	3 (1.7)	75	0 (0.0)	249	3 (1.2)
Daily or more	164	2 (1.2)	78	0 (0.0)	242	2 (0.8)
Not last month	27	1 (3.7)	6	0 (0.0)	33	1 (3.0)
p value		0.508		--		0.470
2014						
Less than daily	144	5 (3.5)	53	0 (0.0)	197	5 (2.5)
Daily or more	162	3 (1.9)	69	0 (0.0)	232	3 (1.3)
Not last month	38	3 (7.9)	7	0 (0.0)	45	3 (6.7)
p value		0.139		--		0.090
2015						
Less than daily	154	3 (2.0)	48	0 (0.0)	204	4 (2.0)
Daily or more	182	3 (1.7)	84	0 (0.0)	266	3 (1.1)
Not last month	43	0 (0.0)	11	0 (0.0)	54	0 (0.0)
p value		1.000		--		0.532
2016						
Less than daily	82	4 (4.9)	44	0 (0.0)	126	4 (3.2)
Daily or more	113	0 (0.0)	59	0 (0.0)	173	0 (0.0)
Not last month	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
p value		0.046		--		0.045
2017						
Less than daily	179	11 (6.2)	60	0 (0.0)	240	11 (4.6)
Daily or more	217	1 (0.5)	97	1 (1.0)	314	2 (0.6)
Not last month	40	2 (5.0)	10	0 (0.0)	50	2 (4.0)
p value		0.002		1.000		0.004

Table 5.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Queensland	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No imprisonment	319	7 (2.2)	150	0 (0.0)	470	7 (1.5)
Imprisonment	37	0 (0.0)	6	0 (0.0)	43	0 (0.0)
p value		1.000		--		1.000
2014						
No imprisonment	289	7 (2.4)	118	0 (0.0)	407	7 (1.7)
Imprisonment	38	0 (0.0)	10	0 (0.0)	48	0 (0.0)
p value		1.000		--		1.000
2015						
No imprisonment	334	6 (1.8)	129	0 (0.0)	465	7 (1.5)
Imprisonment	30	0 (0.0)	12	0 (0.0)	42	0 (0.0)
p value		1.000		--		1.000
2016						
No imprisonment	192	3 (1.6)	98	0 (0.0)	292	3 (1.0)
Imprisonment	27	1 (3.7)	11	0 (0.0)	38	1 (2.6)
p value		0.412		--		0.388
2017						
No imprisonment	367	13 (3.5)	152	1 (0.7)	520	14 (2.7)
Imprisonment	57	1 (1.8)	10	0 (0.0)	67	1 (1.5)
p value		0.704		1.000		1.000

Table 5.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Queensland	Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No condom use	132	2 (1.5)	76	0 (0.0)	208	2 (1.0)
Condom use	47	3 (6.4)	15	0 (0.0)	62	3 (4.8)
p value		0.114		--		0.081
2014						
No condom use	121	4 (3.3)	48	0 (0.0)	170	4 (2.4)
Condom use	48	2 (4.2)	16	0 (0.0)	64	2 (3.1)
p value		1.000		--		0.666
2015						
No condom use	140	2 (1.4)	70	0 (0.0)	211	3 (1.4)
Condom use	41	0 (0.0)	14	0 (0.0)	55	0 (0.0)
p value		1.000		--		1.000
2016						
No condom use	77	2 (2.6)	46	0 (0.0)	125	2 (1.6)
Condom use	28	1 (3.6)	11	0 (0.0)	39	1 (2.6)
p value		1.000		--		0.560
2017						
No condom use	134	3 (2.2)	63	1 (1.6)	197	4 (2.0)
Condom use	49	4 (8.2)	18	0 (0.0)	68	4 (5.9)
p value		0.840		1.000		0.210

Table 5.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Queensland	Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No sex work	346	7 (2.0)	148	0 (0.0)	495	7 (1.4)
Sex work	3	0 (0.0)	5	0 (0.0)	8	0 (0.0)
p value		1.000		--		1.000
2014						
No sex work	312	7 (2.2)	118	0 (0.0)	431	7 (1.6)
Sex work	13	2 (15.4)	6	0 (0.0)	19	2 (10.5)
p value		0.045		--		0.051
2015						
No sex work	368	5 (1.4)	135	0 (0.0)	505	6 (1.2)
Sex work	5	1 (20.0)	9	0 (0.0)	14	1 (7.1)
p value		0.078		--		0.175
2016						
No sex work	208	4 (1.9)	97	0 (0.0)	307	4 (1.3)
Sex work	9	0 (0.0)	9	0 (0.0)	18	0 (0.0)
p value		1.000		--		1.000
2017						
No sex work	413	13 (3.2)	146	1 (0.7)	559	14 (2.5)
Sex work	10	1 (10.0)	11	0 (0.0)	22	1 (4.6)
p value		0.288		1.000		0.444

Table 5.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Queensland Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Non Indigenous	330	7 (2.1)	135	0 (0.0)	466	7 (1.5)
Indigenous	33	0 (0.0)	21	0 (0.0)	54	0 (0.0)
p value		1.000		--		1.000
2014						
Non Indigenous	311	10 (3.2)	108	0 (0.0)	420	10 (2.4)
Indigenous	30	0 (0.0)	19	0 (0.0)	49	0 (0.0)
p value		1.000		--		0.609
2015						
Non Indigenous	337	6 (1.8)	118	0 (0.0)	457	7 (1.5)
Indigenous	41	0 (0.0)	21	0 (0.0)	65	0 (0.0)
p value		1.000		--		0.605
2016						
Non Indigenous	193	4 (2.1)	94	0 (0.0)	289	4 (1.4)
Indigenous	25	0 (0.0)	19	0 (0.0)	44	0 (0.0)
p value		1.000		--		1.000
2017						
Non Indigenous	358	11 (3.1)	135	1 (0.7)	493	12 (2.4)
Indigenous	69	3 (4.4)	30	0 (0.0)	100	3 (3.0)
p value		0.482		1.000		0.727

Table 5.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Queensland Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
English speaking	362	7 (1.9)	154	0 (0.0)	517	7 (1.4)
Non-English speaking	8	0 (0.0)	6	0 (0.0)	14	0 (0.0)
p value		1.000		--		1.000
2014						
English speaking	334	10 (3.0)	125	0 (0.0)	460	10 (2.2)
Non-English speaking	12	1 (8.3)	5	0 (0.0)	17	1 (5.9)
p value		0.326		--		0.332
2015						
English speaking	367	6 (1.6)	142	0 (0.0)	511	7 (1.4)
Non-English speaking	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
p value		1.000		--		1.000
2016						
English speaking	210	3 (1.4)	111	0 (0.0)	323	3 (0.9)
Non-English speaking	9	1 (11.1)	2	0 (0.0)	11	1 (9.1)
p value		0.156		--		0.126
2017						
English speaking	425	14 (3.3)	159	1 (0.6)	584	15 (2.6)
Non-English speaking	13	0 (0.0)	8	0 (0.0)	22	0 (0.0)
p value		1.000		1.000		1.000

Table 5.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Queensland	Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Australia	334	6 (1.8)	141	0 (0.0)	476	6 (1.3)
Other Oceania	21	1 (4.8)	7	0 (0.0)	28	1 (3.6)
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
UK & Ireland	8	0 (0.0)	4	0 (0.0)	12	0 (0.0)
Other	8	0 (0.0)	7	0 (0.0)	15	0 (0.0)
p value		0.739		--		0.690
2014						
Australia	298	9 (3.0)	116	0 (0.0)	415	9 (2.2)
Other Oceania	21	1 (4.8)	7	0 (0.0)	28	1 (3.6)
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
UK & Ireland	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)
Other	14	1 (7.1)	3	0 (0.0)	17	1 (5.9)
p value		0.480		--		0.441
2015						
Australia	333	6 (1.8)	129	0 (0.0)	464	7 (1.5)
Other Oceania	18	0 (0.0)	6	0 (0.0)	24	0 (0.0)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	10	0 (0.0)	6	0 (0.0)	16	0 (0.0)
Other	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
p value		1.000		--		1.000
2016						
Australia	196	3 (1.5)	101	0 (0.0)	298	3 (1.0)
Other Oceania	8	0 (0.0)	4	0 (0.0)	12	0 (0.0)
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
UK & Ireland	7	0 (0.0)	8	0 (0.0)	16	0 (0.0)
Other	5	1 (20.0)	0	0 (0.0)	5	1 (20.0)
p value		0.146		--		0.117
2017						
Australia	398	14 (3.5)	141	1 (0.7)	539	15 (2.8)
Other Oceania	13	0 (0.0)	17	0 (0.0)	31	0 (0.0)
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
UK & Ireland	14	0 (0.0)	5	0 (0.0)	19	0 (0.0)
Other	9	0 (0.0)	2	0 (0.0)	11	0 (0.0)
p value		1.000		1.000		1.000

HCV antibody prevalence

Table 5.3.1 HCV antibody prevalence by gender and survey year

Queensland Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013	372	167 (45)	160	79 (49)	533	247 (46)
2014	327	120 (37)	123	49 (40)	451	169 (37)
2015	379	161 (42)	139	64 (46)	520	226 (43)
2016	204	98 (48)	101	54 (53)	306	153 (50)
2017	425	179 (42)	161	66 (41)	587	245 (42)
X ² p trend		0.846		0.707		0.945

Table 5.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Queensland Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heterosexual	322	142 (44)	119	58 (49)	442	201 (45)
Bisexual	13	6 (46)	28	16 (57)	41	22 (54)
Homosexual	17	6 (35)	2	0 (0)	19	6 (32)
p value		0.763		0.303		0.275
2014						
Heterosexual	275	103 (37)	87	36 (41)	362	139 (38)
Bisexual	11	6 (55)	24	8 (33)	35	14 (40)
Homosexual	18	3 (17)	3	2 (67)	21	5 (24)
p value		0.094		0.565		0.416
2015						
Heterosexual	336	144 (43)	107	47 (44)	443	191 (43)
Bisexual	18	11 (61)	22	12 (55)	41	23 (56)
Homosexual	14	0 (0)	4	2 (50)	18	2 (11)
p value		<0.001		0.655		0.004
2016						
Heterosexual	165	80 (48)	58	31 (53)	224	112 (50)
Bisexual	12	3 (25)	32	19 (59)	44	22 (50)
Homosexual	10	6 (60)	4	1 (25)	14	7 (50)
p value		0.205		0.408		1.000
2017						
Heterosexual	343	142 (41)	113	46 (41)	456	188 (41)
Bisexual	26	17 (65)	27	12 (44)	53	29 (55)
Homosexual	24	7 (29)	8	2 (25)	33	9 (27)
p value		0.024		0.642		0.038

Table 5.3.3 HCV antibody prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<25 years	43	5 (12)	20	5 (25)	63	10 (16)
25-34 years	111	38 (34)	49	24 (49)	160	62 (39)
35-44 years	106	57 (54)	52	24 (46)	158	81 (52)
45+ years	110	66 (60)	39	26 (67)	150	93 (62)
p value		<0.001		0.022		<0.001
2014						
<25 years	35	2 (6)	16	2 (13)	51	4 (8)
25-34 years	105	25 (24)	42	18 (43)	147	43 (29)
35-44 years	97	44 (45)	44	16 (36)	141	60 (43)
45+ years	88	49 (56)	21	13 (62)	110	62 (56)
p value		<0.001		0.020		<0.001
2015						
<25 years	32	7 (22)	12	4 (33)	44	11 (25)
25-34 years	120	37 (31)	43	19 (44)	164	57 (35)
35-44 years	133	56 (42)	46	18 (39)	179	74 (41)
45+ years	93	61 (66)	38	23 (61)	132	84 (64)
p value		<0.001		0.185		<0.001
2016						
<25 years	14	3 (21)	5	2 (40)	19	5 (26)
25-34 years	52	19 (37)	28	14 (50)	80	33 (41)
35-44 years	76	41 (54)	36	21 (58)	112	62 (55)
45+ years	62	35 (56)	32	17 (53)	95	53 (56)
p value		0.023		0.848		0.026
2017						
<25 years	24	2 (8)	11	2 (18)	36	4 (11)
25-34 years	84	30 (36)	42	22 (52)	126	52 (41)
35-44 years	148	65 (44)	53	17 (32)	201	82 (41)
45+ years	168	82 (49)	55	25 (45)	223	107 (48)
p value		0.001		0.081		<0.001

Table 5.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Queensland Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<3 years	51	3 (6)	10	2 (20)	61	5 (8)
3 to 10 years	74	16 (22)	34	15 (44)	108	31 (29)
11+ years	237	139 (59)	113	61 (54)	351	201 (57)
p value		<0.001		0.087		<0.001
2014						
<3 years	39	3 (8)	15	1 (7)	54	4 (7)
3 to 10 years	59	9 (15)	27	7 (26)	86	16 (19)
11+ years	215	106 (49)	80	41 (51)	296	147 (50)
p value		<0.001		0.001		<0.001
2015						
<3 years	42	4 (10)	4	1 (25)	46	5 (11)
3 to 10 years	81	16 (20)	28	10 (36)	110	26 (24)
11+ years	246	138 (56)	103	52 (50)	350	191 (55)
p value		<0.001		0.293		<0.001
2016						
<3 years	16	0 (0)	4	1 (25)	20	1 (5)
3 to 10 years	45	13 (29)	11	3 (27)	56	16 (29)
11+ years	132	77 (58)	82	50 (61)	215	128 (60)
p value		<0.001		0.045		<0.001
2017						
<3 years	31	1 (3)	15	2 (13)	46	3 (7)
3 to 10 years	62	10 (16)	35	7 (20)	97	17 (18)
11+ years	318	161 (51)	111	57 (51)	430	218 (51)
p value		<0.001		<0.001		<0.001

Table 5.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Queensland Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No receptive sharing	49	3 (6)	356	176 (49)	414	187 (45)
Receptive sharing	5	2 (40)	64	38 (59)	71	41 (58)
p value		0.062		0.143		0.050
2014						
No receptive sharing	38	3 (8)	288	113 (39)	336	118 (35)
Receptive sharing	2	1 (50)	57	38 (67)	59	39 (66)
p value		0.192		<0.001		<0.001
2015						
No receptive sharing	35	4 (11)	349	171 (49)	391	177 (45)
Receptive sharing	4	1 (25)	62	34 (55)	68	37 (54)
p value		0.436		0.397		0.163
2016						
No receptive sharing	10	0 (0)	198	102 (52)	217	107 (49)
Receptive sharing	4	0 (0)	47	27 (57)	52	28 (54)
p value		--		0.464		0.557
2017						
No receptive sharing	34	1 (3)	407	182 (45)	449	186 (41)
Receptive sharing	8	2 (25)	68	36 (53)	80	41 (51)
p value		0.088		0.208		0.102

Table 5.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Queensland Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heroin	3	1 (33)	83	51 (61)	88	53 (60)
Methamphetamine	12	2 (17)	137	56 (41)	153	60 (39)
Other opioids	10	2 (20)	178	102 (57)	194	110 (57)
PIEDs	33	0 (0)	27	0 (0)	60	0 (0)
Other drugs	3	0 (0)	33	22 (67)	37	23 (62)
p value		0.068		<0.001		<0.001
2014						
Heroin	1	1 (100)	64	41 (64)	66	42 (64)
Methamphetamine	17	2 (12)	123	43 (35)	141	46 (33)
Other opioids	4	1 (25)	135	71 (53)	141	72 (51)
PIEDs	27	0 (0)	36	0 (0)	69	0 (0)
Other drugs	5	0 (0)	23	7 (30)	31	7 (23)
p value		0.002		<0.001		<0.001
2015						
Heroin	0	0 (0)	105	64 (61)	106	64 (60)
Methamphetamine	14	3 (21)	162	57 (35)	178	61 (34)
Other opioids	5	1 (20)	140	88 (63)	146	90 (62)
PIEDs	25	0 (0)	33	0 (0)	62	0 (0)
Other drugs	2	1 (50)	19	8 (42)	24	11 (46)
p value		0.041		<0.001		<0.001
2016						
Heroin	1	0 (0)	41	27 (66)	43	27 (63)
Methamphetamine	10	0 (0)	105	51 (49)	120	55 (46)
Other opioids	1	0 (0)	81	49 (60)	85	51 (60)
PIEDs	3	0 (0)	15	0 (0)	19	0 (0)
Other drugs	4	1 (25)	21	11 (52)	30	14 (47)
p value		0.412		<0.001		<0.001
2017						
Heroin	4	1 (25)	77	44 (57)	82	46 (56)
Methamphetamine	20	1 (5)	230	87 (38)	255	91 (36)
Other opioids	6	1 (17)	160	93 (58)	170	96 (56)
PIEDs	12	0 (0)	34	2 (6)	47	2 (4)
Other drugs	4	0 (0)	23	7 (30)	30	8 (27)
p value		0.349		<0.001		<0.001

Table 5.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Queensland	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Less than daily	39	2 (5)	203	97 (48)	249	104 (42)
Daily or more	15	3 (20)	222	121 (55)	242	129 (53)
Not last month	7	0 (0)	25	8 (32)	33	8 (24)
p value		0.185		0.066		0.001
2014						
Less than daily	20	2 (10)	163	59 (36)	189	63 (33)
Daily or more	21	2 (10)	186	94 (51)	212	96 (45)
Not last month	13	0 (0)	27	8 (30)	44	8 (18)
p value		0.663		0.009		0.001
2015						
Less than daily	26	3 (12)	173	81 (47)	202	84 (42)
Daily or more	13	2 (15)	241	124 (51)	260	130 (50)
Not last month	7	0 (0)	45	12 (27)	54	12 (22)
p value		0.827		0.009		0.001
2016						
Less than daily	10	0 (0)	101	54 (53)	116	57 (49)
Daily or more	4	0 (0)	146	77 (53)	155	80 (52)
Not last month	5	1 (20)	16	7 (44)	26	10 (38)
p value		0.474		0.766		0.461
2017						
Less than daily	23	1 (4)	201	81 (40)	229	84 (37)
Daily or more	19	2 (11)	278	138 (50)	304	144 (47)
Not last month	4	0 (0)	45	14 (31)	51	15 (29)
p value		0.683		0.022		0.008

Table 5.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Queensland	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No imprisonment	58	5 (9)	400	196 (49)	470	210 (45)
Imprisonment	2	0 (0)	41	27 (66)	43	27 (63)
p value		1.000		0.040		0.023
2014						
No imprisonment	49	3 (6)	322	139 (43)	384	144 (38)
Imprisonment	2	0 (0)	39	19 (49)	42	19 (45)
p value		1.000		0.509		0.327
2015						
No imprisonment	42	4 (10)	403	175 (43)	459	183 (40)
Imprisonment	1	1 (100)	39	29 (74)	40	30 (75)
p value		0.116		<0.001		<0.001
2016						
No imprisonment	16	0 (0)	233	115 (49)	263	122 (46)
Imprisonment	1	0 (0)	33	26 (79)	35	27 (77)
p value		--		0.002		0.001
2017						
No imprisonment	40	2 (5)	450	190 (42)	501	196 (39)
Imprisonment	3	0 (0)	58	34 (59)	64	37 (58)
p value		1.000		0.018		0.004

Table 5.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Queensland Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Non Indigenous	330	145 (44)	135	62 (46)	466	208 (45)
Indigenous	33	18 (55)	21	15 (71)	54	33 (61)
p value		0.243		0.030		0.022
2014						
Non Indigenous	293	105 (36)	104	43 (41)	398	148 (37)
Indigenous	27	14 (52)	15	6 (40)	42	20 (48)
p value		0.099		0.921		0.186
2015						
Non Indigenous	334	135 (40)	114	51 (45)	450	187 (42)
Indigenous	41	25 (61)	23	12 (52)	64	37 (59)
p value		0.012		0.514		0.014
2016						
Non Indigenous	176	80 (45)	82	39 (48)	259	120 (46)
Indigenous	22	14 (64)	18	14 (78)	40	28 (70)
p value		0.107		0.035		0.005
2017						
Non Indigenous	346	134 (39)	130	51 (39)	476	185 (39)
Indigenous	66	41 (62)	29	15 (52)	96	56 (58)
p value		<0.001		0.217		<0.001

Table 5.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Queensland Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
English speaking	362	162 (45)	154	76 (49)	517	239 (46)
Non-English speaking	8	5 (63)	6	3 (50)	14	8 (57)
p value		0.476		1.000		0.419
2014						
English speaking	313	115 (37)	117	47 (40)	431	162 (38)
Non-English speaking	12	5 (42)	5	2 (40)	17	7 (41)
p value		0.729		1.000		0.765
2015						
English speaking	364	153 (42)	137	62 (45)	503	216 (43)
Non-English speaking	8	4 (50)	1	1 (100)	9	5 (56)
p value		0.726		0.457		0.449
2016						
English speaking	191	90 (47)	98	51 (52)	290	142 (49)
Non-English speaking	9	5 (56)	2	2 (100)	11	7 (64)
p value		0.738		0.497		0.375
2017						
English speaking	410	175 (43)	153	61 (40)	563	236 (42)
Non-English speaking	13	3 (23)	8	5 (63)	22	8 (36)
p value		0.253		0.274		0.604

Table 5.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Queensland	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Australia	334	149 (45)	141	71 (50)	476	221 (46)
Other Oceania	21	11 (52)	7	4 (57)	28	15 (54)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	8	4 (50)	4	1 (25)	12	5 (42)
Other	8	3 (38)	7	2 (29)	15	5 (33)
p value		0.864		0.589		0.646
2014						
Australia	277	111 (40)	109	42 (39)	387	153 (40)
Other Oceania	22	5 (23)	6	3 (50)	28	8 (29)
Asia	2	0 (0)	0	0 (0)	2	0 (0)
UK & Ireland	10	3 (30)	4	2 (50)	14	5 (36)
Other	14	1 (7)	3	1 (33)	17	2 (12)
p value		0.044		0.858		0.095
2015						
Australia	330	143 (43)	124	62 (50)	456	206 (45)
Other Oceania	18	7 (39)	6	1 (17)	24	8 (33)
Asia	4	0 (0)	1	0 (0)	5	0 (0)
UK & Ireland	10	5 (50)	6	1 (17)	16	6 (38)
Other	8	2 (25)	1	0 (0)	9	2 (22)
p value		0.401		0.111		0.132
2016						
Australia	178	87 (49)	90	47 (52)	268	134 (50)
Other Oceania	7	3 (43)	3	2 (67)	10	5 (50)
Asia	2	1 (50)	0	0 (0)	2	1 (50)
UK & Ireland	7	4 (57)	7	4 (57)	15	9 (60)
Other	5	1 (20)	0	0 (0)	5	1 (20)
p value		0.812		1.000		0.682
2017						
Australia	383	162 (42)	136	61 (45)	519	223 (43)
Other Oceania	13	6 (46)	16	3 (19)	30	9 (30)
Asia	1	0 (0)	1	1 (100)	2	1 (50)
UK & Ireland	14	8 (57)	5	1 (20)	19	9 (47)
Other	9	1 (11)	2	0 (0)	11	1 (9)
p value		0.194		0.069		0.087

South Australia

Table 6.1.1 Number (percentage) of respondents by demographic characteristics and survey year

South Australia	2013	2014	2015	2016	2017
Number of sites	7	7	7	7	7
N° surveyed	N=248	N=228	N=238	N=247	N=270
Response rate (%)	56%	51%	55%	52%	54%
Gender (%)					
Male	169 (68)	143 (63)	137 (58)	151 (61)	138 (51)
Female	78 (31)	83 (36)	98 (41)	95 (38)	127 (47)
Transgender	1 (<1)	2 (1)	3 (1)	0 (0)	5 (2)
Not reported	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)
Sexual identity (%)					
Heterosexual	193 (78)	177 (78)	187 (79)	196 (79)	190 (70)
Bisexual	26 (10)	28 (12)	26 (11)	20 (8)	37 (14)
Homosexual	8 (3)	5 (2)	12 (5)	10 (4)	25 (9)
Not reported	21 (8)	18 (8)	13 (5)	21 (9)	18 (7)
Aboriginal and Torres Strait Islander origin (%)					
No	201 (81)	197 (86)	210 (88)	192 (78)	210 (78)
Yes	35 (14)	28 (1)	25 (11)	49 (20)	49 (18)
Not reported	12 (5)	3 (1)	3 (1)	6 (2)	11 (4)
Region/country of birth (%)					
Australia	214 (86)	202 (87)	214 (90)	215 (87)	238 (88)
Other Oceania	4 (2)	4 (2)	0 (0)	9 (4)	3 (1)
Asia	3 (1)	2 (1)	2 (1)	0 (0)	2 (1)
UK & Ireland	18 (7)	11 (5)	9 (4)	12 (5)	12 (4)
Other	9 (4)	8 (4)	8 (3)	9 (4)	12 (4)
Not reported	0 (0)	1 (<1)	5 (2)	2 (1)	3 (1)
Main language spoken at home by parents (%)					
English	230 (93)	213 (93)	221 (93)	228 (92)	255 (94)
Non-English	18 (7)	13 (6)	14 (6)	17 (7)	14 (5)
Not reported	0 (0)	2 (1)	3 (1)	2 (1)	1 (<1)
Age and time since first injection (years)					
<i>Median age</i>	40	40	43	43	43
<i>Age range</i>	17-60	18-68	17-70	17-67	18-69
<i>Age group (%)</i>					
<25 years	21 (8)	6 (3)	7 (3)	12 (5)	21 (8)
25+ years	225 (91)	222 (97)	231 (97)	235 (95)	249 (92)
Not reported	2 (1)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age first injection</i>	18	18	19	19	18
<i>Age range</i>	12-48	10-57	12-51	10-55	10-60
N° not reported	8	1	5	5	17
<i>Median yrs since first injection</i>	18	20	22	21	22
<i>Range</i>	<1-46	<1-41	<1-51	<1-47	1-47
<i>Years since first injection</i>					
<3 years	13 (5)	8 (4)	10 (4)	15 (6)	10 (4)
3+ years	227 (92)	218 (96)	223 (94)	227 (92)	243 (90)
Not reported	8 (3)	2 (1)	5 (2)	5 (2)	17 (6)
Imprisonment last year (%)					
No	200 (81)	195 (86)	214 (90)	211 (85)	224 (83)
Yes	25 (10)	19 (8)	13 (5)	24 (10)	32 (12)
Not reported	23 (9)	14 (6)	11 (5)	12 (5)	14 (5)
N° in prison	N=25	N=19	N=13	N=24	N=32
Injected in prison	4 (16)	1 (5)	2 (15)	4 (17)	6 (19)

Table 6.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

South Australia	2013	2014	2015	2016	2017
N° surveyed	N=248	N=228	N=238	N=247	N=270
Drug last injected (%)					
Cocaine	1 (<1)	0 (0)	1 (<1)	1 (<1)	4 (1)
Methamphetamine	93 (38)	116 (51)	125 (53)	147 (60)	133 (49)
Heroin	83 (33)	65 (29)	73 (31)	45 (18)	89 (33)
Pharm. opioids	41 (17)	14 (6)	12 (5)	24 (10)	17 (6)
Methadone	8 (3)	9 (4)	11 (5)	11 (4)	11 (4)
Buprenorphine	0 (0)	2 (1)	1 (<1)	3 (1)	2 (1)
Buprenorphine/naloxone	3 (1)	1 (<1)	1 (<1)	1 (<1)	1 (<1)
PIEDs	1 (<1)	1 (<1)	1 (<1)	2 (1)	2 (1)
More than one	16 (6)	18 (8)	10 (4)	13 (5)	8 (3)
Other	2 (1)	2 (1)	3 (1)	0 (0)	2 (1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Ever injected opioids					
Yes	-	-	-	178 (72)	199 (74)
No	-	-	-	67 (27)	68 (25)
Not reported	-	-	-	2 (1)	3 (1)
Frequency of injection last month (%)					
Not last month	10 (4)	9 (4)	17 (7)	11 (4)	28 (10)
Less than weekly	41 (17)	42 (18)	48 (20)	40 (16)	37 (14)
Weekly not daily	70 (28)	66 (29)	82 (34)	79 (32)	69 (26)
Daily or more	121 (49)	106 (46)	90 (38)	114 (46)	130 (48)
Not reported	6 (2)	5 (2)	1 (<1)	3 (1)	6 (2)
Present when someone injected for the first time in the last 12 months (%)					
Yes	41 (17)	34 (15)	34 (14)	43 (17)	59 (22)
No	176 (71)	190 (83)	202 (85)	202 (82)	208 (77)
Not reported	31 (13)	4 (2)	2 (1)	2 (1)	3 (1)
Overdosed in last 12 months					
Yes	22 (9)	25 (11)	18 (8)	48 (19)	44 (16)
No	212 (85)	198 (87)	218 (92)	194 (79)	220 (81)
Not reported	14 (6)	5 (2)	2 (1)	5 (2)	6 (2)

Table 6.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

South Australia	2013	2014	2015	2016	2017
N° injected last month	N=232	N=214	N=220	N=233	N=236
Places injected last month (%)					
Any public	103 (44)	69 (32)	67 (30)	106 (45)	104 (44)
All private	128 (55)	143 (67)	153 (70)	125 (54)	130 (55)
Not reported	1 (<1)	2 (1)	0 (0)	2 (1)	2 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	187 (81)	174 (81)	178 (81)	180 (77)	188 (80)
Most of the time	35 (15)	30 (14)	36 (16)	40 (17)	40 (17)
Half of the time	3 (1)	4 (2)	2 (1)	6 (3)	4 (2)
Some of the time	2 (1)	2 (1)	1 (<1)	2 (1)	1 (0)
Not last month	2 (1)	0 (0)	1 (<1)	1 (<1)	1 (0)
Not reported	3 (1)	4 (2)	2 (1)	4 (2)	2 (1)
Re-used someone else's used needle & syringe last month (%)					
None	197 (85)	183 (86)	189 (86)	180 (77)	194 (82)
Once	17 (7)	10 (5)	11 (5)	21 (9)	14 (6)
Twice	6 (3)	12 (6)	13 (6)	14 (6)	17 (7)
3-5 times	5 (2)	4 (2)	4 (2)	11 (5)	5 (2)
>5 times	6 (3)	3 (1)	3 (1)	5 (2)	2 (1)
Not reported	1 (<1)	2 (1)	0 (0)	2 (1)	4 (2)
Number of people needle & syringe was re-used after last month (%)					
None	197 (85)	183 (86)	189 (86)	180 (77)	194 (82)
One	14 (6)	11 (5)	14 (6)	18 (8)	22 (9)
Two	3 (1)	1 (<1)	2 (1)	5 (2)	2 (1)
Three to five	3 (1)	0 (0)	1 (<1)	5 (2)	4 (2)
More than five	3 (1)	2 (1)	0 (0)	2 (1)	3 (1)
Don't know	9 (4)	10 (5)	10 (5)	9 (4)	5 (2)
Not reported	3 (1)	7 (3)	4 (2)	14 (6)	6 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	18 (8)	14 (7)	14 (6)	24 (10)	18 (8)
Casual sex partner	2 (1)	1 (<1)	3 (1)	1 (<1)	3 (1)
Close friend	9 (4)	9 (4)	2 (1)	13 (6)	11 (5)
Acquaintance	5 (2)	2 (1)	4 (2)	6 (3)	4 (2)
Other	5 (2)	3 (1)	4 (2)	1 (<1)	3 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	51 (22)	32 (15)	34 (15)	30 (13)	50 (21)
Water	43 (19)	28 (13)	43 (20)	50 (21)	48 (20)
Filter	26 (11)	12 (6)	19 (9)	17 (7)	23 (10)
Drug mix	21 (9)	12 (6)	19 (9)	20 (9)	22 (9)
None	147 (63)	155 (72)	161 (73)	161 (69)	155 (66)
Injected by someone after that person injected themselves or others last month (%)					
No	182 (78)	166 (78)	178 (81)	187 (80)	183 (78)
Yes	39 (17)	40 (19)	42 (19)	43 (18)	50 (21)
Not reported	11 (5)	8 (4)	0 (0)	3 (1)	3 (1)
Source of needle acquisition					
Needle Syringe Program	211 (91)	191 (89)	201 (91)	203 (87)	210 (89)
Chemist/Pharmacy	41 (18)	34 (16)	44 (20)	41 (18)	45 (19)
Personal sources	27 (12)	18 (8)	23 (10)	37 (16)	32 (14)
Dispensing/Vending Machine	20 (9)	22 (10)	37 (17)	47 (20)	43 (18)
Other sources	4 (2)	1 (<1)	4 (2)	3 (1)	4 (2)

Table 6.1.4 Number (percentage) of respondents by treatment for drug use and survey year

South Australia	2013	2014	2015	2016	2017
N° surveyed	N=248	N=228	N=238	N=247	N=270
Ever any treatment/therapy for drug use (%)					
No	72 (29)	72 (33)	76 (32)	85 (34)	73 (27)
Yes	170 (69)	153 (67)	161 (68)	153 (62)	188 (70)
Not reported	6 (2)	3 (1)	1 (<1)	9 (4)	9 (3)
History of methadone maintenance treatment (%)					
Currently	65 (26)	57 (25)	53 (22)	44 (18)	73 (27)
Previously	41 (17)	46 (20)	56 (24)	47 (19)	48 (18)
Never	140 (56)	122 (54)	125 (53)	144 (58)	142 (53)
Not reported	2 (1)	3 (1)	4 (2)	12 (5)	7 (3)
History of buprenorphine (Subutex®) treatment (%)					
Currently	19 (8)	15 (7)	18 (8)	13 (5)	17 (6)
Previously	64 (26)	54 (24)	74 (31)	54 (22)	78 (29)
Never	158 (64)	157 (69)	143 (60)	170 (69)	164 (61)
Not reported	7 (3)	2 (1)	3 (1)	10 (4)	11 (4)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	23 (9)	23 (10)	16 (7)	23 (9)	23 (9)
Previously	57 (23)	37 (16)	48 (20)	36 (15)	71 (26)
Never	163 (66)	164 (72)	170 (71)	180 (73)	171 (63)
Not reported	5 (2)	4 (2)	4 (2)	8 (3)	5 (2)

Table 6.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

South Australia	2013	2014	2015	2016	2017
N° surveyed	N=248	N=228	N=238	N=247	N=270
Previous HIV test (%)					
Yes, ever	207 (83)	176 (77)	212 (89)	198 (80)	210 (78)
Yes, last year	132 (53)	98 (43)	127 (53)	112 (45)	122 (45)
>1 year ago	75 (30)	78 (34)	85 (36)	86 (35)	88 (33)
Never tested	34 (14)	45 (20)	22 (9)	45 (18)	55 (20)
Not reported	7 (3)	7 (3)	4 (2)	4 (2)	5 (2)
Previous HCV test (%)					
Yes, ever	214 (86)	183 (80)	211 (89)	201 (81)	220 (81)
Yes, last year	140 (56)	116 (51)	131 (55)	121 (49)	149 (55)
>1 year ago	74 (30)	67 (29)	80 (34)	80 (32)	71 (26)
Never tested	22 (9)	35 (15)	15 (6)	31 (13)	37 (14)
Not reported	12 (5)	10 (4)	12 (5)	15 (6)	13 (5)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=65	N=50	N=58	N=48	N=68
Antiviral treatment	12 (18)	7 (14)	9 (16)	22 (46)	34 (50)
No antiviral treatment	50 (77)	40 (80)	47 (81)	26 (54)	34 (50)
Not reported	3 (5)	3 (6)	2 (3)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)#*					
N° self-reported HCV diagnosis	N=59	N=48	N=52	N=42	N=64
Antiviral treatment	2 (3)	1 (2)	1 (2)	13 (31)	25 (39)
No antiviral treatment	54 (92)	44 (92)	49 (94)	29 (69)	39 (61)
Not reported	3 (5)	3 (6)	2 (4)	0 (0)	0 (0)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 6.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

South Australia	2013	2014	2015	2016	2017
N° surveyed	N=248	N=228	N=238	N=247	N=270
Sex with a regular partner last month (%)					
No	124 (50)	102 (45)	108 (45)	94 (38)	130 (48)
Yes	118 (48)	119 (52)	116 (49)	146 (59)	131 (49)
Not reported	6 (2)	7 (3)	14 (6)	7 (3)	9 (3)
Condom used with regular partner last month (%)					
N° surveyed	N=118	N=119	N=116	N=146	N=131
Never	86 (73)	89 (75)	87 (75)	112 (77)	95 (73)
Sometimes	14 (12)	14 (12)	11 (9)	12 (8)	14 (11)
Every time	6 (5)	11 (9)	14 (12)	13 (9)	16 (12)
Not reported	12 (10)	5 (4)	4 (3)	9 (6)	6 (5)
Sex with other partner(s) last month (%)					
No	216 (87)	185 (81)	205 (86)	202 (82)	232 (86)
Yes	23 (9)	34 (15)	21 (9)	39 (16)	29 (11)
Not reported	9 (4)	9 (4)	12 (5)	6 (2)	9 (3)
Condom used with other partner(s) last month (%)					
N° surveyed	N=23	N=34	N=21	N=39	N=29
Never	11 (48)	10 (29)	11 (52)	17 (44)	7 (24)
Sometimes	5 (22)	10 (29)	1 (5)	12 (31)	11 (38)
Every time	6 (26)	11 (32)	9 (43)	9 (23)	9 (31)
Not reported	1 (4)	3 (9)	0 (0)	1 (3)	2 (7)
Sex work last month (%)					
No	217 (88)	207 (91)	221 (93)	228 (92)	232 (86)
Yes	20 (8)	10 (4)	9 (4)	11 (4)	22 (8)
Not reported	11 (4)	11 (5)	8 (3)	8 (3)	16 (6)
Condom used at last sex work (%)					
Yes	14 (70)	8 (80)	6 (67)	9 (82)	16 (73)

HIV antibody prevalence

Table 6.2.1 HIV antibody prevalence by gender and survey year

South Australia	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013	154	4 (2.6)	74	3 (4.1)	229	7 (3.1)
2014	137	2 (1.5)	82	0 (0.0)	220	2 (0.9)
2015	122	0 (0.0)	88	0 (0.0)	213	0 (0.0)
2016	150	1 (0.7)	94	0 (0.0)	245	1 (0.4)
2017	132	5 (3.8)	125	0 (0.0)	262	5 (1.9)
X ² p trend		0.761		0.007		0.274

Table 6.2.2 HIV antibody prevalence by sexual identity, gender and survey year

South Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heterosexual	127	2 (1.6)	52	3 (5.8)	180	5 (2.8)
Bisexual	6	1 (16.7)	16	0 (0.0)	22	1 (4.6)
Homosexual	5	1 (20.0)	2	0 (0.0)	7	1 (14.3)
p value		0.032		1.000		0.141
2014						
Heterosexual	110	0 (0.0)	61	0 (0.0)	171	0 (0.0)
Bisexual	9	1 (11.1)	16	0 (0.0)	26	1 (3.9)
Homosexual	2	1 (50.0)	3	0 (0.0)	5	1 (20.0)
p value		0.003		--		0.007
2015						
Heterosexual	109	0 (0.0)	55	0 (0.0)	165	0 (0.0)
Bisexual	4	0 (0.0)	18	0 (0.0)	24	0 (0.0)
Homosexual	3	0 (0.0)	8	0 (0.0)	11	0 (0.0)
p value		--		--		--
2016						
Heterosexual	129	1 (0.8)	66	0 (0.0)	195	1 (0.5)
Bisexual	7	0 (0.0)	12	0 (0.0)	19	0 (0.0)
Homosexual	3	0 (0.0)	7	0 (0.0)	10	0 (0.0)
p value		1.000		--		1.000
2017						
Heterosexual	103	1 (1.0)	79	0 (0.0)	183	1 (0.6)
Bisexual	7	1 (14.3)	26	0 (0.0)	37	1 (2.7)
Homosexual	9	3 (33.3)	16	0 (0.0)	25	3 (12.0)
p value		0.001		--		0.005

Table 6.2.3 HIV antibody prevalence by age group, gender and survey year

South Australia Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
<25 years	7	0 (0.0)	11	0 (0.0)	18	0 (0.0)
25-34 years	25	0 (0.0)	19	2 (10.5)	44	2 (4.6)
35-44 years	57	1 (1.8)	27	0 (0.0)	84	1 (1.2)
45+ years	63	3 (4.8)	17	1 (5.9)	81	4 (4.9)
p value		0.606		0.218		0.483
2014						
<25 years	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
25-34 years	22	0 (0.0)	19	0 (0.0)	41	0 (0.0)
35-44 years	62	1 (1.6)	43	0 (0.0)	105	1 (1.0)
45+ years	48	1 (2.1)	19	0 (0.0)	68	1 (1.5)
p value		1.000		--		1.000
2015						
<25 years	1	0 (0.0)	3	0 (0.0)	4	0 (0.0)
25-34 years	14	0 (0.0)	16	0 (0.0)	31	0 (0.0)
35-44 years	43	0 (0.0)	35	0 (0.0)	78	0 (0.0)
45+ years	64	0 (0.0)	34	0 (0.0)	100	0 (0.0)
p value		--		--		--
2016						
<25 years	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)
25-34 years	24	0 (0.0)	20	0 (0.0)	44	0 (0.0)
35-44 years	44	0 (0.0)	36	0 (0.0)	81	0 (0.0)
45+ years	73	1 (1.4)	35	0 (0.0)	108	1 (0.9)
p value		1.000		--		1.000
2017						
<25 years	11	1 (9.1)	9	0 (0.0)	21	1 (4.8)
25-34 years	17	0 (0.0)	26	0 (0.0)	45	0 (0.0)
35-44 years	41	1 (2.4)	43	0 (0.0)	86	1 (1.2)
45+ years	63	3 (4.8)	47	0 (0.0)	110	3 (2.7)
p value		0.571		--		0.386

Table 6.2.4 HIV antibody prevalence by last drug injected, gender and survey year

South Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heroin	44	0 (0.0)	29	1 (3.5)	73	1 (1.4)
Methamphetamine	57	3 (5.3)	28	2 (7.1)	85	5 (5.9)
Other opioids	40	1 (2.5)	11	0 (0.0)	51	1 (2.0)
Other drugs	13	0 (0.0)	6	0 (0.0)	20	0 (0.0)
p value		0.456		0.825		0.434
2014						
Heroin	37	0 (0.0)	27	0 (0.0)	64	0 (0.0)
Methamphetamine	71	2 (2.8)	39	0 (0.0)	111	2 (1.8)
Other opioids	14	0 (0.0)	11	0 (0.0)	25	0 (0.0)
Other drugs	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)
p value		0.718		--		0.705
2015						
Heroin	40	0 (0.0)	24	0 (0.0)	65	0 (0.0)
Methamphetamine	61	0 (0.0)	50	0 (0.0)	113	0 (0.0)
Other opioids	14	0 (0.0)	9	0 (0.0)	23	0 (0.0)
Other drugs	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)
p value		--		--		--
2016						
Heroin	25	0 (0.0)	18	0 (0.0)	43	0 (0.0)
Methamphetamine	85	1 (1.2)	61	0 (0.0)	147	1 (0.7)
Other opioids	28	0 (0.0)	11	0 (0.0)	39	0 (0.0)
Other drugs	12	0 (0.0)	4	0 (0.0)	16	0 (0.0)
p value		1.000		--		1.000
2017						
Heroin	40	1 (2.5)	46	0 (0.0)	86	1 (1.2)
Methamphetamine	61	4 (6.6)	65	0 (0.0)	128	4 (3.1)
Other opioids	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
Other drugs	10	0 (0.0)	4	0 (0.0)	17	0 (0.0)
p value		0.715		--		0.781

Table 6.2.5 HIV antibody prevalence by years of injection, gender and survey year

South Australia Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
<3 years	3	0 (0.0)	8	0 (0.0)	11	0 (0.0)
3 to 10 years	21	0 (0.0)	9	0 (0.0)	30	0 (0.0)
11+ years	123	4 (3.3)	56	3 (5.4)	180	7 (3.9)
p value		1.000		1.000		0.719
2014						
<3 years	3	0 (0.0)	4	0 (0.0)	7	0 (0.0)
3 to 10 years	26	1 (4.4)	10	0 (0.0)	33	1 (3.0)
11+ years	109	1 (0.9)	68	0 (0.0)	178	1 (0.6)
p value		0.349		--		0.334
2015						
<3 years	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
3 to 10 years	10	0 (0.0)	8	0 (0.0)	18	0 (0.0)
11+ years	106	0 (0.0)	74	0 (0.0)	183	0 (0.0)
p value		--		--		--
2016						
<3 years	9	0 (0.0)	6	0 (0.0)	15	0 (0.0)
3 to 10 years	17	0 (0.0)	8	0 (0.0)	25	0 (0.0)
11+ years	120	1 (0.8)	79	0 (0.0)	200	1 (0.5)
p value		1.000		--		1.000
2017						
<3 years	6	1 (16.7)	4	0 (0.0)	10	1 (10.0)
3 to 10 years	21	1 (4.8)	23	0 (0.0)	47	1 (2.1)
11+ years	105	3 (2.9)	98	0 (0.0)	205	3 (1.5)
p value		0.143		--		0.144

Table 6.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

South Australia Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No receptive sharing	123	3 (2.4)	60	3 (5.0)	184	6 (3.3)
Receptive sharing	20	0 (0.0)	11	0 (0.0)	31	0 (0.0)
p value		1.000		1.000		0.597
2014						
No receptive sharing	109	2 (1.8)	69	0 (0.0)	179	2 (1.1)
Receptive sharing	21	0 (0.0)	7	0 (0.0)	28	0 (0.0)
p value		1.000		--		1.000
2015						
No receptive sharing	95	0 (0.0)	73	0 (0.0)	170	0 (0.0)
Receptive sharing	16	0 (0.0)	11	0 (0.0)	27	0 (0.0)
p value		--		--		--
2016						
No receptive sharing	106	1 (0.9)	71	0 (0.0)	178	1 (0.6)
Receptive sharing	30	0 (0.0)	21	0 (0.0)	51	0 (0.0)
p value		1.000		--		1.000
2017						
No receptive sharing	94	2 (2.1)	91	0 (0.0)	188	2 (1.1)
Receptive sharing	19	2 (10.5)	16	0 (0.0)	37	2 (5.4)
p value		0.131		--		0.127

Table 6.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

South Australia	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Less than daily	63	2 (3.2)	38	3 (7.9)	101	5 (5.0)
Daily or more	80	1 (1.3)	33	0 (0.0)	114	1 (0.9)
Not last month	7	1 (14.3)	2	0 (0.0)	9	1 (11.1)
p value		0.136		0.304		0.061
2014						
Less than daily	58	1 (1.7)	45	0 (0.0)	104	1 (1.0)
Daily or more	72	1 (1.4)	32	0 (0.0)	104	1 (1.0)
Not last month	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		1.000		--		1.000
2015						
Less than daily	68	0 (0.0)	47	0 (0.0)	116	0 (0.0)
Daily or more	43	0 (0.0)	37	0 (0.0)	81	0 (0.0)
Not last month	10	0 (0.0)	4	0 (0.0)	15	0 (0.0)
p value		--		--		--
2016						
Less than daily	64	1 (1.6)	53	0 (0.0)	118	1 (0.9)
Daily or more	73	0 (0.0)	40	0 (0.0)	113	0 (0.0)
Not last month	11	0 (0.0)	0	0 (0.0)	11	0 (0.0)
p value		0.507		--		1.000
2017						
Less than daily	47	1 (2.1)	55	0 (0.0)	105	1 (1.0)
Daily or more	68	3 (4.4)	53	0 (0.0)	123	3 (2.4)
Not last month	13	1 (7.7)	15	0 (0.0)	28	1 (3.6)
p value		0.390		--		0.414

Table 6.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

South Australia	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No imprisonment	122	3 (2.5)	63	3 (4.8)	186	6 (3.2)
Imprisonment	20	1 (5.0)	1	0 (0.0)	21	1 (4.8)
p value		0.459		1.000		0.533
2014						
No imprisonment	114	2 (1.8)	73	0 (0.0)	188	2 (1.1)
Imprisonment	15	0 (0.0)	4	0 (0.0)	19	0 (0.0)
p value		1.000		--		1.000
2015						
No imprisonment	106	0 (0.0)	84	0 (0.0)	193	0 (0.0)
Imprisonment	9	0 (0.0)	1	0 (0.0)	10	0 (0.0)
p value		--		--		--
2016						
No imprisonment	122	0 (0.0)	87	0 (0.0)	210	0 (0.0)
Imprisonment	18	1 (5.6)	5	0 (0.0)	23	1 (4.4)
p value		0.129		--		0.099
2017						
No imprisonment	105	4 (3.8)	109	0 (0.0)	219	4 (1.8)
Imprisonment	19	1 (5.3)	10	0 (0.0)	29	1 (3.5)
p value		0.571		--		0.466

Table 6.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

South Australia		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2013							
No condom use	43	0 (0.0)	38	1 (2.6)	82	1 (1.2)	
Condom use	12	0 (0.0)	6	2 (33.3)	18	2 (11.1)	
p value		--		0.045		0.083	
2014							
No condom use	48	1 (2.1)	39	0 (0.0)	87	1 (1.2)	
Condom use	18	0 (0.0)	7	0 (0.0)	25	0 (0.0)	
p value		1.000		--		1.000	
2015							
No condom use	37	0 (0.0)	41	0 (0.0)	78	0 (0.0)	
Condom use	8	0 (0.0)	11	0 (0.0)	21	0 (0.0)	
p value		--		--		--	
2016							
No condom use	56	0 (0.0)	54	0 (0.0)	111	0 (0.0)	
Condom use	17	1 (5.9)	8	0 (0.0)	25	1 (4.0)	
p value		0.233		--		0.184	
2017							
No condom use	36	2 (5.6)	54	0 (0.0)	91	2 (2.2)	
Condom use	18	2 (11.1)	12	0 (0.0)	30	2 (6.7)	
p value		0.594		--		0.256	

Table 6.2.10 HIV antibody prevalence by sex work last month, gender and survey year

South Australia		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2013							
No sex work	139	3 (2.2)	60	3 (5.0)	200	6 (3.0)	
Sex work	9	1 (11.1)	10	0 (0.0)	19	1 (5.3)	
p value		0.224		1.000		0.475	
2014							
No sex work	126	2 (1.6)	73	0 (0.0)	200	2 (1.0)	
Sex work	2	0 (0.0)	8	0 (0.0)	10	0 (0.0)	
p value		1.000		--		1.000	
2015							
No sex work	114	0 (0.0)	82	0 (0.0)	197	0 (0.0)	
Sex work	4	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
p value		--		--		--	
2016							
No sex work	139	1 (0.7)	86	0 (0.0)	226	1 (0.4)	
Sex work	5	0 (0.0)	6	0 (0.0)	11	0 (0.0)	
p value		1.000		--		1.000	
2017							
No sex work	114	4 (3.5)	107	0 (0.0)	225	4 (1.8)	
Sex work	10	1 (10.0)	10	0 (0.0)	21	1 (4.8)	
p value		0.348		--		0.362	

Table 6.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

South Australia Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Non Indigenous	123	3 (2.4)	62	3 (4.9)	186	6 (3.2)
Indigenous	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
p value		1.000		1.000		0.597
2014						
Non Indigenous	120	2 (1.7)	68	0 (0.0)	189	2 (1.1)
Indigenous	14	0 (0.0)	14	0 (0.0)	28	0 (0.0)
p value		1.000		--		1.000
2015						
Non Indigenous	109	0 (0.0)	77	0 (0.0)	189	0 (0.0)
Indigenous	11	0 (0.0)	10	0 (0.0)	21	0 (0.0)
p value		--		--		--
2016						
Non Indigenous	116	0 (0.0)	74	0 (0.0)	191	0 (0.0)
Indigenous	29	1 (3.5)	19	0 (0.0)	48	1 (2.1)
p value		0.200		--		0.201
2017						
Non Indigenous	105	4 (3.8)	96	0 (0.0)	205	4 (2.0)
Indigenous	23	1 (4.4)	22	0 (0.0)	46	1 (2.2)
p value		1.000		--		1.000

Table 6.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

South Australia Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
English speaking	140	3 (2.1)	70	3 (4.3)	211	6 (2.8)
Non-English speaking	14	1 (7.1)	4	0 (0.0)	18	1 (5.6)
p value		0.320		1.000		0.441
2014						
English speaking	125	2 (1.6)	79	0 (0.0)	205	2 (1.0)
Non-English speaking	10	0 (0.0)	3	0 (0.0)	13	0 (0.0)
p value		1.000		--		1.000
2015						
English speaking	108	0 (0.0)	85	0 (0.0)	196	0 (0.0)
Non-English speaking	12	0 (0.0)	2	0 (0.0)	14	0 (0.0)
p value		--		--		--
2016						
English speaking	136	1 (0.7)	90	0 (0.0)	227	1 (0.4)
Non-English speaking	13	0 (0.0)	3	0 (0.0)	16	0 (0.0)
p value		1.000		--		1.000
2017						
English speaking	122	4 (3.3)	122	0 (0.0)	247	4 (1.6)
Non-English speaking	9	1 (11.1)	3	0 (0.0)	14	1 (7.1)
p value		0.303		--		0.243

Table 6.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

South Australia		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2013							
Australia	128	4 (3.1)	68	3 (4.4)	197	7 (3.6)	
Other Oceania	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
Asia	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
UK & Ireland	15	0 (0.0)	2	0 (0.0)	17	0 (0.0)	
Other	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)	
p value		0.934		0.991		0.883	
2014							
Australia	116	2 (1.7)	78	0 (0.0)	195	2 (1.0)	
Other Oceania	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)	
UK & Ireland	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
Other	7	0 (0.0)	0	0 (0.0)	7	0 (0.0)	
p value		1.000		--		1.000	
2015							
Australia	105	0 (0.0)	82	0 (0.0)	190	0 (0.0)	
Other Oceania	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)	
UK & Ireland	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)	
Other	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)	
p value		--		--		--	
2016							
Australia	126	1 (0.8)	86	0 (0.0)	213	1 (0.5)	
Other Oceania	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
UK & Ireland	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)	
Other	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)	
p value		1.000		--		1.000	
2017							
Australia	116	3 (2.6)	112	0 (0.0)	231	3 (1.3)	
Other Oceania	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)	
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)	
UK & Ireland	3	1 (33.3)	8	0 (0.0)	11	1 (9.1)	
Other	9	0 (0.0)	1	0 (0.0)	12	0 (0.0)	
p value		0.169		--		0.236	

HCV antibody prevalence

Table 6.3.1 HCV antibody prevalence by gender and survey year

South Australia	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013	153	78 (51)	74	32 (43)	228	111 (49)
2014	128	68 (53)	79	40 (51)	208	109 (52)
2015	120	60 (50)	88	40 (45)	211	100 (47)
2016	141	62 (44)	90	27 (30)	232	89 (38)
2017	128	60 (47)	125	54 (43)	258	115 (45)
X ² p trend		0.453		0.481		0.206

Table 6.3.2 HCV antibody prevalence by sexual identity, gender and survey year

South Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heterosexual	126	65 (52)	52	23 (44)	179	89 (50)
Bisexual	6	1 (17)	16	6 (38)	22	7 (32)
Homosexual	5	0 (0)	2	1 (50)	7	1 (14)
p value		0.021		0.888		0.055
2014						
Heterosexual	103	55 (53)	59	30 (51)	162	85 (52)
Bisexual	8	1 (13)	16	8 (50)	25	10 (40)
Homosexual	1	1 (100)	3	2 (67)	4	3 (75)
p value		0.030		1.000		0.314
2015						
Heterosexual	107	53 (50)	55	25 (45)	163	78 (48)
Bisexual	4	1 (25)	18	10 (56)	24	11 (46)
Homosexual	3	2 (67)	8	2 (25)	11	4 (36)
p value		0.711		0.389		0.812
2016						
Heterosexual	120	52 (43)	62	22 (35)	182	74 (41)
Bisexual	7	3 (43)	12	1 (8)	19	4 (21)
Homosexual	3	1 (33)	7	0 (0)	10	1 (10)
p value		1.000		0.041		0.048
2017						
Heterosexual	101	47 (47)	79	36 (46)	181	83 (46)
Bisexual	6	2 (33)	26	14 (54)	36	17 (47)
Homosexual	9	4 (44)	16	2 (13)	25	6 (24)
p value		0.915		0.019		0.107

Table 6.3.3 HCV antibody prevalence by age group, gender and survey year

South Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<25 years	7	1 (14)	11	1 (9)	18	2 (11)
25-34 years	25	11 (44)	19	9 (47)	44	20 (45)
35-44 years	57	26 (46)	27	12 (44)	84	38 (46)
45+ years	63	40 (63)	17	10 (59)	81	51 (63)
p value		0.035		0.060		<0.001
2014						
<25 years	5	1 (20)	1	0 (0)	6	1 (17)
25-34 years	22	7 (32)	19	8 (42)	41	15 (37)
35-44 years	56	28 (50)	41	18 (44)	97	46 (47)
45+ years	45	32 (71)	18	14 (78)	64	47 (73)
p value		0.005		0.034		<0.001
2015						
<25 years	1	0 (0)	3	0 (0)	4	0 (0)
25-34 years	14	7 (50)	16	7 (44)	31	14 (45)
35-44 years	43	16 (37)	35	13 (37)	78	29 (37)
45+ years	62	37 (60)	34	20 (59)	98	57 (58)
p value		0.085		0.121		0.007
2016						
<25 years	9	2 (22)	3	0 (0)	12	2 (17)
25-34 years	23	9 (39)	20	5 (25)	43	14 (33)
35-44 years	41	15 (37)	35	11 (31)	77	26 (34)
45+ years	68	36 (53)	32	11 (34)	100	47 (47)
p value		0.178		0.764		0.085
2017						
<25 years	11	0 (0)	9	2 (22)	21	2 (10)
25-34 years	17	4 (24)	26	8 (31)	45	13 (29)
35-44 years	38	20 (53)	43	22 (51)	83	42 (51)
45+ years	62	36 (58)	47	22 (47)	109	58 (53)
p value		<0.001		0.220		<0.001

Table 6.3.4 HCV antibody prevalence by years since first injection, gender and survey year

South Australia Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<3 years	3	0 (0)	8	2 (25)	11	2 (18)
3 to 10 years	21	4 (19)	9	3 (33)	30	7 (23)
11+ years	122	71 (58)	56	26 (46)	179	98 (55)
p value		<0.001		0.557		0.001
2014						
<3 years	3	1 (33)	4	0 (0)	7	1 (14)
3 to 10 years	22	8 (36)	10	4 (40)	32	12 (38)
11+ years	101	58 (57)	65	36 (55)	167	95 (57)
p value		0.129		0.074		0.016
2015						
<3 years	5	1 (20)	5	2 (40)	10	3 (30)
3 to 10 years	10	3 (30)	8	1 (13)	18	4 (22)
11+ years	104	55 (53)	75	37 (49)	182	92 (51)
p value		0.177		0.129		0.035
2016						
<3 years	9	0 (0)	6	1 (17)	15	1 (7)
3 to 10 years	17	3 (18)	8	1 (13)	25	4 (16)
11+ years	112	57 (51)	75	25 (33)	188	82 (44)
p value		<0.001		0.509		0.001
2017						
<3 years	6	1 (17)	4	1 (25)	10	2 (20)
3 to 10 years	21	1 (5)	23	6 (26)	47	8 (17)
11+ years	90	51 (57)	93	46 (49)	185	97 (52)
p value		<0.001		0.101		<0.001

Table 6.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

South Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No receptive sharing	9	1 (11)	170	83 (49)	183	87 (48)
Receptive sharing	2	1 (50)	27	17 (63)	31	18 (58)
p value		0.345		0.172		0.278
2014						
No receptive sharing	5	1 (20)	163	91 (56)	170	93 (55)
Receptive sharing	1	0 (0)	25	10 (40)	26	10 (38)
p value		1.000		0.139		0.122
2015						
No receptive sharing	8	2 (25)	161	77 (48)	170	80 (47)
Receptive sharing	0	0 (0)	26	14 (54)	26	14 (54)
p value		--		0.569		0.519
2016						
No receptive sharing	11	1 (9)	155	63 (41)	168	64 (38)
Receptive sharing	3	0 (0)	45	17 (38)	49	18 (37)
p value		1.000		0.730		0.863
2017						
No receptive sharing	6	2 (33)	173	75 (43)	185	79 (43)
Receptive sharing	4	0 (0)	29	15 (52)	36	17 (47)
p value		0.467		0.401		0.617

Table 6.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

South Australia Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heroin	3	1 (33)	70	42 (60)	73	43 (59)
Methamphetamine	7	1 (14)	73	26 (36)	84	30 (36)
Other opioids	0	0 (0)	49	25 (51)	51	26 (51)
Other drugs	1	0 (0)	17	12 (71)	20	12 (60)
p value		0.685		0.008		0.020
2014						
Heroin	2	0 (0)	59	36 (61)	62	36 (58)
Methamphetamine	3	0 (0)	103	52 (50)	106	52 (49)
Other opioids	1	1 (100)	19	9 (47)	21	11 (52)
Other drugs	1	0 (0)	18	10 (56)	19	10 (53)
p value		0.072		0.566		0.736
2015						
Heroin	0	0 (0)	63	45 (71)	64	46 (72)
Methamphetamine	8	2 (25)	104	36 (35)	112	38 (34)
Other opioids	1	0 (0)	22	9 (41)	23	9 (39)
Other drugs	1	1 (100)	10	5 (50)	11	6 (55)
p value		0.240		<0.001		<0.001
2016						
Heroin	0	0 (0)	39	22 (56)	40	22 (55)
Methamphetamine	13	1 (8)	125	40 (32)	140	42 (30)
Other opioids	0	0 (0)	35	18 (51)	35	18 (51)
Other drugs	2	0 (0)	12	5 (42)	14	5 (36)
p value		0.685		0.022		0.010
2017						
Heroin	1	1 (100)	80	49 (61)	83	51 (61)
Methamphetamine	7	1 (14)	113	36 (32)	126	40 (32)
Other opioids	0	0 (0)	26	15 (58)	30	17 (57)
Other drugs	2	0 (0)	10	4 (40)	13	4 (31)
p value		0.098		<0.001		<0.001

Table 6.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

South Australia	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Less than daily	7	1 (14)	90	46 (51)	101	50 (50)
Daily or more	4	1 (25)	107	54 (50)	113	55 (49)
Not last month	0	0 (0)	8	3 (38)	9	3 (33)
p value		1.000		0.828		0.687
2014						
Less than daily	3	0 (0)	97	55 (57)	100	55 (55)
Daily or more	3	1 (33)	92	46 (50)	97	48 (49)
Not last month	1	0 (0)	7	3 (43)	8	3 (38)
p value		1.000		0.555		0.529
2015						
Less than daily	4	1 (25)	111	58 (52)	116	60 (52)
Daily or more	4	1 (25)	76	33 (43)	80	34 (43)
Not last month	2	1 (50)	12	4 (33)	14	5 (36)
p value		1.000		0.310		0.301
2016						
Less than daily	8	1 (13)	101	44 (44)	110	45 (41)
Daily or more	6	0 (0)	100	37 (37)	108	38 (35)
Not last month	1	0 (0)	10	4 (40)	11	4 (36)
p value		1.000		0.621		0.659
2017						
Less than daily	6	1 (17)	94	42 (45)	105	44 (42)
Daily or more	4	1 (25)	110	49 (45)	119	54 (45)
Not last month	0	0 (0)	25	13 (52)	28	14 (50)
p value		1.000		0.782		0.717

Table 6.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

South Australia	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No imprisonment	10	2 (20)	169	79 (47)	186	84 (45)
Imprisonment	0	0 (0)	19	13 (68)	20	14 (70)
p value		--		0.073		0.035
2014						
No imprisonment	7	1 (14)	167	91 (54)	176	9 (53)
Imprisonment	0	0 (0)	19	8 (42)	19	8 (42)
p value		--		0.305		0.374
2015						
No imprisonment	8	2 (25)	182	84 (46)	191	87 (46)
Imprisonment	2	1 (50)	8	6 (75)	10	7 (70)
p value		1.000		0.110		0.131
2016						
No imprisonment	11	1 (9)	183	72 (39)	198	75 (38)
Imprisonment	3	0 (0)	19	10 (53)	22	10 (45)
p value		1.000		0.262		0.489
2017						
No imprisonment	8	2 (25)	197	90 (46)	217	98 (45)
Imprisonment	2	0 (0)	25	9 (36)	28	10 (36)
p value		1.000		0.359		0.343

Table 6.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

South Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Non Indigenous	123	59 (48)	62	26 (42)	186	86 (46)
Indigenous	21	16 (76)	10	4 (40)	31	20 (65)
p value		0.017		1.000		0.059
2014						
Non Indigenous	111	55 (50)	66	33 (50)	178	89 (50)
Indigenous	14	11 (79)	13	7 (54)	27	18 (67)
p value		0.040		0.800		0.106
2015						
Non Indigenous	108	55 (51)	77	33 (43)	188	88 (47)
Indigenous	10	5 (50)	10	7 (70)	20	12 (60)
p value		0.955		0.105		0.262
2016						
Non Indigenous	108	40 (37)	71	22 (31)	180	62 (34)
Indigenous	28	19 (68)	18	5 (28)	46	24 (52)
p value		0.003		0.791		0.027
2017						
Non Indigenous	103	48 (47)	96	43 (45)	203	91 (45)
Indigenous	21	10 (48)	22	9 (41)	44	20 (45)
p value		0.932		0.741		0.940

Table 6.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

South Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
English speaking	139	73 (53)	70	30 (43)	210	104 (50)
Non-English speaking	14	5 (36)	4	2 (50)	18	7 (39)
p value		0.271		1.000		0.386
2014						
English speaking	119	66 (55)	76	39 (51)	196	106 (54)
Non-English speaking	7	1 (14)	3	1 (33)	10	2 (20)
p value		0.050		0.615		0.050
2015						
English speaking	106	53 (50)	85	39 (46)	194	92 (47)
Non-English speaking	12	5 (42)	2	1 (50)	14	6 (43)
p value		0.584		1.000		0.741
2016						
English speaking	127	53 (42)	87	26 (30)	215	79 (37)
Non-English speaking	13	8 (62)	2	1 (50)	15	9 (60)
p value		0.170		0.517		0.073
2017						
English speaking	118	55 (47)	122	54 (44)	243	110 (45)
Non-English speaking	9	4 (44)	3	0 (0)	14	4 (29)
p value		0.900		0.258		0.276

Table 6.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

South Australia	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Australia	127	68 (54)	68	30 (44)	196	99 (51)
Other Oceania	2	1 (50)	1	0 (0)	3	1 (33)
Asia	2	1 (50)	1	1 (100)	3	2 (67)
UK & Ireland	15	6 (40)	2	1 (50)	17	7 (41)
Other	7	2 (29)	2	0 (0)	9	2 (22)
p value		0.641		0.655		0.445
2014						
Australia	108	61 (56)	75	37 (49)	184	99 (54)
Other Oceania	4	2 (50)	0	0 (0)	4	2 (50)
Asia	2	0 (0)	0	0 (0)	2	0 (0)
UK & Ireland	7	3 (43)	4	3 (75)	11	6 (55)
Other	6	2 (33)	0	0 (0)	6	2 (33)
p value		0.440		0.615		0.583
2015						
Australia	103	50 (49)	82	36 (44)	188	86 (46)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	2	2 (100)	0	0 (0)	2	2 (100)
UK & Ireland	5	0 (0)	4	3 (75)	9	3 (33)
Other	6	4 (67)	1	1 (100)	7	5 (71)
p value		0.046		0.214		0.207
2016						
Australia	119	51 (43)	83	24 (29)	203	75 (37)
Other Oceania	6	3 (50)	3	2 (67)	9	5 (56)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	7	3 (43)	2	1 (50)	9	4 (44)
Other	8	4 (50)	1	0 (0)	9	4 (44)
p value		0.975		0.374		0.633
2017						
Australia	113	54 (48)	112	47 (42)	228	102 (45)
Other Oceania	1	1 (100)	2	1 (50)	3	2 (67)
Asia	1	0 (0)	1	1 (100)	2	1 (50)
UK & Ireland	2	1 (50)	8	4 (50)	10	5 (50)
Other	9	2 (22)	1	0 (0)	12	2 (17)
p value		0.312		0.846		0.273

Tasmania

Table 7.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Tasmania	2013	2014	2015	2016	2017
Number of sites	3	4	4	4	4
N° surveyed	N=70	N=69	N=48	N=35	N=63
Response rate (%)	33%	36%	20%	25%	30%
Gender (%)					
Male	42 (60)	37 (54)	30 (62)	17 (49)	33 (52)
Female	28 (40)	31 (45)	18 (38)	18 (51)	30 (48)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	61 (87)	52 (75)	39 (81)	31 (89)	51 (81)
Bisexual	3 (4)	3 (4)	2 (4)	2 (6)	6 (10)
Homosexual	2 (3)	2 (3)	3 (6)	1 (3)	3 (5)
Not reported	4 (6)	12 (17)	4 (8)	1 (3)	3 (5)
Aboriginal and Torres Strait Islander origin (%)					
No	60 (86)	56 (81)	39 (81)	31 (89)	55 (87)
Yes	9 (13)	11 (16)	8 (17)	3 (9)	7 (11)
Not reported	1 (1)	2 (3)	1 (2)	1 (3)	1 (2)
Region/country of birth (%)					
Australia	67 (96)	67 (97)	43 (90)	33 (94)	59 (94)
Other Oceania	1 (1)	0 (0)	1 (2)	0 (0)	0 (0)
Asia	0 (0)	0 (0)	0 (0)	0 (0)	2 (3)
UK & Ireland	2 (3)	2 (3)	2 (4)	1 (3)	1 (2)
Other	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Not reported	0 (0)	0 (0)	2 (4)	1 (3)	0 (0)
Main language spoken at home by parents (%)					
English	70 (100)	69 (100)	47 (98)	33 (94)	63 (100)
Non-English	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)
Not reported	0 (0)	0 (0)	1 (2)	1 (3)	0 (0)
Age and time since first injection (years)					
<i>Median age</i>	37	41	42	42	42
<i>Age range</i>	21-63	21-60	23-61	29-59	21-60
<i>Age group (%)</i>					
<25 years	3 (4)	1 (1)	1 (2)	0 (0)	2 (3)
25+ years	66 (94)	68 (99)	47 (98)	35 (100)	61 (97)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age first injection</i>	19	20	20	21	20.5
<i>Age range</i>	12-40	12-53	12-50	14-45	14-57
N° not reported	3	2	0	1	3
<i>Median yrs since first injection</i>	16	18	18	19	19
<i>Range</i>	1-41	1-43	<1-43	7-29	2-46
<i>Years since first injection</i>					
<3 years	3 (4)	1 (1)	2 (4)	0 (0)	1 (2)
3+ years	64 (91)	66 (96)	46 (96)	34 (97)	59 (94)
Not reported	3 (4)	2 (3)	0 (0)	1 (3)	3 (5)
Imprisonment last year (%)					
No	54 (77)	56 (81)	41 (85)	33 (94)	57 (90)
Yes	9 (13)	3 (4)	3 (6)	1 (3)	4 (6)
Not reported	7 (10)	10 (14)	4 (8)	1 (3)	2 (3)
N° in prison	N=9	N=3	N=3	N=1	N=4
Injected in prison	1 (11)	1 (33)	0 (100)	0 (0)	0 (0)

Table 7.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Tasmania	2013	2014	2015	2016	2017
N° surveyed	N=70	N=69	N=48	N=35	N=63
Drug last injected (%)					
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	17 (24)	23 (33)	20 (42)	13 (37)	21 (33)
Heroin	2 (3)	2 (3)	0 (0)	1 (3)	2 (3)
Pharm. opioids	23 (33)	25 (36)	15 (31)	7 (20)	15 (24)
Methadone	19 (27)	10 (14)	11 (23)	10 (29)	15 (24)
Buprenorphine	3 (4)	1 (1)	1 (2)	1 (3)	2 (3)
Buprenorphine/naloxone	1 (1)	0 (0)	0 (0)	1 (3)	1 (2)
PIEDs	1 (1)	0 (0)	1 (2)	0 (0)	1 (2)
More than one	3 (4)	7 (10)	0 (0)	0 (0)	3 (5)
Other	1 (1)	1 (1)	0 (0)	2 (6)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	3 (5)
Ever injected opioids					
Yes	-	-	-	30 (86)	57 (90)
No	-	-	-	4 (11)	5 (8)
Not reported	-	-	-	1 (3)	1 (2)
Frequency of injection last month (%)					
Not last month	5 (7)	1 (1)	4 (8)	7 (20)	5 (8)
Less than weekly	13 (19)	7 (10)	9 (19)	7 (20)	9 (14)
Weekly not daily	26 (37)	24 (35)	15 (31)	14 (40)	17 (27)
Daily or more	24 (34)	36 (52)	19 (40)	7 (20)	32 (51)
Not reported	2 (3)	1 (1)	1 (2)	0 (0)	0 (0)
Present when someone injected for the first time in the last 12 months (%)					
Yes	6 (9)	7 (10)	6 (13)	2 (6)	8 (13)
No	57 (81)	61 (88)	41 (85)	32 (91)	55 (87)
Not reported	7 (10)	1 (1)	1 (2)	1 (3)	0 (0)
Overdosed in last 12 months					
Yes	6 (9)	4 (6)	2 (4)	2 (6)	5 (8)
No	62 (89)	63 (91)	45 (94)	32 (91)	58 (92)
Not reported	2 (3)	2 (3)	1 (2)	1 (3)	0 (0)

Table 7.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Tasmania	2013	2014	2015	2016	2017
N° injected last month	N=63	N=67	N=43	N=28	N=58
Places injected last month (%)					
Any public	16 (25)	15 (22)	15 (35)	9 (32)	22 (38)
All private	46 (73)	52 (78)	28 (65)	19 (68)	36 (62)
Not reported	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	55 (87)	64 (96)	36 (84)	13 (46)	50 (86)
Most of the time	6 (10)	2 (3)	7 (16)	10 (36)	8 (14)
Half of the time	1 (2)	0 (0)	0 (0)	1 (4)	0 (0)
Some of the time	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	4 (14)	0 (0)
Not reported	1 (2)	1 (1)	0 (0)	0 (0)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	61 (97)	61 (91)	40 (93)	24 (86)	55 (95)
Once	1 (2)	4 (6)	1 (2)	2 (7)	1 (2)
Twice	0 (0)	1 (1)	1 (2)	1 (4)	1 (2)
3-5 times	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
>5 times	1 (2)	0 (0)	0 (0)	1 (4)	1 (2)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	61 (97)	61 (91)	40 (93)	24 (86)	55 (95)
One	0 (0)	0 (0)	1 (2)	2 (7)	2 (3)
Two	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)
Three to five	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Don't know	0 (0)	0 (0)	1 (2)	0 (0)	1 (2)
Not reported	2 (3)	6 (9)	1 (2)	0 (0)	0 (0)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	0 (0)	0 (0)	1 (2)	1 (4)	2 (3)
Casual sex partner	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Close friend	0 (0)	0 (0)	0 (0)	3 (11)	0 (0)
Acquaintance	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	6 (10)	7 (10)	2 (5)	4 (14)	8 (14)
Water	10 (16)	14 (21)	2 (5)	4 (14)	6 (10)
Filter	8 (13)	2 (3)	4 (9)	1 (4)	9 (16)
Drug mix	2 (3)	2 (3)	1 (2)	3 (11)	4 (7)
None	46 (73)	46 (69)	36 (84)	21 (75)	40 (69)
Injected by someone after that person injected themselves or others last month (%)					
No	50 (79)	60 (90)	38 (88)	25 (89)	48 (83)
Yes	9 (14)	5 (7)	5 (12)	3 (11)	7 (12)
Not reported	4 (6)	2 (3)	0 (0)	0 (0)	3 (5)
Source of needle acquisition					
Needle Syringe Program	63 (100)	66 (99)	39 (91)	26 (93)	57 (98)
Chemist/Pharmacy	6 (10)	7 (10)	8 (19)	4 (14)	10 (17)
Personal sources	2 (3)	3 (4)	4 (9)	2 (7)	5 (9)
Dispensing/Vending Machine	5 (8)	1 (1)	12 (28)	5 (18)	16 (28)
Other sources	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)

Table 7.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Tasmania	2013	2014	2015	2016	2017
N° surveyed	N=70	N=69	N=48	N=35	N=47
Ever any treatment/therapy for drug use (%)					
No	13 (19)	17 (25)	14 (29)	6 (17)	15 (24)
Yes	56 (80)	52 (75)	34 (71)	28 (80)	47 (75)
Not reported	1 (1)	0 (0)	0 (0)	1 (3)	1 (2)
History of methadone maintenance treatment (%)					
Currently	27 (39)	21 (30)	14 (29)	17 (49)	24 (38)
Previously	14 (20)	16 (23)	8 (17)	4 (11)	16 (25)
Never	29 (41)	32 (46)	25 (52)	12 (34)	22 (35)
Not reported	0 (0)	0 (0)	1 (2)	2 (6)	1 (2)
History of buprenorphine (Subutex®) treatment (%)					
Currently	5 (7)	9 (13)	5 (10)	3 (9)	7 (11)
Previously	18 (26)	13 (19)	7 (15)	5 (14)	11 (17)
Never	46 (66)	45 (65)	35 (73)	26 (74)	44 (70)
Not reported	1 (1)	2 (3)	1 (2)	1 (3)	1 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	3 (4)	5 (7)	2 (4)	1 (3)	2 (3)
Previously	12 (17)	11 (16)	11 (23)	4 (11)	11 (17)
Never	51 (73)	50 (72)	35 (73)	29 (83)	49 (78)
Not reported	4 (6)	3 (4)	0 (0)	1 (3)	1 (2)

Table 7.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Tasmania	2013	2014	2015	2016	2017
N° surveyed	N=70	N=69	N=48	N=35	N=63
Previous HIV test (%)					
Yes, ever	61 (87)	56 (81)	45 (94)	26 (74)	54 (86)
Yes, last year	33 (47)	25 (36)	21 (44)	17 (49)	24 (38)
>1 year ago	28 (40)	31 (45)	24 (50)	9 (26)	30 (48)
Never tested	5 (7)	12 (17)	3 (6)	8 (23)	9 (14)
Not reported	4 (6)	1 (1)	0 (0)	1 (3)	0 (0)
Previous HCV test (%)					
Yes, ever	56 (80)	63 (91)	44 (92)	30 (86)	52 (83)
Yes, last year	33 (47)	38 (55)	23 (48)	21 (60)	31 (49)
>1 year ago	23 (33)	25 (36)	21 (44)	9 (26)	21 (33)
Never tested	6 (9)	3 (4)	2 (4)	3 (9)	8 (13)
Not reported	8 (11)	3 (4)	2 (4)	2 (6)	3 (5)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=21	N=13	N=11	N=9	N=20
Antiviral treatment	1 (5)	4 (31)	2 (18)	2 (22)	11 (55)
No antiviral treatment	20 (95)	9 (69)	9 (82)	5 (56)	9 (45)
Not reported	0 (0)	0 (0)	0 (0)	2 (22)	0 (0)
Treatment for HCV in past 12 months (%)^{##}					
N° self-reported HCV diagnosis	N=21	N=13	N=11	N=9	N=18
Antiviral treatment	0 (0)	0 (0)	0 (0)	2 (22)	7 (39)
No antiviral treatment	21 (100)	13 (100)	11 (100)	5 (56)	11 (61)
Not reported	0 (0)	0 (0)	0 (0)	2 (22)	0 (0)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 7.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Tasmania	2013	2014	2015	2016	2017
N° surveyed	N=70	N=69	N=48	N=35	N=63
Sex with a regular partner last month (%)					
No	23 (33)	28 (41)	16 (33)	17 (49)	29 (46)
Yes	41 (59)	36 (52)	29 (60)	16 (46)	34 (54)
Not reported	6 (9)	5 (7)	3 (6)	2 (6)	0 (0)
Condom used with regular partner last month (%)					
N° surveyed	N=41	N=36	N=29	N=16	N=34
Never	27 (66)	27 (75)	22 (76)	12 (75)	31 (91)
Sometimes	2 (5)	1 (3)	2 (7)	3 (19)	0 (0)
Every time	7 (17)	6 (17)	4 (14)	1 (6)	3 (9)
Not reported	5 (12)	2 (6)	1 (3)	0 (0)	0 (0)
Sex with other partner(s) last month (%)					
No	59 (84)	59 (86)	39 (81)	30 (86)	62 (98)
Yes	5 (7)	4 (6)	6 (13)	1 (3)	1 (2)
Not reported	6 (9)	6 (9)	3 (6)	4 (11)	0 (0)
Condom used with other partner(s) last month (%)					
N° surveyed	N=5	N=4	N=6	N=1	N=1
Never	3 (60)	2 (50)	0 (0)	0 (0)	0 (0)
Sometimes	1 (20)	0 (0)	3 (50)	0 (0)	1 (100)
Every time	1 (20)	1 (25)	3 (50)	1 (100)	0 (0)
Not reported	0 (0)	1 (25)	0 (0)	0 (0)	0 (0)
Sex work last month (%)					
No	58 (83)	56 (81)	45 (94)	31 (89)	59 (94)
Yes	1 (1)	1 (1)	0 (0)	1 (3)	2 (3)
Not reported	11 (16)	12 (17)	3 (6)	3 (9)	2 (3)
Condom used at last sex work (%)					
Yes	1 (100)	1 (100)	--	1 (100)	1 (50)

HIV antibody prevalence

Table 7.2.1 HIV antibody prevalence by gender and survey year

Tasmania Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013	41	0 (0.0)	28	0 (0.0)	69	0 (0.0)
2014	32	0 (0.0)	30	0 (0.0)	63	0 (0.0)
2015	29	0 (0.0)	18	0 (0.0)	47	0 (0.0)
2016	17	0 (0.0)	18	0 (0.0)	35	0 (0.0)
2017	32	0 (0.0)	30	0 (0.0)	62	0 (0.0)
X ² p trend		--		--		--

HCV antibody prevalence

Table 7.3.1 HCV antibody prevalence by gender and survey year

Tasmania Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013	41	19 (46)	28	18 (64)	69	37 (54)
2014	30	16 (53)	30	18 (60)	61	35 (57)
2015	26	16 (62)	18	10 (56)	44	26 (59)
2016	17	7 (41)	18	6 (33)	35	13 (37)
2017	32	14 (44)	29	15 (52)	61	29 (48)
X ² p trend		0.810		0.411		0.456

Table 7.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Tasmania Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heterosexual	36	17 (47)	24	15 (63)	60	32 (53)
Bisexual	1	1 (100)	2	2 (100)	3	3 (100)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.730		0.283		0.081
2014						
Heterosexual	24	14 (58)	24	15 (63)	48	29 (60)
Bisexual	0	0 (0)	3	2 (67)	3	2 (67)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.440		0.726		0.283
2015						
Heterosexual	23	14 (61)	13	7 (54)	36	21 (58)
Bisexual	0	0 (0)	2	1 (50)	2	1 (50)
Homosexual	2	1 (50)	1	1 (100)	3	2 (67)
p value		1.000		1.000		1.000
2016						
Heterosexual	15	7 (47)	16	6 (38)	31	13 (42)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		0.529		0.696
2017						
Heterosexual	28	13 (46)	23	11 (48)	51	24 (47)
Bisexual	0	0 (0)	4	2 (50)	4	2 (50)
Homosexual	2	0 (0)	1	1 (100)	3	1 (33)
p value		0.492		1.000		1.000

Table 7.3.3 HCV antibody prevalence by age group, gender and survey year

Tasmania Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<25 years	2	0 (0)	1	1 (100)	3	1 (33)
25-34 years	11	3 (27)	9	4 (44)	20	7 (35)
35-44 years	17	9 (53)	12	9 (75)	29	18 (62)
45+ years	11	7 (64)	5	3 (60)	16	10 (63)
p value		0.191		0.423		0.188
2014						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	1 (50)	8	5 (63)	10	6 (60)
35-44 years	18	9 (50)	12	6 (50)	31	16 (52)
45+ years	10	6 (60)	10	7 (70)	20	13 (65)
p value		0.848		0.651		0.649
2015						
<25 years	1	1 (100)	0	0 (0)	1	1 (100)
25-34 years	4	3 (75)	6	4 (67)	10	7 (70)
35-44 years	12	4 (33)	7	1 (14)	19	5 (26)
45+ years	9	8 (89)	5	5 (100)	14	13 (93)
p value		0.030		0.013		<0.001
2016						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	3	1 (33)	3	1 (33)
35-44 years	11	6 (55)	11	5 (45)	22	11 (50)
45+ years	6	1 (17)	4	0 (0)	10	1 (10)
p value		0.304		0.314		0.106
2017						
<25 years	2	0 (0)	0	0 (0)	2	0 (0)
25-34 years	3	1 (33)	6	5 (83)	9	6 (67)
35-44 years	12	6 (50)	12	6 (50)	24	12 (50)
45+ years	15	7 (47)	11	4 (36)	26	11 (42)
p value		0.745		0.223		0.385

Table 7.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Tasmania Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	5	2 (40)	8	3 (38)	13	5 (38)
11+ years	34	16 (47)	16	13 (81)	50	29 (58)
p value		1.000		0.022		0.086
2014						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	4	1 (25)	6	4 (67)	10	5 (50)
11+ years	25	15 (60)	23	14 (61)	49	30 (61)
p value		0.299		1.000		0.510
2015						
<3 years	1	0 (0)	1	0 (0)	2	0 (0)
3 to 10 years	6	2 (33)	2	1 (50)	8	3 (38)
11+ years	19	14 (74)	15	9 (60)	34	23 (68)
p value		0.086		0.706		0.078
2016						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	1	0 (0)	1	0 (0)	2	0 (0)
11+ years	16	7 (44)	16	6 (38)	32	13 (41)
p value		1.000		1.000		0.513
2017						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	4	0 (0)	1	1 (100)	5	1 (20)
11+ years	25	14 (56)	27	14 (52)	52	28 (54)
p value		0.067		1.000		0.194

Table 7.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Tasmania Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No receptive sharing	2	0 (0)	56	30 (54)	60	32 (53)
Receptive sharing	0	0 (0)	1	0 (0)	2	1 (50)
p value		--		0.474		1.000
2014						
No receptive sharing	0	0 (0)	52	32 (61)	54	32 (59)
Receptive sharing	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		0.295		0.305
2015						
No receptive sharing	2	0 (0)	36	21 (58)	38	21 (55)
Receptive sharing	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.509		0.499
2016						
No receptive sharing	0	0 (0)	24	9 (38)	24	9 (38)
Receptive sharing	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.285		0.285
2017						
No receptive sharing	1	1 (100)	49	25 (51)	53	25 (47)
Receptive sharing	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		1.000		0.605

Table 7.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Tasmania Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Methamphetamine	1	0 (0)	14	7 (50)	16	8 (50)
Pharmaceutical opioids	0	0 (0)	23	13 (57)	23	13 (57)
OST	0	0 (0)	21	11 (52)	23	13 (57)
Other drugs	2	0 (0)	5	3 (60)	7	7 (43)
p value		--		0.970		0.904
2014						
Methamphetamine	0	0 (0)	18	10 (56)	18	10 (56)
Pharmaceutical opioids	0	0 (0)	24	13 (54)	25	13 (52)
OST	0	0 (0)	11	9 (82)	11	9 (82)
Other drugs	0	0 (0)	6	3 (50)	7	3 (43)
p value		--		0.408		0.307
2015						
Methamphetamine	1	0 (0)	17	9 (53)	18	9 (50)
Pharmaceutical opioids	0	0 (0)	14	11 (79)	14	11 (79)
OST	0	0 (0)	11	6 (55)	11	6 (55)
Other drugs	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		0.286		0.226
2016						
Methamphetamine	0	0 (0)	13	2 (15)	13	2 (15)
Pharmaceutical opioids	0	0 (0)	7	3 (43)	7	3 (43)
OST	0	0 (0)	12	7 (58)	12	7 (58)
Other drugs	0	0 (0)	2	1 (50)	3	1 (33)
p value		--		0.164		0.167
2017						
Methamphetamine	1	1 (100)	19	6 (32)	20	6 (30)
Pharmaceutical opioids	0	0 (0)	12	7 (58)	15	7 (47)
OST	0	0 (0)	18	12 (67)	18	12 (67)
Other drugs	0	0 (0)	8	4 (50)	8	4 (50)
p value		--		0.180		0.162

Table 7.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Tasmania	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Less than daily	1	0 (0)	35	19 (54)	38	21 (55)
Daily or more	1	0 (0)	22	11 (50)	24	12 (50)
Not last month	1	0 (0)	4	2 (50)	5	2 (40)
p value		--		0.919		0.804
2014						
Less than daily	0	0 (0)	27	15 (56)	28	15 (54)
Daily or more	0	0 (0)	30	19 (63)	31	19 (61)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.414		0.429
2015						
Less than daily	2	0 (0)	20	11 (55)	22	11 (50)
Daily or more	0	0 (0)	18	12 (67)	18	12 (67)
Not last month	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.649		0.531
2016						
Less than daily	0	0 (0)	21	10 (48)	21	10 (48)
Daily or more	0	0 (0)	7	2 (29)	7	2 (29)
Not last month	0	0 (0)	6	1 (17)	7	1 (14)
p value		--		0.473		0.310
2017						
Less than daily	0	0 (0)	25	11 (44)	25	11 (44)
Daily or more	1	1 (100)	27	16 (59)	31	16 (52)
Not last month	0	0 (0)	5	2 (40)	5	2 (40)
p value		--		0.569		0.802

Table 7.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Tasmania	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No imprisonment	3	0 (0)	49	24 (49)	54	26 (48)
Imprisonment	0	0 (0)	9	8 (89)	9	8 (89)
p value		--		0.033		0.031
2014						
No imprisonment	0	0 (0)	51	27 (53)	53	27 (51)
Imprisonment	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		1.000		1.000
2015						
No imprisonment	2	0 (0)	36	21 (58)	38	21 (55)
Imprisonment	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000
2016						
No imprisonment	0	0 (0)	32	13 (41)	33	13 (39)
Imprisonment	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000
2017						
No imprisonment	1	1 (100)	51	27 (53)	55	27 (49)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		1.000		1.000

Table 7.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Tasmania Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Non Indigenous	36	17 (47)	23	13 (57)	59	30 (51)
Indigenous	5	2 (40)	4	4 (100)	9	6 (67)
p value		1.000		0.264		0.484
2014						
Non Indigenous	26	15 (58)	23	12 (52)	50	28 (56)
Indigenous	3	1 (33)	6	5 (83)	9	6 (67)
p value		0.573		0.168		0.551
2015						
Non Indigenous	22	14 (64)	13	6 (46)	35	20 (57)
Indigenous	3	2 (67)	5	4 (80)	8	6 (75)
p value		1.000		0.314		0.351
2016						
Non Indigenous	16	7 (44)	15	4 (27)	31	11 (35)
Indigenous	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		0.245		0.544
2017						
Non Indigenous	28	11 (39)	26	13 (50)	54	24 (44)
Indigenous	4	3 (75)	2	1 (50)	6	4 (67)
p value		0.295		1.000		0.404

Table 7.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Tasmania Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
English speaking	41	19 (46)	28	18 (64)	69	37 (54)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2014						
English speaking	30	16 (53)	30	18 (60)	61	35 (57)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2015						
English speaking	25	15 (60)	18	10 (56)	43	25 (58)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
English speaking	15	7 (47)	18	6 (33)	33	13 (39)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		--		1.000
2017						
English speaking	32	14 (44)	29	15 (52)	61	29 (48)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

Table 7.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Tasmania Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Australia	39	17 (44)	27	17 (63)	66	34 (52)
Other Oceania	0	0 (0)	1	1 (100)	1	1 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	2 (100)	0	0 (0)	2	2 (100)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.209		1.000		0.495
2014						
Australia	29	15 (52)	29	17 (59)	59	33 (56)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		1.000		0.503
2015						
Australia	22	13 (59)	17	9 (53)	39	22 (56)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.670		1.000		0.322
2016						
Australia	16	7 (44)	17	6 (35)	33	13 (39)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		1.000		1.000
2017						
Australia	29	13 (45)	28	14 (50)	57	27 (47)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	1	0 (0)	1	1 (100)	2	1 (50)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.835		1.000		0.862

Victoria

Table 8.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Victoria	2013	2014	2015	2016	2017
Number of sites	6	6	6	6	6
N° surveyed	N=448	N=436	N=459	N=423	N=380
Response rate (%)	61%	41%	62%	70%	56%
Gender (%)					
Male	302 (67)	288 (66)	303 (66)	268 (63)	247 (65)
Female	139 (31)	146 (33)	153 (33)	151 (36)	127 (33)
Transgender	4 (<1)	2 (<1)	3 (1)	2 (<1)	3 (1)
Not reported	3 (<1)	0 (0)	0 (0)	2 (<1)	3 (1)
Sexual identity (%)					
Heterosexual	338 (75)	349 (81)	381 (83)	329 (78)	293 (77)
Bisexual	31 (7)	36 (8)	36 (8)	45 (11)	35 (9)
Homosexual	25 (6)	11 (3)	17 (4)	13 (3)	16 (4)
Not reported	54 (12)	40 (9)	25 (5)	36 (9)	36 (9)
Aboriginal and Torres Strait Islander origin (%)					
No	380 (85)	378 (87)	401 (87)	341 (81)	320 (84)
Yes	52 (12)	53 (12)	53 (12)	70 (17)	55 (14)
Not reported	16 (4)	5 (1)	5 (1)	12 (3)	5 (1)
Region/country of birth (%)					
Australia	364 (81)	360 (83)	376 (82)	363 (86)	333 (88)
Other Oceania	10 (2)	10 (2)	18 (4)	8 (2)	9 (2)
Asia	20 (4)	20 (5)	16 (3)	7 (2)	5 (1)
UK & Ireland	22 (5)	20 (5)	27 (6)	16 (4)	13 (3)
Other	30 (7)	25 (6)	20 (4)	20 (5)	19 (5)
Not reported	2 (<1)	1 (<1)	2 (<1)	9 (2)	1 (<1)
Main language spoken at home by parents (%)					
English	393 (88)	378 (87)	414 (90)	380 (90)	336 (88)
Non-English	54 (12)	57 (13)	42 (9)	38 (9)	44 (12)
Not reported	1 (<1)	1 (<1)	3 (1)	5 (1)	0 (0)
Age and time since first injection (years)					
<i>Median age</i>	38	39	40	41	42
<i>Age range</i>	15-66	16-65	18-64	17-69	19-67
<i>Age group (%)</i>					
<25 years	18 (4)	12 (3)	8 (2)	13 (3)	7 (2)
25+ years	429 (96)	422 (97)	450 (98)	409 (97)	370 (97)
Not reported	1 (<1)	2 (<1)	1 (<1)	1 (<1)	3 (1)
<i>Median age first injection</i>	18	18	18	18	18
<i>Age range</i>	10-52	10-52	11-54	10-48	10-58
<i>N° not reported</i>	23	6	10	18	12
<i>Median yrs since first injection</i>	18	20	20	21	23
<i>Range</i>	<1-40	<1-41	<1-41	<1-49	<1-47
<i>Years since first injection</i>					
<3 years	13 (3)	17 (4)	19 (4)	12 (3)	8 (2)
3+ years	412 (92)	399 (92)	429 (93)	393 (93)	360 (95)
Not reported	23 (5)	20 (5)	11 (2)	18 (4)	12 (3)
Imprisonment last year (%)					
No	354 (79)	359 (82)	373 (81)	331 (78)	303 (80)
Yes	48 (11)	50 (11)	61 (13)	60 (14)	50 (13)
Not reported	46 (10)	27 (6)	25 (5)	32 (8)	27 (7)
N° in prison	N=48	N=50	N=61	N=60	N=50
Injected in prison	14 (29)	19 (38)	15 (25)	17 (28)	15 (30)

Table 8.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Victoria	2013	2014	2015	2016	2017
N° surveyed	N=448	N=436	N=459	N=423	N=380
Drug last injected (%)					
Cocaine	1 (<1)	6 (1)	5 (1)	2 (<1)	2 (1)
Methamphetamine	96 (21)	98 (22)	142 (31)	134 (32)	92 (24)
Heroin	241 (54)	240 (55)	237 (52)	222 (52)	234 (62)
Pharm. opioids	19 (4)	18 (4)	16 (3)	12 (3)	11 (3)
Methadone	8 (2)	10 (2)	9 (2)	5 (1)	4 (1)
Buprenorphine	22 (5)	14 (3)	16 (3)	11 (3)	7 (2)
Buprenorphine/naloxone	10 (2)	14 (3)	7 (2)	7 (2)	4 (1)
PIEDs	3 (<1)	0 (0)	4 (1)	1 (<1)	1 (<1)
More than one	43 (10)	27 (6)	19 (4)	24 (6)	19 (5)
Other	4 (<1)	6 (1)	4 (1)	5 (1)	1 (<1)
Not reported	1 (<1)	3 (<1)	0 (0)	0 (0)	5 (1)
Ever injected opioids					
Yes	-	-	-	379 (90)	353 (93)
No	-	-	-	43 (10)	24 (6)
Not reported	-	-	-	1 (<1)	3 (1)
Frequency of injection last month (%)					
Not last month	33 (7)	38 (9)	35 (8)	31 (7)	25 (7)
Less than weekly	84 (19)	68 (16)	74 (16)	58 (14)	70 (18)
Weekly not daily	102 (23)	122 (28)	129 (28)	99 (23)	79 (21)
Daily or more	210 (47)	204 (47)	216 (47)	226 (53)	202 (53)
Not reported	19 (4)	4 (1)	5 (1)	9 (2)	4 (1)
Present when someone injected for the first time in the last 12 months (%)					
Yes	49 (11)	71 (16)	66 (14)	71 (17)	56 (15)
No	318 (71)	349 (80)	379 (83)	339 (80)	309 (81)
Not reported	81 (18)	16 (4)	14 (3)	13 (3)	15 (4)
Overdosed in last 12 months					
Yes	78 (17)	82 (19)	97 (21)	112 (27)	91 (24)
No	358 (80)	339 (78)	353 (77)	298 (70)	272 (72)
Not reported	12 (3)	15 (3)	9 (2)	13 (3)	17 (4)

Table 8.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Victoria	2013	2014	2015	2016	2017
N° injected last month	N=396	N=394	N=419	N=383	N=351
Places injected last month (%)					
Any public	224 (57)	215 (55)	233 (56)	233 (61)	219 (62)
All private	164 (41)	177 (45)	183 (44)	148 (39)	128 (36)
Not reported	8 (2)	2 (<1)	3 (1)	2 (1)	4 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	269 (68)	278 (71)	283 (68)	259 (68)	267 (76)
Most of the time	103 (26)	92 (23)	108 (26)	102 (27)	70 (20)
Half of the time	2 (<1)	10 (3)	15 (4)	9 (2)	3 (1)
Some of the time	8 (2)	3 (1)	9 (2)	7 (2)	1 (<1)
Not last month	2 (<1)	0 (0)	2 (<1)	3 (1)	0 (0)
Not reported	12 (3)	11 (3)	2 (<1)	3 (1)	10 (3)
Re-used someone else's used needle & syringe last month (%)					
None	313 (79)	318 (81)	333 (79)	302 (79)	288 (82)
Once	19 (5)	23 (6)	23 (5)	27 (7)	18 (5)
Twice	18 (5)	15 (4)	27 (6)	20 (5)	18 (5)
3-5 times	20 (5)	17 (4)	21 (5)	17 (4)	11 (3)
>5 times	16 (4)	12 (3)	12 (3)	15 (4)	8 (2)
Not reported	10 (3)	9 (2)	3 (1)	2 (1)	8 (2)
Number of people needle & syringe was re-used after last month (%)					
None	313 (79)	318 (81)	333 (79)	302 (79)	288 (82)
One	30 (8)	31 (8)	42 (10)	35 (9)	22 (6)
Two	8 (2)	6 (2)	9 (2)	7 (2)	7 (2)
Three to five	2 (<1)	1 (<1)	5 (1)	6 (2)	1 (<1)
More than five	6 (2)	2 (<1)	2 (<1)	2 (1)	2 (1)
Don't know	18 (5)	11 (3)	15 (4)	17 (4)	15 (4)
Not reported	19 (5)	25 (6)	13 (3)	14 (4)	16 (5)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	28 (7)	25 (6)	30 (7)	36 (9)	11 (3)
Casual sex partner	5 (1)	0 (0)	5 (1)	2 (1)	6 (2)
Close friend	18 (5)	17 (4)	28 (7)	20 (5)	14 (4)
Acquaintance	14 (4)	7 (2)	12 (3)	7 (2)	10 (3)
Other	6 (2)	5 (1)	5 (1)	6 (2)	11 (3)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	128 (32)	131 (33)	145 (35)	133 (35)	104 (30)
Water	83 (21)	86 (22)	99 (24)	85 (22)	69 (20)
Filter	56 (14)	69 (18)	78 (19)	56 (15)	43 (12)
Drug mix	43 (11)	49 (12)	64 (15)	46 (12)	34 (10)
None	238 (60)	240 (61)	247 (59)	219 (57)	220 (63)
Injected by someone after that person injected themselves or others last month (%)					
No	315 (80)	326 (83)	345 (82)	304 (79)	292 (83)
Yes	58 (15)	53 (13)	67 (16)	75 (20)	54 (15)
Not reported	23 (6)	15 (4)	7 (2)	4 (1)	5 (1)
Source of needle acquisition					
Needle Syringe Program	374 (94)	368 (93)	384 (92)	353 (92)	323 (92)
Chemist/Pharmacy	90 (23)	87 (22)	93 (22)	86 (22)	63 (18)
Personal sources	29 (7)	55 (14)	80 (19)	46 (12)	51 (15)
Dispensing/Vending Machine	1 (<1)	1 (<1)	3 (1)	47 (12)	53 (15)
Other sources	7 (2)	4 (1)	16 (4)	6 (2)	11 (3)

Table 8.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Victoria	2013	2014	2015	2016	2017
N° surveyed	N=448	N=436	N=459	N=423	N=380
Ever any treatment/therapy for drug use (%)					
No	39 (9)	36 (8)	67 (15)	45 (11)	41 (11)
Yes	406 (91)	396 (91)	388 (85)	367 (87)	335 (88)
Not reported	3 (<1)	4 (1)	4 (1)	11 (3)	4 (1)
History of methadone maintenance treatment (%)					
Currently	171 (38)	152 (35)	137 (30)	128 (30)	123 (32)
Previously	142 (32)	153 (35)	151 (33)	153 (36)	156 (41)
Never	133 (30)	126 (30)	162 (35)	122 (29)	97 (26)
Not reported	2 (<1)	5 (1)	9 (2)	20 (5)	4 (1)
History of buprenorphine (Subutex®) treatment (%)					
Currently	44 (10)	48 (11)	40 (9)	45 (11)	31 (8)
Previously	197 (44)	196 (45)	188 (41)	166 (39)	161 (42)
Never	200 (45)	183 (42)	221 (48)	197 (47)	181 (48)
Not reported	7 (2)	9 (2)	10 (2)	15 (4)	7 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	61 (14)	50 (11)	48 (10)	55 (13)	51 (13)
Previously	156 (35)	167 (38)	156 (34)	150 (35)	150 (39)
Never	225 (50)	208 (48)	246 (54)	209 (49)	175 (46)
Not reported	6 (1)	11 (3)	9 (2)	9 (2)	4 (1)

Table 8.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Victoria	2013	2014	2015	2016	2017
N° surveyed	N=448	N=436	N=459	N=423	N=380
Previous HIV test (%)					
Yes, ever	381 (85)	386 (89)	397 (86)	356 (84)	331 (87)
Yes, last year	253 (56)	244 (56)	243 (53)	222 (52)	223 (59)
>1 year ago	128 (29)	142 (33)	154 (34)	134 (32)	108 (28)
Never tested	42 (9)	33 (8)	48 (10)	51 (12)	33 (9)
Not reported	25 (6)	17 (4)	14 (3)	16 (4)	16 (4)
Previous HCV test (%)					
Yes, ever	393 (88)	395 (91)	429 (93)	362 (86)	317 (83)
Yes, last year	268 (60)	263 (60)	278 (61)	252 (60)	234 (62)
>1 year ago	125 (28)	132 (30)	151 (33)	110 (26)	83 (22)
Never tested	13 (3)	19 (4)	17 (4)	18 (4)	19 (5)
Not reported	42 (9)	22 (5)	13 (3)	43 (10)	44 (12)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=178	N=177	N=194	N=166	N=149
Antiviral treatment	12 (7)	11 (6)	13 (7)	35 (21)	70 (50)
No antiviral treatment	161 (90)	166 (94)	170 (88)	130 (78)	78 (52)
Not reported	5 (3)	0 (0)	11 (6)	1 (1)	1 (1)
Treatment for HCV in past 12 months (%)^{#*}					
N° self-reported HCV diagnosis	N=172	N=172	N=191	N=161	N=140
Antiviral treatment	2 (1)	0 (0)	4 (2)	25 (16)	56 (40)
No antiviral treatment	165 (96)	172 (100)	176 (92)	135 (84)	83 (59)
Not reported	5 (3)	0 (0)	11 (6)	1 (1)	1 (1)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 8.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Victoria	2013	2014	2015	2016	2017
N° surveyed	N=448	N=436	N=459	N=423	N=380
Sex with a regular partner last month (%)					
No	244 (54)	240 (55)	260 (57)	223 (53)	217 (57)
Yes	182 (41)	175 (40)	180 (39)	186 (44)	146 (38)
Not reported	22 (5)	21 (5)	19 (4)	14 (3)	17 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=182	N=175	N=180	N=186	N=146
Never	117 (64)	129 (74)	134 (74)	136 (73)	109 (75)
Sometimes	30 (16)	24 (14)	22 (12)	20 (11)	17 (12)
Every time	20 (11)	12 (7)	20 (11)	17 (9)	15 (10)
Not reported	15 (8)	10 (6)	4 (2)	13 (7)	5 (3)
Sex with other partner(s) last month (%)					
No	351 (78)	350 (80)	377 (82)	341 (81)	301 (79)
Yes	70 (16)	60 (14)	64 (14)	60 (14)	52 (14)
Not reported	27 (6)	26 (6)	18 (4)	22 (5)	27 (7)
Condom used with other partner(s) last month (%)					
N° surveyed	N=70	N=60	N=64	N=60	N=52
Never	17 (24)	20 (33)	22 (34)	22 (37)	15 (29)
Sometimes	24 (34)	11 (18)	23 (36)	20 (33)	23 (44)
Every time	24 (34)	21 (35)	16 (25)	18 (30)	10 (19)
Not reported	5 (7)	8 (13)	3 (5)	0 (0)	4 (8)
Sex work last month (%)					
No	390 (87)	372 (85)	416 (91)	370 (87)	335 (88)
Yes	19 (4)	28 (6)	25 (5)	26 (6)	18 (5)
Not reported	39 (9)	36 (8)	18 (4)	27 (6)	27 (7)
Condom used at last sex work (%)					
Yes	12 (63)	16 (57)	18 (72)	16 (62)	14 (78)

HIV antibody prevalence

Table 8.2.1 HIV antibody prevalence by gender and survey year

Victoria	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013	300	5 (1.7)	139	1 (0.7)	446	6 (1.3)
2014	277	4 (1.4)	143	3 (2.1)	421	7 (1.7)
2015	300	10 (3.3)	152	0 (0.0)	455	10 (2.2)
2016	266	6 (2.3)	149	2 (1.3)	419	8 (1.9)
2017	243	6 (2.5)	127	1 (0.8)	376	7 (1.9)
X ² p trend		0.387		0.823		0.522

Table 8.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Victoria	Male		Female		Total	
Sexual identity	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heterosexual	243	2 (0.8)	91	1 (1.1)	337	3 (0.9)
Bisexual	8	0 (0.0)	22	0 (0.0)	31	0 (0.0)
Homosexual	13	2 (15.4)	8	0 (0.0)	24	2 (8.3)
p value		<0.001		1.000		0.006
2014						
Heterosexual	230	4 (1.7)	106	3 (2.8)	337	7 (2.1)
Bisexual	12	0 (0.0)	23	0 (0.0)	35	0 (0.0)
Homosexual	9	0 (0.0)	2	0 (0.0)	11	0 (0.0)
p value		1.000		1.000		1.000
2015						
Heterosexual	259	4 (1.5)	118	0 (0.0)	377	4 (1.1)
Bisexual	17	1 (5.9)	18	0 (0.0)	36	1 (2.8)
Homosexual	9	4 (44.4)	6	0 (0.0)	17	4 (23.5)
p value		<0.001		--		<0.001
2016						
Heterosexual	232	4 (1.7)	94	1 (1.1)	327	5 (1.5)
Bisexual	10	0 (0.0)	34	0 (0.0)	45	0 (0.0)
Homosexual	6	2 (33.3)	6	0 (0.0)	13	2 (15.4)
p value		0.010		1.000		0.029
2017						
Heterosexual	206	3 (1.5)	84	0 (0.0)	290	3 (1.0)
Bisexual	9	0 (0.0)	23	0 (0.0)	34	0 (0.0)
Homosexual	4	2 (50.0)	9	0 (0.0)	16	2 (12.5)
p value		0.004		--		0.037

Table 8.2.3 HIV antibody prevalence by age group, gender and survey year

Victoria Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
<25 years	8	0 (0.0)	10	0 (0.0)	18	0 (0.0)
25-34 years	80	2 (2.5)	48	0 (0.0)	132	2 (1.5)
35-44 years	135	0 (0.0)	48	0 (0.0)	185	0 (0.0)
45+ years	76	3 (4.0)	33	1 (3.0)	110	4 (3.6)
p value		0.086		0.309		0.054
2014						
<25 years	5	0 (0.0)	5	0 (0.0)	11	0 (0.0)
25-34 years	70	3 (4.3)	51	0 (0.0)	121	3 (2.5)
35-44 years	124	0 (0.0)	51	2 (3.9)	175	2 (1.1)
45+ years	76	1 (1.3)	36	1 (2.8)	112	2 (1.8)
p value		0.098		0.531		0.703
2015						
<25 years	4	0 (0.0)	4	0 (0.0)	8	0 (0.0)
25-34 years	60	6 (10.0)	47	0 (0.0)	108	6 (5.6)
35-44 years	125	2 (1.6)	55	0 (0.0)	181	2 (1.1)
45+ years	110	2 (1.8)	46	0 (0.0)	157	2 (1.3)
p value		0.036		--		0.059
2016						
<25 years	4	1 (25.0)	8	0 (0.0)	13	1 (7.7)
25-34 years	49	3 (6.1)	37	1 (2.7)	86	4 (4.7)
35-44 years	114	0 (0.0)	62	0 (0.0)	177	0 (0.0)
45+ years	99	2 (2.0)	42	1 (2.4)	143	3 (2.1)
p value		0.005		0.384		0.008
2017						
<25 years	3	0 (0.0)	4	0 (0.0)	7	0 (0.0)
25-34 years	39	4 (10.3)	22	0 (0.0)	65	4 (6.2)
35-44 years	107	2 (1.9)	51	0 (0.0)	158	2 (1.3)
45+ years	91	0 (0.0)	50	1 (2.0)	143	1 (0.7)
p value		0.014		0.598		0.081

Table 8.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Victoria Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heroin	160	2 (1.3)	76	1 (1.3)	239	3 (1.3)
Methamphetamine	61	3 (4.9)	34	0 (0.0)	96	3 (3.1)
Other opioids	45	0 (0.0)	14	0 (0.0)	59	0 (0.0)
Other drugs	33	0 (0.0)	15	0 (0.0)	51	0 (0.0)
p value		0.258		1.000		0.434
2014						
Heroin	157	4 (2.6)	73	1 (1.4)	230	5 (2.1)
Methamphetamine	55	0 (0.0)	39	1 (2.6)	95	1 (1.1)
Other opioids	40	0 (0.0)	16	0 (0.0)	56	0 (0.0)
Other drugs	23	0 (0.0)	14	1 (7.1)	37	1 (2.7)
p value		0.627		0.344		0.628
2015						
Heroin	155	5 (3.2)	79	0 (0.0)	236	5 (2.1)
Methamphetamine	95	5 (5.3)	44	0 (0.0)	140	5 (3.6)
Other opioids	31	0 (0.0)	17	0 (0.0)	48	0 (0.0)
Other drugs	19	0 (0.0)	12	0 (0.0)	31	0 (0.0)
p value		0.554		--		0.544
2016						
Heroin	150	4 (2.7)	70	2 (2.9)	221	6 (2.7)
Methamphetamine	76	1 (1.3)	55	0 (0.0)	131	1 (0.8)
Other opioids	20	0 (0.0)	14	0 (0.0)	35	0 (0.0)
Other drugs	20	1 (5.0)	10	0 (0.0)	32	1 (3.1)
p value		0.560		0.651		0.434
2017						
Heroin	151	3 (2.0)	79	0 (0.0)	232	3 (1.3)
Methamphetamine	57	3 (5.3)	33	0 (0.0)	92	3 (3.3)
Other opioids	15	0 (0.0)	7	0 (0.0)	24	0 (0.0)
Other drugs	20	0 (0.0)	8	1 (12.5)	28	1 (3.6)
p value		0.525		0.118		0.426

Table 8.2.5 HIV antibody prevalence by years of injection, gender and survey year

Victoria Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
<3 years	5	0 (0.0)	6	0 (0.0)	13	0 (0.0)
3 to 10 years	39	2 (5.1)	26	0 (0.0)	66	2 (3.0)
11+ years	239	3 (1.3)	102	1 (1.0)	344	4 (1.2)
p value		0.219		1.000		0.378
2014						
<3 years	8	0 (0.0)	9	0 (0.0)	17	0 (0.0)
3 to 10 years	24	2 (8.3)	22	0 (0.0)	47	2 (4.3)
11+ years	231	2 (0.9)	106	3 (2.8)	337	5 (1.5)
p value		0.074		1.000		0.416
2015						
<3 years	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)
3 to 10 years	32	4 (12.5)	23	0 (0.0)	57	4 (7.0)
11+ years	248	6 (2.4)	119	0 (0.0)	368	6 (1.6)
p value		0.033		--		0.051
2016						
<3 years	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)
3 to 10 years	30	2 (6.7)	26	1 (3.9)	57	3 (5.3)
11+ years	220	4 (1.8)	110	1 (0.9)	333	5 (1.5)
p value		0.250		0.410		0.150
2017						
<3 years	3	0 (0.0)	3	0 (0.0)	8	0 (0.0)
3 to 10 years	22	1 (4.6)	17	0 (0.0)	39	1 (2.6)
11+ years	218	5 (2.3)	107	1 (0.9)	329	6 (1.8)
p value		0.482		1.000		0.610

Table 8.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Victoria Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No receptive sharing	207	4 (1.9)	99	1 (1.0)	311	5 (1.6)
Receptive sharing	55	0 (0.0)	18	0 (0.0)	73	0 (0.0)
p value		0.582		1.000		0.588
2014						
No receptive sharing	206	2 (1.0)	98	2 (2.0)	305	4 (1.3)
Receptive sharing	37	2 (5.4)	28	1 (3.6)	65	3 (4.6)
p value		0.111		0.533		0.107
2015						
No receptive sharing	212	10 (4.7)	114	0 (0.0)	329	10 (3.0)
Receptive sharing	59	0 (0.0)	24	0 (0.0)	83	0 (0.0)
p value		0.125		--		0.223
2016						
No receptive sharing	191	3 (1.6)	103	2 (1.9)	298	5 (1.7)
Receptive sharing	48	3 (6.3)	31	0 (0.0)	79	3 (3.8)
p value		0.097		1.000		0.372
2017						
No receptive sharing	181	3 (1.7)	97	0 (0.0)	284	3 (1.1)
Receptive sharing	41	2 (4.9)	14	1 (7.1)	55	3 (5.5)
p value		0.230		0.126		0.056

Table 8.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Victoria	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Less than daily	119	1 (0.8)	65	1 (1.5)	185	2 (1.1)
Daily or more	147	3 (2.0)	58	0 (0.0)	209	3 (1.5)
Not last month	24	1 (4.2)	9	0 (0.0)	33	1 (3.0)
p value		0.357		1.000		0.520
2014						
Less than daily	119	0 (0.0)	63	0 (0.0)	183	0 (0.0)
Daily or more	129	4 (3.1)	67	3 (4.5)	196	7 (3.6)
Not last month	26	0 (0.0)	12	0 (0.0)	38	0 (0.0)
p value		0.199		0.313		0.031
2015						
Less than daily	126	6 (4.8)	72	0 (0.0)	200	6 (3.0)
Daily or more	146	4 (2.7)	68	0 (0.0)	215	4 (1.9)
Not last month	25	0 (0.0)	10	0 (0.0)	35	0 (0.0)
p value		0.536		--		0.605
2016						
Less than daily	90	1 (1.1)	64	1 (1.6)	156	2 (1.3)
Daily or more	151	5 (3.3)	70	1 (1.4)	223	6 (2.7)
Not last month	18	0 (0.0)	13	0 (0.0)	31	0 (0.0)
p value		0.622		1.000		0.724
2017						
Less than daily	95	1 (1.1)	51	0 (0.0)	148	1 (0.7)
Daily or more	132	5 (3.8)	63	1 (1.6)	199	6 (3.0)
Not last month	15	0 (0.0)	10	0 (0.0)	25	0 (0.0)
p value		0.596		1.000		0.353

Table 8.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Victoria	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No imprisonment	228	4 (1.8)	118	1 (0.9)	352	5 (1.4)
Imprisonment	38	1 (2.6)	10	0 (0.0)	48	1 (2.1)
p value		0.540		1.000		0.538
2014						
No imprisonment	220	4 (1.8)	129	3 (2.3)	350	7 (2.0)
Imprisonment	38	0 (0.0)	8	0 (0.0)	46	0 (0.0)
p value		1.000		1.000		1.000
2015						
No imprisonment	233	9 (3.9)	135	0 (0.0)	371	9 (2.4)
Imprisonment	48	0 (0.0)	11	0 (0.0)	59	0 (0.0)
p value		0.366		--		0.618
2016						
No imprisonment	201	6 (3.0)	124	0 (0.0)	328	6 (1.8)
Imprisonment	42	0 (0.0)	16	1 (6.3)	59	1 (1.7)
p value		0.594		0.114		1.000
2017						
No imprisonment	189	5 (2.7)	105	1 (1.0)	300	6 (2.0)
Imprisonment	40	0 (0.0)	10	0 (0.0)	50	0 (0.0)
p value		0.590		1.000		0.600

Table 8.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Victoria	Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No condom use	65	1 (1.6)	51	0 (0.0)	117	1 (0.9)
Condom use	32	2 (6.3)	16	0 (0.0)	50	2 (4.0)
p value		0.252		--		0.214
2014						
No condom use	67	1 (1.5)	57	1 (1.8)	124	2 (1.6)
Condom use	22	0 (0.0)	13	0 (0.0)	35	0 (0.0)
p value		1.000		1.000		1.000
2015						
No condom use	75	1 (1.3)	57	0 (0.0)	133	1 (0.8)
Condom use	25	1 (4.0)	15	0 (0.0)	41	1 (2.4)
p value		0.439		--		0.417
2016						
No condom use	74	2 (2.7)	59	1 (1.7)	134	3 (2.2)
Condom use	24	0 (0.0)	13	0 (0.0)	37	0 (0.0)
p value		1.000		1.000		1.000
2017						
No condom use	62	1 (1.6)	45	0 (0.0)	109	1 (0.9)
Condom use	22	1 (4.6)	9	1 (11.1)	32	2 (6.3)
p value		0.458		0.167		0.129

Table 8.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Victoria	Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No sex work	268	5 (1.9)	115	1 (0.9)	388	6 (1.6)
Sex work	7	0 (0.0)	11	0 (0.0)	19	0 (0.0)
p value		1.000		1.000		1.000
2014						
No sex work	241	3 (1.2)	119	3 (2.2)	360	6 (1.7)
Sex work	12	0 (0.0)	15	0 (0.0)	28	0 (0.0)
p value		1.000		1.000		1.000
2015						
No sex work	278	8 (2.9)	133	0 (0.0)	412	8 (1.9)
Sex work	6	2 (33.3)	17	0 (0.0)	25	2 (8.0)
p value		0.016		--		0.107
2016						
No sex work	242	5 (2.1)	122	0 (0.0)	366	5 (1.4)
Sex work	8	0 (0.0)	17	1 (5.9)	26	1 (3.9)
p value		1.000		0.122		0.339
2017						
No sex work	223	5 (2.2)	103	1 (1.0)	332	6 (1.8)
Sex work	4	0 (0.0)	14	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000

Table 8.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Non Indigenous	256	4 (1.6)	119	1 (0.8)	379	5 (1.3)
Indigenous	32	1 (3.1)	17	0 (0.0)	51	1 (2.0)
p value		0.448		1.000		0.533
2014						
Non Indigenous	245	2 (0.8)	120	2 (1.7)	366	4 (1.1)
Indigenous	30	2 (6.7)	20	1 (5.0)	50	3 (6.0)
p value		0.060		0.373		0.040
2015						
Non Indigenous	261	6 (2.3)	134	0 (0.0)	398	6 (1.5)
Indigenous	34	4 (11.8)	18	0 (0.0)	52	4 (7.7)
p value		0.019		--		0.020
2016						
Non Indigenous	213	2 (0.9)	121	1 (0.8)	337	3 (0.9)
Indigenous	46	4 (8.7)	23	0 (0.0)	70	4 (5.7)
p value		0.010		1.000		0.019
2017						
Non Indigenous	207	4 (1.9)	104	0 (0.0)	316	4 (1.3)
Indigenous	34	2 (5.9)	20	1 (5.0)	55	3 (5.5)
p value		0.201		0.161		0.070

Table 8.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
English speaking	254	4 (1.6)	130	1 (0.8)	391	5 (1.3)
Non-English speaking	45	1 (2.2)	9	0 (0.0)	54	1 (1.9)
p value		0.560		1.000		0.542
2014						
English speaking	235	3 (1.3)	129	2 (1.6)	364	5 (1.4)
Non-English speaking	42	1 (2.4)	13	1 (7.7)	56	2 (3.6)
p value		0.484		0.252		0.237
2015						
English speaking	266	9 (3.4)	141	0 (0.0)	410	9 (2.2)
Non-English speaking	31	1 (3.2)	11	0 (0.0)	42	1 (2.4)
p value		1.000		--		1.000
2016						
English speaking	233	6 (2.6)	139	1 (0.7)	376	7 (1.9)
Non-English speaking	30	0 (0.0)	8	0 (0.0)	38	0 (0.0)
p value		1.000		1.000		1.000
2017						
English speaking	203	5 (2.5)	124	1 (0.8)	333	6 (1.8)
Non-English speaking	40	1 (2.5)	3	0 (0.0)	43	1 (2.3)
p value		1.000		1.000		0.576

Table 8.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Victoria		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2013							
Australia	235	3 (1.3)	121	1 (0.8)	363	4 (1.1)	
Other Oceania	10	0 (0.0)	0	0 (0.0)	10	0 (0.0)	
Asia	17	1 (5.9)	3	0 (0.0)	20	1 (5.0)	
UK & Ireland	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)	
Other	22	1 (4.6)	8	0 (0.0)	30	1 (3.3)	
p value		0.486		1.000		0.258	
2014							
Australia	220	3 (1.4)	127	2 (1.6)	348	5 (1.4)	
Other Oceania	9	0 (0.0)	1	0 (0.0)	10	0 (0.0)	
Asia	17	1 (5.9)	2	1 (50.0)	19	2 (10.5)	
UK & Ireland	14	0 (0.0)	6	0 (0.0)	20	0 (0.0)	
Other	16	0 (0.0)	7	0 (0.0)	26	0 (0.0)	
p value		0.599		0.083		0.121	
2015							
Australia	243	9 (3.7)	128	0 (0.0)	373	9 (2.4)	
Other Oceania	14	0 (0.0)	3	0 (0.0)	17	0 (0.0)	
Asia	13	1 (7.7)	3	0 (0.0)	16	1 (6.3)	
UK & Ireland	13	0 (0.0)	13	0 (0.0)	27	0 (0.0)	
Other	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)	
p value		0.719		--		0.613	
2016							
Australia	225	6 (2.7)	134	1 (0.8)	362	7 (1.9)	
Other Oceania	5	0 (0.0)	1	0 (0.0)	7	0 (0.0)	
Asia	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)	
UK & Ireland	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)	
Other	13	0 (0.0)	6	0 (0.0)	19	0 (0.0)	
p value		1.000		1.000		1.000	
2017							
Australia	209	5 (2.4)	116	1 (0.9)	329	6 (1.8)	
Other Oceania	5	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
Asia	4	1 (25.0)	1	0 (0.0)	5	1 (20.0)	
UK & Ireland	8	0 (0.0)	5	0 (0.0)	13	0 (0.0)	
Other	17	0 (0.0)	1	0 (0.0)	19	0 (0.0)	
p value		0.246		1.000		0.250	

HCV antibody prevalence

Table 8.3.1 HCV antibody prevalence by gender and survey year

Victoria	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013	299	199 (67)	138	94 (68)	444	296 (67)
2014	267	183 (69)	138	90 (65)	406	273 (67)
2015	278	207 (74)	143	98 (69)	424	306 (72)
2016	243	167 (69)	130	85 (65)	377	254 (67)
2017	230	160 (70)	118	85 (72)	353	246 (70)
X ² p trend		0.735		0.804		0.702

Table 8.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Victoria	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heterosexual	242	166 (69)	90	63 (70)	335	231 (69)
Bisexual	8	6 (75)	22	12 (55)	31	18 (58)
Homosexual	13	4 (31)	8	6 (75)	24	11 (46)
p value		0.019		0.350		0.040
2014						
Heterosexual	221	149 (67)	102	64 (63)	324	213 (66)
Bisexual	12	9 (75)	22	14 (64)	34	23 (68)
Homosexual	9	6 (67)	2	2 (100)	11	8 (73)
p value		0.859		0.750		0.873
2015						
Heterosexual	245	182 (74)	110	75 (68)	355	257 (72)
Bisexual	12	8 (67)	17	11 (65)	30	19 (63)
Homosexual	7	7 (100)	6	5 (83)	15	13 (87)
p value		0.247		0.695		0.281
2016						
Heterosexual	214	153 (72)	81	51 (63)	296	204 (69)
Bisexual	9	5 (56)	32	21 (66)	42	27 (64)
Homosexual	5	0 (0)	6	4 (67)	12	4 (33)
p value		0.001		0.944		0.038
2017						
Heterosexual	193	135 (70)	76	52 (68)	269	187 (70)
Bisexual	9	6 (67)	23	19 (83)	34	25 (74)
Homosexual	4	1 (25)	9	6 (67)	16	8 (50)
p value		0.185		0.392		0.217

Table 8.3.3 HCV antibody prevalence by age group, gender and survey year

Victoria Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<25 years	8	1 (13)	10	4 (40)	18	5 (28)
25-34 years	79	37 (47)	48	28 (58)	131	67 (51)
35-44 years	135	101 (75)	47	36 (77)	184	137 (74)
45+ years	76	59 (78)	33	26 (79)	110	86 (78)
p value		<0.001		0.030		<0.001
2014						
<25 years	5	2 (40)	5	3 (60)	11	5 (45)
25-34 years	69	42 (61)	48	26 (54)	117	68 (58)
35-44 years	120	80 (67)	49	38 (78)	169	118 (70)
45+ years	71	58 (82)	36	23 (64)	107	81 (76)
p value		0.015		0.093		0.013
2015						
<25 years	4	0 (0)	4	0 (0)	8	0 (0)
25-34 years	54	28 (52)	44	30 (68)	99	58 (59)
35-44 years	117	93 (79)	50	34 (68)	168	127 (76)
45+ years	102	85 (83)	45	34 (76)	148	120 (81)
p value		<0.001		0.030		<0.001
2016						
<25 years	4	1 (25)	8	5 (63)	13	7 (54)
25-34 years	44	26 (59)	31	19 (61)	75	45 (60)
35-44 years	104	78 (75)	55	41 (75)	160	119 (74)
45+ years	91	62 (68)	36	20 (56)	129	83 (64)
p value		0.058		0.258		0.070
2017						
<25 years	3	0 (0)	4	3 (75)	7	3 (43)
25-34 years	36	22 (61)	20	13 (65)	59	35 (59)
35-44 years	101	70 (69)	47	34 (72)	148	104 (70)
45+ years	87	67 (77)	47	35 (74)	136	103 (76)
p value		0.019		0.899		0.046

Table 8.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Victoria Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<3 years	5	2 (40)	6	1 (17)	13	4 (31)
3 to 10 years	38	13 (34)	26	18 (69)	65	31 (48)
11+ years	239	170 (71)	101	74 (73)	343	245 (71)
p value		<0.001		<0.001		<0.001
2014						
<3 years	8	1 (13)	9	3 (33)	17	4 (24)
3 to 10 years	24	16 (67)	22	11 (50)	47	27 (57)
11+ years	221	159 (72)	101	71 (70)	322	230 (71)
p value		0.002		0.024		<0.001
2015						
<3 years	11	2 (18)	6	1 (17)	17	3 (18)
3 to 10 years	31	16 (52)	21	11 (52)	54	27 (50)
11+ years	230	183 (80)	113	84 (74)	344	268 (78)
p value		<0.001		0.003		<0.001
2016						
<3 years	5	2 (40)	7	2 (29)	12	4 (33)
3 to 10 years	28	15 (54)	23	15 (65)	52	31 (60)
11+ years	200	142 (71)	96	65 (68)	299	208 (70)
p value		0.050		0.139		0.017
2017						
<3 years	3	0 (0)	3	1 (33)	8	1 (13)
3 to 10 years	20	9 (45)	17	12 (71)	37	21 (57)
11+ years	201	147 (73)	93	69 (74)	297	217 (73)
p value		0.001		0.264		<0.001

Table 8.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Victoria Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No receptive sharing	9	3 (33)	288	192 (67)	309	203 (66)
Receptive sharing	1	0 (0)	65	45 (69)	73	50 (68)
p value		1.000		0.771		0.682
2014						
No receptive sharing	13	3 (23)	273	182 (67)	296	192 (65)
Receptive sharing	3	0 (0)	56	49 (88)	63	52 (83)
p value		1.000		0.002		0.006
2015						
No receptive sharing	9	1 (11)	291	210 (72)	305	216 (71)
Receptive sharing	5	2 (40)	75	61 (81)	81	64 (79)
p value		0.505		0.106		0.142
2016						
No receptive sharing	9	3 (33)	251	171 (68)	269	182 (68)
Receptive sharing	2	0 (0)	66	48 (73)	71	50 (70)
p value		1.000		0.472		0.656
2017						
No receptive sharing	6	0 (0)	256	177 (69)	265	180 (68)
Receptive sharing	1	0 (0)	50	39 (78)	53	40 (75)
p value		--		0.209		0.277

Table 8.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Victoria Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heroin	4	1 (25)	225	161 (72)	237	170 (72)
Methamphetamine	4	1 (25)	86	53 (62)	96	58 (60)
Other opioids	1	0 (0)	54	36 (67)	59	38 (64)
Other drugs	4	2 (50)	43	26 (60)	51	29 (57)
p value		0.738		0.258		0.080
2014						
Heroin	9	2 (22)	204	150 (74)	223	159 (71)
Methamphetamine	4	1 (25)	84	47 (56)	91	50 (55)
Other opioids	1	0 (0)	48	35 (73)	51	37 (73)
Other drugs	3	1 (33)	33	25 (76)	38	27 (71)
p value		0.923		0.021		0.031
2015						
Heroin	4	1 (25)	220	171 (78)	227	175 (77)
Methamphetamine	9	2 (22)	109	73 (67)	122	79 (65)
Other opioids	0	0 (0)	42	29 (69)	42	29 (69)
Other drugs	4	0 (0)	23	18 (78)	28	18 (64)
p value		0.567		0.163		0.070
2016						
Heroin	2	1 (50)	189	138 (73)	195	142 (73)
Methamphetamine	7	1 (14)	105	66 (63)	119	73 (61)
Other opioids	2	2 (100)	27	16 (59)	30	19 (63)
Other drugs	1	0 (0)	23	13 (57)	25	14 (56)
p value		0.117		0.124		0.099
2017						
Heroin	3	1 (33)	206	158 (77)	217	165 (76)
Methamphetamine	4	0 (0)	83	49 (59)	88	50 (57)
Other opioids	0	0 (0)	21	15 (71)	21	15 (71)
Other drugs	1	0 (0)	23	15 (65)	24	15 (63)
p value		0.386		0.024		0.008

Table 8.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Victoria	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Less than daily	6	1 (17)	168	117 (70)	185	122 (66)
Daily or more	4	2 (50)	193	126 (65)	207	138 (67)
Not last month	2	1 (50)	30	20 (67)	33	22 (67)
p value		0.414		0.688		0.987
2014						
Less than daily	5	0 (0)	166	112 (67)	178	116 (65)
Daily or more	11	3 (27)	171	125 (73)	189	134 (71)
Not last month	1	1 (100)	30	19 (63)	35	21 (60)
p value		0.168		0.386		0.312
2015						
Less than daily	7	0 (0)	178	125 (70)	188	128 (68)
Daily or more	8	3 (38)	190	148 (78)	201	154 (77)
Not last month	2	0 (0)	26	18 (69)	30	19 (63)
p value		0.300		0.211		0.098
2016						
Less than daily	5	2 (40)	133	90 (68)	140	93 (66)
Daily or more	6	1 (17)	186	131 (70)	202	141 (70)
Not last month	1	1 (100)	25	12 (48)	27	14 (52)
p value		0.343		0.079		0.170
2017						
Less than daily	5	0 (0)	132	95 (72)	139	96 (69)
Daily or more	2	0 (0)	180	127 (71)	186	131 (70)
Not last month	1	1 (100)	21	15 (71)	25	18 (72)
p value		0.125		0.963		0.966

Table 8.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Victoria	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No imprisonment	10	4 (40)	325	212 (65)	351	227 (65)
Imprisonment	1	0 (0)	44	34 (77)	47	35 (74)
p value		1.000		0.127		0.184
2014						
No imprisonment	13	2 (15)	307	206 (67)	336	218 (65)
Imprisonment	2	1 (50)	42	33 (79)	45	34 (76)
p value		0.371		0.133		0.155
2015						
No imprisonment	17	3 (18)	324	233 (72)	348	242 (70)
Imprisonment	0	0 (0)	50	42 (84)	52	44 (85)
p value		--		0.071		0.031
2016						
No imprisonment	11	3 (27)	279	176 (63)	298	185 (62)
Imprisonment	0	0 (0)	49	46 (94)	52	49 (94)
p value		--		<0.001		<0.001
2017						
No imprisonment	6	1 (17)	268	183 (68)	283	189 (67)
Imprisonment	2	0 (0)	44	37 (84)	46	37 (80)
p value		1.000		0.033		0.064

Table 8.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Non Indigenous	255	167 (65)	118	79 (67)	377	247 (66)
Indigenous	32	21 (66)	17	13 (76)	51	35 (69)
p value		0.988		0.431		0.660
2014						
Non Indigenous	236	165 (70)	115	70 (61)	352	235 (67)
Indigenous	29	16 (55)	20	17 (85)	49	33 (67)
p value		0.107		0.037		0.935
2015						
Non Indigenous	242	176 (73)	127	87 (70)	369	264 (72)
Indigenous	31	29 (94)	19	11 (58)	50	40 (80)
p value		0.012		0.284		0.209
2016						
Non Indigenous	197	134 (68)	107	68 (64)	307	204 (66)
Indigenous	39	27 (69)	19	13 (68)	59	40 (68)
p value		0.882		0.683		0.841
2017						
Non Indigenous	195	133 (68)	97	67 (69)	297	201 (68)
Indigenous	33	25 (76)	18	15 (83)	51	40 (78)
p value		0.384		0.269		0.124

Table 8.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
English speaking	253	163 (64)	129	87 (67)	389	253 (65)
Non-English speaking	45	35 (78)	9	7 (78)	54	42 (78)
p value		0.081		0.719		0.063
2014						
English speaking	228	153 (67)	124	80 (65)	352	233 (66)
Non-English speaking	39	30 (77)	13	9 (69)	53	39 (74)
p value		0.222		0.735		0.285
2015						
English speaking	245	181 (74)	132	88 (67)	380	270 (71)
Non-English speaking	31	25 (81)	11	10 (91)	42	35 (83)
p value		0.415		0.096		0.092
2016						
English speaking	211	140 (66)	121	79 (65)	336	221 (66)
Non-English speaking	29	24 (83)	7	4 (57)	36	28 (78)
p value		0.075		0.696		0.146
2017						
English speaking	192	130 (68)	115	83 (72)	312	214 (69)
Non-English speaking	38	30 (79)	3	2 (67)	41	32 (78)
p value		0.169		1.000		0.215

Table 8.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Victoria	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Australia	235	154 (66)	120	82 (68)	362	239 (66)
Other Oceania	10	4 (40)	0	0 (0)	10	4 (40)
Asia	16	15 (94)	3	3 (100)	19	18 (95)
UK & Ireland	14	9 (64)	7	4 (57)	21	13 (62)
Other	22	15 (68)	8	5 (63)	30	20 (67)
p value		0.055		0.673		0.022
2014						
Australia	211	142 (67)	122	78 (64)	334	220 (66)
Other Oceania	8	5 (63)	1	1 (100)	9	6 (67)
Asia	17	16 (94)	2	2 (100)	19	18 (95)
UK & Ireland	14	8 (57)	6	4 (67)	20	12 (60)
Other	16	12 (75)	7	5 (71)	23	17 (74)
p value		0.157		0.969		0.101
2015						
Australia	224	167 (75)	119	86 (72)	345	254 (74)
Other Oceania	13	10 (77)	3	3 (100)	16	13 (81)
Asia	13	10 (77)	3	1 (33)	16	11 (69)
UK & Ireland	12	9 (75)	13	5 (38)	26	14 (54)
Other	15	10 (67)	5	3 (60)	20	13 (65)
p value		0.967		0.038		0.202
2016						
Australia	204	138 (68)	118	77 (65)	325	216 (66)
Other Oceania	5	5 (100)	1	1 (100)	7	7 (100)
Asia	6	5 (83)	1	0 (0)	7	5 (71)
UK & Ireland	10	5 (50)	3	1 (33)	13	6 (46)
Other	13	9 (69)	4	3 (75)	17	12 (71)
p value		0.391		0.498		0.179
2017						
Australia	196	133 (68)	107	79 (74)	306	212 (69)
Other Oceania	5	3 (60)	3	2 (67)	9	6 (67)
Asia	4	3 (75)	1	0 (0)	5	3 (60)
UK & Ireland	8	7 (88)	5	3 (60)	13	10 (77)
Other	17	14 (82)	1	0 (0)	19	14 (74)
p value		0.587		0.180		0.936

Western Australia

Table 9.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Western Australia	2013	2014	2015	2016	2017
Number of sites	3	3	2	4	4
N° surveyed	N=220	N=225	N=218	N=425	N=508
Response rate (%)	77%	82%	70%	75%	72%
Gender (%)					
Male	135 (61)	142 (63)	125 (57)	274 (64)	340 (67)
Female	83 (38)	81 (36)	89 (41)	148 (35)	166 (33)
Transgender	1 (<1)	2 (1)	3 (1)	2 (<1)	1 (<1)
Not reported	1 (<1)	0 (0)	1 (<1)	1 (<1)	1 (<1)
Sexual identity (%)					
Heterosexual	177 (80)	184 (82)	173 (79)	336 (79)	421 (83)
Bisexual	19 (9)	25 (11)	16 (7)	33 (8)	32 (6)
Homosexual	7 (3)	6 (3)	8 (4)	14 (3)	9 (2)
Not reported	17 (8)	10 (4)	21 (10)	42 (10)	46 (9)
Aboriginal and Torres Strait Islander origin (%)					
No	191 (87)	200 (89)	184 (84)	326 (77)	397 (78)
Yes	15 (7)	19 (8)	23 (11)	76 (18)	106 (21)
Not reported	14 (6)	6 (3)	11 (5)	23 (5)	5 (1)
Region/country of birth (%)					
Australia	172 (78)	176 (78)	165 (76)	358 (84)	423 (83)
Other Oceania	10 (5)	10 (4)	11 (5)	17 (4)	9 (2)
Asia	1 (<1)	2 (1)	4 (2)	4 (1)	7 (1)
UK & Ireland	19 (9)	18 (8)	18 (8)	19 (4)	45 (9)
Other	14 (6)	16 (7)	14 (6)	13 (3)	16 (3)
Not reported	4 (2)	3 (1)	6 (3)	14 (3)	8 (2)
Main language spoken at home by parents (%)					
English	205 (93)	211 (94)	201 (92)	388 (91)	484 (95)
Non-English	11 (5)	12 (5)	10 (5)	22 (5)	21 (4)
Not reported	4 (2)	2 (1)	7 (3)	15 (4)	3 (1)
Age and time since first injection (years)					
<i>Median age</i>	39	41	41	41	42
<i>Age range</i>	15-66	18-67	15-70	20-68	18-70
<i>Age group (%)</i>					
<25 years	13 (6)	6 (3)	18 (8)	14 (3)	19 (4)
25+ years	204 (93)	217 (96)	198 (91)	408 (96)	484 (95)
Not reported	3 (1)	2 (1)	2 (1)	3 (1)	5 (1)
<i>Median age first injection</i>					
<i>Age range</i>	12-50	11-45	12-57	10-57	10-53
N° not reported	9	5	12	21	33
<i>Median yrs since first injection</i>					
<i>Range</i>	<1-49	<1-49	2-50	<1-51	<1-54
<i>Years since first injection</i>					
<3 years	18 (8)	9 (4)	6 (3)	25 (6)	31 (6)
3+ years	193 (88)	210 (93)	200 (92)	379 (89)	444 (87)
Not reported	9 (4)	6 (3)	12 (6)	21 (5)	33 (7)
Imprisonment last year (%)					
No	178 (81)	175 (78)	178 (82)	348 (82)	386 (76)
Yes	17 (8)	24 (11)	23 (11)	52 (12)	71 (14)
Not reported	25 (11)	26 (12)	17 (8)	25 (6)	51 (10)
N° in prison					
Injected in prison	2 (12)	11 (46)	8 (35)	13 (25)	20 (28)

Table 9.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Western Australia	2013	2014	2015	2016	2017
N° surveyed	N=220	N=225	N=218	N=425	N=508
Drug last injected (%)					
Cocaine	3 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	79 (36)	78 (35)	98 (45)	256 (60)	275 (54)
Heroin	51 (23)	79 (35)	63 (29)	65 (15)	113 (22)
Pharm. opioids	28 (13)	20 (9)	17 (8)	30 (7)	24 (5)
Methadone	10 (5)	6 (3)	6 (3)	8 (2)	28 (6)
Buprenorphine	9 (4)	4 (2)	6 (3)	14 (3)	8 (2)
Buprenorphine/naloxone	13 (6)	7 (3)	4 (2)	8 (2)	9 (2)
PIEDs	5 (2)	6 (3)	1 (<1)	9 (2)	6 (1)
More than one	18 (8)	23 (10)	17 (8)	27 (6)	35 (7)
Other	1 (<1)	1 (<1)	6 (3)	8 (2)	6 (1)
Not reported	3 (1)	1 (<1)	0 (0)	0 (0)	4 (1)
Ever injected opioids					
Yes	-	-	-	297 (70)	363 (71)
No	-	-	-	128 (30)	142 (28)
Not reported	-	-	-	0 (0)	3 (1)
Frequency of injection last month (%)					
Not last month	19 (9)	16 (7)	12 (6)	27 (6)	40 (8)
Less than weekly	28 (13)	23 (10)	25 (11)	65 (15)	57 (11)
Weekly not daily	38 (17)	36 (16)	51 (23)	89 (21)	109 (21)
Daily or more	124 (56)	146 (65)	121 (56)	234 (55)	292 (57)
Not reported	11 (5)	4 (2)	9 (4)	10 (2)	10 (2)
Present when someone injected for the first time in the last 12 months (%)					
Yes	22 (10)	52 (23)	43 (20)	82 (19)	118 (23)
No	150 (68)	161 (72)	163 (75)	326 (77)	363 (71)
Not reported	48 (22)	12 (5)	12 (6)	17 (4)	27 (5)
Overdosed in last 12 months					
Yes	25 (11)	49 (22)	40 (18)	61 (14)	112 (22)
No	183 (83)	164 (73)	166 (76)	344 (81)	368 (72)
Not reported	12 (5)	12 (5)	12 (6)	20 (5)	28 (6)

Table 9.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Western Australia	2013	2014	2015	2016	2017
N° injected last month	N=190	N=205	N=197	N=388	N=458
Places injected last month (%)					
Any public	95 (50)	89 (43)	88 (45)	209 (54)	247 (54)
All private	92 (48)	112 (55)	109 (55)	179 (46)	207 (45)
Not reported	3 (2)	4 (2)	0 (0)	0 (0)	4 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	128 (67)	141 (69)	136 (69)	228 (59)	275 (60)
Most of the time	50 (26)	47 (23)	47 (24)	130 (34)	140 (31)
Half of the time	3 (2)	4 (2)	8 (4)	16 (4)	22 (5)
Some of the time	4 (2)	5 (2)	4 (2)	6 (2)	10 (2)
Not last month	2 (1)	2 (1)	1 (1)	4 (1)	4 (1)
Not reported	3 (2)	6 (3)	1 (1)	4 (1)	7 (2)
Re-used someone else's used needle & syringe last month (%)					
None	148 (78)	157 (77)	144 (73)	280 (72)	331 (72)
Once	11 (6)	15 (7)	15 (8)	23 (6)	33 (7)
Twice	7 (4)	7 (3)	12 (6)	33 (9)	28 (6)
3-5 times	10 (5)	11 (5)	17 (9)	25 (6)	33 (7)
>5 times	8 (4)	9 (4)	7 (4)	20 (5)	23 (5)
Not reported	6 (3)	6 (3)	2 (1)	7 (2)	10 (2)
Number of people needle & syringe was re-used after last month (%)					
None	148 (78)	157 (77)	144 (73)	280 (72)	331 (72)
One	18 (9)	16 (8)	24 (12)	41 (11)	51 (11)
Two	4 (2)	1 (<1)	8 (4)	10 (3)	14 (3)
Three to five	2 (1)	3 (1)	3 (2)	10 (3)	10 (2)
More than five	2 (1)	6 (3)	1 (1)	7 (2)	3 (1)
Don't know	6 (3)	6 (3)	7 (4)	22 (6)	25 (5)
Not reported	10 (5)	16 (8)	10 (5)	18 (5)	24 (5)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	17 (9)	15 (7)	13 (7)	41 (11)	41 (9)
Casual sex partner	3 (2)	2 (1)	1 (1)	3 (1)	4 (1)
Close friend	11 (6)	9 (4)	24 (12)	30 (8)	40 (9)
Acquaintance	9 (5)	3 (1)	4 (2)	17 (4)	16 (3)
Other	7 (4)	5 (2)	7 (4)	5 (1)	12 (3)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	49 (26)	44 (21)	53 (27)	74 (19)	107 (23)
Water	43 (23)	41 (20)	39 (20)	95 (24)	113 (25)
Filter	24 (13)	23 (11)	23 (12)	35 (9)	56 (12)
Drug mix	16 (8)	17 (8)	19 (10)	29 (7)	52 (11)
None	116 (61)	139 (68)	122 (62)	261 (67)	273 (60)
Injected by someone after that person injected themselves or others last month (%)					
No	143 (75)	157 (77)	159 (81)	302 (78)	345 (75)
Yes	35 (18)	36 (18)	36 (18)	83 (21)	104 (23)
Not reported	12 (6)	12 (6)	2 (1)	3 (1)	9 (2)
Source of needle acquisition					
Needle Syringe Program	160 (84)	167 (81)	161 (82)	312 (80)	363 (79)
Chemist/Pharmacy	58 (31)	53 (26)	58 (29)	138 (36)	157 (34)
Personal sources	24 (13)	26 (13)	26 (13)	65 (17)	60 (13)
Dispensing/Vending Machine	2 (1)	3 (1)	5 (3)	9 (2)	12 (3)
Other sources	9 (5)	5 (2)	5 (3)	11 (3)	24 (5)

Table 9.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Western Australia	2013	2014	2015	2016	2017
N° surveyed	N=220	N=225	N=218	N=425	N=508
Ever any treatment/therapy for drug use (%)					
No	67 (30)	56 (25)	63 (29)	148 (35)	168 (33)
Yes	148 (67)	163 (72)	145 (67)	249 (59)	316 (62)
Not reported	5 (2)	6 (3)	10 (5)	28 (7)	24 (5)
History of methadone maintenance treatment (%)					
Currently	39 (18)	41 (18)	41 (19)	48 (11)	71 (14)
Previously	53 (24)	54 (24)	47 (22)	88 (21)	96 (19)
Never	125 (57)	124 (55)	119 (55)	255 (60)	324 (64)
Not reported	3 (1)	6 (3)	11 (5)	34 (8)	17 (3)
History of buprenorphine (Subutex®) treatment (%)					
Currently	19 (9)	16 (7)	15 (7)	14 (3)	35 (7)
Previously	51 (23)	59 (26)	53 (24)	63 (15)	83 (16)
Never	144 (65)	144 (64)	140 (64)	329 (77)	379 (75)
Not reported	6 (3)	6 (3)	10 (5)	19 (4)	11 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	23 (10)	23 (10)	14 (6)	20 (5)	24 (5)
Previously	37 (17)	41 (18)	47 (22)	55 (13)	71 (14)
Never	150 (68)	156 (69)	146 (67)	328 (77)	397 (78)
Not reported	10 (5)	5 (2)	11 (5)	22 (5)	16 (3)

Table 9.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Western Australia	2013	2014	2015	2016	2017
N° surveyed	N=220	N=225	N=218	N=425	N=508
Previous HIV test (%)					
Yes, ever	167 (76)	173 (77)	172 (79)	327 (77)	384 (76)
Yes, last year	95 (43)	98 (44)	109 (50)	203 (48)	226 (44)
>1 year ago	72 (33)	75 (33)	63 (29)	124 (29)	158 (31)
Never tested	39 (18)	36 (16)	37 (17)	75 (18)	84 (17)
Not reported	14 (6)	16 (7)	9 (4)	23 (5)	40 (8)
Previous HCV test (%)					
Yes, ever	167 (76)	190 (84)	184 (84)	322 (75)	397 (78)
Yes, last year	106 (48)	113 (50)	115 (54)	210 (49)	252 (50)
>1 year ago	61 (28)	77 (34)	69 (32)	112 (26)	145 (29)
Never tested	25 (11)	14 (6)	20 (9)	53 (12)	51 (10)
Not reported	28 (13)	21 (9)	14 (6)	50 (12)	60 (12)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=49	N=61	N=54	N=92	N=97
Antiviral treatment	7 (14)	10 (16)	7 (13)	26 (28)	34 (35)
No antiviral treatment	38 (78)	48 (79)	42 (78)	65 (71)	62 (64)
Not reported	4 (8)	3 (5)	5 (9)	1 (1)	1 (1)
Treatment for HCV in past 12 months (%)#*					
N° self-reported HCV diagnosis	N=48	N=59	N=52	N=86	N=90
Antiviral treatment	4 (8)	0 (0)	1 (2)	14 (16)	20 (22)
No antiviral treatment	40 (83)	56 (95)	46 (88)	71 (83)	69 (77)
Not reported	4 (8)	3 (5)	5 (10)	1 (1)	1 (1)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 9.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Western Australia	2013	2014	2015	2016	2017
N° surveyed	N=220	N=225	N=218	N=425	N=508
Sex with a regular partner last month (%)					
No	108 (49)	113 (50)	100 (46)	208 (49)	240 (47)
Yes	96 (44)	93 (41)	104 (48)	193 (45)	228 (45)
Not reported	16 (7)	19 (8)	14 (6)	24 (6)	40 (8)
Condom used with regular partner last month (%)					
N° surveyed	N=96	N=93	N=104	N=193	N=228
Never	70 (73)	73 (78)	76 (73)	132 (68)	157 (69)
Sometimes	13 (14)	8 (9)	9 (9)	35 (18)	35 (15)
Every time	8 (8)	7 (8)	13 (13)	18 (9)	25 (11)
Not reported	5 (5)	5 (5)	6 (6)	8 (4)	11 (5)
Sex with other partner(s) last month (%)					
No	159 (72)	169 (75)	169 (78)	324 (76)	385 (76)
Yes	39 (18)	34 (15)	34 (16)	72 (17)	78 (15)
Not reported	22 (10)	22 (10)	15 (7)	29 (7)	45 (9)
Condom used with other partner(s) last month (%)					
N° surveyed	N=39	N=34	N=34	N=72	N=78
Never	12 (31)	14 (41)	11 (32)	30 (42)	37 (47)
Sometimes	12 (31)	9 (26)	11 (32)	23 (32)	27 (35)
Every time	14 (36)	7 (21)	10 (30)	15 (21)	13 (17)
Not reported	1 (3)	4 (12)	2 (6)	4 (6)	1 (1)
Sex work last month (%)					
No	188 (85)	181 (80)	190 (87)	372 (88)	435 (86)
Yes	11 (5)	14 (6)	14 (6)	24 (6)	24 (5)
Not reported	21 (10)	30 (13)	14 (6)	29 (7)	49 (10)
Condom used at last sex work (%)					
Yes	9 (80)	6 (43)	10 (71)	18 (75)	15 (63)

HIV antibody prevalence

Table 9.2.1 HIV antibody prevalence by gender and survey year

Western Australia	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013	126	3 (2.4)	71	2 (2.8)	199	5 (2.5)
2014	131	1 (0.8)	75	0 (0.0)	208	1 (0.5)
2015	112	1 (0.9)	83	1 (1.2)	198	2 (1.0)
2016	270	2 (0.7)	146	2 (1.4)	419	5 (1.2)
2017	310	3 (1.0)	154	2 (1.3)	466	5 (1.1)
X ² p trend		0.332		0.759		0.403

Table 9.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Western Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heterosexual	110	2 (1.8)	49	2 (4.1)	159	4 (2.5)
Bisexual	4	1 (25.0)	15	0 (0.0)	19	1 (5.3)
Homosexual	4	0 (0.0)	2	0 (0.0)	6	0 (0.0)
p value		0.191		1.000		0.522
2014						
Heterosexual	118	0 (0.0)	52	0 (0.0)	170	0 (0.0)
Bisexual	6	1 (16.7)	15	0 (0.0)	23	1 (4.4)
Homosexual	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
p value		0.071		--		0.146
2015						
Heterosexual	99	0 (0.0)	57	1 (1.8)	158	1 (0.6)
Bisexual	1	0 (0.0)	15	0 (0.0)	16	0 (0.0)
Homosexual	2	1 (50.0)	3	0 (0.0)	5	1 (20.0)
p value		0.029		1.000		0.063
2016						
Heterosexual	228	1 (0.4)	103	2 (1.9)	331	3 (0.9)
Bisexual	7	1 (14.3)	24	0 (0.0)	33	2 (6.1)
Homosexual	9	0 (0.0)	5	0 (0.0)	14	0 (0.0)
p value		0.058		1.000		0.118
2017						
Heterosexual	265	2 (0.8)	116	2 (1.7)	382	4 (1.1)
Bisexual	10	1 (10.0)	22	0 (0.0)	32	1 (3.1)
Homosexual	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)
p value		0.162		1.000		0.401

Table 9.2.3 HIV antibody prevalence by age group, gender and survey year

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
<25 years	8	1 (12.5)	5	0 (0.0)	13	1 (7.7)
25-34 years	41	1 (2.4)	22	0 (0.0)	63	1 (1.6)
35-44 years	36	1 (2.8)	22	0 (0.0)	58	1 (1.7)
45+ years	39	0 (0.0)	22	2 (9.1)	62	2 (3.2)
p value		0.228		0.416		0.518
2014						
<25 years	6	0 (0.0)	0	0 (0.0)	6	0 (0.0)
25-34 years	33	0 (0.0)	14	0 (0.0)	47	0 (0.0)
35-44 years	46	0 (0.0)	26	0 (0.0)	73	0 (0.0)
45+ years	45	1 (2.2)	35	0 (0.0)	81	1 (1.2)
p value		0.646		--		1.000
2015						
<25 years	6	0 (0.0)	6	0 (0.0)	14	0 (0.0)
25-34 years	21	0 (0.0)	14	0 (0.0)	35	0 (0.0)
35-44 years	40	0 (0.0)	34	0 (0.0)	74	0 (0.0)
45+ years	44	1 (2.3)	29	1 (3.5)	74	2 (2.7)
p value		1.000		0.590		0.716
2016						
<25 years	5	0 (0.0)	8	0 (0.0)	14	0 (0.0)
25-34 years	60	0 (0.0)	38	0 (0.0)	98	0 (0.0)
35-44 years	100	1 (1.0)	52	0 (0.0)	152	1 (0.7)
45+ years	103	1 (1.0)	47	2 (4.3)	152	4 (2.6)
p value		1.000		0.279		0.376
2017						
<25 years	14	0 (0.0)	5	0 (0.0)	19	0 (0.0)
25-34 years	53	0 (0.0)	38	0 (0.0)	92	0 (0.0)
35-44 years	114	0 (0.0)	59	0 (0.0)	174	0 (0.0)
45+ years	127	3 (2.4)	49	2 (4.1)	176	5 (2.8)
p value		0.323		0.231		0.064

Table 9.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Western Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heroin	35	1 (2.9)	14	2 (14.3)	49	3 (6.1)
Methamphetamine	35	2 (5.7)	34	0 (0.0)	70	2 (2.9)
Other opioids	36	0 (0.0)	15	0 (0.0)	51	0 (0.0)
Other drugs	19	0 (0.0)	7	0 (0.0)	26	0 (0.0)
p value		0.364		0.046		0.265
2014						
Heroin	47	0 (0.0)	27	0 (0.0)	75	0 (0.0)
Methamphetamine	39	1 (2.6)	30	0 (0.0)	70	1 (1.4)
Other opioids	21	0 (0.0)	15	0 (0.0)	36	0 (0.0)
Other drugs	23	0 (0.0)	3	0 (0.0)	25	0 (0.0)
p value		0.638		--		0.638
2015						
Heroin	38	0 (0.0)	21	1 (4.8)	59	1 (1.7)
Methamphetamine	42	1 (2.4)	42	0 (0.0)	87	1 (1.2)
Other opioids	17	0 (0.0)	15	0 (0.0)	32	0 (0.0)
Other drugs	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)
p value		1.000		0.494		1.000
2016						
Heroin	43	0 (0.0)	20	1 (5.0)	64	1 (1.6)
Methamphetamine	148	2 (1.4)	101	1 (1.0)	251	4 (1.6)
Other opioids	46	0 (0.0)	14	0 (0.0)	60	0 (0.0)
Other drugs	33	0 (0.0)	11	0 (0.0)	44	0 (0.0)
p value		1.000		0.523		1.000
2017						
Heroin	72	0 (0.0)	32	1 (3.1)	105	1 (1.0)
Methamphetamine	166	2 (1.2)	83	1 (1.2)	249	3 (1.2)
Other opioids	41	1 (2.4)	22	0 (0.0)	63	1 (1.6)
Other drugs	31	0 (0.0)	17	0 (0.0)	49	0 (0.0)
p value		0.647		0.711		1.000

Table 9.2.5 HIV antibody prevalence by years of injection, gender and survey year

Western Australia Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
<3 years	7	0 (0.0)	7	0 (0.0)	14	0 (0.0)
3 to 10 years	16	1 (6.3)	11	0 (0.0)	27	1 (3.7)
11+ years	97	2 (2.1)	51	2 (3.9)	149	4 (2.7)
p value		0.475		1.000		0.708
2014						
<3 years	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
3 to 10 years	9	0 (0.0)	9	0 (0.0)	18	0 (0.0)
11+ years	112	1 (0.9)	63	0 (0.0)	177	1 (0.6)
p value		1.000		--		1.000
2015						
<3 years	4	1 (25.0)	1	0 (0.0)	5	1 (20.0)
3 to 10 years	9	0 (0.0)	21	0 (0.0)	32	0 (0.0)
11+ years	93	0 (0.0)	57	1 (1.8)	151	1 (0.7)
p value		0.038		1.000		0.081
2016						
<3 years	14	0 (0.0)	11	0 (0.0)	25	0 (0.0)
3 to 10 years	31	1 (3.2)	24	0 (0.0)	56	1 (1.8)
11 + years	209	0 (0.0)	106	2 (1.9)	317	3 (1.0)
p value		0.177		1.000		0.599
2017						
<3 years	20	0 (0.0)	10	0 (0.0)	30	0 (0.0)
3 to 10 years	38	0 (0.0)	24	0 (0.0)	62	0 (0.0)
11 + years	252	3 (1.2)	120	2 (1.7)	374	5 (1.3)
p value		1.000		1.000		1.000

Table 9.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Western Australia Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No receptive sharing	89	3 (3.4)	45	2 (4.4)	314	5 (3.7)
Receptive sharing	18	0 (0.0)	16	0 (0.0)	34	0 (0.0)
p value		1.000		1.000		0.584
2014						
No receptive sharing	90	1 (1.1)	56	0 (0.0)	147	1 (0.7)
Receptive sharing	25	0 (0.0)	11	0 (0.0)	36	0 (0.0)
p value		1.000		--		1.000
2015						
No receptive sharing	72	1 (1.4)	63	1 (1.6)	136	2 (1.5)
Receptive sharing	28	0 (0.0)	14	0 (0.0)	42	0 (0.0)
p value		1.000		1.000		1.000
2016						
No receptive sharing	176	2 (1.1)	98	1 (1.0)	276	4 (1.5)
Receptive sharing	68	0 (0.0)	31	0 (0.0)	100	0 (0.0)
p value		1.000		1.000		0.577
2017						
No receptive sharing	197	2 (1.0)	105	2 (1.9)	304	4 (1.3)
Receptive sharing	73	1 (1.4)	32	0 (0.0)	105	1 (1.0)
p value		1.000		1.000		1.000

Table 9.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Western Australia	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Less than daily	33	1 (3.0)	25	1 (4.0)	58	2 (3.5)
Daily or more	78	2 (2.6)	37	1 (2.7)	115	3 (2.6)
Not last month	10	0 (0.0)	5	0 (0.0)	16	0 (0.0)
p value		1.000		1.000		1.000
2014						
Less than daily	33	1 (3.0)	23	0 (0.0)	56	1 (1.8)
Daily or more	84	0 (0.0)	47	0 (0.0)	132	0 (0.0)
Not last month	10	0 (0.0)	5	0 (0.0)	16	0 (0.0)
p value		0.339		--		0.353
2015						
Less than daily	44	1 (2.3)	23	1 (4.4)	68	2 (2.9)
Daily or more	57	0 (0.0)	54	0 (0.0)	111	0 (0.0)
Not last month	4	0 (0.0)	4	0 (0.0)	10	0 (0.0)
p value		0.457		0.333		0.232
2016						
Less than daily	101	1 (1.0)	51	0 (0.0)	153	2 (1.3)
Daily or more	148	1 (0.7)	80	1 (1.3)	230	2 (0.9)
Not last month	16	0 (0.0)	10	1 (10.0)	26	1 (3.9)
p value		1.000		0.137		0.398
2017						
Less than daily	103	2 (1.9)	48	1 (2.1)	152	3 (2.0)
Daily or more	172	1 (0.6)	92	1 (1.1)	265	2 (0.8)
Not last month	26	0 (0.0)	13	0 (0.0)	39	0 (0.0)
p value		0.663		1.000		0.591

Table 9.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Western Australia	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No imprisonment	100	3 (3.0)	63	2 (3.2)	163	5 (3.1)
Imprisonment	13	0 (0.0)	3	0 (0.0)	16	0 (0.0)
p value		1.000		1.000		1.000
2014						
No imprisonment	99	1 (1.0)	64	0 (0.0)	163	1 (0.6)
Imprisonment	17	0 (0.0)	3	0 (0.0)	21	0 (0.0)
p value		1.000		--		1.000
2015						
No imprisonment	91	1 (1.1)	72	0 (0.0)	165	1 (0.6)
Imprisonment	13	0 (0.0)	6	0 (0.0)	20	0 (0.0)
p value		1.000		--		1.000
2016						
No imprisonment	218	1 (0.5)	123	1 (0.8)	343	3 (0.9)
Imprisonment	38	1 (2.6)	13	0 (0.0)	51	1 (2.0)
p value		0.275		1.000		0.427
2017						
No imprisonment	232	2 (0.9)	123	2 (1.6)	356	4 (1.1)
Imprisonment	48	0 (0.0)	16	0 (0.0)	65	0 (0.0)
p value		1.000		1.000		1.000

Table 9.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Western Australia		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2013							
No condom use	29	0 (0.0)	33	0 (0.0)	62	0 (0.0)	
Condom use	13	1 (7.7)	7	0 (0.0)	20	1 (5.0)	
p value		0.310		---		0.244	
2014							
No condom use	36	0 (0.0)	32	0 (0.0)	68	0 (0.0)	
Condom use	12	1 (8.3)	2	0 (0.0)	14	1 (7.1)	
p value		0.250		--		0.171	
2015							
No condom use	33	0 (0.0)	34	0 (0.0)	68	0 (0.0)	
Condom use	11	0 (0.0)	8	0 (0.0)	19	0 (0.0)	
p value		--		--		--	
2016							
No condom use	75	1 (1.3)	53	0 (0.0)	129	1 (0.8)	
Condom use	33	0 (0.0)	20	0 (0.0)	53	0 (0.0)	
p value		1.000		--		1.000	
2017							
No condom use	88	0 (0.0)	54	0 (0.0)	142	0 (0.0)	
Condom use	35	0 (0.0)	21	0 (0.0)	56	0 (0.0)	
p value		--		--		--	

Table 9.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Western Australia		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2013							
No sex work	110	3 (2.7)	60	2 (3.3)	171	5 (2.9)	
Sex work	4	0 (0.0)	6	0 (0.0)	10	0 (0.0)	
p value		1.000		1.000		1.000	
2014							
No sex work	100	1 (1.0)	66	0 (0.0)	167	1 (0.6)	
Sex work	10	0 (0.0)	3	0 (0.0)	13	0 (0.0)	
p value		1.000		--		1.000	
2015							
No sex work	99	1 (1.0)	72	1 (1.4)	174	2 (1.2)	
Sex work	6	0 (0.0)	7	0 (0.0)	13	0 (0.0)	
p value		1.000		1.000		1.000	
2016							
No sex work	239	2 (0.8)	125	2 (1.6)	366	5 (1.4)	
Sex work	11	0 (0.0)	12	0 (0.0)	24	0 (0.0)	
p value		1.000		1.000		1.000	
2017							
No sex work	265	3 (1.1)	131	2 (1.5)	398	5 (1.3)	
Sex work	13	0 (0.0)	8	0 (0.0)	21	0 (0.0)	
p value		1.000		1.000		1.000	

Table 9.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Western Australia Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Non Indigenous	109	3 (2.8)	63	2 (3.2)	173	5 (2.9)
Indigenous	7	0 (0.0)	8	0 (0.0)	15	0 (0.0)
p value		1.000		1.000		1.000
2014						
Non Indigenous	119	0 (0.0)	65	0 (0.0)	186	0 (0.0)
Indigenous	6	1 (16.7)	10	0 (0.0)	16	1 (6.3)
p value		0.048		--		0.079
2015						
Non Indigenous	99	1 (1.0)	69	1 (1.5)	171	2 (1.2)
Indigenous	10	0 (0.0)	10	0 (0.0)	20	0 (0.0)
p value		1.000		1.000		1.000
2016						
Non Indigenous	216	1 (0.5)	104	1 (1.0)	320	2 (0.6)
Indigenous	39	1 (2.6)	35	1 (2.9)	76	2 (2.6)
p value		0.283		0.442		0.168
2017						
Non Indigenous	248	0 (0.0)	116	1 (0.9)	364	1 (0.3)
Indigenous	59	3 (5.1)	36	1 (2.8)	97	4 (4.1)
p value		0.007		0.419		0.008

Table 9.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Western Australia Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
English speaking	117	2 (1.7)	66	2 (3.0)	184	4 (2.2)
Non-English speaking	6	1 (16.7)	5	0 (0.0)	11	1 (9.1)
p value		0.140		1.000		0.254
2014						
English speaking	122	1 (0.8)	71	0 (0.0)	195	1 (0.5)
Non-English speaking	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)
p value		1.000		--		1.000
2015						
English speaking	102	1 (1.0)	78	1 (1.3)	183	2 (1.1)
Non-English speaking	7	0 (0.0)	3	0 (0.0)	10	0 (0.0)
p value		1.000		1.000		1.000
2016						
English speaking	247	2 (0.8)	133	2 (1.5)	382	5 (1.3)
Non-English speaking	14	0 (0.0)	7	0 (0.0)	22	0 (0.0)
p value		1.000		1.000		1.000
2017						
English speaking	294	3 (1.0)	147	2 (1.4)	443	5 (1.1)
Non-English speaking	14	0 (0.0)	6	0 (0.0)	20	0 (0.0)
p value		1.000		1.000		1.000

Table 9.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2013							
Australia	98	2 (2.0)	55	2 (3.6)	154	4 (2.6)	
Other Oceania	4	0 (0.0)	5	0 (0.0)	9	0 (0.0)	
Asia	1	1 (100.0)	0	0 (0.0)	1	1 (100.0)	
UK & Ireland	12	0 (0.0)	6	0 (0.0)	18	0 (0.0)	
Other	8	0 (0.0)	5	0 (0.0)	13	0 (0.0)	
p value		0.068		1.000		0.072	
2014							
Australia	106	1 (0.9)	57	0 (0.0)	165	1 (0.6)	
Other Oceania	4	0 (0.0)	5	0 (0.0)	9	0 (0.0)	
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)	
UK & Ireland	13	0 (0.0)	4	0 (0.0)	17	0 (0.0)	
Other	6	0 (0.0)	8	0 (0.0)	14	0 (0.0)	
p value		1.000		--		1.000	
2015							
Australia	82	1 (1.2)	66	1 (1.5)	150	2 (1.3)	
Other Oceania	8	0 (0.0)	2	0 (0.0)	10	0 (0.0)	
Asia	2	0 (0.0)	1	0 (0.0)	4	0 (0.0)	
UK & Ireland	10	0 (0.0)	7	0 (0.0)	17	0 (0.0)	
Other	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)	
p value		1.000		1.000		1.000	
2016							
Australia	231	2 (0.9)	119	2 (1.7)	353	5 (1.4)	
Other Oceania	11	0 (0.0)	6	0 (0.0)	17	0 (0.0)	
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
UK & Ireland	11	0 (0.0)	7	0 (0.0)	18	0 (0.0)	
Other	6	0 (0.0)	7	0 (0.0)	13	0 (0.0)	
p value		1.000		1.000		1.000	
2017							
Australia	251	3 (1.2)	135	2 (1.5)	388	5 (1.3)	
Other Oceania	5	0 (0.0)	3	0 (0.0)	8	0 (0.0)	
Asia	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)	
UK & Ireland	33	0 (0.0)	10	0 (0.0)	43	0 (0.0)	
Other	13	0 (0.0)	1	0 (0.0)	14	0 (0.0)	
p value		1.000		1.000		1.000	

HCV antibody prevalence

Table 9.3.1 HCV antibody prevalence by gender and survey year

Western Australia	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013	123	66 (54)	71	23 (32)	196	90 (46)
2014	128	72 (56)	75	40 (53)	205	113 (55)
2015	107	58 (54)	82	39 (48)	192	98 (51)
2016	263	125 (48)	143	42 (29)	409	169 (41)
2017	296	140 (47)	153	57 (37)	451	198 (44)
X ² p trend		0.272		0.411		0.199

Table 9.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Western Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heterosexual	107	56 (52)	49	17 (35)	156	73 (47)
Bisexual	4	3 (75)	15	5 (33)	19	8 (42)
Homosexual	4	2 (50)	2	0 (0)	6	2 (33)
p value		0.857		0.890		0.832
2014						
Heterosexual	116	64 (55)	52	30 (58)	168	94 (56)
Bisexual	6	4 (67)	15	8 (53)	23	13 (57)
Homosexual	3	1 (33)	3	0 (0)	6	1 (17)
p value		0.652		0.171		0.181
2015						
Heterosexual	94	51 (54)	57	25 (44)	153	77 (50)
Bisexual	1	0 (0)	14	9 (64)	15	9 (60)
Homosexual	2	0 (0)	3	1 (33)	5	1 (20)
p value		0.103		0.418		0.306
2016						
Heterosexual	221	105 (48)	100	26 (26)	321	131 (41)
Bisexual	7	4 (57)	24	12 (50)	33	17 (52)
Homosexual	9	3 (33)	5	0 (0)	14	3 (21)
p value		0.673		0.025		0.155
2017						
Heterosexual	252	117 (46)	116	41 (35)	369	158 (43)
Bisexual	10	6 (60)	21	9 (43)	31	15 (48)
Homosexual	6	0 (0)	3	0 (0)	9	0 (0)
p value		0.039		0.421		0.020

Table 9.3.3 HCV antibody prevalence by age group, gender and survey year

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<25 years	7	1 (14)	5	0 (0)	12	1 (8)
25-34 years	40	17 (43)	22	7 (32)	62	24 (39)
35-44 years	35	22 (63)	22	6 (27)	57	28 (49)
45+ years	39	25 (64)	22	10 (45)	62	36 (58)
p value		0.027		0.281		0.006
2014						
<25 years	6	1 (17)	0	0 (0)	6	1 (17)
25-34 years	32	13 (41)	14	9 (64)	46	22 (48)
35-44 years	45	26 (58)	26	10 (38)	72	36 (50)
45+ years	44	31 (70)	35	21 (60)	80	53 (67)
p value		0.013		0.174		0.023
2015						
<25 years	5	1 (20)	6	1 (17)	13	2 (15)
25-34 years	21	10 (48)	13	8 (62)	34	18 (53)
35-44 years	37	16 (43)	34	14 (41)	71	30 (42)
45+ years	43	30 (70)	29	16 (55)	73	47 (64)
p value		0.030		0.218		0.002
2016						
<25 years	5	0 (0)	7	1 (14)	13	2 (15)
25-34 years	59	16 (27)	38	8 (21)	97	24 (25)
35-44 years	98	53 (54)	51	12 (24)	149	65 (44)
45+ years	99	55 (56)	46	21 (46)	147	77 (52)
p value		<0.001		0.040		<0.001
2017						
<25 years	14	3 (21)	5	0 (0)	19	3 (16)
25-34 years	52	23 (44)	37	9 (24)	90	33 (37)
35-44 years	109	46 (42)	59	21 (36)	169	67 (40)
45+ years	119	66 (55)	49	25 (51)	168	91 (54)
p value		0.041		0.022		0.001

Table 9.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Western Australia Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
<3 years	7	0 (0)	7	1 (14)	14	1 (7)
3 to 10 years	14	6 (43)	11	1 (9)	25	7 (28)
11+ years	96	57 (59)	51	21 (41)	148	79 (53)
p value		0.004		0.072		<0.001
2014						
<3 years	8	0 (0)	1	0 (0)	9	0 (0)
3 to 10 years	9	4 (44)	9	4 (44)	18	8 (44)
11+ years	109	66 (61)	63	35 (56)	174	102 (59)
p value		0.002		0.596		0.001
2015						
<3 years	4	1 (25)	1	0 (0)	5	1 (20)
3 to 10 years	8	5 (63)	21	7 (33)	31	12 (39)
11+ years	89	51 (57)	56	31 (55)	146	83 (57)
p value		0.509		0.099		0.064
2016						
<3 years	14	1 (7)	11	1 (9)	25	2 (8)
3 to 10 years	31	8 (26)	23	3 (13)	55	12 (22)
11+ years	203	107 (53)	104	35 (34)	309	143 (46)
p value		<0.001		0.053		<0.001
2017						
<3 years	19	0 (0)	10	0 (0)	29	0 (0)
3 to 10 years	38	11 (29)	24	5 (21)	62	16 (26)
11+ years	225	119 (53)	104	44 (42)	330	163 (49)
p value		<0.001		0.005		<0.001

Table 9.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Western Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No receptive sharing	9	0 (0)	121	67 (55)	132	69 (52)
Receptive sharing	1	0 (0)	31	11 (35)	34	12 (35)
p value		--		0.048		0.077
2014						
No receptive sharing	6	0 (0)	138	82 (59)	146	83 (57)
Receptive sharing	1	0 (0)	34	17 (50)	35	17 (49)
p value		--		0.320		0.376
2015						
No receptive sharing	2	0 (0)	131	71 (54)	134	71 (53)
Receptive sharing	1	0 (0)	38	22 (58)	41	24 (59)
p value		--		0.687		0.532
2016						
No receptive sharing	16	0 (0)	241	94 (39)	269	102 (38)
Receptive sharing	6	2 (33)	90	45 (50)	99	49 (49)
p value		0.065		0.071		0.045
2017						
No receptive sharing	25	0 (0)	251	110 (44)	292	123 (42)
Receptive sharing	2	0 (0)	92	54 (59)	102	59 (58)
p value		--		0.015		0.006

Table 9.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Western Australia Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Heroin	0	0 (0)	49	29 (59)	49	29 (59)
Methamphetamine	10	1 (10)	56	14 (25)	68	17 (25)
Other opioids	0	0 (0)	48	32 (67)	50	32 (64)
Other drugs	4	0 (0)	19	10 (53)	26	11 (42)
p value		0.512		<0.001		<0.001
2014						
Heroin	1	0 (0)	73	43 (59)	74	43 (58)
Methamphetamine	3	0 (0)	66	31 (47)	70	31 (44)
Other opioids	0	0 (0)	36	24 (67)	36	24 (67)
Other drugs	5	0 (0)	16	11 (69)	24	14 (58)
p value		--		0.165		0.132
2015						
Heroin	0	0 (0)	56	37 (66)	56	37 (66)
Methamphetamine	4	0 (0)	76	28 (37)	82	29 (35)
Other opioids	0	0 (0)	30	23 (77)	31	24 (77)
Other drugs	0	0 (0)	12	6 (50)	15	6 (40)
p value		--		<0.001		<0.001
2016						
Heroin	1	0 (0)	57	37 (65)	60	38 (63)
Methamphetamine	17	2 (12)	218	72 (33)	244	79 (32)
Other opioids	0	0 (0)	53	28 (53)	56	30 (54)
Other drugs	6	0 (0)	29	14 (48)	39	17 (44)
p value		0.638		<0.001		<0.001
2017						
Heroin	3	0 (0)	86	57 (66)	96	64 (67)
Methamphetamine	20	0 (0)	209	69 (33)	241	76 (32)
Other opioids	1	0 (0)	55	33 (60)	62	35 (56)
Other drugs	5	0 (0)	33	16 (48)	42	19 (45)
p value		<0.001		<0.001		<0.001

Table 9.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Western Australia	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Less than daily	8	0 (0)	48	23 (48)	56	23 (41)
Daily or more	3	0 (0)	107	56 (52)	114	59 (52)
Not last month	3	1 (33)	12	4 (33)	16	5 (31)
p value		0.429		0.461		0.181
2014						
Less than daily	5	0 (0)	49	31 (63)	56	32 (57)
Daily or more	2	0 (0)	128	70 (55)	130	70 (54)
Not last month	2	0 (0)	12	7 (58)	15	8 (53)
p value		--		0.585		0.912
2015						
Less than daily	1	0 (0)	65	36 (55)	68	37 (54)
Daily or more	2	0 (0)	105	57 (54)	108	58 (54)
Not last month	1	0 (0)	4	1 (25)	8	1 (13)
p value		--		0.560		0.082
2016						
Less than daily	14	1 (7)	134	60 (45)	152	63 (41)
Daily or more	8	1 (13)	204	84 (41)	223	93 (42)
Not last month	2	0 (0)	19	7 (37)	24	8 (33)
p value		1.000		0.714		0.726
2017						
Less than daily	10	0 (0)	130	56 (43)	148	62 (42)
Daily or more	18	0 (0)	219	111 (51)	254	123 (48)
Not last month	1	0 (0)	34	8 (24)	39	9 (23)
p value		--		0.010		0.010

Table 9.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Western Australia	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
No imprisonment	12	1 (8)	143	69 (48)	161	71 (44)
Imprisonment	1	0 (0)	14	10 (71)	16	11 (69)
p value		1.000		0.160		0.059
2014						
No imprisonment	9	0 (0)	148	85 (57)	160	87 (54)
Imprisonment	0	0 (0)	20	11 (55)	20	11 (55)
p value		--		0.837		0.958
2015						
No imprisonment	4	1 (25)	148	80 (54)	160	82 (51)
Imprisonment	1	0 (0)	16	7 (44)	19	8 (42)
p value		1.000		0.433		0.451
2016						
No imprisonment	19	1 (5)	298	119 (40)	333	129 (39)
Imprisonment	4	1 (25)	43	24 (56)	51	28 (55)
p value		0.324		0.049		0.029
2017						
No imprisonment	25	0 (0)	298	129 (43)	345	142 (41)
Imprisonment	1	0 (0)	56	30 (54)	62	35 (56)
p value		--		0.156		0.025

Table 9.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Western Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
Non Indigenous	106	59 (56)	63	22 (35)	170	82 (48)
Indigenous	7	2 (29)	8	1 (13)	15	3 (20)
p value		0.245		0.261		0.056
2014						
Non Indigenous	117	64 (55)	65	36 (55)	184	101 (55)
Indigenous	6	4 (67)	10	4 (40)	16	8 (50)
p value		0.691		0.500		0.706
2015						
Non Indigenous	95	49 (52)	69	35 (51)	167	85 (51)
Indigenous	10	9 (90)	9	2 (22)	19	11 (58)
p value		0.020		0.159		0.563
2016						
Non Indigenous	209	103 (49)	102	31 (30)	311	134 (43)
Indigenous	39	16 (41)	34	8 (24)	75	26 (35)
p value		0.343		0.444		0.184
2017						
Non Indigenous	235	99 (42)	115	44 (38)	350	143 (41)
Indigenous	58	38 (66)	36	12 (33)	96	51 (53)
p value		0.001		0.593		0.032

Table 9.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Western Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2013						
English speaking	114	62 (54)	66	22 (33)	181	85 (47)
Non-English speaking	6	2 (33)	5	1 (20)	11	3 (27)
p value		0.416		1.000		0.231
2014						
English speaking	119	65 (55)	71	37 (52)	192	103 (54)
Non-English speaking	8	6 (75)	3	2 (67)	11	8 (73)
p value		0.261		1.000		0.216
2015						
English speaking	97	53 (55)	77	37 (48)	177	91 (51)
Non-English speaking	7	4 (57)	3	1 (33)	10	5 (50)
p value		1.000		1.000		1.000
2016						
English speaking	240	113 (47)	130	35 (27)	372	149 (40)
Non-English speaking	14	6 (43)	7	4 (57)	22	11 (50)
p value		0.758		0.101		0.356
2017						
English speaking	281	132 (47)	146	54 (37)	429	187 (44)
Non-English speaking	13	7 (54)	6	3 (50)	19	10 (53)
p value		0.628		0.672		0.437

Table 9.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2013							
Australia	95	51 (54)	55	16 (29)	151	68 (45)	
Other Oceania	4	2 (50)	5	3 (60)	9	5 (56)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	12	6 (50)	6	3 (50)	18	9 (50)	
Other	8	5 (63)	5	1 (20)	13	6 (46)	
p value		0.929		0.395		0.956	
2014							
Australia	103	57 (55)	56	27 (48)	161	85 (53)	
Other Oceania	4	1 (25)	5	3 (60)	9	4 (44)	
Asia	1	0 (0)	1	1 (100)	2	1 (50)	
UK & Ireland	13	11 (85)	5	4 (80)	18	15 (83)	
Other	6	2 (33)	8	5 (63)	14	7 (50)	
p value		0.044		0.590		0.097	
2015							
Australia	77	41 (53)	66	32 (48)	145	74 (51)	
Other Oceania	8	3 (38)	2	1 (50)	10	4 (40)	
Asia	2	1 (50)	4	0 (0)	4	1 (25)	
UK & Ireland	10	7 (70)	6	3 (50)	16	10 (63)	
Other	7	5 (71)	5	2 (40)	12	7 (58)	
p value		0.624		1.000		0.644	
2016							
Australia	224	106 (47)	116	31 (27)	343	139 (41)	
Other Oceania	11	7 (64)	6	2 (33)	17	9 (53)	
Asia	4	2 (50)	0	0 (0)	4	2 (50)	
UK & Ireland	11	5 (45)	7	2 (29)	18	7 (39)	
Other	6	1 (17)	7	4 (57)	13	5 (38)	
p value		0.506		0.382		0.856	
2017							
Australia	240	110 (46)	134	49 (37)	376	160 (43)	
Other Oceania	4	0 (0)	3	2 (67)	7	2 (29)	
Asia	3	2 (67)	2	2 (100)	5	4 (80)	
UK & Ireland	32	17 (53)	10	2 (20)	42	19 (45)	
Other	12	7 (58)	1	0 (0)	13	7 (54)	
p value		0.275		0.166		0.414	

Appendix A: Participating NSP services

Year		'13	'14	'15	'16	'17
Number of NSP sites		50	50	47	50	52
Australian Capital Territory		1	1	1	1	1
Canberra	Directions ACT	✓	✓	✓	✓	✓
New South Wales		19	19	16	17	18
Albury	Albury Community Health Centre	✓	✓			
Ballina	Harm Reduction Services	✓	✓	✓	✓	✓
Blacktown	HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Byron/Tweed	Harm Reduction Services	✓	✓	✓	✓	✓
Coffs Harbour/Grafton	Harm Reduction Services	✓	✓	✓	✓	✓
Camperdown	Royal Prince Alfred Hospital				✓	✓
Canterbury	Harm Minimisation Program			✓	✓	✓
Central Coast	Gosford, Long Jetty and Woy Woy Harm Reduction	✓	✓			
Liverpool	Health ConneXions	✓				
Kings Cross	Clinic 180	✓	✓	✓	✓	✓
Kings Cross	Kirketon Road Centre	✓	✓	✓	✓	✓
Sutherland	KRC South	✓	✓			✓
Mt Druitt	Kelly Close Needle Syringe Program	✓	✓	✓	✓	✓
Kingswood	South Court Primary Care NSP		✓	✓	✓	✓
Newcastle	Hunter Harm Reduction Services	✓	✓	✓	✓	✓
Newcastle	AIDS Council of NSW Hunter	✓	✓	✓	✓	✓
Nimbin/Lismore	Harm Reduction Services	✓	✓	✓	✓	✓
Parramatta	HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Port Kembla	First Step Program	✓	✓	✓	✓	✓
Redfern	Harm Minimisation Program	✓	✓	✓	✓	✓
Surry Hills	NSW Users and AIDS Association	✓	✓	✓	✓	✓
Wagga Wagga	Wagga Wagga Community Health Centre	✓	✓			
Northern Territory		3	3	3	3	3
Alice Springs	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Darwin	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Palmerston	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Queensland		8	7	8	8	9
Brisbane	Biala Community Alcohol and Drug Services	✓	✓	✓	✓	✓
Brisbane	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Cairns	Cairns ATODS NSP	✓	✓	✓	✓	✓
Cairns	Youth Link					✓
Gold Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Ipswich	West Moreton Sexual Health Service	✓		✓	✓	✓
Sunshine Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Toowoomba	Kobi House	✓	✓	✓	✓	✓
Townsville	Townsville ATODS NSP	✓	✓	✓	✓	✓

Year		'13	'14	'15	'16	'17
Number of NSP sites		52	51	47	50	52
South Australia		7	7	7	7	7
Adelaide	Nunkuwarn Yunti Community Health Centre	✓	✓	✓	✓	✓
Adelaide	Streetlink Youth Services	✓	✓	✓	✓	✓
Angle Park	SAVIVE - Central Northern Adelaide Health Service	✓	✓			
Hindmarsh	Hindmarsh Centre	✓	✓	✓	✓	✓
Noarlunga	Noarlunga Primary Health	✓	✓	✓	✓	✓
Port Adelaide	SAVIVE, Central Northern Adelaide Health Service	✓	✓	✓	✓	✓
Salisbury	Anglicare SA Salisbury	✓	✓	✓	✓	✓
Warradale	Drug Arm Australasia			✓	✓	✓
Tasmania		3	4	4	4	4
Burnie	Burnie NSP Service				✓	
Clarence	Clarence Community Health Centre	✓	✓	✓	✓	✓
Glenorchy	Glenorchy NSP Service	✓	✓	✓	✓	✓
Hobart	Hobart NSP Service		✓	✓	✓	✓
Launceston	Salvation Army Launceston	✓	✓	✓		✓
Victoria		6	6	6	6	6
Barwon	Barwon Health Drug and Alcohol Services	✓	✓	✓	✓	✓
Collingwood	Inner Space	✓	✓	✓	✓	✓
Footscray	Health Works	✓	✓	✓	✓	✓
Frankston	Southern Hepatitis/HIV/AIDS Resource & Prevention Service	✓	✓	✓	✓	✓
North Richmond	North Richmond NSP Services	✓	✓	✓	✓	✓
St Kilda	Health Information Exchange	✓	✓	✓	✓	✓
Western Australia		3	3	2	4	4
Bunbury	Peer Based Harm Reduction Western Australia (formerly WASUA)	✓	✓		✓	✓
Northbridge	Hepatitis WA				✓	✓
Perth	Peer Based Harm Reduction Western Australia (formerly WASUA)	✓	✓	✓	✓	✓
Perth	WA AIDS Council Mobile Exchange	✓	✓	✓	✓	✓

Appendix B: Methodological notes

Capillary blood was obtained by finger-prick using disposable lancets and cotton-fibre blotting paper. Dried blood samples were kept at room temperature at the survey sites and couriered to a central laboratory every second or third day. HIV antibody was detected using the Murex 1.2.0 ELISA (Diasorin). Repeatedly reactive specimens were subjected to Western blot confirmatory testing (Bio-Rad New LAV blot 1, France). A modified third generation enzyme immunoassay (Monolisa anti-HCV Plus Version 3 EIA, Biorad, France) was used to test for HCV antibody. A modified cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut off ratio was greater than or equal to one on initial and subsequent testing.

In 2015, HCV RNA was detected and quantified using a modified Abbott RealTime™ (Illinois, United States) HCV RNA assay. The Abbott RealTime HCV RNA assay involves specimen extraction automation using the Abbott M2000SP coupled with the M2000RT Realtime PCR instrument. A bias (+1.91 Log₁₀) applied post run gave a quantifiable DBS HCV viral load (VL) result with a lower limit of detection of 977IU/mL (plasma equivalency). A qualitative result of <12IU/mL detected (trace/equivocal) was applied to samples <977IU/mL (plasma equivalency).

In 2016, HCV RNA was detected and quantified on the Hologic Panther™ using the Aptima™ HCV Quant Dx assay (Hologic, Inc. San Diego, Calif) which has a limit of quantitation (LOQ) 10 IU/mL and an upper limit of quantitation of 108 IU/mL in plasma. An offboard DBS elution protocol was applied prior to sampling. To correct for haematocrit, all post run DBS VL results on the Aptima assay were multiplied by a plasma conversion factor of 36.36. This calculation was based on the following assumptions: 45% haematocrit average per DBS, 50uL DBS volume and 1000ul Aptima transport media volume. A qualitative result of <10IU/mL detected (trace/equivocal) was applied to samples <400IU/mL (plasma equivalency).

Data presented in this report were analysed using Stata, Version 14 (Stata Corporation, College Station TX). Changes in HIV and HCV antibody prevalence overtime were assessed using the χ^2 test for linear trend. Associations between demographic and behavioural variables and HIV and HCV antibody prevalence were assessed using the χ^2 test or Fisher's exact test where expected frequencies were less than five.

Percentage values in tables may not add to 100 due to rounding. Totals in HIV and HCV antibody prevalence tables stratified by gender include people whose gender was not reported or reported as transgender. Time since first injection was calculated by subtracting age at first injection from age at survey completion. Totals in HIV and HCV antibody prevalence tables stratified by time since first injection include people who did not report age at survey completion or age at first injection. Tables reporting HIV antibody prevalence stratified by demographic and drug use characteristics are not included in this report for states and territories or survey years where the number of HIV antibody positive participants was less than 5 in all years.

Where data were collected but no participants endorsed a particular response, results are presented as "0 (0)". The symbol "--" shown in some tables denotes missing data; and is used to identify circumstances where data were not collected in the reported format. The vast majority of survey questions were consistent over all survey years.

NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey period and this data was used to assess response rates. Some clients visited the site more than once during the survey week, and only one attendance per person was included in the response rate denominator. Ethical approvals for the study were obtained from Human Research Ethics Committees associated with the investigators and participating sites. Verbal rather than written informed consent was obtained to assure the anonymity of participants.

Appendix C: List of Tables

1. Demographic characteristics and drug use

Table 1.1.1	Number (percentage) of respondents by demographic characteristics and survey year
Table 1.1.2	Number (percentage) of respondents by last drug injected, frequency of injecting and survey year
Table 1.1.3	Number (percentage) of respondents by injecting behaviour in the last month and survey year
Table 1.1.4	Number (percentage) of respondents by treatment for drug use and survey year
Table 1.1.5	Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year
Table 1.1.6	Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year
Table 1.1.7	Number (percentage) of respondents reporting stigma or discrimination in the last 12 months in 2016

2. HIV antibody prevalence

Table 1.2.1	HIV antibody prevalence by gender and survey year
Table 1.2.2	HIV antibody prevalence by sexual identity, gender and survey year
Table 1.2.3	HIV antibody prevalence by age group, gender and survey year
Table 1.2.4	HIV antibody prevalence by last drug injected, gender and survey year
Table 1.2.5	HIV antibody prevalence by years of injection, gender and survey year
Table 1.2.6	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year
Table 1.2.7	HIV antibody prevalence by frequency of drug injection last month, gender and survey year
Table 1.2.8	HIV antibody prevalence by imprisonment last year, gender and survey year
Table 1.2.9	HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year
Table 1.2.10	HIV antibody prevalence by sex work last month, gender and survey year
Table 1.2.11	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.2.12	HIV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.2.13	HIV antibody prevalence by region/country of birth, gender and survey year

3. HCV antibody prevalence

Table 1.3.1	HCV antibody prevalence by gender and survey year
Table 1.3.2	HCV antibody prevalence by sexual identity, gender and survey year
Table 1.3.3	HCV antibody prevalence by age group, gender and survey year
Table 1.3.4	HCV antibody prevalence by years since first injection, gender and survey year
Table 1.3.5	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year
Table 1.3.6	HCV antibody prevalence by last drug injected, years since first injection and survey year
Table 1.3.7	HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year
Table 1.3.8	HCV antibody prevalence by imprisonment last year, years since first injection and survey year
Table 1.3.9	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.3.10	HCV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.3.11	HCV antibody prevalence by region/country of birth, gender and survey year

4. HCV RNA prevalence

- Table 1.4.1 HCV RNA prevalence by gender and survey year
- Table 1.4.2 HCV RNA prevalence by sexual identity and survey year
- Table 1.4.3 HCV RNA prevalence by age group and survey year
- Table 1.4.4 HCV RNA prevalence by years since first injection and survey year
- Table 1.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month by survey year
- Table 1.4.6 HCV RNA prevalence by last drug injected and survey year
- Table 1.4.7 HCV RNA prevalence by frequency of injection last month and survey year
- Table 1.4.8 HCV RNA prevalence by imprisonment last year and survey year
- Table 1.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status and survey year
- Table 1.4.10 HCV RNA prevalence by main language spoken at home by parents and survey year
- Table 1.4.11 HCV RNA prevalence by region/country of birth and survey year

